Access DB# 36291

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Alycia Berman Examiner #: 76457 Date: 2/24/01
Art Unit: 1619 Phone Number 308-4638 Serial Number: 09/478,882
Mail Box and Bldg/Room Location: 2006 Results Format Preferred (circle): PAPER DISK E-MAIL
3B19

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See attached

Inventors (please provide full names): See attached

Earliest Priority Filing Date: 3/30/97

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Please see attached

1) methionine or cysteine or cystine or glutathione or homocysteine or thiocysteine or taurine or cystathionine or S-alkylcysteine or kanthionine or ergothioneine or [(sulfine or cysteinic or djenkolic (or) acid] or tannin or (condensed (or) ring) or (vitamin C derivatives of claim 1) or thiotaurine or hypotaurine

2) liniment or ointment or cream or creme or lotion or topical or reduction

3) high epigallocatechin acid of claim 3.

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher:	NA Sequence (#)	STN ✓
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up:	Bibliographic ✓	Dr.Link
Date Completed:	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time:	Other	Other (specify)

PTO-1590 (1-2000)

=> d his

```
     (FILE 'HOME' ENTERED AT 14:34:10 ON 13 MAR 2001)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 14:34:37 ON 13 MAR 2001
               ACT ALYSIA478/A
                ---------
L1   (         3)SEA FILE=REGISTRY ABB=ON  PLU=ON  6027-13-0 OR 6027-14-1 OR 454
L2   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  498-40-8
L3   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  13100-82-8
L4   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  "D-ALANINE, 3-SULFO-"/CN
L5   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  5652-32-4
L6   (         3)SEA FILE=REGISTRY ABB=ON  PLU=ON  C3H7NO2S2/MF AND ALANINE AND
L7   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  107-35-7
L8   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  498-59-9
L9   (         2)SEA FILE=REGISTRY ABB=ON  PLU=ON  C7H14N2O4S2/MF AND CYSTEINE A
L10  (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  56-88-2
L11  (        11)SEA FILE=REGISTRY ABB=ON  PLU=ON  C7H14N2O4S/MF AND HOMOCYSTEIN
L12  (        11)SEA FILE=REGISTRY ABB=ON  PLU=ON  L11 AND S AND 2
L13  (         6)SEA FILE=REGISTRY ABB=ON  PLU=ON  L12 NOT (LABELED OR (D OR T)/
L14  (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  21593-77-1
L15  (         2)SEA FILE=REGISTRY ABB=ON  PLU=ON  C6H11NO2S/MF AND CYSTEINE AND
L16  (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  922-55-4
L17  (         5)SEA FILE=REGISTRY ABB=ON  PLU=ON  C6H12N2O4S/MF AND CYSTEINE AN
L18  (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  67-21-0
L19  (        11)SEA FILE=REGISTRY ABB=ON  PLU=ON  C6H13NO2S/MF AND HOMOCYSTEINE
L20  (        10)SEA FILE=REGISTRY ABB=ON  PLU=ON  L19 AND ETHYL
L21  (         8)SEA FILE=REGISTRY ABB=ON  PLU=ON  L20 AND S ETHYL
L22  (         3)SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 NOT (14C OR 11C OR (D OR
L23  (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  300-84-5
L24  (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  2937-54-4
L25           30 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5 O
                ---------
L26           10 S 63-68-3 OR 348-67-4 OR 59-51-8 OR 56-89-3 OR 349-46-2 OR 923-
L27           19 S C10H17N3O6S/MF AND GLYCINE AND GLUTAMYL AND CYSTEINYL
L28           17 S L27 AND GAMMA
L29            6 S L28 NOT (LABELED OR 15N OR 13C# OR 14C# OR (T OR D)/ELS OR 35
L30           15 S L26,L29
L31            3 S 50-81-7 OR 10504-35-5 OR 62624-30-0

     FILE 'HCAPLUS' ENTERED AT 14:40:05 ON 13 MAR 2001
L32         1794 S (NA OR SODIUM)()(ASCORBATE OR ASCORBIC ACID)
L33            5 S ASCORBIC ACID (L) PHOSPHORIC ESTER
L34           27 S ASCORBIC ACID (L) PHOSPHORIC(L)ESTER
L35          802 S ASCORBIC ACID (L) 3 (L) PHOSPHATE
L36           63 S L35 (L) ESTER
L37            0 S TOCOPHEROL (L) ASCORBIC (L) DIPHOSPH? (L) ESTER
L38            0 S TOCOPHER? (L) ASCORB? (L) DIPHOSPH? (L) ESTER
L39            0 S TOCOPHER? (L) ASCORB? (L) PYROPHOSPH? (L) ESTER
L40            3 S TOCOPHER? (L) ASCORB? (L) PYROPHOSPH?
L41            4 S TOCOPHER? (L) ASCORB? (L) DIPHOSPH?
L42            7 S L40,L41
L43           13 S ASCORB? (L) (SULFURIC OR SULPHURIC) (L) ESTER
L44          147 S ASCORB? (L) GLUCOSIDE
L45          151 S ASCORB? (L) GLYCOSIDE
L46          280 S L44,L45

     FILE 'REGISTRY' ENTERED AT 14:54:13 ON 13 MAR 2001
L47           11 S 108910-78-7 OR 23666-04-8 OR 134-03-2 OR 21090-54-0 OR 146614
L48            5 S C6H9O9P/MF AND ASCORBIC ACID
L49           82 S (50-81-7 OR 10504-35-5 OR 62624-30-0)/CRN AND NA/ELS
L50           11 S L49 AND 2/NC
L51            4 S L50 AND C6H8O6
L52            7 S L50 NOT L51
```

```
L53           4 S L52 AND (C6H9O9P OR C6H8O9S)
L54           3 S L52 NOT L53
L55          13 S L48,L51,L53
L56           9 S L47 NOT L55
L57           2 S L56 AND C6H8O6
L58           1 S L57 NOT MG/ELS
                E C6H8O9S/MF
L59           9 S E3 AND OC4/ES
L60           7 S L59 AND ASCORBIC
L61           5 S L60 NOT (ION OR 35S)
L62          10 S ASCORB? (L) TOCOPHER?
L63         804 S 50-81-7/CRN
L64           1 S .ALPHA.-TOCOPHEROL/CN
L65           5 S 59-02-9/CRN AND L63
L66           1 S L65 AND P/ELS
L67         170 S OC4/ES AND OC5-C6/ES AND P/ELS
L68          22 S L67 AND 2/P
L69           3 S L68 AND 3/NR
L70          22 S L55,L58,L61,L69
L71           2 S (THIOTAURINE OR HYPOTAURINE)/CN

     FILE 'HCAPLUS' ENTERED AT 15:17:16 ON 13 MAR 2001
L72       70010 S L30
L73      167687 S METHIONIN# OR CYSTIN# OR CYSTEIN# OR GLUTATHION#
L74       14693 S L25
L75       19263 S HOMOCYSTEIN# OR (SULFINIC OR SULPHINIC)()ACID OR CYSTEINIC AC
L76       14182 S TANNIN
L77       41809 S L31
L78       62577 S ASCORBIC ACID OR VITAMIN C OR ASCORBATE
L79        2047 S L70
L80         378 S L71
L81         452 S THIOTAURIN# OR HYPOTAURIN#
L82      260040 S L72-L81
L83         189 S AMINO ACID (L) (SULFO OR SULPHO)
L84      260165 S L82,L83
L85         150 S L84 AND (HYDROXYCARBOXYLIC OR HYDROXY CARBOXYLIC)()ACID
L86          29 S L84 AND (HYDROXYCARBOXYLATE OR HYDROXY CARBOXYLATE)
                E HYDROXY CARBOXYLIC ACID/CT
                E E7+ALL
L87          31 S E1 AND L84
                E E2+ALL
L88         107 S E6,E7 AND L84
L89         234 S E5 AND L84
L90         342 S L85-L89
L91        6591 S GLYCOLIC ACID
L92         607 S BENZILIC ACID
L93         319 S TROPIC ACID
L94       39086 S LACTIC ACID
L95       11385 S MALIC ACID
L96       40509 S CITRIC ACID
L97         794 S ISOCITRIC ACID
L98         123 S CITRAMALIC ACID
L99         256 S TARTRONIC ACID
L100      15294 S TARTARIC ACID
L101       4475 S GLUCONIC ACID
L102        206 S GALACTONIC ACID
L103          0 S ALPHA HYDROXYISOBUTYLIC ACID
L104          0 S ALPHA HYDROXY ISOBUTYLIC ACID
L105          0 S HYDROXY ISO BUTYLIC ACID
L106          0 S HYDROXYISO BUTYLIC ACID
L107          3 S ISOBUTYLIC ACID
L108         18 S ALPHA HYDROXY ISOBUTYRIC ACID
L109        439 S ALPHA HYDROXYISOBUTYRIC ACID
L110         93 S PHENYL LACTIC ACID
L111          0 S MULDIC ACID
L112          5 S MULDIC
```

```
L113        112 S ATROLACTIC ACID
L114       1085 S GLUCONOLACTONE
L115        145 S GALACTONOLACTONE
L116        127 S RIBONIC ACID
L117        254 S RIBONOLACTONE
L118        100 S PANTOIC ACID
L119        508 S PANTOLACTONE
L120          0 S PANTOTHEINIC ACID
L121       2396 S PANTOTHENIC ACID
L122        201 S ALPHA HYDROXYBUTYRIC ACID
L123       1650 S BETA HYDROXYBUTYRIC ACID
L124       1070 S QUINIC ACID
L125       9025 S PYRUVIC ACID
L126        681 S PHENYLPYRUVIC ACID
L127        504 S METHYL PYRUVATE
L128        814 S ETHYL PYRUVATE
L129        230 S BENZOYLFORMIC ACID
L130        157 S METHYL BENZOYLFORMATE
L131        119 S ETHYL BENZOYLFORMATE

     FILE 'REGISTRY' ENTERED AT 15:42:39 ON 13 MAR 2001
L132         18 S 79-14-1 OR 76-93-7 OR 16202-15-6 OR 552-63-6 OR 17126-67-9 OR
L133         17 S 6915-15-7 OR 594-61-6 OR 515-30-0 OR 90-80-2 OR 1112-33-0 OR
L134          1 S 526-95-4
L135          1 S (L-GLUCONIC ACID OR DL-GLUCONIC ACID)/CN
L136          1 S 576-36-3
L137          1 S (L-GALACTONIC ACID OR DL-GALACTONIC ACID)/CN
L138          1 S 20312-36-1
                E C9H10O3/MF
L139          3 S E3 AND BENZENEPROPANOIC ACID AND ALPHA HYDROXY
L140          1 S 2782-07-2
L141          3 S C6H10O6/MF AND GALACTONIC ACID AND GAMMA LACTONE
L142          1 S 642-98-8
L143          0 S (L-RIBONIC ACID OR DL-RIBONIC ACID)/CN
L144         51 S C5H10O6/MF
L145          4 S L144 AND RIBONIC
L146          2 SS L145 NOT (14C OR 13C)
L147          1 S 5336-08-3
L148          4 S C5H8O5/MF AND RIBONIC AND GAMMA LACTONE
L149          3 S L148 NOT 13C
L150         50 S L132-L142,L146,L147,L149

     FILE 'HCAPLUS' ENTERED AT 15:52:30 ON 13 MAR 2001
L151     146938 S L150 OR L91-L131
L152      10362 S L84 AND L151
L153      10461 S L90,L152
L154        654 S L153 AND COSMETIC#/SC,SX,CW,BI
L155       2542 S L153 AND (CREAM OR CREME OR LOTION OR LINIMENT OR OINTMENT OR
L156        358 S L153 AND ?EMULS?
L157        253 S L153 AND SUSPEN?
L158        388 S L154 AND L155-L157
L159        238 S L158 AND SKIN
L160          1 S L158 AND AIRBORNE PARTICLE
L161          4 S L158 AND STRESS?
L162          8 S L158 AND ENVIRON?
L163         10 S L160-L162
L164          8 S L159 AND L163
L165          2 S L163 NOT L164

     FILE 'REGISTRY' ENTERED AT 15:58:05 ON 13 MAR 2001
L166         45 S L30 OR L25

     FILE 'HCAPLUS' ENTERED AT 15:59:05 ON 13 MAR 2001
L167      80367 S L166
L168     189133 S L72-L75,L80,L81,L167
L169     189258 S L83,L168
```

```
L170      64637 S L32-L46,L77,L78,L79
L171     150101 S L151 OR (HYDROXYCARBOXYLIC OR HYDROXY CARBOXYLIC)()ACID OR HY
                E HYDROXY CARBOXYLIC ACIDS/CT
L172        310 S E3+NT
                E E3+ALL
L173       3478 S E2
                E E2+ALL
L174       1213 S E6,E7
L175     260166 S L169,L76,L170
L176       2904 S L175 AND (CREAM OR CREME OR OINTMENT OR LOTION OR LINIMENT OR
L177       7943 S L175 AND (?EMULS? OR SUSPEN? OR DISPERS?)
L178       6396 S L175 AND (SKIN OR EPIDERM? OR DERM?)
                E SKIN/CT
L179       2239 S E3+NT AND L175
                E E3+ALL
L180        409 S E45+NT AND L175
L181       1189 S E46+NT AND L175
L182        235 S E47+NT AND L175
                E E46+ALL
L183         69 S E4 AND L175
L184       1189 S E3+NT AND L175
L185        885 S L178-L184 AND L176
L186        504 S L178-L184 AND L177
L187       1156 S L185,L186
L188        264 S L187 AND L171-L174
L189        880 S L187 AND COSMETIC#/SC,SX,CW,BI
L190        227 S L189 AND L171-L174
L191        264 S L188,L190
L192        169 S L191 AND (PD<=19970330 OR PRD<=19970330 OR AD<=19970330 OR PY
                E EGAWA M/AU
L193         25 S E3,E7
                E SAKAMOTO T/AU
L194        197 S E3
                E SAKAMOTO TETSUO/AU
L195        109 S E3
                E KOHNO Y/AU
L196         74 S E3
                E KOHNO YOSHI/AU
L197         18 S E21
L198          1 S L193-L197 AND L191
                E SHISEIDO/PA,CS
L199         19 S E3,E4 AND L191
L200          1 S L192 AND ?STRESS?
L201          5 S L192 AND ENVIRON?
L202          1 S L192 AND AIRBORN?
L203         23 S L198-L202
L204         19 S L203 AND L192
L205          4 S L203 NOT L204
L206          3 S L205 AND CREAM
L207          7 S L204 AND CREAM
L208         10 S L206,L207
L209         12 S L204 NOT L208
L210         10 S L209 NOT (CLAY OR KERATOSIS)
L211         20 S L208,L210
L212        135 S L192 AND L176
L213        100 S L212 AND COSMETIC#/SC
L214         93 S L213 AND SKIN
L215         31 S L212-L214 AND L30,L25,L71
L216          4 S L215 NOT 62/SC,SX
L217          2 S L216 NOT (3 OR 18)/SC,SX
L218          2 S L216 NOT L217
L219         29 S L215 NOT L218
L220         72 S L214 NOT L215-L219
L221         35 S L212 NOT L213
L222         15 S L221 AND 62/SC,SX
L223        106 S L219,L220,L211
```

```
L224          32 S L212 NOT L223
L225           4 S L224 AND (TOPICAL AND (SKIN DISORDER OR COMPOSITION))/TI
L226           2 S L224 AND PENETRATION/TI
L227           6 S L225,L226
L228           4 S L227 NOT METHOTREXATE
L229         110 S L223,L228

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:31:05 ON 13 MAR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 13 Mar 2001  VOL 134 ISS 12
FILE LAST UPDATED: 12 Mar 2001  (20010312/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 This file supports REGlstRY for direct browsing and searching of
 all substance data from the REGISTRY file.  Enter HELP FIRST for
 more information.

Now you can extend your author, patent assignee, patent information,
and title searches back to 1907.  The records from 1907-1966 now have
this searchable data in CAOLD.  You now have electronic access to all
of CA: 1907 to 1966 in CAOLD and 1967 to the present in HCAPLUS on STN.


=> d all tot


L229 ANSWER 1 OF 110  HCAPLUS  COPYRIGHT 2001 ACS
AN   2000:738879  HCAPLUS
DN   133:301197
TI   Oxalic acid or oxalate compositions and methods for bacterial, viral, and
     other diseases or conditions
IN   Hart, Francis J.
PA   USA
SO   U.S., 50 pp., Cont.-in-part of U. S. Ser. No. 629,538.
     CODEN: USXXAM
DT   Patent
LA   English
IC   ICM  A61K031-194
     ICS  A61K031-225
NCL  514574000
CC   63-6 (Pharmaceuticals)
     Section cross-reference(s): 1, 17, 18, 62
FAN.CNT 2
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   US 6133318         A    20001017      US 1998-14943    19980128 <--
     US 6133317         A    20001017      US 1996-629538   19960409 <--
PRAI US 1995-6785      19951115  <--
     US 1996-629538    19960409  <--
     US 1997-36983     19970129  <--
AB   A single medicine oxalic acid or oxalate or "magic bullet" and method for
     treatment or prevention of infectious or pathogenic microbial, bacterial,
     viral and other diseases in warm-blooded animals, including humans and
```

pets, is provided. A compn. includes at least one therapeutically effective form of oxalic acid or oxalate selected from ester, lactone or salt form including sodium oxalate, oxalic acid dihydrate, anhyd. oxalic acid, oxamide, and oxalate salts, natural or processed foods including molds, plants or vegetables contg. oxalic acid or oxalate, beverages, liqs. or juices contg. oxalic acid or oxalate, additives contg. oxalic acid or oxalate, and combinations thereof. The compn. may also contain a pharmaceutically acceptable carrier or diluent for the therapeutically effective form of oxalic acid or oxalate. Methods are provided including the steps of periodically administering, by topical, oral, or parenteral application, a therapeutically effective dosage of a compn. including at least one therapeutically effective form of oxalic acid or oxalate and improving chemotherapy reducing the intake of oxalic acid or oxalate blockers such as **citric acid, ascorbic acid (vitamin C)**, pyridoxine hydrochloride (vitamin B6), calcium, alc., resins, clays, foods contg. calcium, beverages contg. alc., **citric acid**, or **ascorbic acid**, red meat or white meat of fowl contg. pyridoxine hydrochloride, or other foods nutritional supplements or beverages contg. oxalic acid or oxalate blockers.

ST oxalate antitumor antibacterial antiviral nutrient food

IT Brain, disease
(Creutzfeldt-Jakob; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Imaging
(NMR; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases and protection from radiation)

IT Streptococcus
(Viridans-group; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Actinomyces
(actinomycosis from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Bacilli
(anaerobic; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Bacillus anthracis
(anthrax from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Antiarteriosclerotics
(antiatherosclerotics; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Food
(aq.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Tomography
(axial, computerized; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases and protection from radiation)

IT Bartonella
(bartonellosis from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Antitumor agents
(brain; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(capsules; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Fruit and vegetable juices
(carrot juice; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)

IT Uterus, neoplasm
(cervix, inhibitors; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Antitumor agents

(cervix; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Meat
(chicken; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Digestive tract
(disease, oxalate-induced; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Nervous system
(disease, viral; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Blood
(disease; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(drops; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Plant (Embryophyta)
(edible; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Treponema
(endemic treponematosis from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Intestine, disease
(enterocolitis; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT **Cosmetics**
(exfoliate; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Kidney, disease
(failure, oxalate-induced; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Necrosis
(gas gangrene; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(gels; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Alcoholic beverages
(gin; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Bacilli
(gram-neg.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Bacilli
(gram-pos.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(granules; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Petrolatum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrophilic; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Respiratory tract
(infection, viral; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(inhalants; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Brain, neoplasm
(inhibitors; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems

(injections, i.v.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(injections, s.c.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(injections; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Kidney, disease
(injury, oxalate-induced; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Carrot
(juice; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Leptospira
(leptospirosis from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(liqs.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Listeria monocytogenes
(listeriosis from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(**lotions**; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(lozenges; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Antitumor agents
(mammary gland; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Radiography
(mammog.; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases and protection from radiation)
IT Burkholderia pseudomallei
(melioidosis from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(microcapsules; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(nasal sprays; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(nasal; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Mammary gland
(neoplasm, inhibitors; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Clostridium
(of gas gangrene; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Colorimetry
(of oxalate; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(**ointments, creams**; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(**ointments**; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(oral; oxalate compns. for prevention and treatment of cancer,

microbial infections and other diseases)
IT Ear
(otitis; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Bakers' yeast
Beer
Blood analysis
Bread
Carrot
Cereal (grain)
Chive (Allium schoenoprasum)
Coconut (Cocos nucifera)
Dairy products
Feed
Fruit
Garlic (Allium sativum)
Meat
Parsley (Petroselinum crispum)
Pepper (spice)
Preservatives
Spinach (Spinacia oleracea)
Urine analysis
Wine
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Clays, biological studies
Resins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Smectite-group minerals
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Electromagnetic wave
Magnetic field
Microwave
Radiotherapy
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases and protection from radiation)
IT Adenoviridae
Almond (Prunus amygdalus)
Alphavirus
Alzheimer's disease
Anti-AIDS agents
Anti-Alzheimer's agents
Antibacterial agents
Antimicrobial agents
Antiparkinsonian agents
Antitumor agents
Antiviral agents
Arbovirus
Arenavirus
Autoimmune disease
B19 virus
Bacteremia
Bacteroides
Beet
Beverages
Biocides
Bunyavirus
Campylobacter
Cardiovascular agents

Cashew (Anacardium occidentale)
Cat (Felis catus)
Cattle
Celery (Apium graveolens)
Chemotherapy
Clostridium botulinum
Clostridium tetani
Cytomegalovirus
Dog (Canis familiaris)
Enterobacteriaceae
Enterococcus
Erysipelothrix
Filovirus
Flavivirus
Flavoring materials
Food
Food additives
Fruit and vegetable juices
Goat
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Haemophilus
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Hepatitis delta virus
Herpes virus B
Hodgkin's disease
Horse (Equus caballus)
Human coxsackievirus
Human echovirus
Human herpesvirus
Human herpesvirus 3
Human herpesvirus 4
Human herpesvirus 6
Human immunodeficiency virus 1
Human papillomavirus
Human poliovirus
Immunotherapy
Influenza A virus
Influenza B virus
Influenza C virus
Kale
Leprosy
Lyme disease
Measles virus
Meningitis
Mold (fungus)
Molluscum contagiosum virus
Mouthwashes
Mumps virus
Mycobacterium
Neisseria
Neisseria gonorrhoeae
Neisseria meningitidis
Nocardia
Orbivirus
Osteomyelitis
Parkinson's disease
Parvovirus
Peanut (Arachis hypogaea)
Pneumonia
Rabies virus
Radish (Raphanus sativus)
Reoviridae
Respiratory syncytial virus

Rhinovirus
Rubella virus
Salmonella
Shigella
Spirochaeta
Staphylococcus
Streptococcus
Streptococcus pneumoniae
Surgery
Togaviridae
Tomato juice
Tuberculosis
Tuberculostatics
Vegetable
Walnut
(oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Mineral elements, biological studies
RL: BAC (Biological activity or effector, except adverse); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate-contg.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Diarrhea
Dyspepsia
Kidney, disease
(oxalate-induced; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(parenterals; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Meat
(poultry; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(powders; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Respiratory tract
(sinusitis; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(solns.; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Bread
(sourdough; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)

IT Brain, disease
(spongiform encephalopathy; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Beverages
(sports; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(sprays; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(sticks; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Drug delivery systems
(sublingual; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT Diet

(supplements; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(suppositories; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT **Lupus erythematosus**
(systemic; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(tablets; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Brushes
Dental materials and appliances
(toothbrushes, cleaning of; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(topical; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Drug delivery systems
(transdermal; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Francisella tularensis
(tularemia from; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Meat
(turkey; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Drugs
(veterinary; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT Alcoholic beverages
(vodka; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT Imaging
(x-ray; oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases and protection from radiation)
IT 12441-09-7D, Sorbitan, esters, polyethoxylated
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Polysorbate; oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)
IT 64-17-5, Ethanol, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT **50-81-7, Ascorbic acid**, biological studies
58-56-0, Pyridoxine hydrochloride **77-92-9**, biological studies
7440-70-2, Calcium, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT 65-23-6, Pyridoxine 7440-09-7, Potassium, biological studies
RL: BAC (Biological activity or effector, except adverse); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)
IT 67-48-1, Choline chloride 91-53-2, Ethoxyquin **107-35-7**, **Taurine** 471-34-1, Calcium carbonate, biological studies
1314-13-2, Zinc oxide, biological studies 1318-00-9, Vermiculite
1336-80-7, Iron choline citrate complex 1344-43-0, Manganous oxide, biological studies 1344-67-8, Copper chloride 5700-49-2, Ethylene diamine dihydroiodide 7447-40-7, Potassium chloride, biological studies

7487-88-9, Magnesium sulfate, biological studies 7542-09-8, Cobalt carbonate 7647-14-5, Sodium chloride, biological studies 7720-78-7, Ferrous sulfate 7757-93-9, Dicalcium phosphate 7778-18-9, Calcium sulfate 7778-80-5, Potassium sulfate, biological studies 7789-80-2, Calcium iodate 10102-18-8, Sodium selenite
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxalate compns. and oxalate blockers for prevention and treatment of cancer, microbial infections and other diseases)

IT 144-62-7, Ethanedioic acid, biological studies
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT 62-76-0, Sodium oxalate 144-62-7D, Oxalic acid, esters, lactones, or salts 471-46-5, Oxamide 6153-56-6, Oxalic acid dihydrate
RL: BAC (Biological activity or effector, except adverse); FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

IT 57-55-6, 1,2-Propanediol, biological studies 67-64-1, Acetone, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxalate compns. for prevention and treatment of cancer, microbial infections and other diseases)

RE.CNT 103
RE

(1) America'S Parmaceutical Research Companies; Health Guide-Seventh in a Series, HIV/AIDS 1997
(2) America'S Pharmaceutical Companies; Cancer Treatments 1997, P1
(3) American Cancer Society; Cancer Facts & Figures-1995 1995
(4) American Heart Association; Breast Cancer Update, News from the World of Medicine 1995, P108
(5) American Heart Association; Cancer Treatment Choices, News from the World of Medicine 1996, P139
(6) American Heart Association; Cancer Update, News from the World of Medicine 1995, P113
(7) American Heart Association; Early Alzheimer's Warning? News from the World of Medicine 1995, P105
(8) Anon; Better Nutrition-Veggie Corner-Broccoli and Watercress Are Rich Cancer Fighters 1994, P22
(9) Anon; Bone Mass, Cancer May be Linked 1997, P4D
(10) Anon; Breakthroughs In Cancer Research, Nathaniel Mead, Natural Health 1996
(11) Anon; Cabbages and Cancer 1995
(12) Anon; Carper, Jean, Foods That Fight Cancer, Reader's Digest 1994, P119
(13) Anon; Cut the Fat, Not the Protein! Food&Health, Organic Gardening 1996, P20
(14) Anon; Editors Desk-Novel Cancer Therapies Deserve a Fair Hearing 1994, P6
(15) Anon; Folic Acid 1994
(16) Anon; Garlic's Breath of Health, LEND 1995
(17) Anon; Gopher://gopher nih gov/00/clin/cdcs/67, kidney-Prevention and Treatment of Kidney Stones national Institute of Health Consensus Development Conference Statement 1988, P1
(18) Anon; Health & Healing, Tomorrow's Medicine Today 1994, V5(2)
(19) Anon; Health & Healing, Tomorrow's Medicine Today 1995, V5(5)
(20) Anon; Health & Healing, Tomorrow's Medicine Today 1995, V5(3)
(21) Anon; Health & Healing, Tomorrow's Medicine Today 1995, Supplement
(22) Anon; Houpis, Molina, Reamer, Lynch, Volante, and Reider, Towards the Synthesis of HIV-Protease Inhibitors Synthesis of Optically Pure 3-Carboxyl-decahydroisoquinolines, Tetrahedron Letter 1993, V34(16), P2593
(23) Anon; Journal National Cancer Institute 1993, 85
(24) Anon; Laurel Farms Believes that the Kombucha Tea Mushroom is a Gift from God P1

(25) Anon; Letters, Natural Health Beta-Carotene Debate Continues 1994
(26) Anon; Mood Foods, Food & Health, Organic Gardening 1996, P22
(27) Anon; More power to the people? AARP Bulletin 1995, V36(3)
(28) Anon; NIH Specification 11-133 Open Formula Rat and Mouse Ration 9NIH0-07 1986
(29) Anon; NIH Specification 11-137 Crude Protein Autoclavable (NIH-31) 1986
(30) Anon; Nau, Jean-Yves Preventing Spread of BSE, The Lancet 1994, V344, P808
(31) Anon; New Method Proposed to Determine Efficacy of Both Retinoids and Antioxidants in Preventing Cancer, Primary Care & Cancer 1996, P32
(32) Anon; News from the World of Medicine 1995, P147
(33) Anon; On the Cancer Front, News from the World of Medicine 1995, P127
(34) Anon; Oncology P1206
(35) Anon; Parade Magazine Special Intelligence Report, men Should Think Twice Before Eating Steak 1994, P16
(36) Anon; Perspective, The Antioxidant Nutrients, The Regulatory Nutrients 1995, P320
(37) Anon; Readers Digest, News from the World of Medicine Device Spots Colon Cancer & Indoor Tanning? 1994
(38) Anon; Reversing Bone Loss, News from the World of Medicine, American Heart Association 1995, P99
(39) Anon; Spring Valley Vitamins, nutritional facts on package label 1997
(40) Anon; Sunscreen:Slather It On, Do Fats Fuel Prostate Cancer? 1994
(41) Anon; The Merck Index, 11th Edition 1995, P1093
(42) Anon; The Merck Manual, Diagnosis and Therapy 1987, P2465
(43) Anon; The latest findings:Help for Headaches, Family circle 1995, P53
(44) Anon; http://www/mcs/net/.ltorsim.joyce/new,html, Essiac Tea From Canada Comes A Remedy Called Essiac 1995, P1
(45) Arif; US 5324443 1994 HCAPLUS
(46) Berkeley; Nutritional Protocol for HIV 1994, P1
(47) Berkely, B; Nutritional Protocol for HIV 1994
(48) Berkow; The Merck Manual of Diagnosis and Therapy, 15th Edition 1987, P70
(49) Berkow; The Merck Manual of Medical Information, Home Edition 1997, P789
(50) Biland; US 3542573 1970
(51) Bock, F; Journal of the National Cancer Institute, Carcinogenic Activity of Cigarette Smoke Condensate I Effect of Trauma & Remote X-Irriation 1959, V22(2), P401 MEDLINE
(52) Chem One Corporation; Product Data Sheet 1995
(53) Child; US 4760157 1988 HCAPLUS
(54) Chou; US 4285972 1981 HCAPLUS
(55) Chou; US 4340609 1982 HCAPLUS
(56) Chou; Kidney Stone Question and Answer, Family Circle Magazine 1995, P64
(57) Cope; US 5330972 1994 HCAPLUS
(58) Costello; US 5137722 1992
(59) Cowdry, E; Journal of the American Cancer Society, Combined Action of Cigarette Tar & Beta Radiation of Mice 1961, V14, P344 MEDLINE
(60) Davis; Lets Get Well 1972, P195
(61) Duke, J; Eat Your Weedies 1993, P31
(62) Duke, L; Weeds? or Wonder Drugs? 1994, P38
(63) Dyer; An Index of Tumor Chemotheraphy, NIH 1949, 2015, P10
(64) Dyer; An Index of Tumor Chemotherapy 1949, P1
(65) Ferguson, K; VA Hospital Fayetteville, AR Low Oxalate Diet
(66) Glum, G; gopher://wiretap/spies/com/oo/lLibrary/Finge/Pharm/essiac txt, Essiac:a natural herbal alternative cancer treatment 1993, P1
(67) Gould; US 4156067 1979 HCAPLUS
(68) Graves; US 5245095 1993 HCAPLUS
(69) Haigh; US 5310554 1994 HCAPLUS
(70) Hanson; US 4900746 1990 HCAPLUS
(71) Hart; The Relationship Between Oxalic Acid and Pyridoine:Treatment for Tumor Reduction 1994, P1
(72) Hirai; US 5455372 1995 HCAPLUS
(73) Hirsch; US 5292773 1994 HCAPLUS
(74) Hirsch; Organ Systems:Infectious Diseases 1996, P876
(75) Hodgkinson, A; Oxalic Acid in Biology and Medicine 1977, P1
(76) Hurley, J; Organic Gardening Articles, Calcium From the Garden 1986, P96
(77) Jawetz; Review of Medical Microbiology, 8th Edition 1968, P1
(78) Kim; US 5292511 1994

(79) Kotulak; The Chicago Tribune 1995, P127
(80) Lerner; US 5470874 1995 HCAPLUS
(81) Lundin; Health Physics, Mortality of Uranium Miners in Relation to Radiation Exposure, Hard-Rock Mining and Cigarette Smoking 1969, V16, P571
(82) Mangels, R; http://www/envirolink/org/arrs/VRG/calcium-.html, Calcium in the Vegan Diet 1991, P1
(83) Mattern, V; Don't Weed 'em, Eat 'em 1994, P71
(84) Mihelic; US 5401325 1995 HCAPLUS
(85) Mihelic; US 5401326 1995 HCAPLUS
(86) Ney, D; The Low Oxalate Diet Book for the Prevention of the Oxalate Kidney Stones 1981, P944
(87) Nichols; Over the Garden Gate, The Morning News 1996
(88) Occupational Health Services; msds on Oxalic Acid 1994
(89) Olin; US 5183674 1993
(90) Olin; US 5346707 1994
(91) Perricone; US 5376361 1994 HCAPLUS
(92) Raloff, J; Science News 1997, V151, P239
(93) Robbins, J; Diet for a New America Losing A War We Could Prevent 1987, P248
(94) Saltman; US 5151274 1992 HCAPLUS
(95) Smith, G; Toxification and Detoxification of Plant Compounds by Ruminants, an Overview, abstract only 1990
(96) Solaray Inc; CranActin the one that guarantees bacterial antiadherence properties 1996
(97) Stephens; US 3787589 1974
(98) Svendsen, L; Journal of Ethnopharmacology, Testing Garlic for Possible Anti-Ageing Effects on Long-term Growth Characteristics, Morphology and Macro Molecular Synthesis of Human Fibroblasts in Culture 1994, P125 MEDLINE
(99) Todd; US 5314686 1994 HCAPLUS
(100) U S Department Of Health & Human Services Public Health Service National Institutes Of Health; Eat More Fruits & Vegetables 1991
(101) Walser; US 5175144 1992 HCAPLUS
(102) Weil; Andrew Natural Health, Natural Medicine How Not to Get Cancer 1990, P169
(103) Wullschleger; US 5227248 1993

L229 ANSWER 2 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:139142 HCAPLUS
DN 132:185278
TI **Cosmetics** containing **moisturizers** and polymer **emulsifying** agents
IN Sato, Hiroyoshi; Yajima, Isao
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K007-02; A61K007-06; A61K007-035
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000063258	A2	20000229	JP 1998-250419	19980820

AB **Cosmetics** which show an excellent **moisturizing** activity, comprise (1) .gtoreq. 1 substances selected from the group consisting of collagens, elastins, keratins, vitamin E, and derivs. thereof and (2) **emulsifying** polymers. A **skin**-care **lotion** contained isooctyl myristate 5, squalane 5, cetostearyl alc. 2, **citric acid** 0.04, propylene glycol 11, methylparaben 0.3, Na hexametaphosphate 0.1, N,N-dimethylaminoethyl methacrylate-N-vinylpyrrolidone-stearyl acrylate-tripropylene glycol diacrylate copolymer 0.05, keratin 0.05, xanthan gum 0.1, and ion-exchanged water q.s. to 100 %.
ST **cosmetic emulsifier** aminoalkyl methacrylate copolymer

moisturizer
IT **Cosmetics**
(cleansing; **cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT Collagens, biological studies
Elastins
Keratins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT **Cosmetics**
(**creams**; **cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT **Cosmetics**
(**emulsions**; **cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT **Cosmetics**
(foundations, **emulsions**; **cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT **Cosmetics**
(**lotions**; **cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT 50-14-6, Vitamin D2 58-95-7, Vitamin E acetate 68-26-8, Retinol 94-44-0, Benzyl nicotinate 1406-18-4, Vitamin E 10191-41-0, dl-.alpha.-Tocopherol **146684-33-5**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)
IT 160364-67-0P
RL: BUU (Biological use, unclassified); IMF (Industrial manufacture); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**cosmetics** contg. **moisturizers** and polymer **emulsifying** agents)

L229 ANSWER 3 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:648765 HCAPLUS
DN 131:276780
TI **Skin** preparations containing keratin-softening agents and sequestering agents
IN Maruyama, Nao; Nishiyama, Seiji
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11279018	A2	19991012	JP 1998-102032	19980330.

AB The invention provides a **skin** prepns., e.g. anti-wrinkle **cosmetic**, contg. keratin-softening agent, e.g. an oxysterol, and a sequestering agent, e.g. edetate, citrate, and **ascorbate**, wherein the use of the sequestering agents improves stability of the keratin-softening agent in the prepn. A **skin cream** contg. 25-hydroxycholesterol 2, cetanol 0.5, vaseline 2, squalene 7, glycerin monostearate 2.5, polyoxyethylene sorbitan monostearate 1.5, pantothenyl Et ether 0.5, jojoba oil 5, propylene glycol 5, glycerin 5, montmorillonite 5, disodium edetate 0.05, **ascorbic acid** 0.05, KOH 0.3, and water q.s. to 100 % was prepd.
ST **cosmetic** oxysterol stability sequestering agent; edetate hydroxycholesterol antiwrinkle **cosmetic** stability

IT **Cosmetics**
(**creams**, wrinkle-preventing; **skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
(**creams**; **skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
(foundations; **skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
(lipsticks; **cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
(**lotions**; **skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
(packs; **skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
Sequestering agents
(**skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT Sodium polyphosphates
Sterols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **Cosmetics**
(wrinkle-preventing; **skin cosmetics** contg. keratin-softening agents and sequestering agents)
IT **50-81-7**, L-**Ascorbic acid**, biological studies
77-92-9, biological studies 139-33-3, Disodium edetate 150-38-9, Trisodium edetate **526-95-4**, **Gluconic acid** 561-63-7, 19-Hydroxy cholesterol 566-28-9, 7-Ketocholesterol 570-91-2, 6-Ketocholesterol 994-36-5, Sodium citrate 2140-46-7, 25-Hydroxy cholesterol 13095-61-9, 26-Hydroxy cholesterol 50921-59-0, 22-Oxocholesterol oxime 82048-76-8
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin cosmetics** contg. keratin-softening agents and sequestering agents)

L229 ANSWER 4 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:561584 HCAPLUS
DN 131:175090
TI **Topical compositions** containing lecithins and **moisturizers** for the treatment **skin disorders**
IN Crandall, Wilson Trafton
PA USA
SO U.S., 9 pp., Cont.-in-part of U.S. 5,639,740.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-685
ICS A61K031-23
NCL 514078000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): **62**
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5945409	A	19990831	US 1997-876764	19970616	<--
	US 5639740	A	19970617	US 1995-403241	19950310	<--
	AU 9725503	A1	19981020	AU 1997-25503	19970325	<--
	WO 9842309	A1	19981001	WO 1998-US5910	19980325	

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9867750 A1 19981020 AU 1998-67750 19980325
PRAI US 1995-403241 19950310 <--
WO 1997-US4985 19970325 <--
US 1997-876764 19970616
WO 1998-US5910 19980325

AB The present invention comprises methods and compns. for topically treating and **moisturizing** keratinous structures of humans and animals including **skin**, hair, fingernails, toenails, hooves, and horns. The compn. comprises water-**dispersible** lecithin and compds. selected from the group consisting of elastin, elastin fragments, elastin-**glycolic acid**, collagen, collagen fragments, yeast exts., **skin** respiratory factor, glucosamine, glucosamine sulfate, hyaluronic acid, hyaluronate, chondroitin sulfate, cholic acid, deoxycholic acid, ginseng ext., aloe vera powder, aloe vera oil, RNA and DNA fragments, ascorbyl palmitate, **ascorbic acid**, retinol palmitate, dehydroxycholesterol, vitamin E, vitamin E lineolate, panthenol Et ether, glycerol ceramides, glycogen, DL-pyroglutamic acid, urea, sodium lactate, lactate, glycerin, sorbitol, oils of borage, evening primrose, black currant, almond and canola, vanishing **cream**, cholesterol, flavonoids, witch hazel, chamomile, parsley, hibiscus, capric and caprylic triglycerides, amino acids, allantoin, sodium, calcium, potassium, phosphate, chloride, sodium lactate, alpha hydroxy acids, cocoa butter, coconut oil, jojoba oil, safflower oil, wheat germ oil, sesame oil, selachyl alc., shark oil, cerebrosides, proanthocyanidin, farnesol, candelilla, carnauba wax, vitamin E nicotinate, manganese **ascorbate**, zinc, oleyl alc., polysorbate 80, spermaceti, glycerol monostearate, beeswax, silicone oil, paraffin wax, ozokerite, and PEG 75 lanolin.

ST topical lecithin **moisturizer skin** disorder

IT Glycerides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(almond; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(borage seed; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(currant, Ribes nigrum seed; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Lanolin
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(evening primrose; topical compns. contg. lecithins and

moisturizers for treatment **skin** disorders)
IT Ginseng (Panax)
Yeast
(exts.; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT DNA
RNA
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fragments; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Drug delivery systems
(gels, topical; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT **Skin, disease**
(ichthyosis; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Drug delivery systems
(liposomes; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Drug delivery systems
(**lotions**; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT **Cosmetics**
(**moisturizers**; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT **Cosmetics**
(nail **lotions**; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Drug delivery systems
(**ointments**, **creams**; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Drug delivery systems
(**ointments**; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sesame; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(shark oil; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Waxes
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spermaceti; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Drug delivery systems
(sprays; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)
IT Aloe barbadensis
Beeswax
Chamomile
Eczema
Hair preparations
Hibiscus
Ozocerite

Parsley (Petroselinum crispum)
Psoriasis
Witch hazel
(topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Amino acids, biological studies
Candelilla wax
Canola oil
Carnauba wax
Ceramides
Cerebrosides
Cocoa butter
Coconut oil
Collagens, biological studies
Elastins
Flavonoids
Jojoba oil
Lanolin
Lecithins
Paraffin waxes, biological studies
Polysiloxanes, biological studies
Proanthocyanidins
Safflower oil
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Drug delivery systems
(topical, micelles; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wheat germ; topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

IT **50-21-5**, biological studies 50-70-4, Sorbitol, biological studies **50-81-7**, L-**Ascorbic acid**, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 57-13-6, Urea, biological studies 57-88-5, Cholesterol, biological studies 64-17-5, Ethanol, biological studies 69-72-7, biological studies 72-17-3, Sodium lactate **77-92-9**, biological studies **79-14-1**, biological studies 79-81-2, Retinol palmitate 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 97-59-6, Allantoin 110-27-0, Isopropyl myristate 111-02-4, Squalene 124-06-1, Ethyl myristate 137-66-6, Ascorbyl palmitate 142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 149-87-1, DL-Pyroglutamic acid 593-31-7, Selachyl alcohol 667-83-4 1406-18-4, Vitamin E 3079-28-5, N-Decylmethyl sulfoxide 3416-24-8, Glucosamine 4602-84-0, Farnesol 5333-42-6 9004-61-9, Hyaluronic acid 9005-65-6, Polysorbate 80 9005-79-2, Glycogen,, biological studies 9006-65-9, Dimethicone 9007-28-7, Chondroitin sulfate 16351-10-3 29031-19-4, Glucosamine sulfate. 31566-31-1, Glycerol monostearate 36148-84-2, Vitamin E linoleate 43119-47-7, Vitamin E nicotinate, 106392-12-5, Poloxamer 407
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. contg. lecithins and **moisturizers** for treatment **skin** disorders)

RE.CNT 15
RE
(1) Anon; Merck Index, (9th Edition) 1976, P711
(2) Catz; US 5238933 1993 HCAPLUS
(3) Crandall; US 5639740 1997 HCAPLUS
(4) Elias; The Journal of Investigative Dermatology 1979, V73, P339 HCAPLUS
(5) Fawzi; US 4783450 1988 HCAPLUS
(6) Grate; US 3062721 1962
(7) Loucks; US 4701471 1987 HCAPLUS

(8) Luisi; Colloid & Polymer Science 1990, V268, P356 HCAPLUS
(9) Oleniacz; US 3957971 1976 HCAPLUS
(10) Sakai; US 4760096 1988 HCAPLUS
(11) Scartazzini; Journal of Physical Chemistry 1988, V92, P829 HCAPLUS
(12) Schmolka; Journal of Biomedical Material Research 1972, V6, P571 HCAPLUS
(13) Smith; US 3952099 1976 HCAPLUS
(14) Tosti; US 4981681 1991 HCAPLUS
(15) Williman; Journal of Pharmaceutical Sciences 1992, V81(9), P871

L229 ANSWER 5 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:439233 HCAPLUS
DN 131:92343
TI **Skin cream** composition containing fatty acid esters
IN Mausner, Jack
PA Chanel, Inc., USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-48
NCL 424401000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5922331	A	19990713	US 1997-824524	19970326 <--

AB An improved **skin cream** compn. according to the present invention provides protection against lumpiness, edema, and other effects of liposuction and **cosmetic** surgery, as well as increasing the smoothness of the **skin**. In general, a **skin cream** compn. according to the present invention comprises: water, and **emulsified** and **dispersed** in the water: (1) a long-chain fatty acid ester of **ascorbic acid**; (2) a short-chain carboxylic acid ester of tocopherol; (3) a glyceryl ester complex comprising at least one glyceryl ester selected from the group consisting of glyceryl linoleate, glyceryl linolenate, and glyceryl arachidonate; (4) a first complex consisting essentially of water, propylene glycol, lecithin, caffeine benzoate, and palmitoyl carnitine; (5) a second complex consisting essentially of water, caffeine, carnitine, and hydrolyzed glycosaminoglycans; (6) a third complex consisting essentially of glycerol, butcher broom ext., passion flower ext., glycogen, hydrolyzed collagen, and PEG 6-32; (7) calendula ext.; (8) a water-glycol ext. of chamomile; (9) hydrophilic microcapsules; (10) lipophilic microcapsules; and (11) microcapsules comprising methylsilanol elastinate. Other, optional **cosmetic** ingredients and ancillary ingredients can also be used. Formulation of a **cream** contg. above ingredients is disclosed.

ST **skin cream** fatty acid ester

IT Tocopherols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(butanoic and propanoic acid esters; **skin cream** compn. contg. fatty acid esters)

IT **Cosmetics**
(**creams**; **skin cream** compn. contg. fatty acid esters)

IT Tocopherols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters; **skin cream** compn. contg. fatty acid esters)

IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ethoxylated; **skin cream** compn. contg. fatty acid esters)

IT Passionflower (Passiflora)
(ext., **skin cream** compn. contg. fatty acid esters)
IT Chamomile
Ruscus aculeatus
(ext.; **skin cream** compn. contg. fatty acid esters)
IT Calendula
(hydrolyzed; **skin cream** compn. contg. fatty acid esters)
IT Collagens, biological studies
Glycosaminoglycans, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydrolyzed; **skin cream** compn. contg. fatty acid esters)
IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(long-chain, esters; **skin cream** compn. contg. fatty acid esters)
IT Elastins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(methylsilanol derivs.; **skin cream** compn. contg. fatty acid esters)
IT Aloe barbadensis
Antioxidants
Emulsifying agents
Microcapsules
Odor and Odorous substances
Preservatives
Solvents
Thickening agents
(**skin cream** compn. contg. fatty acid esters)
IT Jojoba oil
Lecithins
Paraffin oils
Petrolatum
Phospholipids, biological studies
Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin cream** compn. contg. fatty acid esters)
IT **50-81-7D, Ascorbic acid;**, fatty acid ester
56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 56-86-0, Glutaminic acid, biological studies 56-87-1, Lysine, biological studies 57-10-3, Palmitic acid, biological studies 57-10-3D, Palmitic acid, esters 57-11-4, Octadecanoic acid, biological studies 57-11-4D, Stearic acid, esters 57-13-6, Urea, biological studies 57-50-1, Sucrose, biological studies 57-55-6, 1,2-Propanediol, biological studies 58-95-7, Tocopheryl acetate 69-65-8, Mannitol 70-26-8, Ornithine 71-00-1, Histidine, biological studies 72-17-3, Sodium lactate 72-19-5, Threonine, biological studies 74-79-3, L-Arginine, biological studies **77-92-9**, biological studies 79-09-4D, Propionic acid, esters with tocopherols 79-63-0, Lanosterol 98-79-3 99-76-3, Methylparaben 104-29-0, Chlorphenesin 107-21-1, 1,2-Ethanediol, biological studies 107-88-0, 1,3-Butylene glycol 107-92-6D, Butyric acid, esters with tocopherols 111-01-3, Squalane 121-79-9, Propyl gallate 122-87-2, Glycin 122-99-6, Phenoxyethanol 124-07-2, Octanoic acid, biological studies 143-07-7D, Lauric acid, esters 334-48-5, Capric acid 372-75-8, Citrulline 506-30-9, Arachidic acid 515-69-5, Bisabolol 538-23-8, Tricaprylin 544-63-8, Myristic acid, biological studies 621-70-5, Tricaproin 621-71-6, Tricaprin 1330-84-3 1398-61-4, Chitin 2364-67-2, Palmitoyl carnitine; 5743-17-9, Caffeine benzoate 7647-14-5, Sodium chloride, biological studies 9005-32-7, Alginic acid

9005-79-2, Glycogen, biological studies 9006-65-9, Dimethicone 18089-54-8D, Methylsilanol, elastin derivs. 24937-16-4, Nylon 12 25322-68-3 25395-66-8, Ascorbyl stearate 27475-47-4, Ascorbyl myristate 28874-51-3 34513-50-3, Octyldodecanol 36653-82-4, Cetyl alcohol 37348-65-5, Glyceryl linoleate 39236-46-9 72123-35-4 82785-49-7, Glyceryl linolenate 131257-12-0D, Carbomer 430, preneutralized 229473-34-1, Glyceryl arachidonate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin cream** compn. contg. fatty acid esters)

RE.CNT 36
RE
(1) Abber; US 4460371 1984 HCAPLUS
(2) Arraudeau; US 4820510 1989 HCAPLUS
(3) Arraudeau; US 5053220 1991 HCAPLUS
(4) Beck; US 5034226 1991
(5) Coopersmith; US 4125549 1978 HCAPLUS
(6) Deckner; US 4481186 1984 HCAPLUS
(7) Fellow; US 4752496 1988 HCAPLUS
(8) Fellows; US 4925667 1990 HCAPLUS
(9) Goodman; US 4883659 1989 HCAPLUS
(10) Gueyne; US 4927952 1990 HCAPLUS
(11) Gueyne; US 5037803 1991 HCAPLUS
(12) Jones; US 5116607 1992
(13) Kan; US 3864275 1975
(14) Kigasawa; US 4952560 1990 HCAPLUS
(15) Matsunaga; US 4369037 1983 HCAPLUS
(16) Mausner; US 5093109 1992 HCAPLUS
(17) Mausner; US 5204105 1993 HCAPLUS
(18) Mausner; US 5215759 1993 HCAPLUS
(19) Mausner; US 5254331 1993 HCAPLUS
(20) Mausner; US 5352441 1994 HCAPLUS
(21) Mausner; US 5391373 1995
(22) Mausner; US 5571503 1996 HCAPLUS
(23) Minetti; US 4758599 1988 HCAPLUS
(24) Murui; US 4423031 1983 HCAPLUS
(25) Nakane; US 5182103 1993 HCAPLUS
(26) Ootsu; US 4400295 1983 HCAPLUS
(27) Papantoniou; US 3911105 1975 HCAPLUS
(28) Qunanian; US 4988502 1991 HCAPLUS
(29) Robertson; US 5053221 1991
(30) Seguin; US 4549990 1985 HCAPLUS
(31) Shah; US 4980155 1990 HCAPLUS
(32) Shepherd; US 3697643 1972
(33) Suzuki; US 5061481 1991 HCAPLUS
(34) Tietjen; US 4574082 1986 HCAPLUS
(35) Vanlerberghe; US 3966398 1976 HCAPLUS
(36) Vanlerberghe; US 4247411 1981 HCAPLUS

L229 ANSWER 6 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:253707 HCAPLUS
DN 130:329024
TI W/O-type **cosmetic emulsions**
IN Nanba, Tomiyuki; Takahashi, Hideki; Takada, Sadaki; Uenuma, Mikiko
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11106310	A2	19990420	JP 1997-282832	19970930

OS MARPAT 130:329024
AB W/O-type **cosmetic emulsions** showing **emulsion** stability comprise silylated polysaccharides, silicone oils, water and substances selected from glutamate, glycine, sodium chloride, L-**ascorbic acid**-2-**glucoside** and **citric acid** salts. A **cream** contained decamethylcyclopentasiloxane 10.5, dimethylpolysiloxane 4.0, petrolatum 5.0, squalane 1.0, vitamin E acetate 0.01, silylated polysaccharides 2.0, sodium glutamate 5.0, preservatives 0.2, ethanol 17.0 and purified water to 100 wt.%.
ST **cosmetic emulsion** silylated polysaccharide silicone oil
IT Foundations (**cosmetics**)
Skin creams
Stability
Sunscreens
Water-in-oil **emulsions**
(W/O-type **cosmetic emulsions**)
IT Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process); USES (Uses)
(W/O-type **cosmetic emulsions**)
IT Polysaccharides, biological studies
RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process); USES (Uses)
(silylated; W/O-type **cosmetic emulsions**)
IT 56-40-6, Glycine, biological studies 68-04-2, Sodium citrate 142-47-2, Sodium glutamate 541-02-6, Decamethylcyclopentasiloxane 556-67-2, Octamethylcyclotetrasiloxane 7732-18-5, Water, biological studies 9004-57-3D, Ethyl cellulose, reaction products with tristrimethylsiloxysilylpropyl glycidyl ether 9005-12-3D, Methylphenyl siloxane, phenyl-modified 9016-00-6, Dimethylpolysiloxane 9057-02-7D, Pullulan, reaction products with tristrimethylsiloxysilylpropylisocyanate 25357-82-8D, reaction products with pullulan 71224-92-5D, reaction products with Et cellulose 129499-78-1, L-**Ascorbic acid** 2-**glucoside**
RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process); USES (Uses)
(W/O-type **cosmetic emulsions**)

L229 ANSWER 7 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:205210 HCAPLUS
DN 130:242155
TI Functional oxygenated composition containing phospholipids and fluorocarbons
IN Zastrow, Leonhard; Golz, Karin; Stanzl, Klaus
PA Lancaster Group G.m.b.H., Germany
SO U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 596,095, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K009-133
ICS A61K035-72; A61K035-74
NCL 424074000
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5885564	A	19990323	US 1997-877040	19970617 <--
	DE 4327679	A1	19950216	DE 1993-4327679	19930813 <--
PRAI	DE 1993-4327679	19930813 <--			
	US 1996-596095	19960507 <--			

AB The invention provides a **skin**-care prepn. which contains phospholipids, oxygen-loaded fluorocarbons, nutrients, active and/or protective substances. The proportion of fluorocarbon lies in the 0.2 to

100% by wt./vol. range. The lipid fraction contains 30-99 % phosphatidylcholines in the form of asym. lamellar aggregates. The compn. also contains a product obtained by gentle disintegration of **suspensions** or **dispersions** of cells of plants, bacteria or yeasts by ultrasonic and/or high-pressure homogenization under up to 25 MPa; and a **cosmetic** or **dermatol.** carrier suitable for use on the **skin.** This compn. is based for its oxygen content on the synergy between fluorocarbons and the disintegration products. An aq. phospholipid soln. was homogenized with a high purity fluorocarbon mixt. (90% perfluorodecalin and 10% perfluorodibutylmethylamine, crit. soly. temp. 26.degree.) to give an aggregate **dispersion.** An **emulsion** contained the above fluorocarbon aggregates 0.1, yeast exts. 0.1, perfumes 0.3, C12-15 alkyl benzoate 3.5, Steareth-2 3, Steareth-21 1.9, caprylic/capric glyceride PEG ester 2.5, acrylate copolymer 0.4, triethanolamine 0.4, jojoba oil 1.5, Babassu oil 1, vitamin E 0.5, preservatives 0.3, and distd. water q.s. to 100 %.

ST topical oxygenated compn phospholipid fluorocarbon

IT Perfluorocarbons
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C6-9; functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)

IT Chamomile
Cosmetic emulsions
Ointments (drug delivery systems)
Skin cleansers
(functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)

IT Enzymes, biological studies
Fluoro hydrocarbons
Hormones (animal), biological studies
Nucleic acids
Phosphatidylcholines, biological studies
Phospholipids, biological studies
Proteins (general), biological studies
Vitamins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)

IT Aloe barbadensis
Bacteria (Eubacteria)
Bark
Cereal (grain)
Green algae (Chlorophyta)
Mimosa tenuiflora
Plant (Embryophyta)
Yeast
(homogenized; functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)

IT Vegetable
(seeds, homogenized; functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)

IT **50-21-5, Lactic acid.**, biological studies
50-81-7, Vitamin C, biological studies
77-92-9, Citric acid, biological studies
87-69-4, Tartaric acid 110-15-6, Succinic acid, biological studies 110-17-8, Fumaric acid, biological studies 306-94-5, Perfluorodecalin 311-89-7, Perfluorotributylamine 423-55-2, Perfluorooctylbromide 514-03-4, Perfluorodibutylmethylamine
526-95-4, Gluconic acid 1340-08-5, Vitamin P 1406-18-4, Vitamin E **6915-15-7, Malic acid** 9003-99-0, Peroxidase 11103-57-4, Vitamin A 12001-76-2, Vitamin B 26446-59-3, PerfluoroButyltetrahydrofuran
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)
IT 7782-44-7, Oxygen, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transported in phospholipid fluorocarbon aggregates; functional oxygenated topical compns. contg. phospholipids and fluorocarbons and biol. substances)
RE.CNT 5
RE
(1) Anon; DE 4127442 1993 HCAPLUS
(2) Fructus; US 5576064 1996 HCAPLUS
(3) Huffstuttler; US 5466455 1995
(4) Parnell; US 5015474 1991 HCAPLUS
(5) Spearmon; US 4861593 1989

L229 ANSWER 8 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1999:175586 HCAPLUS
DN 130:200763
TI Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous **penetration** enhancers
IN Perricone, Nicholas V.
PA USA
SO U.S., 8 pp., Cont.-in-part of U.S. 5,643,586.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-48
NCL 424401000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5879690	A	19990309	US 1997-851222	19970505 <--
	US 5643586	A	19970701	US 1995-525977	19950907 <--
	WO 9850014	A1	19981112	WO 1998-US9106	19980504
	W: BR, CA, GB, IL, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	GB 2339536	A1	20000202	GB 1999-25341	19980504
	EP 989845	A1	20000405	EP 1998-920978	19980504
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9809212	A	20000627	BR 1998-9212	19980504
	JP 2000514837	T2	20001107	JP 1998-548365	19980504
PRAI	US 1995-525977	19950907 <--			
	US 1995-435944	19950427 <--			
	US 1997-851222	19970505			
	WO 1998-US9106	19980504			

AB Compns. for the topical treatment of sagging s.c. muscle and overlying cutaneous tissue contain an active ingredient exhibiting or producing catecholamine activity such as catecholamines and/or related compds. in a **dermatol**. acceptable carrier that contains at least one percutaneous penetration enhancer. Exemplary catecholamines include adrenaline, norepinephrine, dopamine and their precursors; catecholamine precursors such as tyrosine and phenylalanine are preferred. Many embodiments, particularly those employing tyrosine and/or phenylalanine as a catecholamine precursor, further contain a neurotransmitter synthesis enhancer such as dimethylaminoethanol, and other co-factors such as vitamin B6 and **pantothenic acid** or calcium pantothenate are included in the compn. to enhance the action of the active ingredients. Other compds. that scavenge free radicals and antioxidants may also be added (no data).
ST topical catecholamine muscle tissue penetration enhancer
IT Hydrocolloids

(patches; topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Radicals, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(scavengers; topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Neurotransmitters
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis enhancer; topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Absorption
Antiaging **cosmetics**
Antioxidants
Electroporation
Iontophoresis
Moisturizers (**cosmetics**)
Permeation enhancers
Sound and Ultrasound
Surfactants
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Catecholamines, biological studies
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Alcohols, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Alkanes, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Amides, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Amines, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Esters, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Fatty acids, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Polyhydric alcohols
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT Sulfoxides
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c.

muscle tissue using percutaneous penetration enhancers)
IT Terpenes, biological studies
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-43-4, Adrenaline 51-61-6, Dopamine, biological studies 51-67-2, Tyramine 59-92-7, Dopa, biological studies 60-18-4, Tyrosine, biological studies 63-91-2, Phenylalanine, biological studies 65-23-6, Pyridoxine **79-83-4, Pantothenic acid** 108-01-0, Dimethylaminoethanol 137-08-6, Calcium pantothenate 299-42-3, Ephedrine 300-62-9, Amphetamine 8059-24-3, Vitamin B6 17528-72-2, Tetrahydrobiopterin
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
IT **50-81-7D, Ascorbic acid**, satd. fatty acid esters 57-13-6, Urea, biological studies 112-80-1, Oleic acid, biological studies 137-66-6, Ascorbyl palmitate 6829-55-6, Tocotrienol 12619-70-4, Cyclodextrin
RL: BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(topical administration of catecholamines and related compds. to s.c. muscle tissue using percutaneous penetration enhancers)
RE.CNT 7
RE
(1) Meisner; US 4590067 1986 HCAPLUS
(2) Meisner; US 4647453 1987 HCAPLUS
(3) Meisner; US 4772591 1988 HCAPLUS
(4) Perricone; US 5376361 1994 HCAPLUS
(5) Perricone; US 5554647 1996 HCAPLUS
(6) Schinitsky; US 4938969 1990 HCAPLUS
(7) Smith, E; Percutaneous Penetration Enhancers 1995, P1

L229 ANSWER 9 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:677809 HCAPLUS
DN 129:280778
TI Compositions for external use for prevention of **environmental stress**
IN **Egawa, Mariko; Sakamoto, Tetsuo; Kohno, Yoshiyuki**
PA **Shiseido** Co., Ltd., Japan
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-48; A61K031-195; A61K031-235; A61K031-375
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843597	A1	19981008	WO 1998-JP1420	19980330 <--
	W: KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 10330244	A2	19981215	JP 1998-96755	19980325 <--
	EP 914815	A1	19990512	EP 1998-911080	19980330 <--
	R: DE, ES, FR, GB, IT, NL				

PRAI JP 1997-95307 19970330 <--
WO 1998-JP1420 19980330
AB A topical compn. for prevention of **environmental stress**, comprises at least one member selected from among **sulfo amino acids**, metabolic intermediates of the **sulfo amino acids, tannin**, and

vitamin C. In this compn., the **sulfo amino acid** is **glutathione** and the metabolic intermediates are **thiotaurine** or **hypotaurine.** Further, the compn. may contain a **hydroxy carboxylic acid.** The compn. is suitable particularly for removing **stress** having an adverse effect on the **skin** among **stresses** created by **airborne** fine particles. A **lotion** contained tocopherol acetate 0.01, glycerin 4, 1,3-butylene glycol 4, **thiotaurine** 0.1, ethanol 7, polyoxyethylene oleyl ether 0.5, methylparaben 0.2, **citric acid** 0.05, Na citrate 0.1, perfumes 0.05, and distd. water to 100 %.

ST antioxidant **sulfo amino acid** **cosmetic; environmental stress skin** **lotion thiotaurine**

IT **Airborne** particles
Antioxidants
Cosmetic packs
Lotions (**cosmetics**)
Skin creams
(**cosmetics** contg. antioxidants for prevention of **environmental stress**)

IT **Hydroxy carboxylic acids**
Tannins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. antioxidants for prevention of **environmental stress**)

IT **Stress** (animal)
(on **skin; cosmetics** contg. antioxidants for prevention of **environmental stress**)

IT Foundations (**cosmetics**)
(powders; **cosmetics** contg. antioxidants for prevention of **environmental stress**)

IT **Amino acids,** biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**sulfo; cosmetics** contg. antioxidants for prevention of **environmental stress**)

IT **50-81-7, Vitamin C,** biological studies
70-18-8, Glutathione, biological studies
300-84-5, Hypotaurine. 2937-54-4, Thiotaurine
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. antioxidants for prevention of **environmental stress**)

L229 ANSWER 10 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:672448 HCAPLUS
DN 129:280777
TI Topical **moisturizing** composition containing water-**dispersible** lecithin
IN Crandall, Wilson T.
PA USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K007-06
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9842309	A1	19981001	WO 1998-US5910	19980325

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

	AU 9725503	A1	19981020	AU 1997-25503	19970325 <--
	US 5945409	A	19990831	US 1997-876764	19970616 <--
	AU 9867750	A1	19981020	AU 1998-67750	19980325
PRAI	US 1997-876764	19970616			
	US 1995-403241	19950310	<--		
	WO 1997-US4985	19970325	<--		
	WO 1998-US5910	19980325			

AB Methods and compns. for topically treating and **moisturizing** keratinous structures of humans and animals including **skin**, hair, fingernails, toenails, hooves and horns are disclosed. The methods and compns. comprise applying to the keratinous tissue a water-**dispersible** lecithin. A soln. of 20 g soy lecithin in 20 mL iso-Pr palmitate was mixed with 2 mL of almond oil and 80 mL of 20% Pluronic soln. to obtain a gel. The **moisturizing** effect of the gel on the **skin** of volunteers was studied.

ST topical **moisturizer** lecithin **cosmetic** hair fingernail

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(almond; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Fats and Glyceridic oils, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(aloe vera; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Vegetable oils
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(borage seed; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Essential oils
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(chamomile; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Lanolin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ethoxylated; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Ginseng (Panax)
Yeast
(ext.; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT DNA
RNA
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fragments; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Ceramides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(glycerol; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Fish oils
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(shark oil; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Waxes
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(spermaceti; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT **Cosmetics**
(sprays; topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Antibacterial agents
Antimicrobial agents
Antiviral agents
Beeswax
Cosmetic gels
Fungicides
Hair preparations
Liposomes (**cosmetics**)
Lotions (**cosmetics**)
Nail (anatomical)
Ozocerite
Protozoacides
Skin creams
Solvents
(topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT Amino acids, biological studies
Carboxylic acids, biological studies
Carnauba wax
Cerebrosides
Cocoa butter
Coconut oil
Collagens, biological studies
Elastins
Evening primrose oil
Flavonoids
Glycerides, biological studies
Jojoba oil
Lanolin
Lecithins
Paraffin waxes, biological studies
Polysiloxanes, biological studies
Proanthocyanidins
Safflower oil
Sesame oil
Tocopherols
Wheat germ oil
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT **50-21-5**, **Lactic acid**, biological studies
50-70-4, Sorbitol, biological studies **50-81-7**, **Ascorbic acid**, biological studies 56-81-5, Glycerol, biological studies 57-13-6, Urea, biological studies 57-88-5, Cholesterol, biological studies 69-72-7, Salicylic acid, biological studies 72-17-3, Sodium lactate **77-92-9**, **Citric acid**, biological studies **79-14-1**, **Glycolic acid**, biological studies 79-81-2, Retinol palmitate 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 97-59-6, Allantoin 111-02-4, Squalene 137-66-6, Ascorbyl palmitate 143-28-2, Oleyl alcohol 149-87-1, DL-Pyroglutamic acid 434-16-2, 7-Dehydrocholesterol 593-31-7, Selachyl alcohol 1406-18-4, Vitamin e 3416-24-8, Glucosamine 4602-84-0, Farnesol 9004-61-9, Hyaluronic acid 9005-65-6, Polysorbate 80 9005-79-2, Glycogen, biological studies 9006-65-9, Dimethicone 9007-28-7, Chondroitin sulfate 10527-68-1 16351-10-3 29031-19-4, Glucosamine

sulfate 31566-31-1, Glycerol monostearate 36148-84-2, Vitamin e linoleate 43119-47-7, Vitamin e nicotinate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical **moisturizing** compn. contg. water-**dispersible** lecithin)

IT 3079-28-5, N-Decylmethyl sulfoxide 106392-12-5, Poloxamer 407
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(topical **moisturizing** compn. contg. water-**dispersible** lecithin)

L229 ANSWER 11 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:672445 HCAPLUS
DN 129:293690
TI **Cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores
IN Crotty, Brian Andrew; Miner, Philip Edward; Johnson, Anthony William; Znaiden, Alexander Paul; Corey, Joseph Michael; Vargas, Anthony; Meyers, Alan Joel; Lange, Beth Anne
PA Unilever PLC, UK; UNILEVER N.V.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 38
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9842303	A1	19981001	WO 1998-EP1423	19980310	<--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	US 5968537	A	19991019	US 1997-904712	19970801	
	AU 9868308	A1	19981020	AU 1998-68308	19980310	<--
	EP 969806	A1	20000112	EP 1998-913708	19980310	<--
	R: AT, CH, DE, ES, FR, GB, IT, LI, SE, IE					
	BR 9808272	A	20000516	BR 1998-8272	19980310	<--
	US 6174536	B1	20010116	US 1999-236163	19990122	<--
PRAI	US 1997-39378	19970320	<--			
	US 1998-72355	19980123				
	US 1997-904712	19970801				
	WO 1998-EP1423	19980310				

AB A **cosmetic** product is provided for delivery of **skin** actives through adhesive strips which concurrently remove keratotic plugs from **skin** pores. The product is a strip including a flexible substrate sheet onto which a compn. contg. an adhesive polymer is deposited. The compn. is essentially a polymer of anionic, cationic, nonionic, amphoteric or zwitterionic variety which increases in tackiness upon being wetted, with wetting occurring just prior to application onto the **skin** thereby enhancing the compn.'s adhesivity.
Skin agents delivered through the adhesive strip include vitamins, herbal exts., alpha- and beta-**hydroxycarboxylic acids**, ceramides, anti-inflammatories, antimicrobials, vasoconstrictors, zinc salts and mixts. thereof. The strips are sealably enclosed within a pouch for purposes of **moisture** protection. Poly(Me vinyl ether-maleic anhydride) (Gantrez S97) was coated on PGI 5255 rayon and dried at 75.degree. and cut into small patches. The patches were applied to the faces of panelists in an area contg. several plugged pores. The patches

were allowed to dry, then peeled off to show 90-100% of plugs were removed.
ST **cosmetic** polymer keratotic plug **skin** remover
IT Anti-inflammatory drugs
Antimicrobial agents
Vasoconstrictors
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT Keratins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT Ceramides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT **Hydroxy carboxylic acids**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT Polymers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT Vitamins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT Polyester fibers, biological studies
Polypropene fibers, biological studies
Rayon, biological studies
RL: BUU (Biological use, unclassified); DEV (Device component use); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT Herb
(exts.; **cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT **50-81-7, Ascorbic acid**, biological studies
124-68-5, 2-Amino-2-methyl-1-propanol 137-66-6, Ascorbyl palmitate 490-83-5, Dehydroascorbic acid 1406-18-4, Vitamin e 7440-66-6D, Zinc, salts 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8, Polyvinyl pyrrolidone 9004-53-9, Dextrin 9011-16-9, Poly(methyl vinyl ether-maleic anhydride) 11103-57-4, Vitamin a 12001-76-2, Vitamin b 25395-66-8, L-Ascorbyl stearate 29061-67-4 38599-26-7 75537-01-8, Gantrez s 97 167973-55-9, Vitazyme c
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)
IT 214121-64-9, Veratec 9408810
RL: BUU (Biological use, unclassified); DEV (Device component use); BIOL (Biological study); USES (Uses)
(**cosmetic** product comprising polymers for removing keratotic plugs from **skin** pores)

L229 ANSWER 12 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:479389 HCAPLUS
DN 129:99841
TI Gel compositions containing gellants in the form of alkyl amides of tri-carboxylic acids
IN Guskey, Gerald John; Swaile, David Frederick

PA Procter & Gamble Co., USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-32
ICS A61K007-027; A61K007-48; C11D003-32; C07C233-18
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827948	A1	19980702	WO 1997-US22953	19971205 <--
	W: AU, BR, CA, CN, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6190673	B1	20010220	US 1996-771090	19961220 <--
	AU 9857003	A1	19980717	AU 1998-57003	19971205 <--
	EP 952812	A1	19991103	EP 1997-953202	19971205 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1245421	A	20000223	CN 1997-181570	19971205 <--
	BR 9714163	A	20000425	BR 1997-14163	19971205 <--
PRAI	US 1996-771090	19961220 <--			
	WO 1997-US22953	19971205			

OS MARPAT 129:99841
AB The present invention relates to gel compns. comprising alkyl amides of tri-basic carboxylic acids and methods of making gel compns. In particular, the present invention relates to select compns. in the form of gels that provide improved residue characteristics and efficacy performance. A **cosmetic** gel contained cyclomethicone 72, octyldodecanol 18, and 1,2,3-propanetributylamide 10%.
ST antiperspirant gellant amide hydroxystearate
IT Soaps
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(bars; gelling agents for improved gel stability and/or hardness)
IT Aloe barbadensis
Cosmetic gels
Gelation agents
Lipsticks
Makeups
Moisturizers (**cosmetics**)
Skin creams
Yeast
(gelling agents for improved gel stability and/or hardness)
IT Amides, biological studies
Kaolin, biological studies
Lanolin
Petrolatum
Tannins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(gelling agents for improved gel stability and/or hardness)
IT Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyether-, solvents; gelling agents for improved gel stability and/or hardness)
IT Polyethers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polysiloxane-, solvents; gelling agents for improved gel stability and/or hardness)
IT Fish oils
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(shark-liver oil; gelling agents for improved gel stability and/or hardness)

IT Paraffin oils
Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(solvents; gelling agents for improved gel stability and/or hardness)
IT **Cosmetics**
(sticks; gelling agents for improved gel stability and/or hardness)
IT 31807-55-3, Isododecane 34464-38-5, Isodecane 60908-77-2, Isohexadecane
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(anhyd. carriers; gelling agents for improved gel stability and/or hardness)
IT 56-81-5, 1,2,3-Propanetriol, biological studies **77-92-9D**, alkyl amides 97-59-6, Allantoin 99-14-9D, Tricarballylic acid, alkyl amides 106-14-9 139-13-9D, Nitrilotriacetic acid, alkyl amides 141-23-1, Methyl 12-hydroxystearate 144-55-8, Sodium bicarbonate, biological studies 499-12-7D, Aconitic acid, alkyl amides 505-95-3 506-13-8 557-34-6, Zinc acetate 1304-85-4, Bismuth subnitrate 1314-13-2, Zinc oxide, biological studies 3397-16-8D, N-Stearoylglutamic acid, alkyl and alkylamine derivs. 3397-65-7D, N-Lauroylglutamic acid, alkyl and alkylamide derivs. 3486-35-9, Zinc carbonate 7059-49-6, 12-Hydroxystearamide 7354-07-6 7704-34-9, Sulfur, biological studies 8011-96-9, Calamine 9005-25-8, Starch, biological studies 9006-65-9, Dimethicone 10043-35-3, Boric acid (H3BO3), biological studies 16169-46-3 16170-20-0 17449-63-7 21645-51-2, Aluminum hydroxide, biological studies 36826-83-2, Stearyl 12-hydroxystearate 74815-67-1 89332-54-7 109570-04-9D, alkyl and alkylamine derivs. 133849-08-8D, alkyl and alkylamine derivs. 166527-38-4 166527-39-5 166527-40-8 166527-41-9 166527-42-0 209805-26-5 209805-27-6 209805-28-7
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(gelling agents for improved gel stability and/or hardness)

L229 ANSWER 13 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:457162 HCAPLUS
DN 129:113305
TI Antiaging **cosmetics** containing tocopherol ascorbic phosphoric diester
IN Tokue, Wataru; Ito, Kenzo; Tominaga, Naoki
PA **Shiseido** Co., Ltd., Japan
SO U.S., 6 pp. Cont.-in-part of U. S. Ser. No. 371,484, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-42
ICS A61K031-66
NCL 424059000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5776438	A	19980707	US 1996-645681	19960514 <--
PRAI US 1992-854624	19920626 <--			
US 1995-371484	19950111 <--			

AB An external prepn. contg. DL-.alpha.-tocopherol 2-L-ascorbic phosphoric diester (I) and/or a salt thereof, and at least one UV absorbing agent is disclosed. The crosslinking of collagen is suppressed and an excellent cutaneous aging resisting effect is obtained. A **lotion** contained I 0.05, sodium 2-hydroxy 4-methoxybenzophenone-5-sulfonate 0.1, tocopherol acetate 0.01, glycerin 4.0, 1,3-butylene glycol 4.0, ethanol 8.0, polyoxyethylene (60) hardened castor oil 0.5, Me para-hydroxybenzoate 0.2, **citric acid** 0.05, sodium citrate 0.1, perfume 0.05, and water q.s. 100%. The antiaging effect of the **lotion** is shown in the mice.
ST antiaging **cosmetic** tocopherol ascorbic phosphoric diester

IT Antiaging **cosmetics**
Cosmetics
Lotions (cosmetics)
Skin creams
(antiaging **cosmetics** contg. tocopherol ascorbic phosphoric diester)
IT **Cosmetics**
(foams; antiaging **cosmetics** contg. tocopherol ascorbic phosphoric diester)
IT 131-57-7, 2-Hydroxy-4-methoxy-benzophenone 21245-02-3 70356-09-1, 4-tert-Butyl-4'-methoxy-dibenzoylmethane 96436-87-2 **146614-91-7** 209978-89-2
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging **cosmetics** contg. tocopherol ascorbic phosphoric diester)

L229 ANSWER 14 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:385476 HCAPLUS
DN 129:58791
TI Stabilized **ascorbic acid** compositions containing solvents and **penetration** enhancer
IN Perricone, Nicholas V.; Potini, Chim
PA Perricone, Nicholas V., USA
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A01N043-08
ICS A61K031-34
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): **62**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9823152	A1	19980604	WO 1997-US20900	19971117 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6162419	A	20001219	US 1996-756461	19961126 <--
EP 944310	A1	19990929	EP 1997-947537	19971117 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRAI US 1996-756461 19961126 <--
WO 1997-US20900 19971117
AB Fatty acid esters of **ascorbic acid**, particularly satd. fatty acid esters such as ascorbyl palmitate, their salts, **ascorbic acid** and its salts are solubilized in large amts., e.g., up to about 25 % by wt., and stabilized using special solvent systems. Useful solvents include polyethylene glycol, ethoxydiglycol, propylene glycol, butylene glycol, propylene carbonate, glycerin, a capric glyceride, a caprylic glyceride, an alkyl lactate, an alkyl adipate, an isosorbide, and mixts. thereof. Preferred **dermatol.** compns. made using these solvents with **ascorbic acid** and/or at least one of its derivs. also include dimethylaminoethanol, tyrosine, proline, **cystine**, a penetration enhancer such as oleic acid, urea or mixts. thereof, and at least 1 natural and/or chem. antioxidant. Natural antioxidants that contain at least about 50 % polyphenols and 50 % catachins such as grape seed or green tea exts. are employed in some embodiments. Thus, a **cream** contained ascorbyl palmitate 5.00, L-tyrosine 5.00, urea 3.50, propylene glycol 3.00, glyceryl monostearate 3.00, myristyl myristate 2.00, DMAE 2.00, PEG-20 stearate 0.60, zinc sulfate 0.50, pentithiene 0.50, Germaben-11E 0.50, xanthan gum 0.40, TiO2 0.25, disodium-EDTA 0.25, vitamin E linoleate 0.20, and water qs to 100.0%.
ST **ascorbic acid** stabilization topical
IT Antioxidants

Cosmetics
Skin creams
Topical drug delivery systems
(stabilized **ascorbic acid** compns. contg. solvents and penetration enhancer)

IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized **ascorbic acid** compns. contg. solvents and penetration enhancer)

IT 51-84-3, Acetylcholine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(precursors; stabilized **ascorbic acid** compns. contg. solvents and penetration enhancer)

IT **50-21-5D**, **Lactic acid**, alkyl esters
50-81-7D, **Ascorbic acid**, fatty acid esters or salts 56-45-1, L-Serine, biological studies 57-13-6, Urea, biological studies 60-18-4, L-Tyrosine, biological studies 62-49-7, Choline 106-19-4, Dipropyl adipate 108-01-0 108-32-7 111-90-0 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 124-07-2D, Caprylic acid, glycerides 141-43-5, biological studies 334-48-5D, Decanoic acid, glycerides 1421-89-2, Dimethylaminoethanol acetate 1854-30-4 6183-26-2 6283-92-7, Lauryl lactate 6938-94-9, Diisopropyl adipate 25265-75-2, Butylene glycol 25322-68-3 42131-28-2, Isostearyl lactate 51222-59-4 59686-69-0, Diisocetyl adipate 64296-33-9 185323-25-5 185323-27-7 208461-65-8 208534-73-0 208539-84-8
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilized **ascorbic acid** compns. contg. solvents and penetration enhancer)

L229 ANSWER 15 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:323122 HCAPLUS
DN 129:19525
TI Potentilla erecta extract in the **cosmetic** and pharmaceutical field
IN Bonte, Frederic; Dumas, Marc; Chaudagne, Catherine; Meybeck, Alain
PA LVMH Recherche, Fr.; Bonte, Frederic; Dumas, Marc; Chaudagne, Catherine; Meybeck, Alain
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM A61K007-48
ICS A61K007-06; A61K035-78
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9819664	A2	19980514	WO 1997-FR1988	19971106 <--
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2755367	A1	19980507	FR 1996-13585	19961107 <--
	EP 946138	A2	19991006	EP 1997-913260	19971106 <--
	R: DE, ES, FR, GB, IT				
PRAI	FR 1996-13585	19961107 <--			
	WO 1997-FR1988	19971106			

AB The invention concerns the use of an ext. of P. erecta in the **cosmetic** and pharmaceutical field, in particular in **dermatol**. It concerns more particularly all the applications seeking to reinforce the **dermo-epidermic** junction or to improve hair condition, by improving the synthesis of collagen VII by keratinocytes and/or fibroblasts. Particularly, these applications concern the strengthening of the **skin**, the redn. of wrinkles or hair care. The invention also concerns a novel method of cell culture, in

particular of human fibroblasts or keratinocytes, for promoting the formation of collagen VII. Thus, an antiaging **cosmetic** contained Potentilla ext.0.2, vitamin A palmitate 0.08, magnesium ascorbyl phosphate 2.0, wheat ceramides 0.3, and perfume qsp 100 g.

ST Potentilla ext **cosmetic** pharmaceutical

IT Glycols, uses
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(C2-6; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT **Hydroxy carboxylic acids**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C3-12; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT Antiaging **cosmetics**
Cosmetics
Epidermolysis bullosa
Hair **lotions**
Makeups
Powders (**cosmetics**)
Seborrhea
Skin
Sunscreens
Wrinkle-preventing **cosmetics**
(Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT Amino acids, biological studies
Ceramides
Cerebrosides
Phospholipids, biological studies
Retinoids
Tocopherols
Vitamins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT C1-4 alcohols
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT Collagens, biological studies
RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(VII; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT Flavonoids
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biflavonoids; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT Arctium lappa
Centella asiatica
Coleus
Commiphora mukul
Loquat (Eriobotrya japonica)
Potentilla recta
Pygeum africanum
Siegesbeckia orientalis
Tephrosia
(ext.; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT **Skin aging**
(wrinkles; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT **50-21-5, Lactic acid**, biological studies
50-81-7, Vitamin C, biological studies
50-81-7D, Vitamin C, derivs. 58-08-2,
Caffeine, biological studies 58-55-9, Theophylline, biological studies

68-26-8, Retinol 68-26-8D, Vitamin A, derivs. 69-89-6D, Xanthine, derivs. 72-19-5, Threonine, biological studies 74-79-3, L-Arginine, biological studies **77-92-9**, biological studies 79-81-2, Vitamin A palmitate 93-60-7, Methyl nicotinate 108-46-3, 1,3-Benzenediol, biological studies 372-75-8, Citrulline 464-92-6, Asiatic acid 481-49-2, Cepharanthine 1321-23-9, Chloroxylenol 5466-77-3, Parsol MCX 6805-41-0, Escin **6915-15-7**, **Malic acid** 13463-41-7, Zinc pyrithione 13463-67-7, Titanium oxide, biological studies 16830-15-2, Asiaticoside 18449-41-7, Madecassic acid 34540-22-2, Madecassoside 66575-29-9, Forskolin 108910-78-7, **Ascorbic acid**, phosphate, magnesium salt
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT 57-55-6, 1,2-Propanediol, uses 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 107-21-1, 1,2-Ethanediol, uses 110-63-4, 1,4-Butanediol, uses
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

IT 9081-34-9, 5.alpha.-Reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; Potentilla erecta ext. for **cosmetics** and pharmaceuticals)

L229 ANSWER 16 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:248467 HCAPLUS
DN 128:312728
TI Means and procedure for decolorization of hair and kits for coloring and decolorization of hair
IN Kunz, Manuela; Le Cruer, Dominique
PA Wella A.-G., Germany
SO Ger., 10 pp.
CODEN: GWXXAW
DT Patent
LA German
IC ICM A61K007-13
ICS A61K007-135; D06P001-19; D06P003-04; D06L003-10
CC 62-3 (Essential Oils and **Cosmetics**)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 19649242	C1	19980416	DE 1996-19649242	19961128	<--
	WO 9823247	A1	19980604	WO 1997-EP5457	19971004	<--
	W: BR, JP, US					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 877593	A1	19981118	EP 1997-912112	19971004	<--
	R: DE, ES, FR, GB, IT					
	BR 9707311	A	19990413	BR 1997-7311	19971004	<--
	JP 2000505162	T2	20000425	JP 1998-524177	19971004	<--
PRAI	DE 1996-19649242	19961128	<--			
	DE 1996-19649243	19961128	<--			
	WO 1997-EP5457	19971004				

AB A method is disclosed for non-oxidative coloring of hair and a means for decolorization of non-oxidatively colored hair, e.g., hair colored with a nitro dye.
ST hair nitro dye decolorization kit
IT Dyes
(aniline; decolorization of hair and kits for coloring and decolorization of hair)
IT **Cosmetic emulsions**
Cosmetic gels
Decolorizing agents
Skin creams
(decolorization of hair and kits for coloring and decolorization of hair)

IT Tablets (drug delivery systems)
(effervescent tablets; decolorization of hair and kits for coloring and decolorization of hair)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process); USES (Uses)
(**hydroxy**; decolorization of hair and kits for coloring and decolorization of hair)
IT Hair dyes
(non-oxidative; decolorization of hair and kits for coloring and decolorization of hair)
IT Effervescent materials
(pharmaceutical tablets; decolorization of hair and kits for coloring and decolorization of hair)
IT **50-21-5, Lactic acid**, biological studies
50-81-7, Ascorbic acid, biological studies
64-19-7, Acetic acid, biological studies 69-72-7, Salicylic acid, biological studies **70-18-8**, Reduced **glutathione**, biological studies **77-92-9, Citric acid**, biological studies **79-14-1, Glycolic acid**, biological studies **87-69-4, Tartaric acid**, biological studies 89-65-6, Isoascorbic acid **90-80-2**, **Gluconic acid** lactone 610-81-1, 4-Amino-3-nitrophenol 6358-09-4 **6915-15-7, Malic acid** 7664-38-2, Phosphoric acid, biological studies 29705-39-3 33229-34-4 84041-77-0
RL: BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process); USES (Uses)
(decolorization of hair and kits for coloring and decolorization of hair)

L229 ANSWER 17 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:198237 HCAPLUS
DN 128:208784
TI **Cosmetic** and/or **dermatological** acid composition containing poly(2-acrylamido-2-methylpropane sulfonic acid) crosslinked and neutralized to at least 90%
IN Dupuis, Christine; Hansenne, Isabelle; Maubru, Mireille; Sebillotte, Arnaud Laurence; Lorant, Raluca
PA L'Oreal S. A., Fr.
SO Fr. Demande, 19 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM A61K007-48
ICS A61K007-06; A61K007-02; A61K007-42; A61K007-16; A61K009-06; A61K047-32; A61K007-04
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 37, 38, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	FR 2750326	A1	19980102	FR 1996-8108	19960628	<--
	FR 2750326	B1	19980731			
	EP 815845	A1	19980107	EP 1997-401255	19970604	<--
	EP 815845	B1	20000126			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	AT 189117	E	20000215	AT 1997-401255	19970604	<--
	ES 2144831	T3	20000616	ES 1997-401255	19970604	<--
	JP 10067616	A2	19980310	JP 1997-170758	19970626	<--
	JP 2941234	B2	19990825			
	CA 2209430	AA	19971228	CA 1997-2209430	19970627	<--
	BR 9702539	A	19980929	BR 1997-2539	19970627	<--
PRAI	FR 1996-8108		19960628	<--		

AB **Cosmetic** and/or **dermatol**. compns. having an aq. acid medium contain .gtoreq.1 poly(2-acrylamido-2-methylpropanesulfonate) which

is crosslinked and .gtoreq.90% neutralized. The compns. are characterized in that the pH of the aq. medium .ltoreq.5 and preferably 1-4 and the polymer is crosslinked with .gtoreq.1 monomer having .gtoreq.2 olefinic double bonds. The compns. may be used in shampoos or hair-care products; hygienic products; **cosmetics**; sunscreens; non-therapeutic **cosmetics** for the **skin**, scalp, eyelashes, eyebrows, nails or mucus membranes; or non-therapeutic products for depigmentation of the face or body. The compns. may also be used to thicken or form gels for **dermatol. ointments**. Thus, 2-acrylamido-2-methylpropanesulfonic acid was polymd. and neutralized with NH3 and then crosslinked with trimethylolpropane triacrylate to give a neutralized crosslinked polymer having hydrodynamic radius 440 nm. The prepd. crosslinked polymer was used to prep. a thick, transparent stable gel sunscreen.

ST polyacrylamidomethylpropanesulfonate crosslinked neutralized **cosmetic dermatol** compn

IT Oral drug delivery systems
(buccal; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT Bath preparations
(douches; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT **Ointments** (drug delivery systems)
(gels; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**, active org. acid; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT Crosslinking
Crosslinking agents
(in prepn. of neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT Insect repellents
(mosquito; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT Antiaging **cosmetics**
Cosmetics
Hair preparations
Moisturizers (**cosmetics**)
Mouthwashes
Ointments (drug delivery systems)
Shampoos
Skin preparations (pharmaceutical)
Skin-lightening **cosmetics**
Sunscreens
(neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT Gels (drug delivery systems)
(**ointments**; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT **50-81-7, Ascorbic acid**, biological studies
65-85-0, Benzoic acid, biological studies 69-72-7D, Salicylic acid, derivs. **77-92-9, Citric acid**, biological studies **80-69-3, Tartronic acid**
87-69-4, Tartaric acid, biological studies
90-64-2, Mandelic acid 104-98-3, Urocanic acid 110-17-8, Fumaric acid,

biological studies 302-79-4D, Retinoic acid, derivs. 331-39-5
501-30-4, Kojic acid **526-95-4, Gluconic acid**
685-73-4, Galacturonic acid **828-01-3 6915-15-7,**
Malic acid 17812-24-7, Ribonic
acid 17941-34-3, Aleuritic acid 27503-81-7,
2-Phenylbenzimidazole-5-sulfonic acid 56039-58-8 92761-26-7
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active org. acid; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT 15625-89-5, Trimethylolpropane triacrylate
RL: MOA (Modifier or additive use); USES (Uses)
(crosslinking agent; neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

IT 201338-10-5P, 2-Acrylamido-2-methylpropanesulfonic acid-trimethylolpropane triacrylate copolymer ammonium salt
RL: BUU (Biological use, unclassified); IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(neutralized crosslinked poly(acrylamidomethylpropanesulfonate) for **cosmetic** and/or **dermatolog.** compns. in aq. acid medium)

L229 ANSWER 18 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1998:65788 HCAPLUS
DN 128:132271
TI **Skin moisturizing** and protective **cosmetic** compositions
IN Stork Nunes, Almir; Chitarra Souza, Simoni; Martins Matheus, Luiz Gustavo
PA Industria e Comercio de Cosmeticos Natura Ltda., Brazil; Stork Nunes, Almir; Chitarra Souza, Simoni; Martins Matheus, Luiz Gustavo
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 9801107	A1	19980115	WO 1997-BR25	19970704	<--
W: CA, MX, US					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
BR 9602991	A	19980428	BR 1996-2991	19960705	<--
CA 2231275	AA	19980115	CA 1997-2231275	19970704	<--
EP 859589	A1	19980826	EP 1997-935379	19970704	<--
R: ES, FR, GB, IT					

PRAI BR 1996-2991 19960705 <--
WO 1997-BR25 19970704

AB The present invention refers to **skin moisturizing** and protective **cosmetic** compns. against UV and IR radiation, comprising a new active components assocn., formulated with vehicles and additives. Specifically, these compns. contain an active component set comprising: (a) a phys. filter, constituted of coated titanium dioxide and/or titanium dioxide and mica, at 0.5-6.0 %; (b) a chem. filter, constituted of at least one component of the group constituted of octyl metoxycinnamate, Bu methoxy dibenzoyl methane, benzophenone 3, at 2.7-20.0 %; (c) an antiradicals agent, being this natural melanin, at 0.005-1.0 %; (d) a **moisturizing** agent, which can be assocd. with a complementary antiradical agent, at 0.1-2.0 %; (e) oligoelements, which can exhibit **moisturizing** action, at 0.5-5.0 %.

ST sunscreen **moisturizer** antioxidant combination

IT Flavonoids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)
(bioflavonoids; **skin moisturizing** and protective **cosmetic** compns.)
IT Vinyl polymers
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(carboxy-contg.; **skin moisturizing** and protective **cosmetic** compns.)
IT **Cosmetics**
(emollients; **skin moisturizing** and protective **cosmetic** compns.)
IT Seaweed
(exts.; **skin moisturizing** and protective **cosmetic** compns.)
IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lanolin; **skin moisturizing** and protective **cosmetic** compns.)
IT Antioxidants
Preservatives
Radical scavengers
Sequestering agents
Sunscreens
(**skin moisturizing** and protective **cosmetic** compns.)
IT Lactoferrins
Melanins
Mica-group minerals, biological studies
Paraffin oils
Polysiloxanes, biological studies
Vegetable oils
Waxes
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin moisturizing** and protective **cosmetic** compns.)
IT 50-00-0, Formaldehyde, biological studies **50-21-5D, Lactic acid**, esters **50-81-7, Ascorbic acid**, biological studies 52-51-7, 2-Bromo-2-nitropropane-1,3-diol 57-10-3D, Palmitic acid, esters 57-11-4D, Stearic acid, esters 60-00-4, EDTA, biological studies 60-33-3D, Linoleic acid, esters 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, esters 70-51-9, Deferrioxamine 112-80-1D, Oleic acid, esters 112-92-5, Octadecanol 119-61-9, Benzophenone, biological studies 122-99-6, Phenoxyethanol 128-37-0, BHT, biological studies 143-07-7D, Lauric acid, esters 143-28-2, Oleyl alcohol 153-18-4, Rutin 488-28-8, Rhamnitol 531-75-9, Esculin 661-19-8, Behenyl alcohol 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 4080-31-3, Quaternium 15 5466-77-3 9004-34-6D, Cellulose, derivs. 9005-25-8, Starch, biological studies 10191-41-0, dl-.alpha.-Tocopherol 13463-67-7, Titania, biological studies 25013-16-5, BHA 39236-46-9, Imidazolidinylurea 62076-18-0 78491-02-8, Diazolidinylurea 112725-59-4, Butyl methoxy dibenzoylmethane
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin moisturizing** and protective **cosmetic** compns.)

L229 ANSWER 19 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:809805 HCAPLUS
DN 128:93012
TI Topical composition containing natural herb extracts for the treatment of spider veins
IN Becker, Philip E.; Doepker, Mary Lou
PA Swedish Herbal Systems, Inc., USA

SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-00
NCL 424401000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5698206	A	19971216	US 1996-760981	19961205 <--

AB A compn. for topical application to the **skin** having an effective amt. of natural herbs placed in a carrier oil for use in combination with an oral **vitamin C** is disclosed. The compn. provides for treatment of surface vein disorders, namely spider and varicose veins, by rejuvenating the veins and assocd. vein valves providing normal blood transfer. A **lotion** contained water 63.80, mineral oil 4.00, sesame oil 2.50, sea kelp 0.8, soybean oil 4.40, alga ext. 1.90, stearic acid. 3.00, glyceryl stearate 5.00, PEG-100 cetyl alc. 0.5, panthenol 0.05, jojoba oil 0.30, Germaben II 0.50, triethanolamine 0.50, calendula oil 0.20, marigold ext. 0.60, chickweed ext. 0.80, **lactic acid** 2.50, carrot oil 0.02, niacin 0.02, niacin 0.02, propylene glycol 5.00, vitamin E 0.01, white willow ext. 0.8, arnica ext. 0.80, horse chestnut ext. 0.80, red clover ext. .80, and glidant/hydanthion 0.40%. When the **lotion** is gently rubbed into the **skin** it begins to reduce the size and coloration of the spider veins in 4 wk. Continuation of the **lotion** in a reduced amt. provides maintenance by helping to further reduce spider veins as well as inhibition the causation of new veins.

ST topical **cosmetic** herb ext spider vein

IT Chickweed
(ext.; topical compn. contg. natural herb exts. for treatment of spider veins)

IT Algae
Arnica
Clover (Trifolium pratense)
Herb
Horse chestnut (Aesculus)
Marigold
Willow (Salix)
(exts.; topical compn. contg. natural herb exts. for treatment of spider veins)

IT Calendula
Carrot
(oils; topical compn. contg. natural herb exts. for treatment of spider veins)

IT Vein
(spider; topical compn. contg. natural herb exts. for treatment of spider veins)

IT **Cosmetic** gels
Cosmetics
Lotions (cosmetics)
Seaweed
Skin creams
(topical compn. contg. natural herb exts. for treatment of spider veins)

IT Jojoba oil
Paraffin oils
Sesame oil
Soybean oil
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical compn. contg. natural herb exts. for treatment of spider veins)

IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);

BIOL (Biological study); USES (Uses)
(topical compn. contg. natural herb exts. for treatment of spider veins)
IT Venous diseases
(varicose vein; topical compn. contg. natural herb exts. for treatment of spider veins)
IT **50-21-5**, **Lactic acid**, biological studies
50-81-7, **Vitamin c**, biological studies
59-67-6, Niacin, biological studies 81-13-0, Panthenol 1406-18-4, Vitamin e
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical compn. contg. natural herb exts. for treatment of spider veins)
IT 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 102-71-6, Triethanolamine, biological studies 461-72-3, Hydantoin 11099-07-3, Glyceryl stearate 25322-68-3, Peg 36653-82-4, Cetyl alcohol
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(topical compn. contg. natural herb exts. for treatment of spider veins)

L229 ANSWER 20 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:754297 HCAPLUS
DN 128:53070
TI **Skin** preparations containing Tiliaceae plant extracts
IN Imahori, Atsuko
PA NOEVIR Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K035-78
ICS A61K007-00; A61K007-48; A61K031-20; A61K031-23; A61K031-70; A61K035-28; A61K035-50; A61K038-00; A61K038-22; A61K038-27
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09301880	A2	19971125	JP 1996-148052	19960517 <--

PI JP 09301880 A2 19971125 JP 1996-148052 19960517 <--
AB The **skin** prepns., useful for conditioning **skin**, preventing **skin** aging, and promoting wound healing, etc., contain Tiliaceae plant exts. and .gtoreq.1 selected from C2-22 .alpha.-**hydroxycarboxylic acid**, their salts, their derivs., vitamins, animal-derived bioactive substances, e.g. placenta ext., FGF, FGF, nucleic acids, etc., which are capable of activating cells. A **lotion** contg. .alpha.-hydroxyacetic acid and essential oils of Tilia cordata flower diminished age-related **skin** symptoms, e.g. wrinkle, elasticity, etc.
ST **skin** conditioner Tiliaceae plant ext; cell activator Tiliaceae plant ext **cosmetic**; **hydroxycarboxylate** Tiliaceae plant ext **skin** conditioner; vitamin Tiliaceae plant ext ski conditioner
IT Proteins (specific proteins and subclasses)
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(eggshell membrane; **skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT Placenta
Spleen
(exts.; **skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**,

vitamins, etc.)
IT **Carboxylic acids, biological studies**
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**, C2-22; **skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT Egg shell
(membrane, sol. proteins of; **skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT Anti-inflammatory drugs
Antiaging **cosmetics**
Linden (Tilia europaea)
Linden (Tilia grandifolia)
Linden (Tilia platyphyllos)
Linden (Tilia ulmifolia)
Skin conditioners
Tiliaceae
Topical drug delivery systems
Wound healing promoters
(**skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT Nucleic acids
Vitamins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT Linden (Tilia cordata)
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT **Cosmetics**
(wrinkle-preventing; **skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)
IT 50-14-6, Ergocalciferol **50-81-7**, **Vitamin C**, biological studies 58-85-5, Vitamin H 59-67-6, Nicotinic acid, biological studies 67-97-0, Cholecalciferol **79-14-1**, .alpha.-Hydroxyacetic acid, biological studies 83-88-5, Vitamin B2, biological studies 1340-08-5, Vitamin P 1406-16-2, Vitamin D 1406-18-4, Vitamin E 8059-24-3, Vitamin B6 11103-57-4, Vitamin A 62229-50-9, **Epidermal** growth factor 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 108910-78-7
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**skin** conditioners contg. Tiliaceae plant exts. and bioactive substances, e.g. .alpha.-**hydroxycarboxylates**, vitamins, etc.)

L229 ANSWER 21 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:743975 HCAPLUS
DN 127:362479
TI Foamable **cosmetic** mask product containing an effervescent agent and an acid
IN Davis, Jeffrey
PA Bristol-Myers Squibb Co., USA
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA English

IC ICM A61K007-48
ICS A61K007-50
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 806201	A2	19971112	EP 1997-303055	19970502 <--
EP 806201	A3	19981216		
R: DE, ES, FR, GB, IT, SE, IE				
US 5720949	A	19980224	US 1996-643814	19960506 <--
CA 2202735	AA	19971106	CA 1997-2202735	19970415 <--

PRAI US 1996-643814 19960506 <--

AB A **cosmetic** mask product is disclosed comprising first and second compns. for sequential application to the face of a consumer, one of said compn. contg. an effervescent agent and the other of said compn. contg. an acid component. A **cream** contained sodium bicarbonate 5.0, sodium Me cocoyl taurate 5.0, cetearyl alc. 3.5, glyceryl stearate 1.5, cetyl alc. 5.0, PEG-100 stearate 1.5, PEG-40 castor oil 1.5, essential oil 0.01, preservative 1.0, colors 0.4, xanthan gum 1.5, trisodium EDTA 0.2, and water q.s. 100%. A gel activator contained butylene glycol 78.0, hydroxyethyl Et cellulose 1.0, sodium hydroxide 2.0, **lactic acid** 9.1, and water q.s. 100%. The **cream** is applied on the face uniformly followed by application of the gel activator compn. over the **cream** and admixed into the **cream** by gentle massage. After about 10 min the mask is removed from the face and the face is washed.

ST **cosmetic** mask effervescent agent acid; bicarbonate lactate **cosmetic** mask foam

IT Sulfates, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alkyl derivs.; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT Fatty acid salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ammonium salts; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT Irritants
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(counter; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT Alkyl phenols
Fatty acids, biological studies
Fatty alcohols
Lanolin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(ethoxylated; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT **Cosmetics**
(face masks; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT Ethoxylated alcohols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fatty; foamable **cosmetic** mask product contg. effervescent agent and acid)

IT **Skin creams**
(foamable **cosmetic** mask product contg. effervescent agent and

acid)
IT Abrasives
Amphoteric surfactants
Anionic surfactants
Betaines
Biocides
Carbohydrates, biological studies
Chelating agents
Clays, biological studies
Cosmetic gels
Effervescent materials
Emulsifying agents
Fatty acid esters
Fatty alcohols
Gelation agents
Nonionic surfactants
Polyoxyalkylenes, biological studies
Sulfobetaines
Surfactants
Thickening agents
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(foamable **cosmetic** mask product contg. effervescent agent and acid)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy**; foamable **cosmetic** mask product contg. effervescent agent and acid)
IT **Acne**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitors; foamable **cosmetic** mask product contg. effervescent agent and acid)
IT Fatty acid salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(potassium salts; foamable **cosmetic** mask product contg. effervescent agent and acid)
IT Fatty acid salts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sodium salts; foamable **cosmetic** mask product contg. effervescent agent and acid)
IT **50-21-5**, biological studies **77-92-9**, biological studies
79-14-1, Glycolic acid, biological studies
87-69-4, Tartaric acid, biological studies
90-64-2, Mandelic acid 107-36-8D, Isethionic acid, fatty acid esters
107-97-1D, Sarcosin, fatty acyl derivs. 144-55-8, Carbonic acid monosodium salt, biological studies 298-14-6, Potassium bicarbonate
497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium carbonate 584-08-7, Potassium carbonate 1066-33-7, Ammonium bicarbonate 4316-74-9D, Sodium methyl taurate, cocoyl derivs.
6915-15-7, Malic acid 9004-34-6, Cellulose, biological studies 9004-58-4, Hydroxyethyl ethyl cellulose 11099-07-3, Glyceryl stearate 12441-09-7D, Sorbitan, ethoxylated esters
23522-05-6D, **Taurin**, fatty acid esters 25322-68-3
25322-68-3D, esters 106392-12-5, Polyoxyethylene polyoxypropylene block copolymer
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(foamable **cosmetic** mask product contg. effervescent agent and acid)

L229 ANSWER 22 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:731707 HCAPLUS

DN 128:16289
TI Compositions for external use
IN Kondo, Chiharu; Senoo, Masami
PA Kosei Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-00; A61K007-42; A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09291011	A2	19971111	JP 1996-127955	19960424 <--

AB Compns. [**cosmetics** or topical prepns.] for external use comprise: (A) apple exts. and (B) tyrosinase inhibitors, active oxygen scavengers, antioxidants, cell activators, antiinflammatories and/or **moisturizers**. A **skin**-care and antiaging **lotion** contained glycerin 5.0, 1,3-butylene glycol 6.5, POE sorbitan monolaurate 1.2, ethanol 8.0, apple exts. 0.01, superoxide dismutase 0.01, preservatives, perfumes, and purified water to 100 %.
ST **skin cosmetic** apple ext tyrosinase inhibitor; active oxygen scavenger apple ext **cosmetic**; antioxidant apple ext **cosmetic**; cell activator apple ext **cosmetic**; antiinflammatory **moisturizer** apple ext **cosmetic**
IT Animal cells
(activators; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT Apple
(exts.; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT Plant (Embryophyta)
(medicinal, exts.; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT **Cosmetics**
(packs; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT Anti-inflammatory drugs
Antiaging **cosmetics**
Antioxidants
Cosmetic emulsions
Cosmetic gels
Cosmetics
Lotions (**cosmetics**)
Moisturizers (**cosmetics**)
Ointments (drug delivery systems)
Skin cleansers
Skin creams
Topical drug delivery systems
(**skin**-care **cosmetics** contg. apple exts. and other substances)
IT Carotenes, biological studies
Collagens, biological studies
DNA
Elastins
Mucopolysaccharides, biological studies
Proteins (general), biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**skin**-care **cosmetics** contg. apple exts. and other substances)
IT Hair conditioners
(tonics; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT 7782-44-7, Oxygen, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active, scavengers; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT 9002-10-2, Tyrosinase
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; **skin**-care **cosmetics** contg. apple exts. and other substances)
IT 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-70-4, Sorbitol, biological studies **50-81-7**, **Vitamin c**, biological studies **52-90-4D**, **Cysteine**, derivs. 53-86-1, Indomethacin 56-65-5, Atp, biological studies 57-13-6, Urea, biological studies 57-88-5, Cholesterol, biological studies 60-32-2, .epsilon.-Aminocaproic acid 61-19-8, Amp, biological studies 61-68-7, Mefenamic acid 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-89-6, Xanthine **70-18-8**, **Glutathione**, biological studies 71-00-1, Histidine, biological studies 73-22-3, Tryptophan, biological studies 73-40-5, Guanine **79-14-1**, **Glycolic acid**, biological studies 87-89-8, myo-Inositol 97-59-6, Allantoin 98-79-3, Pyrrolidonecarboxylic acid 99-20-7 110-15-6, Butanedioic acid, biological studies 117-39-5, Quercetin 120-80-9, 1,2-Benzenediol, biological studies 123-31-9, Hydroquinone, biological studies 128-37-0, Bht, biological studies 149-91-7, Gallic acid, biological studies 463-40-1 471-53-4, Glycyrrhetinic acid 489-84-9, Guaiazulene 499-44-5, Hinokitiol 506-26-3, .gamma.-Linolenic acid 522-12-3, Quercitrin 635-65-4, Bilirubin, biological studies 1314-13-2, Zinc oxide, biological studies 1406-16-2, Vitamin d 1406-18-4, Vitamin e 7235-40-7, .beta.-Carotene 9004-61-9, Hyaluronic acid 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9050-30-0, Heparan sulfate 9054-89-1, Superoxide dismutase 9056-36-4, Keratan sulfate 10417-94-4, Eicosapentaenoic acid 11103-57-4, Vitamin a 12001-76-2, Vitamin b 15307-79-6, Diclofenac sodium salt 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 24967-94-0, **Dermatan** sulfate 25013-16-5, Bha 103000-77-7, Glycyrrhezinic acid 169799-44-4, Keratin
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**skin**-care **cosmetics** contg. apple exts. and other substances)

L229 ANSWER 23 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:666029 HCAPLUS
DN 127:298550
TI Rough **skin**-preventing and **skin**-lightening **cosmetics**
IN Tokue, Wataru; Ito, Kenzo
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-00; A61K007-42; A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09263514	A2	19971007	JP 1996-103894	19960329 <--

AB Rough **skin**-preventing and **skin**-lightening **cosmetics** comprise: (A) L-**ascorbic acid** or its derivs., hydroquinone **glycoside** or its derivs. and/or kojic acid or its derivs., (B) UV absorbers, and (C) .alpha.-hydroxy acids selected from **lactic acid, tartaric acid, citric acid, glycolic acid** and their salts. A **lotion** contained ethanol 5.0, POE oleyl ether 0.8, methylparaben 0.1, arbutin 2.0, **lactic acid** 0.5, Na hydroxymethoxybenzophenonesulfonate 1.0 and purified water to 100 parts.

ST **skin cosmetic ascorbate** hydroquinone **glycoside**

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy**; rough **skin**-preventing and **skin**-lightening **cosmetics**)

IT **Cosmetics**
(packs; rough **skin**-preventing and **skin**-lightening **cosmetics**)

IT **Cosmetic emulsions**
Lotions (**cosmetics**)
Skin creams
Skin-lightening **cosmetics**
UV stabilizers
(rough **skin**-preventing and **skin**-lightening **cosmetics**)

IT **Skin diseases**
(rough **skin**; rough **skin**-preventing and **skin**-lightening **cosmetics**)

IT **Cosmetics**
(**skin**; rough **skin**-preventing and **skin**-lightening **cosmetics**)

IT **50-21-5, Lactic acid**, biological studies
50-81-7, L-Ascorbic acid, biological studies
77-92-9, Citric acid, biological studies
79-14-1, Glycolic acid, biological studies
87-69-4, Tartaric acid, biological studies
123-31-9D, Hydroquinone, glycosides 501-30-4, Kojic acid 5466-77-3, 2-Ethylhexyl p-methoxycinnamate 6628-37-1, Sodium 5-Benzoyl-4-hydroxy-2-methoxy-Benzenesulfonate **37627-95-5, L-Ascorbic acid**-2-sulfate 70356-09-1 76840-16-9 108910-78-7, L-**Ascorbic acid** phosphate Magnesium salt
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(rough **skin**-preventing and **skin**-lightening **cosmetics**)

L229 ANSWER 24 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:616931 HCAPLUS
DN 127:267823
TI X-ray induced **skin** damage protective composition containing **glutathione** and a selenoamino acid
IN Hersh, Theodore; Warshaw, Michael A.
PA Thione International, Inc., USA
SO U.S., 9 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-48
NCL 424401000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5667791	A	19970916	US 1996-658105	19960531 <--
	US 5840681	A	19981124	US 1997-929397	19970915 <--

PRAI US 1996-658105 19960531 <--
AB A topical compn. contg. **glutathione** and a selenoamino acid in a carrier for reducing and repairing X-ray radiation-induced **skin** damage is disclosed. An **ointment** contained propylene glycol 1, vitamin B5 1, cholesterol 2.8, stearyl alc. 2.9, white wax 8, white petrolatum 83.46, **glutathione** 0.15, selenomethionine 0.03, acetyl L-carnitine hydrochloride 0.03, superoxide dismutase 0.03, and green tea 0.6%.
ST X ray **skin** damage selenoamino acid; **glutathione** X ray **skin** damage **ointment**
IT Tea products
(green, japanese; x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)
IT **Skin diseases**
(injury; x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)
IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(selenium derivs.; x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)
IT Injury
(**skin**; x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)
IT **Cosmetic emulsions**
Cosmetic gels
Lotions (**cosmetics**)
Skin creams
X-ray
(x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)
IT **50-81-7, Vitamin c**, biological studies
79-83-4, Vitamin b5 1406-18-4, Vitamin e 9054-89-1, Superoxide dismutase 11103-57-4, Vitamin a
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)
IT **70-18-8, Glutathione**, biological studies 1464-42-2, Selenomethionine 3040-38-8, Acetyl L-carnitine 5080-50-2, Acetyl L-carnitine hydrochloride
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(x-ray induced **skin** damage protective compn. contg. **glutathione** and selenoamino acid)

L229 ANSWER 25 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:590240 HCAPLUS
DN 127:225114
TI **Cosmetics** containing L-**ascorbic acid** phosphate magnesium salt and pionin
IN Shirano, Minoru; Karakida, Fumihito; Shigematsu, Masatsune; Kawasaki, Yoshimi
PA Tsumura and Co., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09227352	A2	19970902	JP 1996-61616	19960226 <--

PI
AB **Cosmetics** showing **skin**-lightening and antioxidant activities comprise L-**ascorbic acid phosphate**

magnesium salt 0.001-5.0 and pionin 0.00001-0.005 wt.%. A **cosmetic lotion** contained L-**ascorbic acid phosphate** magnesium salt 3.0, pionin 0.002, **citric acid** 0.005, 1,3-butylene glycol 5.0, Et p-hydroxybenzoate 0.25, POE oleate 1.0 and water to 100 parts.

ST **cosmetic ascorbic acid** phosphate magnesium pionin

IT Antioxidants
Lotions (**cosmetics**)
Skin-lightening **cosmetics**
(**cosmetics** contg. L-**ascorbic acid** phosphate magnesium salt and pionin)

IT 15763-48-1, Pionin 108910-78-7, L-**Ascorbic acid** phosphate magnesium salt
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. L-**ascorbic acid** phosphate magnesium salt and pionin)

L229 ANSWER 26 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:575486 HCAPLUS
DN 127:166783
TI Compositions for external use
IN Kondo, Chiharu; Takayama, Akemi; Senoo, Masaki; Takemoto, Hiroko
PA Kosei Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K007-06; A61K007-50
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): **62**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09183718	A2	19970715	JP 1995-353525	19951229 <--

AB Compns. for external use comprise: (A) phytic acid and/or its salts and (B) active oxygen scavengers, antioxidants, antiinflammatories, cell activators and/or **moisturizers**. **Ointments** and other dosage forms are formulated. **Cosmetic** formulations also are described.

ST external pharmaceutical dosage form phytic acid; **cosmetic** phytic acid

IT Animal cells
(activators; compns. for external use)

IT Anti-inflammatory drugs
Antioxidants
Chinese medicines
Cosmetics
Moisturizers (**cosmetics**)
Royal jelly
(compns. for external use)

IT Carotenes, biological studies
Collagens, biological studies
Elastins
Flavonoids
Proteins (general), biological studies
RNA
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for external use)

IT Drug delivery systems
(external; compns. for external use)

IT Bifidobacterium

Carrot
Cork tree (Phellodendron)
Ganoderma lucidum
Garlic (Allium sativum)
Lactic acid bacteria
Placenta
Rosemary
Swertia japonica
Yeast
(exts.; compns. for external use)

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**; compns. for external use)

IT Plant (Embryophyta)
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal, exts.; compns. for external use)

IT Natural products (pharmaceutical)
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toki and other exts.; compns. for external use)

IT 7782-44-7, Oxygen, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(active scavengers; compns. for external use)

IT 50-28-2, Estradiol, biological studies 50-28-2D, Estradiol, derivs. 50-33-9, Phenylbutazone, biological studies **50-81-7**, **Vitamin C**, biological studies **50-81-7D**, **Vitamin C**, derivs. 53-86-1, Indomethacin 56-65-5, ATP, biological studies 57-88-5, Cholesterol, biological studies 60-32-2 61-19-8, 5'-Adenylic acid, biological studies 61-19-8D, 5'-Adenylic acid, derivs. 61-68-7, Mefenamic acid 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-72-7D, Salicylic acid, derivs. 69-89-6D, Xanthine, derivs. **70-18-8**, **Glutathione**, biological studies **70-18-8D**, **Glutathione**, derivs. 71-00-1, Histidine, biological studies 73-22-3, Tryptophan, biological studies 73-40-5D, Guanine, derivs. **79-14-1**, **Glycolic acid**, biological studies **79-14-1D**, **Glycolic acid**, derivs. 83-86-3, Phytic acid 83-86-3D, Phytic acid, derivs. 97-59-6, Allantoin 110-15-6, Butanedioic acid, biological studies 110-15-6D, Butanedioic acid, derivs. 117-39-5, Quercetin 120-80-9, Catechin, biological studies 120-80-9D, Catechin, derivs. 123-31-9, 1,4-Benzenediol, biological studies 128-37-0, biological studies 149-91-7, Gallic acid, biological studies 149-91-7D, Gallic acid, derivs. 463-40-1 463-40-1D, derivs. 471-53-4, Glycyrrhetinic acid 481-49-2, Cepharantin 489-84-9, Guaiazulene 499-44-5, Hinokitiol 506-26-3, .gamma.-Linolenic acid 506-26-3D, .gamma.-Linolenic acid, derivs. 522-12-3, Quercitrin 635-65-4, Bilirubin, biological studies 1314-13-2, Zinc oxide, biological studies 1405-86-3, Glycyrrhizinic acid 1406-16-2D, Vitamin D, derivs. 1406-18-4, Vitamin E 1406-18-4D, Vitamin E, derivs. **6915-15-7**, **Malic acid 6915-15-7D**, **Malic acid**, derivs. 7235-40-7, .beta.-Carotene 9004-61-9, Hyaluronic acid 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9050-30-0, Heparan sulfate 9054-89-1, Superoxide dismutase 9056-36-4, Keratan sulfate 10417-94-4, Eicosapentaenoic acid 10417-94-4D, Eicosapentaenoic acid, derivs. 11103-57-4D, Vitamin A, derivs. 12001-76-2D, Vitamin B, derivs. 15307-79-6, Sodium diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 24967-94-0, **Dermatan** sulfate 25013-16-5, BHA 169799-44-4, Keratin
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for external use)

L229 ANSWER 27 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:571494 HCAPLUS
DN 127:180929
TI **Skin moisturizers** containing amine compounds, antioxidants, and amino acids
IN Nakajima, Atsushi; Fukuda, Masataka
PA Kao Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09175983	A2	19970708	JP 1995-343197	19951228 <--

OS MARPAT 127:180929
AB **Skin** prepns. which improve **skin** conditions and prevent aging, comprise (1) amine compds. with general formula R1XCH2CH(OH)CH2NR2CR3R4CR5R6(OH) [I; R1 =(hetero)hydrocarbyl; R2-R6 = H, (hetero)carbyl; X = O, COO], (2) antioxidants, and (3) amino acids. A **skin** essence contained I (R1= Me, R2 = CH2CH2OH, R3 - R6 = H, X= O) 0.1, ethoxylated hydrogenated castor oils 1, carotene 0.2, urea 1, .epsilon.-aminocaproic acid 0.3, Na2HPO4 0.75, **citric acid** 0.25, glycerol 10, ethanol 4, glycine 0.2, Carbopol-941 1.5, KOH 0.45, preservatives q.s., and distd. water to 100 %.
ST **skin moisturizer** amine antioxidant amino acid
IT Antiaging **cosmetics**
Antioxidants
Moisturizers (**cosmetics**)
(**skin moisturizers** contg. amine compds. and antioxidants and amino acids)
IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin moisturizers** contg. amine compds. and antioxidants and amino acids)
IT **50-81-7, Ascorbic acid**, biological studies
52-90-4, Cysteine, biological studies 54-12-6, Tryptophan 56-12-2, .gamma.-Aminobutyric acid, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-84-8, Asparaginic acid, biological studies 56-85-9, Glutamine, biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies 59-02-9, .alpha.-Tocopherol 70-47-3, Asparagine, biological studies 71-00-1, Histidine, biological studies 74-79-3, Arginine, biological studies 119-13-1, .delta.-Tocopherol 121-79-9, Propyl gallate 128-37-0, biological studies 148-03-8, .beta.-Tocopherol 432-70-2, .alpha.-Carotene 472-93-5, .gamma.-Carotene 1034-01-1, Octyl gallate 1166-52-5, Dodecyl gallate 7235-40-7, .beta.-Carotene 7616-22-0, .gamma.-Tocopherol 9001-05-2, Catalase 9001-48-3, **Glutathione** reductase 9013-66-5, **Glutathione** peroxidase 9054-89-1, Superoxide dismutase 25013-16-5 158314-48-8 163340-07-6 193982-22-8
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin moisturizers** contg. amine compds. and antioxidants and amino acids)

L229 ANSWER 28 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:534460 HCAPLUS
DN 127:135789
TI L-2-Oxothiazolidine-4-carboxylic acid derivatives and their use for **skin** care

IN Galey, Jean-Baptiste
PA Oreal S. A., Fr.
SO Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM C07D277-14
ICS A61K007-48
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **62**

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 780383	A1	19970625	EP 1996-402549	19961126 <--
R: DE, ES, FR, GB, IT				
FR 2742750	A1	19970627	FR 1995-15334	19951222 <--
FR 2742750	B1	19980130		
JP 09176138	A2	19970708	JP 1996-340211	19961219 <--
CN 1159447	A	19970917	CN 1996-123167	19961221 <--
US 6004543	A	19991221	US 1996-771836	19961223 <--
PRAI FR 1995-15334	19951222 <--			

OS MARPAT 127:135789
GI



I

AB Title compds. I [R1 = H, optionally branched, unsatd., or substituted C1-8 alkyl, optionally substituted benzyl; R2 = H, optionally branched, unsatd., or substituted C1-24 alkyl, optionally substituted arom. groups, optionally unsatd. heterocycles] are useful in **skin** care products. The compds. are precursors of **cysteine** and .alpha.-hydroxy acids, and are thereby useful for prevention or treatment of **skin** photo-aging, and for depigmentation of **skin** (no data). In particular, I [R1/R2 = Et/Me (II), Et/H, Et/Pr, Et/Ph, Et/dodecyl, PhCH2/Me] were prepd. by reaction of L-2-oxothiazolidine-4-carboxylic acid with corresponding .alpha.-bromo esters R2CHBrCO2R1 and K2CO3 in DMF at 90.degree.. A protective **cream** contained (by wt.) 1% II, 3% ethoxylated PEG 50, 3% diglyceryl monostearate, 24% vaseline, 5% cetyl alc., and water qsp. 100%.

ST oxothiazolidinecarboxylate ester prepn **skin** antiaging agent; photoaging **skin** oxothiazolidinecarboxylate hydroxy acid ester

IT **Carboxylic acids, preparation**
RL: PNU (Preparation, unclassified); PREP (Preparation)
(**hydroxy**, precursors of; prepn. of oxothiazolidinecarboxylic acid esters for **skin** care)

IT Antiaging **cosmetics**
Cosmetics
Skin
Skin aging
Skin-lightening **cosmetics**
(prepn. of oxothiazolidinecarboxylic acid esters for **skin** care)

IT **3374-22-9P, Cysteine**
RL: PNU (Preparation, unclassified); PREP (Preparation)
(precursors of; prepn. of oxothiazolidinecarboxylic acid esters for **skin** care)
IT 192932-50-6P, 2-Oxothiazolidine-4-carboxylic acid 1-(ethoxycarbonyl)ethyl ester 192932-52-8P, 2-Oxothiazolidine-4-carboxylic acid (ethoxycarbonyl)methyl ester 192932-54-0P, 2-Oxothiazolidine-4-carboxylic acid 1-(ethoxycarbonyl)butyl ester 192932-56-2P, 2-Oxothiazolidine-4-carboxylic acid (ethoxycarbonyl)phenylmethyl ester 192932-58-4P, 2-Oxothiazolidine-4-carboxylic acid 1-(ethoxycarbonyl)tridecyl ester 192932-60-8P, 2-Oxothiazolidine-4-carboxylic acid 1-[(benzyloxy)carbonyl]ethyl ester
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxothiazolidinecarboxylic acid esters for **skin** care)
IT 105-36-2, Ethyl bromoacetate 535-11-5, Ethyl 2-bromopropanoate 615-83-8, Ethyl 2-bromopentanoate 2882-19-1, Ethyl bromophenylacetate 3017-53-6, Benzyl 2-bromopropanoate 14980-92-8, Ethyl 2-bromotetradecanoate 19771-63-2, L-2-Oxothiazolidine-4-carboxylic acid
RL: RCT (Reactant)
(starting material; prepn. of oxothiazolidinecarboxylic acid esters for **skin** care)

L229 ANSWER 29 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:499089 HCAPLUS
DN 127:140210
TI **Cosmetic skin** cleanser based on natural active substances
IN Menzel, Anette; Macchio, Ralph; Stanzl, Klaus; Zastrow, Leonhard
PA Lancaster Group G.m.b.H., Germany; Menzel, Anette; Macchio, Ralph; Stanzl, Klaus; Zastrow, Leonhard
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61K007-50
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9725974	A1	19970724	WO 1997-DE117	19970117	<--
	W: CA, MX, US					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	DE 19603019	A1	19970807	DE 1996-19603019	19960117	<--
	DE 19603019	C2	19981015			
	CA 2240457	AA	19970724	CA 1997-2240457	19970117	<--
	EP 877597	A1	19981118	EP 1997-908122	19970117	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
	US 5993857	A	19991130	US 1998-91975	19980626	<--
PRAI	DE 1996-19603019	19960117	<--			
	WO 1997-DE117	19970117	<--			

AB A **cosmetic skin** cleanser based on natural active substances, with a particularly gentle and mild effect on the **skin**, consists of an aq., non-oily **suspension** consisting of: poly(oxymethylene-urea) microspheres (160-200 .mu.m diam.) carrying a liq. natural vegetable oil in their interior; naturally based agents for increasing water deposits on the **skin** selected from aloe vera gel, jojoba oil, cetearyl glucosides, Lipacide PVB, and mixts. thereof as well as propylene glycol, .gtoreq.1 natural **emulsifier**, natural substances having a cleansing effect, and further additives and carrier substances. On rubbing the compn. on the **skin**, the microspheres exert a mild abrasive action, removing dead cells from the **skin**;

the microspheres are ruptured during this process, releasing the oil contained therein. Thus, a cleanser was prepd. by successively mixing and homogenizing the following 8 phases: (A) cetearyl glucoside 5, hexyl laurate 7, beeswax 1, isononyl isononanoate 8, wheat proteins 0.3, and **vitamins C** and E 0.1; (B) D-**gluconic acid** 5, propylene glycol 2, triethanolamine 0.2, and water 42.1; (C) laureth-7/polyacrylamide/C13-14 isoparaffin 4; (D) preservative 0.8; (E) perfume 0.5; (F) decyl polyglucose 7; (G) aloe vera gel 1, deionized water 1; (H) polyethylene 11 wt.%, and combining with 4 wt.% poly(oxymethylene-urea) capsules contg. .apprx.65% jojoba oil.

ST vegetable oil microsphere **skin** cleanser

IT Alkyl glycosides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(C16-18; **cosmetic skin** cleanser based on natural active substances)

IT Antioxidants
Microspheres
Moisturizers (**cosmetics**)
Radical scavengers
Skin cleansers
(**cosmetic skin** cleanser based on natural active substances)

IT Jojoba oil
Proteins (general), biological studies
Vegetable oils
Vitamins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic skin** cleanser based on natural active substances)

IT Aloe barbadensis
(gel; **cosmetic skin** cleanser based on natural active substances)

IT Aminoplasts
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(microspheres; **cosmetic skin** cleanser based on natural active substances)

IT Wheat
(proteins of; **cosmetic skin** cleanser based on natural active substances)

IT **50-81-7**, **Vitamin C**, biological studies
1406-18-4, Vitamin E 53240-01-0, Decyl polyglucose 167139-92-6, Lipacide PVB
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic skin** cleanser based on natural active substances)

IT 57-55-6, 1,2-Propanediol, biological studies
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses)
(**cosmetic skin** cleanser based on natural active substances)

IT 9011-05-6, Urea/formaldehyde copolymer
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(microspheres; **cosmetic skin** cleanser based on natural active substances)

L229 ANSWER 30 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:491402 HCAPLUS
DN 127:99538
TI **Topical compositions**
IN Hoshino, Taku; Kondo, Chiharu; Senoo, Masami; Yamashita, Eiji
PA Kosei K. K., Japan; Itano Reito K. K.

SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K031-12
ICS A61K007-00; A61K007-48; A61K031-045; A61K031-07; A61K031-095; A61K031-19; A61K031-21; A61K031-35; A61K031-355; A61K031-375; A61K031-40; A61K031-415; A61K031-44; A61K031-51; A61K031-525; A61K031-575; A61K031-59; A61K031-70; A61K031-715
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09143063	A2	19970603	JP 1995-326241	19951122 <--

PI JP 09143063 A2 19970603 JP 1995-326241 19951122 <--
AB Topical compns. for **cosmetic** or therapeutic use comprise (A) astaxanthin and (B) active ingredients such as **moisturizers**, antioxidants and active oxygen removers. As an example, a **cosmetic emulsion** contained stearic acid 18.0, cetanol 4.0, triethanolamine 2.0, glycerin 5.0, astaxanthin 1.0, **lactic acid** 1.0, and purified water to 100%.
ST topical compn astaxanthin
IT Animal cells
Anti-inflammatory drugs
(activators; topical compns.)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**; topical compns.)
IT Plant (Embryophyta)
(medicinal; topical compns.)
IT Antioxidants
Cosmetics
Euphausia
Moisturizers (**cosmetics**)
Topical drug delivery systems
(topical compns.)
IT Collagens, biological studies
Elastins
Keratins
Mucopolysaccharides, biological studies
Natural products (pharmaceutical)
Nucleic acids
RNA
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns.)
IT 9002-10-2, Tyrosinase
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; topical compns.)
IT 472-61-7P
RL: BUU (Biological use, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(topical compns.)
IT **50-21-5, Lactic acid**, biological studies
50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazon, biological studies **50-81-7, Vitamin C**, biological studies 53-86-1, Indomethacine 56-65-5, ATP, biological studies 57-88-5, Cholesterol, biological studies 58-85-5, Biotin 60-32-2, .epsilon.-Aminocaproic acid 61-19-8, AMP, biological studies 61-68-7, Mefenamic acid 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-89-6, Xanthine 71-00-1, Histidine, biological studies 73-22-3, Tryptophan, biological studies 73-40-5, Guanine **77-92-9, Citric acid**, biological studies

79-14-1, Glycolic acid, biological studies
97-59-6, Allantoin 110-15-6, Succinic acid, biological studies
117-39-5, Quercetin 123-31-9, Hydroquinone, biological studies
128-37-0, BHT, biological studies 149-91-7, Gallic acid, biological studies 463-40-1, .alpha.-Linolenic acid 471-53-4, Glycyrrhetinic acid
481-49-2, Cepharanthin 489-84-9, Guaiazulene 506-26-3, .gamma.-Linolenic acid 522-12-3, Quercitrin 564-73-8, Hinokiol
635-65-4, Bilirubin, biological studies 1314-13-2, Zinc oxide, biological studies 1405-86-3, Glycyrrhizic acid 1406-16-2, Vitamin D
1406-18-4, Vitamin E **6915-15-7, Malic acid**
7782-44-7, Oxygen, biological studies 9004-61-9, Hyaluronic acid
9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate
9054-89-1, Superoxide dismutase 9056-36-4, Keratan sulfate 11103-57-4, Vitamin A 12001-76-2, Vitamin B 15307-79-6, Sodium diclofenac
15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 24967-94-0, **Dermatan** sulfate 25013-16-5, BHA 25378-27-2, Eicosapentaenoic acid
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns.)

L229 ANSWER 31 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:433153 HCAPLUS
DN 127:55657
TI Collagenase inhibitors containing dicarboxylic acids
IN Sakaki, Sachiko; Masaki, Hitoshi
PA Noevir K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K031-19
ICS A61K031-19; C12N009-99
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 1, 7, 17, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09124472	A2	19970513	JP 1995-303897	19951027 <--

AB Collagenase inhibitors contain .gtoreq.1 dicarboxylic acids. The inhibitors preferably contain chelating agents. The inhibitors are useful for treatment of aging- and UV-induced **skin** disorders, osteoporosis, corneal ulcer, rheumatoid arthritis, osteoarthritis, etc., and promote wound healing. Azelaic acid (I) inhibited collagenase activity. A **cream** contg. I, 1,10-decamethylenedicarboxylic acid, and **ascorbic acid** promoted healing from surfactant-induced ulcer formed on the back of mice.
ST dicarboxylic acid collagenase inhibitor; chelating agent dicarboxylic acid collagenase inhibitor
IT Antiaging **cosmetics**
Chelating agents
Health food
Wound healing promoters
(collagenase inhibitors contg. dicarboxylic acids and optional chelating agents)
IT Sodium polyphosphates
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(collagenase inhibitors contg. dicarboxylic acids and optional chelating agents)
IT **50-81-7, Ascorbic acid**, biological studies
70-51-9, Deferoxamine **77-92-9, Citric acid**, biological studies 110-15-6, Succinic acid, biological studies
110-94-1, Glutaric acid 111-16-0, Pimelic acid 111-20-6, Sebacic acid, biological studies 123-99-9, Azelaic acid, biological studies
124-04-9, Adipic acid, biological studies 139-33-3 505-48-6, Suberic

acid **526-95-4, Gluconic acid** 693-23-2, Dodecanedioic acid 1852-04-6, Undecanedioic acid 50813-16-6, Sodium Metaphosphate
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(collagenase inhibitors contg. dicarboxylic acids and optional chelating agents)
IT 9001-12-1, Collagenase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(collagenase inhibitors contg. dicarboxylic acids and optional chelating agents)

L229 ANSWER 32 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:383489 HCAPLUS
DN 127:23560
TI Antiaging **cosmetics** containing aminoethyl compounds and alga extracts
IN Tominaga, Naoki
PA **Shiseido** Co., Ltd., Japan; Sogo Yatsuko K. K.
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-00; A61K007-48; A61K031-185; A61K035-80
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 11
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09095415	A2	19970408	JP 1995-276830	19950929 <--

AB Antiaging **cosmetics** contain aminoethyl compds. such as 2-aminoethylsulfonic acid and 2-aminoethylsulfinic acid in combination with alga exts. to inhibit **skin** collagen crosslinking. A **skin lotion** contained 2-aminoethylsulfonic acid 0.05, alga exts. 1.0, tocopherol acetate 0.01, glycerin 4.0, 1,3-butylene glycol 4.0, ethanol 4.0, ethoxylated hardened castor oil 0.5, methylparaben 0.2, **citric acid** 0.05, Na citrate 0.1, perfumes 0.05, and purified water to 100 wt.%.
ST antiaging **cosmetic** aminoethyl compd alga ext
IT Algae
Antiaging **cosmetics**
(antiaging **cosmetics** contg. aminoethyl compds. and alga exts.)
IT Seaweed
(exts.; antiaging **cosmetics** contg. aminoethyl compds. and alga exts.)
IT **107-35-7**, 2-Aminoethylsulfonic acid **300-84-5**, 2-Aminoethylsulfinic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging **cosmetics** contg. aminoethyl compds. and alga exts.)

L229 ANSWER 33 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:383488 HCAPLUS
DN 127:23559
TI Antiaging **cosmetics** containing aminoethyl compounds and tea extracts
IN Tominaga, Naoki
PA **Shiseido** Co., Ltd., Japan; Sogo Yatsuko K. K.
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00

ICS A61K007-00; A61K007-48; A61K031-185; A61K035-78
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 11
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09095414	A2	19970408	JP 1995-276829	19950929 <--

AB Antiaging **cosmetics** contain aminoethyl compds. such as 2-aminoethylsulfonic acid and 2-aminoethylsulfinic acid in combination with tea exts. to inhibit **skin** collagen crosslinking. A **skin lotion** contained 2-aminoethylsulfonic acid 0.05, tea exts. 1.0, tocopherol acetate 0.01, glycerin 4.0, 1,3-butylene glycol 4.0, ethanol 4.0, ethoxylated hardened castor oil 0.5, methylparaben 0.2, **citric acid** 0.05, Na citrate 0.1, perfumes 0.05, and purified water to 100 wt.%.
ST antiaging **cosmetic** aminoethyl compd tea ext
IT Antiaging **cosmetics**
Tea products
(antiaging **cosmetics** contg. aminoethyl compds. and tea exts.)
IT Seaweed
(exts.; antiaging **cosmetics** contg. aminoethyl compds. and alga exts.)
IT **107-35-7**, 2-Aminoethylsulfonic acid **300-84-5**, 2-Aminoethylsulfinic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging **cosmetics** contg. aminoethyl compds. and tea exts.)

L229 ANSWER 34 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:361733 HCAPLUS
DN 126:334215
TI **Skin** and hair **cosmetic** compositions containing amides for improving water retention
IN Nakajima, Atsushi; Fukuda, Masataka; Morita, Takeshi; Uesaka, Toshio; Sadahiro, Tomoko
PA Kao Corporation, Japan; Nakajima, Atsushi; Fukuda, Masataka; Morita, Takeshi; Uesaka, Toshio; Sadahiro, Tomoko
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K007-06
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9714401	A1	19970424	WO 1996-JP2982	19961015 <--
W: CN, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 09110667	A2	19970428	JP 1995-267422	19951016 <--
JP 09165313	A2	19970624	JP 1995-327224	19951215 <--
JP 09208442	A2	19970812	JP 1996-13917	19960130 <--
EP 805674	A1	19971112	EP 1996-933648	19961015 <--
R: DE, FR, GB				

PRAI JP 1995-267422 19951016 <--
JP 1995-327224 19951215 <--
JP 1996-13917 19960130 <--
WO 1996-JP2982 19961015 <--
OS MARPAT 126:334215
AB **Cosmetic** compns. comprising .gtoreq.1 amide HOCH2CH(OH)CH2OCH(CH2OR1)CH2N(R3R4)C(O)R2 [I; R1, R2 = C1-40 (hydroxylated) hydrocarbyl; R3 = C1-6 alkylene, single bond; R4 = H, C1-12 alkoxy, HOCH2CH(OH)CH2O] or related compds. and .gtoreq.1 ingredient selected from polyhydric alcs., vegetable exts., and org. acids or salts thereof can enhance the water-retaining ability of the horny layer,

decrease **skin** roughness, and prevent the formation of wrinkles. Thus, an oil-in-water-type **moisturizing lotion** contained I [R1 = C16H33, R2 = C13H27, R3 = (CH2)3, R4 = OMe] 3.0, cholesterol 0.5, 1-(2-hydroxyethylamino)-3-isostearyloxy-2-propanol 0.2, 2-(2-hydroxyethoxy)ethylguanidine 0.5, cetyl alc. 1.0, Vaseline 2.0, squalane 5.0, dimethylpolysiloxane 2.0, glycerol 4.0, 1,3-propanediol 2.0, PEG-20 sorbitan monooleate 0.5, sorbitan monostearate 0.3, tuberose acid polysaccharide 5.0, cholesteryl mono-n-hexadecenyl succinate 1.0, stearyl glycyrrhetinate 1.0, tocopherol 1.0, succinic acid 0.55, NaH2PO4 0.9, Carbopol 940 0.15, KOH 0.045, and water to 100.0%.

ST amide polyol **skin** humectant

IT Catalpa
(Japanese, ext.; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Polianthes
(acidic heteropolysaccharide of callus of; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Alkyl glycosides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alkoxylated; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(dicarboxylic, monoesters; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Sterols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters, with dicarboxylic acids; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Agrimony
Citrus
Euphorbia lathyris
Hamamelis
Peony
Plectranthus glaucocalyx
Thujopsis dolabrata
(ext.; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Plant (Embryophyta)
(exts.; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Acidic polysaccharides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hetero-; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Conditioning shampoos
Cosmetics
Hair conditioners
Hair preparations
Humectants
Moisturizers (**cosmetics**)
Skin creams
(**skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT Amides, biological studies
Carboxylic acids, biological studies
Polyhydric alcohols
Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin** and hair **cosmetic** compns. contg. amides for improving water retention)

IT **Cosmetics**
(wrinkle-preventing; **skin** and hair **cosmetic** compns. contg. amides for improving water retention)
IT **50-21-5**, biological studies 50-70-4, D-Glucitol, biological studies 50-99-7, D-Glucose, biological studies **52-90-4**, L-**Cysteine**, biological studies 56-12-2, .gamma.-Aminobutyric acid, biological studies 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 56-84-8, L-Aspartic acid, biological studies 56-85-9, L-Glutamine, biological studies 56-86-0, L-Glutamic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Sucrose, biological studies 57-55-6, 1,2-Propanediol, biological studies 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies 70-47-3, L-Asparagine, biological studies 74-79-3, L-Arginine, biological studies **77-92-9**, **Citric acid**, biological studies **79-14-1**, biological studies 87-99-0, Xylitol 107-21-1, 1,2-Ethanediol, biological studies 107-88-0, 1,3-Butylene glycol 110-15-6, Butanedioic acid, biological studies 110-16-7, 2-Butenedioic acid (Z)-, biological studies 110-17-8, 2-Butenedioic acid (E)-, biological studies 110-63-4, 1,4-Butanediol, biological studies 110-94-1, Pentanedioic acid 141-82-2, Malonic acid, biological studies 149-32-6 463-40-1, Linolenic acid 504-63-2, 1,3-Propanediol 506-32-1, Arachidonic acid 544-63-8, Myristic acid, biological studies 585-88-6, Maltitol 617-73-2, 2-Hydroxyoctanoic acid 1109-28-0, Maltotriose 7493-90-5, Threitol 9004-53-9D, Dextrin, limit, reduced 25265-71-8, Dipropylene glycol 25322-68-3 30399-84-9, Isooctadecanoic acid 56090-54-1, Triglycerol 56491-53-3, Tetraglycerol 59113-36-9, Diglycerol
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin** and hair **cosmetic** compns. contg. amides for improving water retention)

L229 ANSWER 35 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:276777 HCAPLUS
DN 126:320918
TI **Cosmetic** compositions containing N-acyl-ethylene-triacetic acids for promotion of **skin** exfoliation
IN Ptchelintsev, Dmitri
PA Avon Products, Inc., USA
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A01N037-12
ICS A61K031-195
NCL 514561000
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 1, 23
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5621008	A	19970415	US 1995-549419	19951027 <--
	US 5728733	A	19980317	US 1996-762716	19961210 <--
PRAI	US 1995-549419	19951027 <--			

OS MARPAT 126:320918
AB Disclosed is the novel use of N-acyl-N,N',N'-ethylenediaminetriacetic acids and N-acyl-N,N',N'-(ethylenedioxy) diethylenedinitrilotriacetic acids as active ingredients in preventative as well as therapeutic topical compns. to promote exfoliation and alleviate symptoms of **skin** conditions caused by abnormal keratinization. Efficacy of a 0.2% hydroalc. soln. of N-lauroyl-N,N',N''-ethylenediaminetriacetic acid in exfoliation of **skin** was shown in human volunteers. A **lotion** contained sodium N-acyl-N,N',N'-ethylenediaminetriacetic 1.0, glycerin 5.0, ammonium hydroxide 2.5, thickener 0.5,

octylmethoxycinnamate 2.0, polyoxyethylene stearate 3.5, alc. 10.0, fragrance 10.0, water q.s. 100%.

ST **cosmetic** acyl ethylenetriacetic acid **skin** exfoliation

IT Keratins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agents for lysis of; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT **Skin diseases**
(corn; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT Analgesics
Antiaging **cosmetics**
Antibiotics
Dandruff
Fungicides
Lotions (cosmetics)
Perfumes
Skin creams
Sunscreens
Suntanning agents
(**cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT Ceramides
Essential fatty acids
Hormones (animal), biological studies
Retinoids
Steroids, biological studies
Tocopherols
Vitamins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT Alcohols, biological studies
Paraffin oils
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-Me, Me hydrogen polysiloxane-; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT Polysiloxanes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-Me, Me hydrogen, polyoxyalkylene-; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT Cyclosiloxanes
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-Me; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT **Skin diseases**
(dry **skin**; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

IT **Carboxylic acids, biological studies**
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy**; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin**

exfoliation)
IT **Skin diseases**
(ichthyosis; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT **Skin diseases**
(keratinization; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT Radicals, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(scavengers; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT Exfoliation
(**skin**; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT Foot
(toe, disease, corn; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT **Cosmetics**
(wrinkle-preventing; **cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT 50-23-7, Hydrocortisone 50-27-1, Estriol 50-28-2, Estradiol, biological studies **50-81-7, Vitamin c,** biological studies 58-95-7, Tocopheryl acetate 60-54-8, Tetracycline 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 73-31-4, Melatonin 79-81-2, Retinyl palmitate 94-36-0, Benzoyl peroxide, biological studies 96-26-4, Dihydroxyacetone 106-51-4, 2,5-Cyclohexadiene-1,4-dione, biological studies 114-07-8, Erythromycin 137-58-6, Lidocaine 302-79-4, Retinoic acid 501-30-4, Kojic acid 688-57-3D, N-acyl derivs. 1406-18-4, Vitamin e 2398-96-1, Tolnaftate 11111-12-9, Cephalosporin 12001-79-5, Vitamin k 22916-47-8, Miconazole 23593-75-1, Clotrimazole 65277-42-1, Ketoconazole 65472-88-0, Naftifine 102641-08-7, Bth 148124-42-9
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)
IT 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 1314-13-2, Zinc oxide, biological studies 1336-21-6, Ammonium hydroxide 5466-77-3 9004-99-3, Polyoxyethylene stearate 13463-67-7, Titanium dioxide, biological studies 15087-24-8, Benzylidene camphor 70356-09-1, Parsol 1789
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. acylethylenetriacetic acids for promotion of **skin** exfoliation)

L229 ANSWER 36 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:267030 HCAPLUS
DN 126:255278
TI **Cosmetics** containing **hydroxycarboxylic acids** and plant extracts
IN Dampeirou, Christian
PA C3d Sarl, Fr.
SO Fr. Demande, 28 pp.
CODEN: FRXXBL
DT Patent
LA French

IC ICM A61K007-48
ICS A61K035-78
ICI A61K035-78, A61K031-335, A61K031-19
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2736263	A1	19970110	FR 1995-8242	19950707 <--
	FR 2736263	B1	19970926		
	WO 9702807	A1	19970130	WO 1996-FR1051	19960705 <--
	W: CN, JP, KR, US				
	CN 1195285	A	19981007	CN 1996-196759	19960705 <--
	JP 11508910	T2	19990803	JP 1996-505552	19960705 <--
	US 6190664	B1	20010220	US 1998-981701	19980206 <--
PRAI	FR 1995-8242	19950707 <--			
	WO 1996-FR1051	19960705 <--			

AB **Cosmetic** compns. with depigmentation activity contain a mixt. of **hydroxycarboxylic acids** or their derivs., at least 1 component chosen from e.g., kojic acid, caffeic acid, fusaric acid, and an active component from the exts. of plants such as Morus alba, lemon, Gingko biloba, ginseng. Thus, a compn. contained kojic acid 10, EDTA 0.5, Na sulfite 0.3, Na metabisulfite 0.3, **glycolic acid** 28.5, and exts. from Tanlex VB 2, Saxifraga 1, naringin (ext. from grape-fruit) 0.75, Sohakuhi 7.5, Morus alba 13, lemon 2.5, and water 0.5%. The effectiveness of this compn. in depigmentation of **skin** was demonstrated in rats.

ST **cosmetic hydroxycarboxylate** plant ext; carboxylate hydroxy **cosmetic** plant ext

IT Aloe ferox
Barberry
Birch
Calluna
Corn
Cosmetics
Cucumber
Drug delivery systems
Eclipta alba
Elder
Ginkgo biloba
Ginseng
Grapefruit
Hop
Laminaria
Lemon
Lettuce
Licorice (Glycyrrhiza)
Linden
Matricaria
Mulberry
Mulberry (Morus alba)
Plant (Embryophyta)
Poria cocos
Rose
Sage
Sanguisorba
Saxifraga
Scutellaria
Skin creams
Soybean
Spirulina
Strawberry
Vegetable
(**cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

IT Ceramides

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

IT **Skin pigmentation disorders**
(depigmentation; **cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy; cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

IT 9002-10-2, Tyrosinase
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(**cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

IT 11042-64-1, .gamma.-Oryzanol
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

IT **50-21-5, Lactic acid**, biological studies
50-81-7, Ascorbic acid, biological studies
77-92-9, Citric acid, biological studies
79-14-1, Glycolic acid, biological studies
123-99-9, Azelaic acid, biological studies 331-39-5, Caffeic acid 501-30-4, Kojic acid 536-69-6, Fusaric acid **6915-15-7, Malic acid** 28805-76-7, Aminobutyric acid 31883-16-6, 5-Hydroxy-2-hydroxymethyl-.gamma.-pyridone
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. **hydroxycarboxylic acids** and plant exts.)

L229 ANSWER 37 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:218613 HCAPLUS
DN 126:216458
TI **Cosmetic** compositions for topical delivery of active ingredients containing surfactants
IN McAtee, David Michael; Albacarys, Lourdes Dessus; Listro, Joseph Anthony
PA Procter & Gamble Company, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-50
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703648	A1	19970206	WO 1996-US11789	19960717 <--
	W: AU, CA, CN, CZ, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5665364	A	19970909	US 1995-506149	19950724 <--
	CA 2227956	AA	19970206	CA 1996-2227956	19960717 <--
	AU 9666770	A1	19970218	AU 1996-66770	19960717 <--
	AU 706920	B2	19990701		
	EP 841899	A1	19980520	EP 1996-926730	19960717 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1195980	A	19981014	CN 1996-196874	19960717 <--
	JP 11509553	T2	19990824	JP 1996-506809	19960717 <--
	US 5811111	A	19980922	US 1997-833016	19970403 <--
PRAI	US 1995-506149	19950724 <--			
	WO 1996-US11789	19960717 <--			

OS MARPAT 126:216458
AB The compns. of the present invention are useful for the topical delivery

of a wide variety of active ingredients. These compns. are particularly useful for treating conditions such as acne and its attendant **skin** lesions, blemishes, and other imperfections. These compns. are nonirritating to the **skin** and also provide **skin** feel benefits. These compns. can be in the form of leave-on products and products that are rinsed or wiped from the **skin** after use. A cleansing gel contained glycerin 4.00, Na2EDTA, dimethicone 0.20, PVP/MA decadiene cross-polymer 1.00, **glycolic acid** 2.00, sodium hydroxide 0.80, cetyl di-Me betaine 1.00, sodium lauryl sulfate 0.5, and water q.s. 100%.

ST **cosmetic** cleansing compn surfactant

IT Sulfobetaines
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cocoamidopropyl hydroxy deriv.; **cosmetic** compns. for topical delivery of active ingredients contg. surfactants)

IT **Acne**
Amphoteric surfactants
Anionic surfactants
Cationic surfactants
Cosmetic gels
Humectants
Lotions (cosmetics)
Skin cleansers
(**cosmetic** compns. for topical delivery of active ingredients contg. surfactants)

IT **50-21-5, Lactic acid,** biological studies
50-23-7, Hydrocortisone 56-81-5, Glycerol, biological studies 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies **79-14-1, Glycolic acid,** biological studies 83-86-3, Phytic acid 94-36-0, Benzoyl peroxide, biological studies 96-26-4, Dihydroxyacetone 101-20-2, 3,4,4'-Trichlorocarbanilide 107-43-7D, Betaine, cocoamidopropyl deriv. 108-46-3, Resorcinol, biological studies 122-99-6, Phenoxyethanol 123-99-9, Azelaic acid, biological studies 131-57-7, Oxybenzone 137-16-6, Sodium lauroyl sarcosinate 151-21-3, Sodium lauryl sulfate, biological studies 302-79-4, trans-Retinoic acid 616-91-1, n-Acetyl **cysteine** 693-33-4 770-35-4, Phenoxyisopropanol 820-66-6, Stearyldimethyl betaine 1120-01-0, Sodiumcetyl sulfate 3380-34-5, 2,4,4'-Trichloro-2'-hydroxydiphenyl ether 4759-48-2 6180-61-6 7381-01-3, Sodiumlauroyl isethionate 15687-27-1, Ibuprofen 22204-53-1, Naproxen 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid 57267-78-4D, Ammonium isethionate, cocoacyl derives. 57828-26-9, Lipoic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for topical delivery of active ingredients contg. surfactants)

L229 ANSWER 38 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:218612 HCAPLUS
DN 126:216457
TI Topical **cosmetic** compositions having improved **skin** feel containing surfactants
IN McAtee, David Michael; Albacarys, Lourdes Dessus; Hasenoehrl, Eric John; Listro, Joseph Anthony
PA Procter & Gamble Company, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-50
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI. WO 9703647	A1	19970206	WO 1996-US11788	19960717 <--

W: AU, CA, CN, CZ, JP, KR, MX
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5607980	A	19970304	US 1995-505988	19950724	<--
CA 2227967	AA	19970206	CA 1996-2227967	19960717	<--
AU 9666769	A1	19970218	AU 1996-66769	19960717	<--
AU 706358	B2	19990617			
EP 841898	A1	19980520	EP 1996-926729	19960717	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

CN 1200030	A	19981125	CN 1996-196875	19960717	<--
JP 11509552	T2	19990824	JP 1996-506808	19960717	<--

PRAI US 1995-505988 19950724 <--
WO 1996-US11788 19960717 <--

OS MARPAT 126:216457

AB Topical **cosmetic** compns. having improved **skin** feel are claimed. These compns. can be in the form of leave-on products or products that are rinsed or wiped from the **skin** after use. These compns. are also useful for conditioning, desquamating, and cleansing the **skin** and for relieving dry **skin**. A topical personal care compn. comprising: (a) from 0.1 % to 20 % by wt. of an amphoteric surfactant R1[CONH(CH2)m]nN+R2R3R4X (R1 = C9-22 alkyls; m = 1-3; n = 0, 1; R2, R3 = C1-3 alkyl, monohydroxyalkyl; R4 = C1-5 alkyl, monohydroxyalkyl; X = CO2, SO3, and SO4) and pharmaceutically acceptable salts of the foregoing compds.; (b) from 0.1 % to 20 % by wt. of an anionic surfactant; (c) from 0.1 % to 15 % by wt. of a cationic surfactant; and (d) from 0.1 % to 99.7 % by wt. water. Formulations of various **cosmetic** cleansers are disclosed.

ST topical **cosmetic skin** feel surfactant

IT Sulfobetaines
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cocoamidopropyl hydroxy deriv.; topical **cosmetic** compns. having improved **skin** feel contg. surfactants)

IT Amphoteric surfactants
Anionic surfactants
Cationic surfactants
Cosmetic gels
Humectants
Lotions (**cosmetics**)
Skin cleansers
(topical **cosmetic** compns. having improved **skin** feel contg. surfactants)

IT **50-21-5**, **Lactic acid**, biological studies
50-23-7, Hydrocortisone 56-81-5, Glycerol, biological studies 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies **79-14-1**, **Glycolic acid**, biological studies 83-86-3, Phytic acid 94-36-0, Benzoyl peroxide, biological studies 96-26-4, Dihydroxyacetone 101-20-2, 3,4,4'-Trichlorocarbanilide 107-43-7D, Betaine, cocoamidopropyl deriv. 108-46-3, Resorcinol, biological studies 122-99-6, Phenoxyethanol 123-99-9, Azelaic acid, biological studies 131-57-7, Oxybenzone 137-16-6, Sodium lauroyl sarcosinate 151-21-3, Sodium lauryl sulfate, biological studies 302-79-4, trans-Retinoic acid 616-91-1, n-Acetyl **cysteine** 693-33-4, Cetyl betaine 770-35-4, Phenoxyisopropanol 820-66-6, Stearyldimethyl betaine 1120-01-0, Sodiumcetyl sulfate 3380-34-5, 2,4,4'-Trichloro-2'-hydroxydiphenyl ether 4759-48-2, 13 cis-Retinoic acid 6180-61-6 7381-01-3, Sodiumlauroyl isethionate 15687-27-1, Ibuprofen 22204-53-1, Naproxen 27503-81-7, 2-Phenylbenzimidazole-5-sulfonic acid 57267-78-4D, Ammonium isethionate, cocoacyl derives. 57828-26-9, Lipoic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(topical **cosmetic** compns. having improved **skin** feel contg. surfactants)

L229 ANSWER 39 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:121413 HCAPLUS

DN 126:135447
TI Alpha hydroxyacid esters for treatment of **skin** aging
IN Yu, Ruey J.; Van Scott, Eugene J.
PA Yu, Ruey J., USA; Van Scott, Eugene J.
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-44
CC 62-3 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9640047	A1	19961219	WO 1996-US8605	19960606	<--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA					
	JP 3016588	B2	20000306	JP 1991-505539	19910121	<--
	US 5686489	A	19971111	US 1995-486045	19950607	<--
	AU 9660357	A1	19961230	AU 1996-60357	19960606	<--
	AU 701517	B2	19990128			
	EP 831767	A1	19980401	EP 1996-917991	19960606	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI					
	US 6051609	A	20000418	US 1998-222997	19981230	
	US 6191167	B1	20010220	US 1999-255702	19990223	

PRAI	US 1995-486045	19950607	<--
	US 1986-945680	19861223	<--
	US 1990-467958	19900122	<--
	WO 1991-US412	19910121	<--
	WO 1996-US8605	19960606	<--
	US 1997-926030	19970909	
	US 1997-998864	19971229	
	US 1998-185608	19981104	

OS MARPAT 126:135447
AB Alpha hydroxyacid esters and related compds. on topical application induced increased **skin** thickness due to new biosynthesis of **dermal** components including glycosaminoglycans, proteoglycans, collagen and elastin. Such **dermal** effects are desirable and beneficial for topical use and treatment of aging related integumental changes including age spots, **skin** lines, wrinkles, photoaging and aging **skin**. Thus, 30 g tri-Et citrate (I) and 5 mL propylene glycol were mixed with 65 g of a hydrophilic **ointment** until a consistent **cream** was obtained. Efficacy of formulations contg. I in treatment of **skin** disorders is disclosed.
ST hydroxyacid ester **skin** aging **cosmetic**; **skin** disorder ethyl citrate **cream**
IT Tocopherols
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Tocopherol; alpha hydroxyacid esters for treatment of **skin** aging)
IT Antiaging **cosmetics**
(alpha hydroxyacid esters for treatment of **skin** aging)
IT Collagens, biological studies
Glycosaminoglycans, biological studies
Proteoglycans, biological studies
Skin creams
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alpha hydroxyacid esters for treatment of **skin** aging)
IT Coal tar

Elastins
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alpha hydroxyacid esters for treatment of **skin** aging)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters; alpha hydroxyacid esters for treatment of **skin** aging)

IT **Cosmetics**
(wrinkle-preventing; alpha hydroxyacid esters for treatment of **skin** aging)

IT **50-21-5D**, esters **50-81-7D**, **Ascorbic acid**, esters **76-93-7D**, esters **77-92-9D**, esters 77-95-2D, **Quinic acid**, esters **79-14-1D**, esters **80-69-3D**, esters **87-69-4D**, esters 89-65-6D, Isoascorbic acid, esters 90-64-2D, esters 96-82-2D, Lactobionic acid, esters **300-85-6D**, 3-Hydroxybutanoic acid, esters **320-77-4D**, **Isocitric acid**, esters 473-81-4D, 2,3-Dihydroxypropanoic acid, esters **515-30-0D**, esters **526-95-4D**, **Gluconic acid**, esters 526-99-8D, Galactaric acid, esters 544-57-0D, 2-Hydroxytetracosanoic acid, esters **552-63-6D**, **Tropic acid**, esters **594-61-6D**, 2-Methyl **lactic acid**, esters 597-44-4D, **Citramalic acid**, esters **600-15-7D**, 2-Hydroxybutanoic acid, esters 617-31-2D, 2-Hydroxypentanoic acid, esters 617-73-2D, 2-Hydroxyoctanoic acid, esters 629-22-1D, 2-Hydroxyoctadecanoic acid, esters 636-69-1D, 2-Hydroxyheptanoic acid, esters 666-99-9D, Agaricic acid, esters 685-73-4D, D-Galacturonic acid, esters 764-67-0D, 2-Hydroxyhexadecanoic acid, esters **828-01-3D**, esters **1112-33-0D**, **Pantoic acid**, esters 1713-85-5D, Chlorolactic acid, esters 2507-55-3D, 2-Hydroxytetradecanoic acid, esters 2782-86-7D, Heptonic acid, esters 2984-55-6D, 2-Hydroxydodecanoic acid, esters 3402-98-0D, Iduronic acid, esters 3956-93-2D, Idonic acid, esters 5393-81-7D, 2-Hydroxydecanoic acid, esters 6064-63-7D, 2-Hydroxyhexanoic acid, esters 6556-12-3D, D-Glucuronic acid, esters 6814-36-4D, Mannuronic acid, esters 6906-37-2D, Mannonic acid, esters **6915-15-7D**, esters 7007-81-0D, Trethocanic acid, esters 7558-19-2D, Hexaric acid, esters 7760-07-8D, Hexonic acid, esters 10191-35-2D, 2,3,4-Trihydroxybutanoic acid, esters 13171-74-9D, Pentonic acid, esters 13382-27-9D, **Galactonic acid**, esters 13752-83-5D, Arabinonic acid, esters 15769-56-9D, Guluronic acid, esters 15896-36-3D, 2-Hydroxynonanoic acid, esters 16742-48-6D, 2-Hydroxyeicosanoic acid, esters **17812-24-7D**, **Ribonic acid**, esters 17828-56-7D, Xylonic acid, esters 18299-27-9D, Aleuritic acid, esters 19790-86-4D, 2-Hydroxyundecanoic acid, esters 20246-52-0D, Talonic acid, esters 20246-53-1D, Gulonic acid, esters 23351-51-1D, Glucoheptonic acid, esters 24871-35-0D, Altronic acid, esters 25525-21-7D, Glucaric acid, esters 28223-40-7D, Lyxonic acid, esters 28223-42-9D, Allonic acid, esters 28223-51-0D, Alluronic acid, esters 28223-52-1D, Taluronic acid, esters 30923-19-4D, Lyxuronic acid, esters 30923-20-7D, Riburonic acid, esters 30923-21-8D, Xyluronic acid, esters 30923-39-8D, Arabinuronic acid, esters 35388-57-9D, Piscidic acid, esters 38742-06-2D, Hexulosonic acid, esters 73689-06-2D, esters 84710-55-4D, Threuronic acid, esters 84710-56-5D, Erythruronic acid, esters 84710-57-6D, Altruronic acid, esters 136599-01-4D, esters
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alpha hydroxyacid esters for treatment of **skin** aging)

IT 50-03-3, Hydrocortisone 21 acetate 50-23-7, Hydrocortisone 51-21-8, 5-Fluorouracil 55-56-1, Chlorhexidine 57-41-0, Phenytoin 58-32-2, Dipyridamole 58-73-1, Diphenhydramine 58-95-7, Tocopheryl acetate 59-01-8, Kanamycin 59-46-1, Procaine 60-54-8, Tetracycline 68-26-8, Retinol 76-25-5, Triamcinolone acetonide 79-81-2, Retinyl palmitate 94-36-0, Benzoyl peroxide, biological studies 114-07-8, Erythromycin

118-60-5, Octyl salicylate 123-31-9, 1,4-Benzenediol, biological studies 123-31-9D, 1,4-Benzenediol, monomethyl and benzyl ethers 126-07-8, Griseofulvin 127-47-9, Retinyl acetate 131-53-3, Dioxybenzone 131-57-7, Oxybenzone 137-58-6, Lidocaine 140-65-8, Pramoxine 150-13-0, p-Aminobenzoic acid 302-79-4, Retinoic acid 356-12-7, Fluocinonide 443-48-1, Metronidazole 483-63-6, Crotamiton 1400-61-9, Nystatin 1404-04-2, Neomycin 2152-44-5, Betamethasone valerate 5466-77-3 5593-20-4, Betamethasone dipropionate 10118-90-8, Minocycline 12633-72-6, Amphotericin 13463-41-7, Zinc pyrithione 13609-67-1, Hydrocortisone 17-butyrate 15687-27-1, Ibuprofen 16110-51-3, Cromolyn 18323-44-9, Clindamycin 22204-53-1, Naproxen 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25122-46-7, Clobetasol propionate 27220-47-9, Econazole 38304-91-5, Minoxidil 56093-45-9, Selenium sulfide 57524-89-7, Hydrocortisone 17 valerate 58817-05-3 59277-89-3, Acyclovir 65277-42-1, Ketoconazole
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alpha hydroxyacid esters for treatment of **skin** aging)

L229 ANSWER 40 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:107334 HCAPLUS
DN 126:122314
TI **Skin**-lightening **cosmetics** containing Brassica extracts
IN Naito, Kazufumi; Yamada, Katsuhisa; Sawaki, Shigeru
PA Kyoei Chemical Ind, Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 11
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08325130	A2	19961210	JP 1995-130465	19950529 <--

AB **Skin**-lightening **cosmetics** contg. Brassica exts. (showing inhibitory effects on tyrosinase and lipoxygenase activities) are claimed. A **lotion** contained **ascorbic acid** **phosphate** magnesium salt 2.0, ethanol 10.0, glycerin **3** .0, 1,**3**-butylene glycol 2.0, **citric acid** 0.1, sodium citrate 0.**3**, carboxyvinyl polymer 0.1, the ext. 10.0 parts and purified water q.s.
ST **skin** lightening **cosmetic** Brassica ext
IT Brassica campestris
Brassica hirta
Brassica juncea
Brassica nigra
Skin-lightening **cosmetics**
(**skin**-lightening **cosmetics** contg. Brassica exts.)
IT 9002-10-2, Tyrosinase 9029-60-1, Lipoxygenase
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitors; **skin**-lightening **cosmetics** contg. Brassica exts.)

L229 ANSWER 41 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:107069 HCAPLUS
DN 126:122295
TI **Skin** and hair preparations with good **moisturizing** property
IN Yamamoto, Kazumi
PA Yamamoto Kazumi, Japan; Nippon Kankyo Yakuhin Kk
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF

DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K007-06; A61K007-50
CC 62-1 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08325134	A2	19961210	JP 1995-152648	19950526 <--

AB **Skin** and hair prepns. contain **lactic acid**, Ca lactate, **ascorbic acid**, mineral-contg. water, and Me benzoate. The prepns. remove damaged stratum cornea by scrubbing and **moisturize** the **skin** and hair. **Lactic acid**, Ca lactate, **ascorbic acid**, Me benzoate, and com. available mineral water contg. Ca, P, Mg, S, Si, K, Fe, Zn, Mn, etc., were mixed, dried, and pulverized into powders.
ST **skin** hair prepn lactate **ascorbate moisturizer** ; methyl benzoate calcium lactate **moisturizer cosmetic** ; mineral water **ascorbate skin** hair prepn
IT Mineral waters
(in **skin** and hair prepns. with good **moisturizing** property)
IT Hair preparations
Moisturizers (**cosmetics**)
Powders (**cosmetics**)
(**skin** and hair prepns. with good **moisturizing** property)
IT **50-21-5**, **Lactic acid**, biological studies
50-81-7, **Ascorbic acid**, biological studies
93-58-3, Methyl benzoate 814-80-2, Calcium lactate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(in **skin** and hair prepns. with good **moisturizing** property)

L229 ANSWER 42 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:93425 HCAPLUS
DN 126:108673
TI **Skin**-care bath preparations containing **moisturizers**
IN Nakamura, Kenji; Nakagawa, Momoki
PA Nakamura Kenji, Japan; Nakagawa Momoki
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-50
ICS A61K007-00; A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08319230	A2	19961203	JP 1995-148166	19950523 <--

AB The title prepns. contain **moisturizers** comprising reaction products of carboxylic acid-modified chitosan with hydrolyzed collagen. Powd. chitosan was treated with **lactic acid** in H2O at 40.degree. for 5 h, then treated with hydrolyzed collagen at 30.degree. for 3 h to give a **moisturizer**. The **moisturizer** was mixed with Na2CO3, vitamins, and Ag zeolite and molded into a bath prepn.
ST **moisturizer** acylated chitosan collagen bath prepn
IT Zeolites (synthetic), biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(Ag; bath prepns. contg. silver-contg. bactericides and **moisturizers** prepd. from acylated chitosan and hydrolyzed collagen)
IT Bath preparations

Moisturizers (**cosmetics**)
(bath prepns. contg. **moisturizers** prepd. from acylated chitosan and hydrolyzed collagen)

IT Antibacterial agents
(bath prepns. contg. silver-contg. bactericides and **moisturizers** prepd. from acylated chitosan and hydrolyzed collagen)

IT Collagens, biological studies
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydrolyzates, reaction products with acylated chitosan; bath prepns. contg. **moisturizers** prepd. from acylated chitosan and hydrolyzed collagen)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(reaction product with chitosan and hydrolyzed collagen; bath prepns. contg. **moisturizers** prepd. from acylated chitosan and hydrolyzed collagen)

IT **50-21-5DP**, reaction products with chitosan and hydrolyzed collagen **50-81-7DP**, **Ascorbic acid**, reaction products with chitosan and hydrolyzed collagen **77-92-9DP**, **Citric acid**, reaction products with chitosan and hydrolyzed collagen 124-04-9DP, Hexanedioic acid, reaction products with chitosan and hydrolyzed collagen **6915-15-7DP**, reaction products with chitosan and hydrolyzed collagen 9012-76-4DP, Chitosan, reaction products with carboxylic acids and hydrolyzed collagen
RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bath prepns. contg. **moisturizers** prepd. from acylated chitosan and hydrolyzed collagen)

L229 ANSWER 43 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1997:44459 HCAPLUS
DN 126:65184
TI **Cosmetics** containing novel **ascorbic acid** derivatives
IN Motoyoshi, Katsuhiro; Suzuki, Toshimitsu
PA Pola Kasei Kogyo Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C07F009-655
ICS A61K007-00; A61K007-48; C07D407-04
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08269074	A2	19961015	JP 1995-96259	19950329 <--

OS MARPAT 126:65184
GI



I

AB **Cosmetics** esp. for rough **skin** contain novel **ascorbic acid** derivs.(I) [R1-2 = H, alkyl, (un)substituted Ph, or linkage; X, Y = Mg or other metal, org. amines] in addn. to other ingredients. 5,6-O-benzylideneascorbic acid **phosphate** K salt was prepd. by reaction of L-**ascorbic acid** with benzylidenedimethylacetal to form 6-O-benzylideneascorbic acid and then reaction with phosphorus oxychloride and KOH to yield 5,6-O-benzylideneascorbic acid **phosphate** K salt. A **cosmetic lotion** contain 5,6-O-benzylideneascorbic acid **phosphate** K salt 0.5, sodium citrate 0.15, **citric acid** 0.1, perfumes 0.05, Et paraben 0.05, ethoxylated hardened castor oil 1, 1,**3**-butylene glycol 2, ethanol 15 and purified water to 100 parts.

ST **cosmetic ascorbic acid** deriv prepn

IT **Cosmetic emulsions**
Cosmetics
Lotions (**cosmetics**)
Skin creams
(**cosmetics** contg. novel **ascorbic acid** derivs.)

IT **Skin diseases**
(rough **skin**; **cosmetics** contg. novel **ascorbic acid** derivs.)

IT **50-81-7**, L-**Ascorbic acid**, reactions
10025-87-3, Phosphorus oxychloride 184356-58-9 184356-59-0
RL: RCT (Reactant)
(**cosmetics** contg. novel **ascorbic acid** derivs.)

IT 15042-01-0P 184356-60-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(**cosmetics** contg. novel **ascorbic acid** derivs.)

IT 185077-00-3P 185077-01-4P 185226-04-4P 185226-05-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**cosmetics** contg. novel **ascorbic acid** derivs.)

L229 ANSWER 44 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:607483 HCAPLUS
DN 125:230177
TI **Cosmetic** compositions having containing plant extracts for **skin** depigmentation
IN Hanna, Raja
PA Hanna, Claude, Fr.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM A61K007-48
ICS A61K035-78
CC 62-3 (Essential Oils and **Cosmetics**)

Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9624327	A1	19960815	WO 1996-FR211	19960208 <--
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2730408	A1	19960814	FR 1995-1498	19950209 <--
	FR 2730408	B1	19970905		
	AU 9647232	A1	19960827	AU 1996-47232	19960208 <--
PRAI	FR 1995-1498	19950209 <--			
	WO 1996-FR211	19960208 <--			

AB Compns. and prepns. having depigmenting activity, and the pharmaceutical and **cosmetic** uses thereof, are disclosed. Such plant-based compns. regulate **skin** pigmentation and essentially comprise a fruit exts., aq. exts., or hydroalcoholic exts. of Punica granatum, Terminalia chebula, T. bellerica, Phyllanthus emblica, and Cydonia oblonga, contg. at least one .alpha.-hydroxyacid, **ascorbic acid**, and at least one polyphenol as the active ingredients. The juices have tyrosinase inhibition activity. Thus 100 kg of fresh fruits of Punica g. was pressed to obtain 72 kg juices which was filtered and lyophilized. A **lotion** contained glycerol stearate 3, cetostearylic alc. 2, ethoxylated cetostearylic alc. 3, glycerol monooleate 0.5, octyldodecanol 10, dioctylcyclohexane 6, lyophilized Punica g. exts. 1, mixt. of nipaesters in phenoxyethanol 0.5, fragrances 0.2, and water q.s. 73.8%.

ST **cosmetic** pharmaceutical plant ext **skin** depigmentation; **lotion** Punica ext **skin** depigmentation

IT Pomegranate
Terminalia bellirica
Terminalia chebula
(**cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT Emblic
(ext.; **cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT Quince
(Cydonia oblonga, **cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **Cosmetics**
(**creams, cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **Skin, disease**
(depigmentation, **cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **Cosmetics**
(**emulsions, cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **Cosmetics**
(gels, **cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **Carboxylic acids, biological studies**
RL: BOC (Biological occurrence); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(**hydroxy, cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **Cosmetics**
(**lotions, cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT **50-81-7, Ascorbic acid**, biological studies
27073-41-2
RL: BOC (Biological occurrence); BUU (Biological use, unclassified); THU

(Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(**cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-64-1, Acetone, uses 78-93-3, Methylethylketone, uses
RL: NUU (Nonbiological use, unclassified); USES (Uses)
(**cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

IT 9002-10-2, Tyrosinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; **cosmetic** compns. having contg. plant exts. for **skin** depigmentation)

L229 ANSWER 45 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:567279 HCAPLUS
DN 125:204120
TI Sebum secretion inhibitors for improvement of oily **skin**
IN Hikima, Toshio; Oota, Cheko
PA Kanebo Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K035-72
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08188517	A2	19960723	JP 1995-18657	19950110 <--

AB Sebum secretion inhibitors for improvement of oily **skin** comprise baker's yeast exts. with/without astringents selected from **citric acid**, **tartaric acid**, **lactic acid**, **malic acid**, zinc p-phenolsulfonate, aluminum chlorhydroxide and **tannin**. A **skin lotion** contained ethanol 10.0, polyoxyethylene sorbitan monolaurate 0.5, perfumes 0.05, glycerin 5.0, Saccharomyces cerevisiae exts. 0.1, and purified water 84.35 wt.%.

ST sebum secretion inhibitor oily **skin**; Saccharomyces ext sebum inhibitor oily **skin**; astringent sebum inhibitor oily **skin**

IT Saccharomyces cerevisiae
(exts.; sebum secretion inhibitors for improvement of oily **skin**)

IT **Skin, disease**
(oily **skin**; sebum secretion inhibitors for improvement of oily **skin**)

IT **Astringents**
Sebum
(sebum secretion inhibitors for improvement of oily **skin**)

IT **Tannins**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sebum secretion inhibitors for improvement of oily **skin**)

IT **Cosmetics**
(**skin**; sebum secretion inhibitors for improvement of oily **skin**)

IT Yeast
(bakers', exts.; sebum secretion inhibitors for improvement of oily **skin**)

IT **50-21-5, Lactic acid**, biological studies
77-92-9, biological studies **87-69-4**, biological studies
127-82-2, Zinc p-phenolsulfonate 1327-41-9, Aluminum chlorhydroxide
6915-15-7, Malic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(sebum secretion inhibitors for improvement of oily **skin**)

L229 ANSWER 46 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:494351 HCAPLUS
DN 125:150781
TI Anti-irritant **skin** formulations containing potassium or lithium cations
IN Hahn, Gary Scott; Thueson, David Orel
PA Cosmederm Technologies, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9619181	A1	19960627	WO 1995-US16751	19951221 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5756107	A	19980526	US 1994-362055	19941221 <--
CA 2208079	AA	19960627	CA 1995-2208079	19951221 <--
AU 9646060	A1	19960710	AU 1996-46060	19951221 <--
EP 796078	A1	19970924	EP 1995-944196	19951221 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

PRAI US 1994-362055 19941221 <--
WO 1995-US16751 19951221 <--

AB **Cosmetic** and pharmaceutical compns. for inhibiting **skin** irritation attributable to chem. irritants or **environment** conditions, contain an anti-irritant amt. of aq.-sol. potassium or lithium cation. A soln. of 250 mM lithium acetate decreased the **skin** irritation caused by application of 7.5% **lactic acid** in 10% ethanol by 70%.

ST antiirritant **skin** formulation potassium lithium cation; **cosmetic skin** irritation potassium lithium cation; pharmaceutical **skin** irritation potassium lithium cation

IT Antiperspirants
Asthma
Bath preparations
Burn
Deodorants
Dermatitis
Eczema
Hair preparations
Infection
Insect repellents
Mouthwashes
Pruritus
Psoriasis
Shampoos
Sunscreens
(anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Alcohols, biological studies
Carboxylic acids, biological studies
Peroxides, biological studies
Retinoids
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant **skin** formulations contg. potassium or lithium

cations)
IT Aloe barbadensis
Chamomile
Cola nitida
Detergents
Inflammation inhibitors
Soaps
Steroids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Analgesics
Antibiotics
Contraceptives
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Acne**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Cold
Wind
(irritation from; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Humidity
(low, irritation from; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Amino acids, biological studies
Borates
Carbonates, biological studies
Caseins, biological studies
Fatty acids, biological studies
Hypophosphates
Lanolin
Nitrates, biological studies
Peroxysulfates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium or lithium salts; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium salts; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Melaleuca, ext.; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Shaving preparations
(aftershaves, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Hair preparations
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidandruff, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Hair preparations
(bleaches, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(body rinses, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Ion channel blockers

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
(cleansing, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Hair preparations
(conditioners, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Eye, disease
(conjunctivitis, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
(**creams**, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
(depilatories, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Digestive tract
Respiratory tract
(disease, irritation, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Nose
(disease, rhinitis, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Hair preparations
(dyes, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
(**emulsions**, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Pharmaceutical dosage forms
(enemas, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Skin**
(**epidermis**, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Skin, disease**
(**epidermis**, irritation, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
(exfoliating, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
(face cleansers, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Pharmaceutical dosage forms
(foams, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Cosmetics**
Pharmaceutical dosage forms
(gels, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Tea products
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(green, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT **Carboxylic acids, biological studies**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**hydroxy**, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Pharmaceutical dosage forms
(inhalants, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Eye, disease
Skin, disease
(irritation, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical natural products
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(licorice, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(liqs., anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Peptides, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lithium salts, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(**lotions**, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(lozenges, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(**moisturizers**, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(**ointments**, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(**ointments**, **creams**, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(ophthalmic, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(oral, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Carboxylic acids, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(oxo, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycarboxylic, potassium or lithium salts; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(rectal, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Light
(solar, irritation from; anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(sticks, anti-irritant **skin** formulations contg. potassium or lithium cations)

IT Hair preparations
(straighteners, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Sunburn and Suntan**
(suntanning agents, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(**suspensions**, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **Cosmetics**
(toners, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Pharmaceutical dosage forms
(vaginal, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT Hair preparations
(wave-setting, anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **50-21-5**, **Lactic acid**, biological studies
50-21-5D, **Lactic acid**, salts 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies **76-93-7**, biological studies **77-92-9**, biological studies **77-92-9D**, salts **79-14-1**, biological studies **79-14-1D**, salts **87-69-4**, biological studies 90-64-2, Mandelic acid **90-80-2**, **Gluconolactone** 94-36-0, Benzoyl peroxide, biological studies 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal **127-17-3**, **Pyruvic acid**, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin **526-95-4**, **Gluconic acid** 5393-81-7, .alpha.-Hydroxy decanoic acid **6915-15-7**, **Malic acid** 70424-62-3
126094-21-1
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant **skin** formulations contg. potassium or lithium cations)
IT **50-21-5D**, **Lactic acid**, potassium or lithium salts **50-81-7D**, **Ascorbic acid**, potassium or lithium salts 56-84-8D, L-Aspartic acid, potassium or lithium salts 57-03-4D, potassium or lithium salts 57-10-3D, Hexadecanoic acid, potassium or lithium salts 57-11-4D, Octadecanoic acid, potassium or lithium salts 57-13-6, Urea, biological studies 58-05-9D, Folinic acid, potassium or lithium salts 58-08-2, Caffein, biological studies 64-18-6D, Formic acid, potassium or lithium salts 64-19-7D, Acetic acid, potassium or lithium salts 65-85-0D, Benzoic acid, potassium or lithium salts 68-11-1D, Thioglycolic acid, potassium or lithium salts 69-72-7D, potassium or lithium salts 69-89-6, Xanthine **77-92-9D**, potassium or lithium salts 79-09-4D, Propionic acid, potassium or lithium salts **79-83-4D**, potassium or lithium salts 81-07-2D, potassium or lithium salts **87-69-4D**, potassium or lithium salts 88-99-3D, Phthalic acid, potassium or lithium salts 94-13-3D, Propyl paraben, potassium or lithium salts 97-59-6, Allantoin 99-76-3D, Methyl paraben, potassium or lithium salts 100-88-9D, Cyclamate, potassium or lithium salts 110-15-6D, Butanedioic acid, potassium or lithium salts 110-16-7D, Maleic acid, potassium or lithium salts 110-44-1D, Sorbic acid, potassium or lithium salts 112-80-1D, 9-Octadecenoic acid (Z)-, potassium or lithium salts 112-85-6D, Behenic acid, potassium or lithium salts 141-22-0D, Ricinoleic acid, potassium or lithium salts 143-07-7D, Dodecanoic acid, potassium or lithium salts 144-62-7D, Ethanedioic acid, potassium or lithium salts 151-41-7D, Lauryl sulfate, potassium or lithium salts 515-69-5, .alpha.-Bisabolol

526-95-4D, Gluconic acid, potassium or lithium salts 544-63-8D, Tetradecanoic acid, potassium or lithium salts 546-89-4, Lithium acetate 1405-86-3, Glycyrrhizinic acid 7447-40-7, Potassium chloride, biological studies 7447-41-8, Lithium chloride (LiCl), biological studies 7664-93-9D, Sulfuric acid, potassium or lithium salts 7757-79-1, Potassium nitrate, biological studies 7778-80-5, Potassium sulfate, biological studies 7790-69-4, Lithium nitrate 10377-48-7, Lithiumsulfate
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. potassium or lithium cations)

L229 ANSWER 47 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:494350 HCAPLUS
DN 125:150780
TI Anti-irritant **skin** formulations containing magnesium, manganese, or lanthanide cations
IN Hahn, Gary Scott; Thueson, David Orel
PA Cosmederm Technologies, USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9619182	A1	19960627	WO 1995-US16763	19951221 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2208500	AA	19960627	CA 1995-2208500	19951221 <--
AU 9646064	A1	19960710	AU 1996-46064	19951221 <--
EP 799018	A1	19971008	EP 1995-944200	19951221 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
PRAI US 1994-362097	19941221 <--			
WO 1995-US16763	19951221 <--			

AB **Cosmetic** and pharmaceutical compns. for inhibiting **skin** irritation attributable to chem. irritants or **environment** conditions, contain an anti-irritant amt. of aq.-sol. divalent magnesium cation or divalent manganese cation, or trivalent lanthanide cations of at. nos. 56-71. A soln. of 250 mM manganese acetate decreased the **skin** irritation caused by application of 7.5% **lactic acid** in 10% ethanol by 65%.
ST antiirritant **skin** formulation magnesium manganese cation; **cosmetic skin** irritation magnesium manganese cation; pharmaceutical **skin** irritation magnesium manganese cation; lanthanide magnesium cation antiirritant **skin** formulation
IT Antiperspirants
Asthma
Bath preparations
Burn
Deodorants
Dermatitis
Eczema
Hair preparations
Infection
Insect repellents
Mouthwashes

Pruritus
Psoriasis
Shampoos
Sunscreens
(anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Alcohols, biological studies
Carboxylic acids, biological studies
Peroxides, biological studies
Retinoids
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Aloe barbadensis
Chamomile
Cola nitida
Detergents
Inflammation inhibitors
Soaps
Steroids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Analgesics
Antibiotics
Contraceptives
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Acne**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Cold
Wind
(irritation from; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Humidity
(low, irritation from; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Amino acids, biological studies
Borates
Carbonates, biological studies
Caseins, biological studies
Fatty acids, biological studies
Hypophosphates
Lanolin
Nitrates, biological studies
Peptides, biological studies
Peroxysulfates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(magnesium and manganese and lanthanide salts; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Melaleuca, ext.; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Shaving preparations
(aftershaves, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Hair preparations
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antidandruff, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Hair preparations
(bleaches, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(body rinses, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(cleansing, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Hair preparations
(conditioners, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Eye, disease
(conjunctivitis, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(**creams**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(depilatories, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Digestive tract
Respiratory tract
(disease, irritation, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Nose
(disease, rhinitis, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Hair preparations
(dyes, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(**emulsions**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Pharmaceutical dosage forms
(enemas, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Skin**
(**epidermis**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Skin, disease**
(**epidermis**, irritation, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(exfoliating, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
(face cleansers, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Pharmaceutical dosage forms
(foams, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT **Cosmetics**
Pharmaceutical dosage forms
(gels, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)
IT Tea products
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(green, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Carboxylic acids, biological studies**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**hydroxy**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(inhalants, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Eye, disease
Skin, disease
(irritation, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical natural products
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(licorice, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Cosmetics**
(liqs., anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Cosmetics**
(**lotions**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(lozenges, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Cosmetics**
(**moisturizers**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(**ointments**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(**ointments**, **creams**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(ophthalmic, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(oral, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Carboxylic acids, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(oxo, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycarboxylic, magnesium and manganese and lanthanide salts; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(rectal, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Light

(solar, irritation from; anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Cosmetics**
(sticks, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Hair preparations
(straighteners, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Sunburn and Suntan**
(suntanning agents, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Cosmetics**
(**suspensions**, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **Cosmetics**
(toners, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Pharmaceutical dosage forms
(vaginal, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT Hair preparations
(wave-setting, anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **50-21-5**, **Lactic acid**, biological studies
64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies **76-93-7**, biological studies **77-92-9**, biological studies **77-92-9D**, salts **79-14-1**, biological studies **79-14-1D**, salts **87-69-4**, biological studies 90-64-2, Mandelic acid **90-80-2**, **Gluconolactone** 94-36-0, Benzoyl peroxide, biological studies 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal **127-17-3**, **Pyruvic acid**, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin **526-95-4**, **Gluconic acid** 5393-81-7, .alpha.-Hydroxy decanoic acid **6915-15-7**, **Malic acid** 70424-62-3 126094-21-1
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

IT **50-21-5D**, **Lactic acid**, magnesium and manganese and lanthanide salts **50-81-7D**, **Ascorbic acid**, magnesium and manganese and lanthanide salts 56-84-8D, L-Aspartic acid, magnesium and manganese and lanthanide salts 57-03-4D, magnesium and manganese and lanthanide salts 57-10-3D, Hexadecanoic acid, magnesium and manganese and lanthanide salts 57-11-4D, Octadecanoic acid, magnesium and manganese and lanthanide salts 57-13-6, Urea, biological studies 58-05-9D, Folinic acid, magnesium and manganese and lanthanide salts 58-08-2, Caffein, biological studies 64-18-6D, Formic acid, magnesium and manganese and lanthanide salts 64-19-7D, Acetic acid, magnesium and manganese and lanthanide salts 65-85-0D, Benzoic acid, magnesium and manganese and lanthanide salts 68-11-1D, Thioglycolic acid, magnesium and manganese and lanthanide salts 69-72-7D, magnesium and manganese and lanthanide salts 69-89-6, Xanthine **77-92-9D**, magnesium and manganese and lanthanide salts 79-09-4D, Propionic acid, magnesium and manganese and lanthanide salts **79-83-4D**, magnesium and manganese and lanthanide salts 81-07-2D, magnesium and manganese and lanthanide salts **87-69-4D**, magnesium and manganese and lanthanide salts 88-99-3D, Phthalic acid, magnesium and manganese and lanthanide salts 94-13-3D, Propyl paraben, magnesium and manganese and lanthanide salts 97-59-6, Allantoin 99-76-3D, Methyl

paraben, magnesium and manganese and lanthanide salts 100-88-9D, Cyclamate, magnesium and manganese and lanthanide salts 110-15-6D, Butanedioic acid, magnesium and manganese and lanthanide salts 110-16-7D, Maleic acid, magnesium and manganese and lanthanide salts 110-44-1D, Sorbic acid, magnesium and manganese and lanthanide salts 112-80-1D, 9-Octadecenoic acid (Z)-, magnesium and manganese and lanthanide salts 112-85-6D, Behenic acid, magnesium and manganese and lanthanide salts 141-22-0D, Ricinoleic acid, magnesium and manganese and lanthanide salts 142-72-3, Magnesium acetate 143-07-7D, Dodecanoic acid, magnesium and manganese and lanthanide salts 144-62-7D, Ethanedioic acid, magnesium and manganese and lanthanide salts 151-41-7D, Lauryl sulfate, magnesium and manganese and lanthanide salts 515-69-5, .alpha.-Bisabolol **526-95-4D, Gluconic acid**, magnesium and manganese and lanthanide salts 544-63-8D, Tetradecanoic acid, magnesium and manganese and lanthanide salts 1405-86-3, Glycyrrhizinic acid 3632-91-5, Magnesium gluconate 7487-88-9, Magnesium sulfate, biological studies 7647-17-8, Cesium chloride, biological studies 7664-93-9D, Sulfuric acid, magnesium and manganese and lanthanide salts 7786-30-3, Magnesium chloride, biological studies 7789-18-6, Cesium nitrate 10099-58-8, Lanthanum chloride 10099-59-9, Lanthanum nitrate 10138-52-0, Gadolinium chloride 10168-81-7, Gadolinium nitrate 10361-79-2, Praseodymium chloride 10361-80-5, Praseodymium nitrate 10377-60-3, Magnesium nitrate
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. magnesium, manganese, or lanthanide cations)

L229 ANSWER 48 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:494349 HCAPLUS
DN 125:150779
TI Anti-irritant **skin** formulations containing aluminum or tin cations
IN Hahn, Gary Scott; Thueson, David Orel
PA Cosmederm Technologies, USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9619183	A1	19960627	WO 1995-US16765	19951221	<--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	CA 2208078	AA	19960627	CA 1995-2208078	19951221	<--
	AU 9645285	A1	19960710	AU 1996-45285	19951221	<--
	EP 801554	A1	19971022	EP 1995-943956	19951221	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
	BR 9510478	A	19981215	BR 1995-10478	19951221	<--
PRAI	US 1994-362058	19941221	<--			
	WO 1995-US16765	19951221	<--			

AB **Cosmetic** and pharmaceutical compns. for inhibiting **skin** irritation attributable to chem. irritants or **environment** conditions, contain an anti-irritant amt. of aq.-sol. trivalent aluminum cation or divalent tin cation. A soln. of 250 mM stannous chloride decreased the **skin** irritation caused by application of 7.5% **lactic acid** in 10% ethanol by 50%.

ST antiirritant **skin** formulation aluminum tin cation;
cosmetic skin irritation aluminum tin cation;
pharmaceutical **skin** irritation aluminum tin cation

IT Amino acids, biological studies
Borates
Carbonates, biological studies
Caseins, biological studies
Fatty acids, biological studies
Hypophosphates
Lanolin
Nitrates, biological studies
Peptides, biological studies
Peroxysulfates
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aluminum and tin salts; anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Antiperspirants
Asthma
Bath preparations
Burn
Deodorants
Dermatitis
Eczema
Hair preparations
Infection
Insect repellents
Mouthwashes
Pruritus
Psoriasis
Shampoos
Sunscreens
(anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Alcohols, biological studies
Carboxylic acids, biological studies
Peroxides, biological studies
Retinoids
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Aloe barbadensis
Chamomile
Detergents
Inflammation inhibitors
Soaps
Steroids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Analgesics
Antibiotics
Contraceptives
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Cola nitida
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ext.; anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **Acne**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Cold
Wind
(irritation from; anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Humidity
(low, irritation from; anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Essential oils
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Melaleuca, ext.; anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Shaving preparations
(aftershaves, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Hair preparations
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidandruff, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Hair preparations
(bleaches, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(body rinses, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(cleansing, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Hair preparations
(conditioners, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Eye, disease
(conjunctivitis, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(**creams**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(depilatories, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Digestive tract
Respiratory tract
(disease, irritation, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Nose
(disease, rhinitis, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Hair preparations
(dyes, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(**emulsions**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(enemas, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Skin**
(**epidermis**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Skin, disease**
(**epidermis**, irritation, anti-irritant **skin**

formulations contg. aluminum or tin cations)
IT **Cosmetics**
(exfoliating, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(face cleansers, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(foams, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
Pharmaceutical dosage forms
(gels, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Tea products
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(green, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Carboxylic acids, biological studies**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**hydroxy**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(inhalants, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Skin, disease**
(irritation, Anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Eye, disease
(irritation, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical natural products
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(licorice, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(liqs., anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(**lotions**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(lozenges, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT **Cosmetics**
(**moisturizers**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(**ointments**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(**ointments**, **creams**, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(ophthalmic, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Pharmaceutical dosage forms
(oral, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Carboxylic acids, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(oxo, anti-irritant **skin** formulations contg. aluminum or tin cations)
IT Amino acids, biological studies

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycarboxylic, aluminum and tin salts; anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(potassium, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Pharmaceutical dosage forms
(rectal, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Ion channel blockers
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Light
(solar, irritation from; anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **Cosmetics**
(sticks, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Hair preparations
(straighteners, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **Sunburn and Suntan**
(suntanning agents, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **Cosmetics**
(**suspensions**, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **Cosmetics**
(toners, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Pharmaceutical dosage forms
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Pharmaceutical dosage forms
(vaginal, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT Hair preparations
(wave-setting, anti-irritant **skin** formulations contg. aluminum or tin cations)

IT 7446-70-0, Aluminum chloride, biological studies 7783-47-3, Stannous fluoride
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **50-21-5**, **Lactic acid**, biological studies
50-21-5D, **Lactic acid**, salts 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 69-72-7D, salts 76-03-9, Trichloroacetic acid, biological studies **76-93-7**, biological studies **77-92-9**, biological studies **77-92-9D**, salts **79-14-1**, biological studies **79-14-1D**, salts **87-69-4**, biological studies 90-64-2, Mandelic acid **90-80-2**, **Gluconolactone** 94-36-0, Benzoyl peroxide, biological studies 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal **127-17-3**, **Pyruvic acid**, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin **526-95-4**, **Gluconic acid** 5393-81-7, .alpha.-Hydroxy decanoic acid **6915-15-7**, **Malic acid** 70424-62-3

126094-21-1
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(anti-irritant **skin** formulations contg. aluminum or tin cations)

IT **50-21-5D, Lactic acid,** aluminum and tin salts
50-81-7D, Ascorbic acid, aluminum and tin salts 56-84-8D, L-Aspartic acid, aluminum and tin salts 57-03-4D, aluminum and tin salts 57-10-3D, Hexadecanoic acid, aluminum and tin salts 57-11-4D, Octadecanoic acid, aluminum and tin salts 57-13-6, Urea, biological studies 58-05-9D, Folinic acid, aluminum and tin salts 58-08-2, Caffein, biological studies 64-18-6D, Formic acid, aluminum and tin salts 64-19-7D, Acetic acid, aluminum and tin salts 65-85-0D, Benzoic acid, aluminum and tin salts 68-11-1D, Thioglycolic acid, aluminum and tin salts 69-72-7D, aluminum and tin salts 69-89-6, Xanthine **77-92-9D,** aluminum and tin salts 79-09-4D, Propionic acid, aluminum and tin salts **79-83-4D,** aluminum and tin salts 81-07-2D, aluminum and tin salts **87-69-4D,** aluminum and tin salts 88-99-3D, Phthalic acid, aluminum and tin salts 94-13-3D, Propyl paraben, aluminum and tin salts 97-59-6, Allantoin 99-76-3D, Methyl paraben, aluminum and tin salts 100-88-9D, Cyclamate, aluminum and tin salts 110-15-6D, Butanedioic acid, aluminum and tin salts 110-16-7D, Maleic acid, aluminum and tin salts 110-44-1D, Sorbic acid, aluminum and tin salts 112-80-1D, 9-Octadecenoic acid (Z)-, aluminum and tin salts 112-85-6D, Behenic acid, aluminum and tin salts 141-22-0D, Ricinoleic acid, aluminum and tin salts 143-07-7D, Dodecanoic acid, aluminum and tin salts 144-62-7D, Ethanedioic acid, aluminum and tin salts 151-41-7D, Lauryl sulfate, aluminum and tin salts 515-69-5, .alpha.-Bisabolol **526-95-4D, Gluconic acid,** aluminum and tin salts 544-63-8D, Tetradecanoic acid, aluminum and tin salts 1405-86-3, Glycyrrhizinic acid 7664-93-9D, Sulfuric acid, aluminum and tin salts 7772-99-8, Stannous chloride, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-irritant **skin** formulations contg. aluminum or tin cations)

L229 ANSWER 49 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:494170 HCAPLUS
DN 125:132809
TI Bioactive agent-containing biocomplex for correcting biological information transfer using three biological information blocks
IN Danielov, Michael M.
PA Dns Scientific, Inc., USA
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-21
ICS A61K039-395; A61K031-55; A61K031-44; A61K031-24
CC 1-12 (Pharmacology)
Section cross-reference(s): 2, **62**, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617621	A1	19960613	WO 1995-US15919	19951206 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5885974	A	19990323	US 1994-350234	19941206 <--
	AU 9645108	A1	19960626	AU 1996-45108	19951206 <--
PRAI	US 1994-350234	19941206 <--			
	WO 1995-US15919	19951206 <--			

AB Methods are disclosed for correcting biol. information transfer in a patient in need of such therapy which comprise administration of a compn. comprising a therapeutically effective amt. of a biocomplex comprising .gtoreq.1 bioactive agent from each of the 3 informational blocks of biol. information transfer, each agent present in an amt. sufficient to correct the biol. information transfer of the patient under treatment and resulting in the resumption of normal cell metab., and the amt. being less than the buffering amt. of said agent; together with a carrier therefor.

ST biol information transfer block therapeutic; cell metab information transfer biocomplex therapeutic

IT **Acne**
Alopecia
Animal cell
Antioxidants
Circulation
Cosmetics
Eczema
Metabolism
Pharmaceutical dosage forms
Pharmaceuticals
Pruritus
Psoriasis
Seborrhea
Signal transduction, biological
Skin, disease
Therapeutics
(bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Albumins, biological studies
Calmodulins
Carbohydrates and Sugars, biological studies
Catecholamines
Cerebrosides
Coenzymes
Collagens, biological studies
Elastins
Gelatins, biological studies
Glycolipids
Lipids, biological studies
Orosomucoids
Peptides, biological studies
Phosphatidic acids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines
Phosphatidylinositols
Phosphatidylserines
Phosphoinositides
Phospholipids, biological studies
Prostaglandins
Protamines
Proteins, biological studies
Sphingolipids
Steroids, biological studies
Sulfatides
Vitamins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Animal growth regulator receptors
Estrogen receptors
Prostaglandin receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Brain
(ext.; bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Shock
(post-trauma; bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Cell membrane
(substitute cell membrane delivery system; bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Prostaglandins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(A, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Prostaglandins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(D, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Prostaglandins
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(E, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(animal growth regulator, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT **Skin**
(cellulite, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Glycerides
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Phosphoinositides
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-, 4-phosphates, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT **Skin, disease**
(dry, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(estrogen, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Corticosteroid receptors
Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(glucocorticosteroid, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Lipoproteins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high-d., bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)
IT Phosphatidylcholines, biological studies
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Elastins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrolyzates, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Lipoproteins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(low-d., bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Corticosteroid receptors
Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(mineralocorticosteroid, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT **Dermatitis**
(neuro-, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT **Skin, disease**
(oily, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Pharmaceutical dosage forms
(**ointments, creams,** bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Pharmaceutical dosage forms
(ophthalmic, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Pharmaceutical dosage forms
(parenterals, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prostaglandin, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT **Sunburn and Suntan**
(suntanning agents, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Pharmaceutical dosage forms
(topical, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Injury
(trauma, shock following; bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Phosphoinositides
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tri-, 4,5-bis(phosphates), bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Collagens, biological studies
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type I, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Collagens, biological studies
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type II, bioactive agent-contg. biocomplex for correcting biol.

information transfer and cell metab., and therapeutic use)

IT Collagens, biological studies
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type III, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Lipoproteins
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(very-low-d., bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT **Skin, disease**
(wrinkle, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(.alpha.2-adrenergic, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT Receptors
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(.beta.2-adrenergic, bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT 60-92-4, Cyclic AMP
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT 50-14-6, Ergocalciferol 50-23-7, Hydrocortisone 50-28-2, .beta.-Estradiol, biological studies **50-81-7**, L-**Ascorbic acid**, biological studies 51-61-6, Dopamine, biological studies 52-39-1, Aldosterone 52-89-1, L-**Cysteine** hydrochloride 53-59-8, .beta.-NADP 53-84-9, .beta.-NAD 54-47-7, Pyridoxal-5-phosphate 55-31-2, Epinephrine hydrochloride 56-65-5, Adenosine triphosphate, biological studies 56-81-5D, 1,2,3-Propanetriol, 1,2-diacyl derivs. **56-89-3**, L-**Cystine**, biological studies 57-11-4, Octadecanoic acid, biological studies 57-83-0, Progesterone, biological studies 57-87-4, Ergosterol 57-88-5, Cholesterol, biological studies 58-56-0, Pyridoxine hydrochloride 58-85-5, Biotin 58-95-7, .alpha.-Tocopherol acetate 59-30-3, Folic acid, biological studies 60-18-4, L-Tyrosine, biological studies 60-33-3, 9,12-Octadecadienoic acid (Z,Z)-, biological studies 63-91-2, L-Phenylalanine, biological studies 65-71-4, Thymine 66-22-8, Uracil, biological studies 67-03-8, Thiamine hydrochloride 71-30-7, Cytosine 73-22-3, L-Tryptophan, biological studies 73-24-5, Adenine, biological studies 73-40-5, Guanine 79-81-2, Retinol palmitate 85-61-0, Coenzyme A, biological studies 86-01-1, Guanosine triphosphate 96-26-4, Dihydroxyacetone 98-92-0, Nicotinamide 112-85-6, Behenic acid 113-79-1, Arginine vasopressin 117-39-5, Quercetin 122-32-7, Triolein 123-33-1, Maleic hydrazide 135-16-0, Tetrahydrofolic acid 137-08-6, **Pantothenic acid** hemicalcium salt 145-42-6, Sodium taurocholate 154-87-0, Cocarboxylase 329-56-6, Arterenol hydrochloride 361-09-1, Sodium cholate 363-24-6, Prostaglandin E2 463-40-1, Linolenic acid 481-39-0, Juglone 506-21-8, Linolelaidic acid 506-30-9, Arachidic acid 537-40-6, Trilinolein 551-11-1, Prostaglandin F2.alpha. 555-43-1, Tristearin 606-68-8 620-64-4, Triarachidin 745-65-3, Prostaglandin E1 863-57-0, Sodium glycocholate 987-65-5, Adenosine triphosphate disodium salt 1105-02-8, Corticosterone-21-sulfate 1184-16-3 1340-08-5, Vitamin P 1407-47-2, Angiotensin 1731-94-8, Nonadecanoic acid methyl ester 2566-90-7 2644-64-6, Dipalmitoylphosphatidylcholine 2752-99-0, Trierucin 3026-45-7, Dipalmitoylphosphatidylethanolamine 4537-76-2, Distearoylphosphatidylethanolamine 4537-77-3, Dipalmitoylphosphatidylglycerol 4537-78-4, Distearoylphosphatidylglycero

l 4539-70-2, Distearoylphosphatidylcholine 4999-79-5, Estradiol-3-sulfate sodium salt 6064-90-0, Heneicosanoic acid methyl ester 6610-25-9, Arachidonic acid sodium salt 7235-40-7, .beta.-Carotene 7665-99-8, Cyclic GMP 9001-62-1, Lipase 9002-60-2, Adrenocorticotropic hormone, biological studies 9002-60-2D, Adrenocorticotropic hormone, 1-24 fragment 9002-64-6, Parathyroid hormone 9002-64-6D, Parathyroid hormone, 1-36 fragment 9002-67-9, Luteinizing hormone 9002-68-0, Follicle-stimulating hormone 9002-71-5, Thyrotropic hormone 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9004-61-9, Hyaluronic acid 9005-49-6, Heparin sulfate, biological studies 9007-12-9, Thyrocalcitonin 9007-92-5, Glucagon, biological studies 9015-73-0 9026-43-1, Protein kinase 9041-08-1, Heparin sodium salt 10417-94-4 10529-43-8, Cholecalciferol sulfate 11000-17-2, Vasopressin 11061-68-0, Human insulin 11128-99-7, Angiotensin II 12629-01-5, Human growth hormone 13487-42-8 13699-48-4, Dimyristoylphosphatidylcholine 14465-68-0 15866-84-9, Adenosine triphosphate calcium salt 18641-57-1, Tribehenin 20255-95-2, Dimyristoylphosphatidylethanolamine 20290-75-9 22251-85-0, Flavin mononucleotide sodium salt 24967-93-9, Chondroitin sulfate A 24967-94-0, **Dermatan** sulfate 25322-46-7, Chondroitin sulfate C 26536-13-0, Trinonadecanoin 27964-99-4, Poly-D-lysine hydrobromide 28845-86-5, 13,16,19-Docosatrienoic acid, (Z,Z,Z)- 28874-58-0 35121-78-9, Prostaglandin I2 37221-79-7, Vasoactive intestinal peptide 37377-93-8, .beta.-Lipotropin 37377-93-8D, .beta.-Lipotropin, fragment 37839-81-9, Cyclic AMP sodium salt 40245-60-1, Cyclic GMP sodium salt 41598-07-6, Prostaglandin D2 52910-82-4, Aldosterone-21-hemisuccinate 55672-92-9, Coenzyme A sodium salt 59392-49-3, Gastric inhibitory peptide 60617-12-1, .beta.-Endorphin 60617-12-1D, .beta.-Endorphin, fragment 61361-72-6, Dimyristoylphosphatidylglycerol 61849-14-7, Prostaglandin I2 sodium salt 78392-27-5, Cholecalciferol sulfate sodium salt 80380-39-8, Tri-11-eicosenoin 85166-31-0, D-myo-Inositol-1,4,5-triphosphate 92216-45-0, D-myo-Inositol-2,4,5-triphosphate 96012-99-6, Guanosine triphosphate lithium salt 99660-95-4 100775-23-3, Corticosterone-21-sulfate potassium salt 108340-81-4, D-myo-Inositol, 1,4,5-tris(dihydrogen phosphate), hexasodium salt 135271-36-2, D-myo-Inositol-1,4,5-triphosphate potassium salt
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

IT 7440-70-2, Calcium, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(intracellular, mobilization; bioactive agent-contg. biocomplex for correcting biol. information transfer and cell metab., and therapeutic use)

L229 ANSWER 50 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:464554 HCAPLUS
DN 125:123264
TI Shelf-stable **skin** cleansing liquid with gel-forming polymer, lipid, and crystalline ethylene glycol fatty acid ester
IN Kacher, Mark Leslie; Dixon, Thomas Jefferson; Koczwara, Constance Sagel; Tollens, Fernando Ray; Schmidt, Robert Raymond; Evans, Marcus Wayne; Geary, Nicholas William
PA Procter and Gamble Co., USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-50
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617592	A2	19960613	WO 1995-US15674	19951201 <--

W: BR, CA, CN, JP, MX
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2207031 AA 19960613 CA 1995-2207031 19951201 <--
EP 796084 A2 19970924 EP 1995-942536 19951201 <--
EP 796084 B1 19990506
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
BR 9509865 A 19970930 BR 1995-9865 19951201 <--
CN 1169112 A 19971231 CN 1995-196673 19951201 <--
AT 179595 E 19990515 AT 1995-942536 19951201 <--
JP 11507323 T2 19990629 JP 1995-517676 19951201 <--
US 5674511 A 19971007 US 1996-722699 19960930 <--
PRAI US 1994-350368 19941206 <--
WO 1995-US15674 19951201 <--

AB The title cleansing liq. can provide good cleansing, lather, and good sensory feel and yet provides a lipid-**moisturizing** benefit via deposition of the lipid on the **skin** of the user. The liq. compn. is stable and on a macro scale is homogeneous. The dual cleansing and lipid-**moisturizing** liq. compn. comprises: (1) 5-30 parts lipid **skin-moisturizing** agent; (2) 1-15 parts ethylene glycol fatty acid ester as stabilizer; (3) 0.05-3 parts water-**dispersible** gel-forming polymer; (4) 5-30 parts lathering synthetic surfactant; and (5) water. The synthetic surfactant and any soap has a combined crit. micelle concn. equil. surface tension value of 15-50, and the lathering **skin** cleansing liq. compn. has a lipid deposition value (LDV) of 5-1000 .mu.g lipid/cm2 of **skin**. Thus, ethylene glycol distearate (EGDS) was added to a mixt. of various surfactant types in water at 71.degree. to maximize solubilization of EGDS, and quickly cooled to 27-43.degree. to induce crystn. of EGDS. A cleanser contained K myristate 6.0, myristic acid 0.3, Na C12-14 alkyl glyceryl ether sulfonate 5.8, triethanolamine lauroyl sarcosinate 2.7, coco betaine 3.8, EGDS 4.2, Polyquaternium 10 0.25, petrolatum 13.6, mineral oil 3.4, glycerin 8.6, perfume 0.8, tetra-Na EDTA 0.15, DMDM hydantoin (preservative) 0.4, and H2O 49.9 parts.

ST ethylene glycol fatty ester stabilizer cleanser

IT Polymers, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(gel-forming, water-**dispersible**; shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT Glycosides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(poly-, alkyl; shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT Beeswax
Surfactants
(shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT Betaines
Esters, biological studies
Glycerides, biological studies
Lanolin
Lipids, biological studies
Paraffin oils
Paraffin waxes and Hydrocarbon waxes, biological studies
Petrolatum
Phospholipids, biological studies
Siloxanes and Silicones, biological studies
Soaps
Waxes and Waxy substances
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT Amines, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(N-oxides, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Phenols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alkyl, ethoxylated, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Polysaccharides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(cationic, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT **Cosmetics**
(cleansing, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Glycerides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Sulfonic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters, with alkyl glyceryl ethers; shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Fatty acids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters, with polyols; shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Amides
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(fatty, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Steroids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Imines
Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polymers, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sulfo, alkyl esters, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)
IT Betaines
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(sulfo-, shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT 9004-34-6, Cellulose, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(resins; shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT **50-21-5D, Lactic acid**, O-acyl esters
50-99-7D, Glucose, esters, alkyl derivs. 56-86-0D, Glutamic acid, N-acyl derivs. 79-10-7D, 2-Propenoic acid, polymers 79-41-4D, polymers 107-21-1D, 1,2-Ethanediol, esters 107-36-8D, Isethionic acid, esters 107-97-1D, Sarcosine, N-acyl, esters 151-21-3, Sodium lauryl sulfate, biological studies 2235-54-3, Ammonium lauryl sulfate 3416-24-8D, Glucosamine, N-acyl, alkyl derivs. 5138-18-1D, Sulfosuccinic acid, alkyl esters 7631-98-3, Sodium lauryl sarcosinate 7664-38-2D, Phosphoric acid, alkyl esters 7664-93-9D, Sulfuric acid, esters with .alpha.-olefins and polyoxyalkylenes 9000-30-0, Guar gum 9003-04-7, Sodium polyacrylate 9003-29-6 9003-29-6D, hydrogenated 9004-62-0, Hydroxyethylcellulose 9004-82-4, Sodium laureth sulfate 9006-65-9, Dimethicone 12441-09-7D, Sorbitan, esters 13429-27-1, Potassium myristate 16693-53-1, Triethanolamine lauroyl sarcosinate 25322-68-3 25426-60-2 26426-80-2, Isobutylene/maleic anhydride copolymer 26590-05-6, Polyquaternium 7 32612-48-9, Ammonium laureth sulfate 37961-36-7, Sodium lauryl isethionate 52619-75-7D, **Taurine** methyl ester, acyl derivs. 80455-45-4 81859-24-7, Polyquaternium 10 106392-12-5, Poloxamer 110617-70-4, Tetronic 179266-74-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

IT 627-83-8, Ethylene glycol distearate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(stabilizer; shelf-stable **skin** cleansing liq. with gel-forming polymer, lipid, and cryst. ethylene glycol fatty acid ester)

L229 ANSWER 51 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:409590 HCAPLUS
DN 125:67245
TI **Skin** preparations containing diesters of astaxanthine and water-soluble vitamins
IN Suzuki, Kazunari; Masaki, Hitoshi; Takei, Masumi
PA Noevir Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-48; C07F009-117; C07F009-58; C07F009-6524; C07F009-6536; C07F009-655
ICA C07C403-22
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08073311	A2	19960319	JP 1994-234259	19940902 <--

OS MARPAT 125:67245
GI



I

AB **Skin** prepns. contain .gtoreq.1 selected from diesters I [A = P(O)(OH)OX; X = residue of thiamine, riboflavin, 1-.beta.-D-ribofuranosylnicotinamide, 1-.beta.-D-ribofuranosylnicotinic acid, pyridoxal, pyridoxine, pyridoxamine, **pantothenic acid**, **ascorbic acid**] (II), I [A = P(O)(OH)OP(O)(OH)OX; X has the same definition as in the above], and I [A = SO3X; X has the same definition as in the above]. The derivs. of astaxanthine, which show singlet O-eliminating action, show water soly. and are hydrolyzed by esterase on or in the **skin** to show synergistic aging-preventive action of astaxanthine and the water-sol. vitamins. Glycerin, propylene glycol, EtOH, II (X = thiamine residue), p-MeC6H4CO2Me, and H2O were mixed to give a **lotion**.

ST astaxanthine vitamin complex antiaging **cosmetic**; solubilized astaxanthine aging preventive **cosmetic**

IT **Cosmetics**
(antiaging, antiaging **cosmetics** contg. (pyro)phosphates or sulfates of astaxanthine and water-sol. vitamins)

IT 178278-75-6 178278-77-8 178406-07-0 178406-08-1 178406-09-2 178406-10-5 178406-11-6 178406-12-7
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging **cosmetics** contg. (pyro)phosphates or sulfates of astaxanthine and water-sol. vitamins)

L229 ANSWER 52 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:313756 HCAPLUS
DN 124:325031
TI **Cosmetic** compositions for **skin** depigmentation containing synergistic combination of a tyrosinase inhibitor and an organic acid or its derivatives
IN Thorel, Jean Noel
PA Fr.
SO Fr. Demande, 13 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM A61K031-375
ICS A61K031-19
ICI A61K031-375, A61K031-335, A61K033-24, A61K031-375, A61K033-06; A61K031-19, A61K031-335, A61K033-24, A61K031-19, A61K033-06
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2723316	A1	19960209	FR 1994-9875	19940804 <--
	FR 2723316	B1	19961004		

AB The title compns. are used for treatment of **skin** pigmentations. A **cosmetic** compn. contained flavonoids of liquorice ext. 0.05, isoquercetin 0.10, amino-2-deoxy-2-glucose 0.10, **lactic acid** 5.00, **citric acid** 0.03, TiO2 20.00, benzophenone-3 2.00, excipients and water q.s. 100%.

ST **cosmetic skin** depigmentation synergistic tyrosinase inhibitor; org acid **skin** depigmentation synergistic **cosmetic**

IT Melanins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Anthocyanins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Flavanols
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Flavonoids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Leucoanthocyanins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Phospholipids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Triterpenes and Triterpenoids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT **Cosmetics**
(**creams, cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT **Cosmetics**

(**lotions, cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Flavonoids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo, **cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Flavonoids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo hydroxy, poly-; **cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT Flavonoids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo prenyl, **cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT **Skin, disease**
(pigmentation, **cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT **Sunburn and Suntan**
(suntanning agents, **cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT 1335-30-4, Aluminum silicate
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT **50-21-5, Lactic acid**, biological studies
50-81-7, Ascorbic acid, biological studies
77-92-9, Citric acid, biological studies
131-57-7, Benzophenone-3 137-66-6, Ascorbyl palmitate 482-35-9, Isoquercetin 3416-24-8, Amino-2-deoxy-2-glucose 13463-67-7, Titaniumoxide, biological studies 23666-04-8 62596-29-6, Morusin 68401-05-8, Kuwanone 126236-47-3, Amyrin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

IT 9002-10-2, Tyrosinase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitor; **cosmetic** compns. for **skin** depigmentation contg. synergistic combination of a tyrosinase inhibitor and an org. acid or its derivs.)

L229 ANSWER 53 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:303959 HCAPLUS
DN 124:325025
TI Use of an agonist of a receptor associated with a chloride channel in the treatment of wrinkles
IN De Lacharriere, Olivier; Breton, Lionel
PA Oreal S. A., Fr.
SO Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K031-195
ICS A61K031-44; A61K031-445; A61K031-515; A61K031-55; A61K031-56;

A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 704210	A2	19960403	EP 1995-402155	19950926 <--
	EP 704210	A3	19970423		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	BR 9504741	A	19961015	BR 1995-4741	19950927 <--
	JP 08099862	A2	19960416	JP 1995-251587	19950928 <--
	JP 2736316	B2	19980402		
	CA 2159555	AA	19960331	CA 1995-2159555	19950929 <--
	HU 73064	A2	19960628	HU 1995-2870	19950929 <--
	CN 1130059	A	19960904	CN 1995-118674	19950929 <--
	RU 2128497	C1	19990410	RU 1995-116594	19950929 <--
	US 5869068	A	19990209	US 1995-538119	19951002 <--
	US 5976559	A	19991102	US 1998-50959	19980331 <--
PRAI	FR 1994-11742	19940930 <--			
	US 1995-538119	19951002 <--			

AB Agonists of a receptor assocd. with a chloride channel, such as glycine, are used for **skin** tissue relaxation and treatment of wrinkles. The compn. are used as topical or parenteral and may contain retinoids or hydroxyacids. A face **lotion** contained Z-glycine 8, antioxidants 0.05, preservative 0.3, EtOH 8, and water q.s. 100%.
ST receptor agonist chloride channel wrinkle treatment; **lotion** glycine antiwrinkle **cosmetic**
IT Retinoids
Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonist of receptor assocd. with chloride channel in treatment of wrinkles)
IT **Cosmetics**
(**creams**, wrinkle-preventing, agonist of receptor assocd. with chloride channel in treatment of wrinkles)
IT **Carboxylic acids, biological studies**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hydroxy**, agonist of receptor assocd. with chloride channel in treatment of wrinkles)
IT **Cosmetics**
(wrinkle-preventing, **lotions**; agonist of receptor assocd. with chloride channel in treatment of wrinkles)
IT **Cosmetics**
(wrinkle-preventing, gels, agonist of receptor assocd. with chloride channel in treatment of wrinkles)
IT 56-12-2, .gamma.-Aminobutyric acid, biological studies 56-40-6, Glycine, biological studies 56-45-1, Serine, biological studies 67-52-7D, Barbituric acid, derivs. 68-26-8, Retinol 68-26-8D, Retinol, esters **107-35-7**, **Taurine** 107-95-9, .beta.-Alanine 302-79-4, Retinoic acid 302-79-4D, Retinoic acid, derivs. 498-94-2, Isonipecotic acid 1138-80-3, N-(Benzyloxycarbonyl)-glycine 1622-62-4, Flunitrazepam 12794-10-4, Benzodiazepine 64603-90-3, Isoguvacine 176660-06-3
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonist of receptor assocd. with chloride channel in treatment of wrinkles)

L229 ANSWER 54 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1996:89330 HCAPLUS
DN 124:126898
TI Antiaging **cosmetics** containing collagen crosslinking inhibitors and UV protective agents
IN Tominaga, Naoki
PA **Shiseido** Co., Ltd., Japan; Sogo Pharmaceutical Co., Ltd.
SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 688559	A1	19951227	EP 1995-114397	19950913 <--
R: DE, ES, FR, GB, IT				
JP 09020639	A2	19970121	JP 1995-195965	19950707 <--
US 5747049	A	19980505	US 1995-529601	19950918 <--
US 6077520	A	20000620	US 1998-23047	19980213 <--

PRAI JP 1995-195965 19950707 <--
US 1995-529601 19950918 <--

AB An anti-aging prepn., a collagen crosslinking inhibitory prepn. which inhibits collagen crosslinking occurring predominantly in the **dermis** to maintain **skin** elasticity and to prevent wrinkles or sagging, and an anti-UV prepn. which protects the **skin** from bad influences of excessive UV rays of sunlight are disclosed. The prepns. contain one or two aminoethyl compds., NH2CH2CH2X wherein X represents -SO2H or -SO2SH, and preferably contg. at least one UV protective agent. A **lotion** contained 2-aminoethylthiosulfonic acid 0.05, Na hydroxy-4-methoxybenzophenone-5-sulfonate 0.1, tocopherol acetate 0.01, glycerol 4.0, 1,3-butylene glycol 4.0, ethanol 8.0, polyoxyethylene hydrogenated castor oil 0.5, methylparaben 0.2, **citric acid** 0.05, Na citrate 0.1, perfume 0.05, and purified water to 100%.

ST antiaging **cosmetic taurine** aminoethylsulfinate sunscreen

IT **Sunscreens**
(antiaging **cosmetics** contg. aminoethyl compds. and sunscreens)

IT Collagens, biological studies
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(of **skin**; antiaging **cosmetics** contg. aminoethyl compds. and sunscreens)

IT **Cosmetics**
(antiaging, antiaging **cosmetics** contg. aminoethyl compds. and sunscreens)

IT 131-57-7, 2-Hydroxy-4-methoxy-benzophenone **300-84-5**, 2-Aminoethylsulfinic acid **2937-54-4** 6628-37-1 70356-09-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging **cosmetics** contg. aminoethyl compds. and sunscreens)

L229 ANSWER 55 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:992734 HCAPLUS
DN 124:15301
TI **Cosmetic** compositions containing retinal and liposoluble antioxidants
IN Navarro, Roger; Peyrot, Nicole; Delaunois, Marlene
PA Pierre Fabre Dermo-Cosmetique, Fr.
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM A61K007-48
ICS A61K031-07
CC 62-6 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9526709	A1	19951012	WO 1995-FR434	19950405 <--
W: AU, CA, JP, US				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
FR 2718021 A1 19951006 FR 1994-3970 19940405 <--
FR 2718021 B1 19960628
AU 9523103 A1 19951023 AU 1995-23103 19950405 <--
PRAI FR 1994-3970 19940405 <--
WO 1995-FR434 19950405 <--
AB A **skin**-care or **cosmetic** retinal-contg. compn. wherein the compn. has a pH of 3 to 6 and contains a stabilizing system such as liposol. antioxidants is disclosed. A **lotion** contained retinal 0.05, propylene glycol 60, BHT 0.01, water 100g, and **lactic acid** q.s. for pH = 4.5. The loss of retinal after 12 mo at pH = 7 was 15.7 and at pH = 4.5 was 1.8%.
ST **cosmetic** compn retinal antioxidant
IT **Cosmetics**
(**cosmetic** compns. contg. retinal)
IT Amines, biological studies
Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. retinal)
IT Antioxidants
(**cosmetic** compns. contg. retinal and liposol. antioxidants)
IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(amino, **cosmetic** compns. contg. retinal)
IT **Cosmetics**
(gels, **cosmetic** compns. contg. retinal)
IT Acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inorg., **cosmetic** compns. contg. retinal)
IT **Cosmetics**
(**lotions**, **cosmetic** compns. contg. retinal)
IT **50-21-5**, **Lactic acid**, biological studies
58-95-7, Tocopheryl acetate **77-92-9**, **Citric acid**, biological studies **87-69-4**, **Tartaric acid**, biological studies 110-44-1, Sorbic acid 121-79-9, Propyl gallate 128-37-0, biological studies 137-66-6, Ascorbyl palmitate 500-38-9 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1336-21-6, Ammonium hydroxide 7647-01-0, Hydrochloric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 20229-76-9, L-**Ascorbic acid**, 6-acetate 25013-16-5, Butylhydroxyanisole
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. retinal)
IT 59-02-9, .alpha.-Tocopherol 116-31-4, Retinal
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetic** compns. contg. retinal and liposol. antioxidants)

L229 ANSWER 56 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:986644 HCAPLUS
DN 124:37384
TI **Skin cosmetics** containing .alpha.-**hydroxycarboxylic acids**
IN Yamamoto, Naomi; Tsubone, Kazuyuki
PA Kanebo Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07242529	A2	19950919	JP 1994-60285	19940303 <--

AB **Skin**-conditioning **cosmetics** contain (A) .gtoreq.1 amino acids, glycyrrhizic acids and/or glycyrrhetic acids, ceramide, glucosylceramide, and/or galactosylceramide, or vitamins and (B) .gtoreq.1 C3-5 .alpha.-**hydroxycarboxylic acids**. **Skin lotion** contg. 0.05 wt.% Na lactate (I) and 0.01 wt.% N-methylserine (II) showed better **skin**-conditioning effect than controls contg. I or II, resp.

ST **hydroxycarboxylate** amino acid **cosmetic** conditioner; glycyrrhizate **hydroxycarboxylate cosmetic** conditioner; ceramide glycosylceramide **hydroxycarboxylate cosmetic** conditioner; galactosylceramide vitamin **hydroxycarboxylate cosmetic** conditioner

IT Amino acids, biological studies
Ceramides
Vitamins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin**-conditioning **cosmetics** contg. **hydroxycarboxylic acids**)

IT **Cosmetics**
(conditioners, **skin**-conditioning **cosmetics** contg. **hydroxycarboxylic acids**)

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy, skin**-conditioning **cosmetics** contg. **hydroxycarboxylic acids**)

IT **50-21-5**, biological studies 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 56-86-0, Glutamic acid, biological studies 58-95-7, Vitamin E acetate 68-26-8, Retinol 72-17-3, Sodium lactate 72-18-4, Valine, biological studies 81-13-0, Panthenol 471-53-4, Glycyrrhetic acid 1405-86-3, Glycyrrhizic acid 2480-26-4, N-Methylserine 13832-70-7 43119-47-7, Vitamin E nicotinate 53956-04-0, Monoammonium glycyrrhizate 68797-35-3, Dipotassium glycyrrhizate 85305-87-9, Glucosylceramide 85305-88-0, Galactosylceramide 108910-78-7, **Ascorbic acid** phosphate magnesium salt
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin**-conditioning **cosmetics** contg. **hydroxycarboxylic acids**)

L229 ANSWER 57 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:951387 HCAPLUS
DN 123:349890
TI Artificial tanning compositions having improved color development
IN Tanner, Paul Robert; Robinson, Larry Richard
PA Procter and Gamble Co., USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9526179	A1	19951005	WO 1995-US3445	19950317 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2186502	AA	19951005	CA 1995-2186502	19950317 <--
	EP 752843	A1	19970115	EP 1995-914757	19950317 <--

EP 752843 B1 20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 09510971 T2 19971104 JP 1995-525199 19950317 <--
AT 197895 E 20001215 AT 1995-914757 19950317 <--
US 5603923 A 19970218 US 1995-533023 19950925 <--
PRAI US 1994-219061 19940329 <--
WO 1995-US3445 19950317 <--

AB Artificial tanning compns. that provide improved color development and good chem. and phys. stability comprise dihydroxyacetone, certain amino acids or their pharmaceutically acceptable salts, and a topical carrier; the compns. have pH <4. A stabilizing salt (metabisulfite, sulfite, H sulfite) and a sunscreen may also be present. Thus, an artificial tanning **cream** was prepd. by combining the following phases: (A) water (to 100 wt.%), glycerin 5.00, Mg Al silicate 0.50, xanthan gum 0.30, di-Na EDTA 0.10, C10-30-alkyl acrylate polymer 0.025; (B) octyl palmitate 3.00, propoxylated methylglucose distearate 2.00, cetyl alc. 2.00, stearyl alc. 2.00, polysorbate 60 1.00, dimethicone 1.00, steareth-20 1.00, glyceryl stearate + PEG-100 stearate 0.25, DEA-cetyl phosphate 0.10; (C) water 13.5, dihydroxyacetone 5.00, butylene glycol 2.50, **citric acid** 2.00, L-lysine 0.50, dimethylol-5,5-dimethylhydantoin + iodopropynyl butylcarbamate 0.25; and (D) fragrance 0.15 wt.%.

ST tanning compn hydroxyacetone amino acid; sulfite stabilizer **skin** tanning compn

IT Amino acids, biological studies
Disulfites
Sulfites
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(artificial tanning compns. having improved color development)

IT Sulfites
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydrogen, artificial tanning compns. having improved color development)

IT **Sunburn and Suntan**
(suntanning agents, artificial tanning compns. having improved color development)

IT **52-90-4**, **Cysteine**, biological studies 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-85-9, Glutamine, biological studies 56-87-1, L-Lysine, biological studies 60-18-4, Tyrosine, biological studies 61-90-5, L-Leucine, biological studies **63-68-3**, **Methionine**, biological studies 63-91-2, Phenylalanine, biological studies 70-47-3, Asparagine, biological studies 71-00-1, Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 74-79-3, Arginine, biological studies 96-26-4, Dihydroxyacetone 147-85-3, Proline, biological studies 657-26-1, Lysine dihydrochloride 657-27-2, Lysine monohydrochloride 7631-90-5, Sodium hydrogen sulfite 7681-57-4, Sodium metabisulfite 7757-83-7, Sodium sulfite 7773-03-7, Potassium hydrogen sulfite 10117-38-1, Potassium sulfite 10192-30-0, Ammonium hydrogen sulfite 10196-04-0, Ammonium sulfite 16731-55-8, Potassium metabisulfite 32736-64-4, Ammonium metabisulfite
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(artificial tanning compns. having improved color development)

L229 ANSWER 58 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:947066 HCAPLUS
DN 123:349899
TI **Skin** treatment composition for increasing sphingolipid biosynthesis in the **skin**
IN Zhang, Kelly H.; Kosturko, Richard; Bartolone, John B.; Rawlings, Anthony V.
PA Chesebrough-Pond's, USA

SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-00
ICS A61K007-48
NCL 424401000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5451405	A	19950919	US 1994-232896	19940425 <--
EP 684040	A2	19951129	EP 1995-302500	19950413 <--
EP 684040	A3	19951213		
R: CH, DE, ES, FR, GB, IT, LI, NL, SE				
CA 2147341	AA	19951026	CA 1995-2147341	19950419 <--
ZA 9502356	A	19961021	ZA 1995-2356	19950421 <--
ZA 9503256	A	19961021	ZA 1995-3256	19950421 <--
JP 07291851	A2	19951107	JP 1995-99358	19950425 <--

PRAI US 1994-232896 19940425 <--

AB The title compn. for enhancing biosynthesis of sphingolipids, lipids, and ceramides in the **skin**, comprises .alpha.-hydroxy acids, e.g. L-**lactic acid** or salts thereof 0.001-20% and N-acetyl-L-**cysteine** 0.001-20%. The compn. improves the appearance of wrinkled, flaky, or aged **skin**. A **cream** contained L-**lactic acid** 10, mineral oil 4, N-acetyl-L-**cysteine** 1, Brij-56 4, cetyl alc. 4, triethanolamine 0.75, butane-1,3-diol 3, xanthan gum 0.3, preservatives 0.4, perfumes q.s, BHT 0.01, and water to 100%.

ST antiaging **cosmetic** lactate acetylcysteine sphingolipid biosynthesis

IT Ceramides
Lipids, biological studies
Sphingolipids
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(antiaging **cosmetics** contg. .alpha.-hydroxy acids and acetyl **cysteine** for increasing sphingolipid biosynthesis in **skin**)

IT **Cosmetics**
(antiaging, antiaging **cosmetics** contg. .alpha.-hydroxyacids and acetyl **cysteine** for increasing sphingolipid biosynthesis in **skin**)

IT **Alcohols, biological studies**
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(**carboxy**, antiaging **cosmetics** contg. .alpha.-hydroxy acids and acetyl **cysteine** for increasing sphingolipid biosynthesis in **skin**)

IT **Carboxylic acids, biological studies**
RL: BOC (Biological occurrence); BIOL (Biological study); OCCU (Occurrence)
(**hydroxy**, antiaging **cosmetics** contg. .alpha.-**hydroxy** acids and acetyl **cysteine** for increasing sphingolipid biosynthesis in **skin**)

IT **79-33-4**, L-**Lactic acid**, biological studies
87-69-4, L-**Tartaric acid**, biological studies
616-91-1, N-Acetyl-L-**cysteine** 617-73-2, 2-Hydroxy octanoic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging **cosmetics** contg. .alpha.-hydroxy acids and acetyl **cysteine** for increasing sphingolipid biosynthesis in **skin**)

L229 ANSWER 59 OF 110 HCAPLUS COPYRIGHT 2001 ACS

AN 1995:863678 HCAPLUS
DN 123:265797
TI Stabilized **cosmetic emulsions** of **ascorbic acid**
IN Candau, Didier; Collin, Nathalie
PA Oreal S. A., Fr.
SO Fr. Demande, 20 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM A61K007-48
ICS A61K007-40; A61K009-107; A61K031-375
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2715844	A1	19950811	FR 1994-1282	19940204 <--
	FR 2715844	B1	19960329		
	EP 670157	A1	19950906	EP 1995-400134	19950123 <--
	EP 670157	B1	19971001		
	R: DE, ES, FR, GB, IT				
	ES 2109779	T3	19980116	ES 1995-400134	19950123 <--
	CA 2141765	AA	19950805	CA 1995-2141765	19950203 <--
	JP 07256086	A2	19951009	JP 1995-17348	19950203 <--
	JP 2898213	B2	19990531		
	US 5552446	A	19960903	US 1995-383431	19950203 <--
	US 5629004	A	19970513	US 1996-607494	19960227 <--
PRAI	FR 1994-1282	19940204 <--			
	US 1995-383431	19950203 <--			

AB Stabilized **cosmetic emulsions** of **ascorbic acid** (I), having pH .gtoreq.3.5, contg. **emulsifiers** are claimed. A **cosmetic cream** contained cetyldimethiconecopolyol 2, triglyceryl trioleate 5, cyclopentadimethylsiloxane 8, cyclohexadimethylsiloxane 4, a mixt. of cyclopentadimethylsilosane:dimethiconol (90:10) 4, apricot oil 3, glycerin 3, I 5, NaCl 0.5, diazolidinylurea 0.2, butylparaben/sorbic acid 0.4, fragrance 0.3, and water q.s. 100.
ST **cosmetic emulsion ascorbic acid** stability; **cream cosmetic** cetyldimethiconecopolyol **ascorbic acid** stability
IT Chelating agents
Emulsifying agents
Sunscreens
(stabilized **cosmetic emulsions** of **ascorbic acid**)
IT Siloxanes and Silicones, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(stabilized **cosmetic emulsions** of **ascorbic acid**)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(.alpha.-**hydroxy**; stabilized **cosmetic emulsions** of **ascorbic acid**)
IT **Cosmetics**
(**creams**, stabilized **cosmetic emulsions** of **ascorbic acid**)
IT Polyoxyalkylenes, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-Me, Me hydrogen siloxane-, stabilized **cosmetic emulsions** of **ascorbic acid**)
IT Siloxanes and Silicones, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(di-Me, Me hydrogen, polyoxyalkylene-, stabilized **cosmetic emulsions** of **ascorbic acid**)
IT **Skin, disease**
(pigmentation, stabilized **cosmetic emulsions** of **ascorbic acid**)
IT **Cosmetics**
(wrinkle-preventing, stabilized **cosmetic emulsions** of **ascorbic acid**)
IT **50-21-5, Lactic acid,** biological studies
50-81-7, Ascorbic acid, biological studies
7651-99-2, Pentasodium ethylenediaminetetra(methylenephosphonate)
145686-34-6, Cetyldimethicone copolyol
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(stabilized **cosmetic emulsions** of **ascorbic acid**)

L229 ANSWER 60 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:851840 HCAPLUS
DN 123:265796
TI Stabilized **cosmetic** or **dermatologic** composition containing several precursors of a same active agent
IN Bernard, Dominique; Nguyen, Quang Lan
PA Oreal S. A., Fr.
SO Eur. Pat. Appl., 9 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K007-48
ICS A61K007-06; A61K031-70
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 667145	A1	19950816	EP 1995-400062	19950112	<--
	EP 667145	B1	19960925			
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
	FR 2715565	A1	19950804	FR 1994-1031	19940131	<--
	FR 2715565	B1	19960315			
	AT 143256	E	19961015	AT 1995-400062	19950112	<--
	ES 2095174	T3	19970201	ES 1995-400062	19950112	<--
	CA 2141372	AA	19950801	CA 1995-2141372	19950130	<--
	JP 08053323	A2	19960227	JP 1995-13168	19950130	<--
	JP 2705910	B2	19980128			
	US 5607921	A	19970304	US 1995-380977	19950131	<--
PRAI	FR 1994-1031	19940131	<--			

AB Stabilized **cosmetic** or **dermatol.** compns. contain several precursors of a same active agent which are released by enzymic reaction in the **skin.** A **cream** contained karite butter 20, cyclomethicon 5, glyceryl monostearate 6, vaseline 7, Mg ascorbyl **phosphate** 1.5, glucosylated **ascorbic acid** 1.5, polyol **3**, xanthan gum 0.05, Mg sulfate 0.4, preservatives and fragrances 1, and water q.s. 100.
ST **cosmetic skin** enzymic reaction precursor; glucosyled **ascorbic acid cream**
IT Antioxidants
(derivs.; stabilized **cosmetic** or **dermatol.** compn. contg. several precursors of a same active agent)
IT Lipopeptides
Sialic acids
Vitamins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(derivs.; stabilized **cosmetic** or **dermatol.** compn. contg. several precursors of a same active agent)
IT Radicals, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(free; stabilized **cosmetic** or **dermatol.** compn.
contg. several precursors of a same active agent)

IT Esters, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(stabilized **cosmetic** or **dermatol.** compn. contg.
several precursors of a same active agent)

IT **Cosmetics**
(antiaging, stabilized **cosmetic** or **dermatol.** compn.
contg. several precursors of a same active agent)

IT **Alcohols, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**carboxy**, derivs.; stabilized **cosmetic** or
dermatol. compn. contg. several precursors of a same active
agent)

IT **Cosmetics**
(**creams**, stabilized **cosmetic** or **dermatol.**
compn. contg. several precursors of a same active agent)

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy**, derivs.; stabilized **cosmetic** or
dermatol. compn. contg. several precursors of a same active
agent)

IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lipo, derivs.; stabilized **cosmetic** or **dermatol.**
compn. contg. several precursors of a same active agent)

IT **Cosmetics**
(**moisturizers**, stabilized **cosmetic** or
dermatol. compn. contg. several precursors of a same active
agent)

IT **Skin, disease**
(pigmentation, stabilized **cosmetic** or **dermatol.**
compn. contg. several precursors of a same active agent)

IT **50-81-7D, Ascorbic acid**, glucosylated
50-99-7D, Glucose, derivs. 57-48-7D, Fructose, derivs. 58-95-7, Tocopheryl acetate 59-23-4D, Galactose, derivs. 79-81-2, Retinol palmitate 117-39-5, Quercetine 117-39-5D, Quercetine, esters 127-47-9, Retinol acetate 137-66-6, **Ascorbic acid** palmitate 1811-31-0D, N-Acetylgalactosamine, derivs. 2438-80-4D, Fucose, derivs. 3458-28-4D, Mannose, derivs. 7069-42-3, Retinol propionate 7512-17-6D, N-Acetylglucosamine, derivs. 10597-89-4D, derivs. **23313-12-4** 43119-47-7, Tocopherol nicotinate 53859-19-1, Retinol phosphate 108910-78-7 125913-31-7, **Ascorbic acid** phosphate 143549-76-2 169105-06-0
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(stabilized **cosmetic** or **dermatol.** compn. contg.
several precursors of a same active agent)

L229 ANSWER 61 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:721436 HCAPLUS
DN 123:122734
TI Depigmentation composition for the simultaneous treatment of the superficial and deep **skin** layers
IN Ribier, Alain; Simonnet, Jean-Thierry; Fanchon, Chantal; Arnaud-Sebillotte, Laurence; Segot, Evelyne
PA Oreal S. A., Fr.
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT Patent
LA French

IC ICM A61K007-00
CC 62-3 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 661038	A1	19950705	EP 1994-402980	19941221 <--
	EP 661038	B1	19960724		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	FR 2714601	A1	19950707	FR 1993-15870	19931230 <--
	FR 2714601	B1	19960209		
	AT 140612	E	19960815	AT 1994-402980	19941221 <--
	ES 2092876	T3	19961201	ES 1994-402980	19941221 <--
	CA 2138875	AA	19950701	CA 1994-2138875	19941222 <--
	JP 07324029	A2	19951212	JP 1994-326418	19941227 <--
	BR 9405484	A	19950919	BR 1994-5484	19941229 <--
	HU 71380	A2	19951128	HU 1994-3828	19941229 <--
	CN 1114558	A	19960110	CN 1994-120479	19941229 <--
	CN 1051919	B	20000503		
	RU 2105540	C1	19980227	RU 1994-45127	19941229 <--
	US 5607692	A	19970304	US 1994-366739	19941230 <--
PRAI	FR 1993-15870	19931230 <--			

AB Depigmentation compns. comprising **dispersion** of lipid vesicles for the simultaneous penetration into the superficial and the deep **skin** layers are claimed. Double liposome **creams** contained 31.3 g of vesicles for the deep layer (**epidermis**) comprising triglyceryl cetyl ether 7.6, cholesterol 7.6, sodium acylglutamate 0.8, kojic acid 2.0, glycerol 12.0, preservatives 0.1, and water q.s. 100 g; 25.0 g of vesicles for superficial layer (stratum corneum) comprising Chimexan NS:dimyristylphosphate (95:5) 20.00, N-octanoyl-5-salicylic acid 2.0, glycerol 15.0, preservatives 0.2, and water q.s. 100 g; and vegetable oils 4.5, preservatives 0.3, carboxyvinyl polymer 0.9, NaOH 1.8, and water q.s. 100%.

ST **cosmetic dispersion** lipid vesicle **skin** layer; depigmentation **cosmetic dispersion** liposome **cream**

IT Pigments
(depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Fatty acids, biological studies
Glycerides, biological studies
Inflammation inhibitors
Lipids, biological studies
Phospholipids, biological studies
Sunscreens
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Keratosis**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitors; depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Cosmetics**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(antiaging, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Alcohols, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**carboxy**, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Skin, disease**
(depigmentation, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Glycerides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(egg yolk, hydrogenated, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Skin**
(**epidermis**, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Phospholipids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydrogenated, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy**, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Steroids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy, ethoxylated, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Amino acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(lipo, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Cosmetics**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(liposomes, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Cosmetics**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**moisturizers**, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyhydric, alkyl ethers; depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(soya, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **Skin**
(stratum corneum, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT Lecithins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(sunflower-oil, depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT 16177-21-2, Sodium glutamate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(acyl; depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

IT **50-81-7**, L-**Ascorbic acid**, biological studies
50-99-7, Glucose, biological studies 57-13-6, Urea, biological studies
57-88-5, Cholesterol, biological studies 69-72-7, biological studies
108-46-3, 1,3-Benzenediol, biological studies 123-31-9, 1,4-Benzenediol, biological studies 302-79-4, Retinoic acid 331-39-5 501-30-4, Kojic acid 2197-63-9, Dicetylphosphate 6640-03-5, Dimyristyl phosphate
9004-61-9, Hyaluronic acid 9004-99-3, Polyethylene glycol stearate
9005-25-8, Starch, biological studies 25168-73-4, Saccharose stearate
25618-55-7D, Polyglycerol, C16-18-glycol derivs., lauryl ethers
26266-57-9, Sorbitan palmitate 27195-16-0, Saccharose distearate
51827-83-9 56090-54-1D, Triglycerol, hexadecyl ethers 63119-59-5, Diglycerol distearate 74563-64-7, Phytanetriol 78418-01-6, Octanoyl-5-salicylic acid 99734-29-9, Tetraglyceryl tristearate
119831-19-5 128895-87-4, Triglycerol monohexadecyl ether 143747-72-2, Triglycerol, diether with 1-hexadecanol 166050-05-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)
IT 9002-10-2, Tyrosinase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitors; depigmentation compn. for simultaneous treatment of superficial and deep **skin** layers)

L229 ANSWER 62 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:719443 HCAPLUS
DN 123:92918
TI **skin** preparations containing .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging
IN Okabe, Jiro; Takei, Masumi
PA Noevir Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K031-19; A61K031-355; A61K035-78; A61K038-00; A61K038-17
ICA A61K035-54
ICI A61K031-19, A61K031-355
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07138142	A2	19950530	JP 1993-281600	19931015 <--

PI JP 07138142 A2 19950530 JP 1993-281600 19931015 <--
AB **Skin** prepns. for **skin** roughness and aging contain .alpha.-hydroxy acids, eggshell proteins, and optionally collagens and/or elastins, **tannins**, and vitamin E. As an example, a **cream** contained beeswax 6.0, cetanol 5.0, reduced lanolin 8.0, squalane 37.5, fatty acid glyceride 4.0, glycerol monostearate 2.0, polyoxyethylene sorbitan monolaurate 2.0, propylene glycol 5.0, Me p-hydroxybenzoate 0.1, **glycolic acid** 0.5 eggshell protein 0.3, collagen 0.01, elastins 0.01, perfumes 0.2 wt.%, and purified water.
ST **cosmetic** hydroxy acid **skin** roughness aging
IT **Cosmetics**
(**ointments**; **skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT **Skin, disease**
(roughness; **skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT Collagens, biological studies
Elastins
Tannins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)
(**skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT **Skin, disease**
(aging, **skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT **Alcohols, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**carboxy, skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT **Cosmetics**
(**creams, skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT Proteins, specific or class
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(eggshell, **skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy, skin** prepns. contg. .alpha.-**hydroxy** acids and other ingredients for **skin** roughness and aging)
IT **Cosmetics**
(**lotions, skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)
IT 94-26-8, Butyl p-hydroxybenzoate 99-76-3, Methyl p-hydroxybenzoate 1406-18-4, Vitamin E
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin** prepns. contg. .alpha.-hydroxy acids and other ingredients for **skin** roughness and aging)

L229 ANSWER 63 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:693751 HCAPLUS
DN 123:122753
TI **Cosmetics** containing **pantolactones**
IN Katsumata, Manabu; Kiuchi, Keiko; Uchikuga, Saburo
PA Sogo Yatsuko Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K031-185; A61K031-365; C07C309-14; C07C317-28; C07C381-04; C07D307-33
ICI A61K031-365, A61K031-185
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07126148	A2	19950516	JP 1993-300756	19931108 <--

OS MARPAT 123:122753
GI



I

AB **Cosmetics** contain **pantolactones** I [R = H, (un)satd. linear or branched C1-22 alkyl, acyl] as active ingredients. The prepns. are safe and show fibroblast proliferation effect, **skin** -lightening effect, and/or **moisturizing** effect. Human fibroblasts were cultured in media contg. 0.001% d-**pantolactone** to show 149% proliferation, vs. 100%, for controls. Formulation examples are given.

ST **pantolactone skin** lightening **moisturizer**; fibroblast proliferation **pantolactone cosmetic**

IT Fibroblast
(**skin**-lightening and/or **moisturizing** **cosmetics** contg. **pantolactones**)

IT **Cosmetics**
(**moisturizers**, **skin**-lightening and/or **moisturizing cosmetics** contg. **pantolactones**)

IT **Cosmetics**
(**skin**-lightening, **skin**-lightening and/or **moisturizing cosmetics** contg. **pantolactones**)

IT **107-35-7, Taurine 300-84-5, Hypotaurine 2937-54-4, Thiotaurine** 165327-29-7 165327-31-1
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin**-lightening and/or **moisturizing** **cosmetics** contg. **pantolactones**)

IT 28227-35-2P 165327-30-0P 165524-42-5P 166020-02-6P
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**skin**-lightening and/or **moisturizing** **cosmetics** contg. **pantolactones**)

IT 79-50-5, DL-**Pantolactone** **599-04-2**, D-**Pantolactone** 5405-40-3, L-**Pantolactone**
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); USES (Uses)
(**skin**-lightening and/or **moisturizing** **cosmetics** contg. **pantolactones**)

L229 ANSWER 64 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:604438 HCAPLUS
DN 123:17500
TI **Cosmetics** containing .gamma.-amino-.**beta.**-**hydroxybutyric acid** and **ascorbic acid** esters with **skin** aging-preventing and **skin**-lightening effects
IN Hasunuma, Kyotaro
PA Kanebo Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07082135	A2	19950328	JP 1993-249863	19930909 <--

OS MARPAT 123:17500
AB **Cosmetics** contain .gamma.-amino-.**beta.**-**hydroxybutyric acid** (I) and its salts and **ascorbic acid** (II) phosphates, sulfates, their salts, and other **ascorbic acid** derivs. A **skin** **cream** contg. I and II 2-phosphate Mg salt promoted corneum turn

over rate, improved rough **skin**, and showed **skin** -conditioning and -lightening effects.

ST aminohydroxybutyrate **ascorbic acid skin** conditioner; GABA **ascorbic acid skin** conditioner; lightening **skin** GABA **ascorbic acid**; antiaging **cosmetic** aminohydroxybutyrate **ascorbic acid**

IT **Cosmetics**
(antiaging, **cosmetics** contg. aminohydroxybutyric acid (salts) and **ascorbic acid** phosphates or sulfates or polyoxyethylene ethers for **skin** aging prevention and **skin** lightening)

IT **Cosmetics**
(**skin**-lightening, **cosmetics** contg. aminohydroxybutyric acid (salts) and **ascorbic acid** phosphates or sulfates or polyoxyethylene ethers for **skin** aging prevention and **skin** lightening)

IT 352-21-6, .gamma.-Amino-.**beta.**-**hydroxybutyric acid** 16748-85-9 **56939-67-4, Ascorbic acid** sulfate 66651-98-7 84309-23-9, **Ascorbic acid** 2-phosphate magnesium salt 86404-04-8 119604-13-6 120730-19-0 125913-31-7, **Ascorbic acid** phosphate 159668-16-3
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**cosmetics** contg. aminohydroxybutyric acid (salts) and **ascorbic acid** phosphates or sulfates or polyoxyethylene ethers for **skin** aging prevention and **skin** lightening)

L229 ANSWER 65 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:532339 HCAPLUS
DN 122:273794
TI **Skin** care composition comprising thiol proteases from the stratum corneum
IN Watkinson, Allan
PA Unilever PLC, UK; Unilever N. V.
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K038-48; C12N009-64
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 3
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9507686	A1	19950323	WO 1994-EP2999	19940908	<--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN					
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	CA 2168869	AA	19950323	CA 1994-2168869	19940908	<--
	AU 9476953	A1	19950403	AU 1994-76953	19940908	<--
	EP 719134	A1	19960703	EP 1994-927584	19940908	<--
	R: CH, DE, ES, FR, GB, IT, LI, NL, SE					
	US 5545402	A	19960813	US 1994-304722	19940912	<--
	ZA 9407138	A	19960315	ZA 1994-7138	19940915	<--
PRAI	GB 1993-19104		19930915	<--		
	WO 1994-EP2999		19940908	<--		

AB A compn. for topical applications to the **skin** for alleviation or prevention of dry flaky **skin** condition, dandruff or acne comprising one or more stratum corneum thiol proteases. The compn. may further comprise a mild reducing agent and/or an addnl. enzyme selected

from glycosidases, other proteases, lipases and mixts. thereof. Optional addnl. active ingredients include sunscreens, lipids, **hydroxy carboxylic acids** and keotcarboxylic acids. Thiol proteases was sepd. from the stratum corneum and characterized. A topical **lotion** contained stratum corneum thiol protease 1.0, **cysteine** 0.1, EtOH 10.0, BHT 0.01, perfume q.s. and water q.s. 100%.

ST **skin** care stratum corneum thiol protease; **lotion** **cysteine** stratum corneum thiol protease

IT **Acne**
Dandruff
Reducing agents
Sunscreens
(**skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT Ceramides
Enzymes
Fatty acids, biological studies
Glycosphingolipids
Phospholipids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT **Alcohols, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**carboxy, skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT **Cosmetics**
(**creams, skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT Glycerides, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(di-, galactosyl, **skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT **Cosmetics**
(**emulsions, skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters, **skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(esters, polymers, polyol; **skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT **Carboxylic acids, biological studies**
Steroids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxy, skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT **Cosmetics**
(**lotions, skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo, **skin** care compn. comprising stratum corneum trypsin-like enzymes)

IT **Skin**
(stratum corneum, **skin** care compn. comprising stratum corneum

trypsin-like enzymes)
IT **52-90-4, Cysteine**, biological studies 9001-62-1, Lipase 9001-92-7, Protease 56467-83-5, Ceramidase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin** care compn. comprising stratum corneum trypsin-like enzymes)
IT 37353-41-6P, Thiol protease
RL: BOC (Biological occurrence); BUU (Biological use, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(**skin** care compn. comprising thiol proteases from the stratum corneum)

L229 ANSWER 66 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:503349 HCAPLUS
DN 122:273789
TI **Skin**-lightening **cosmetics** containing indomethacin and L-**ascorbic acids**
IN Togya, Hiroshi; Yokota, Tomohiro
PA Kanebo Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 07033638	A2	19950203	JP 1993-200451	19930719 <--

AB The title **cosmetics** are harmless and storage-stable and have anti-inflammatory effect. A **lotion** was prepd. from olive oil 15.0, iso-Pr myristate 5.0, polyoxyethylene nonylphenyl ether 0.5, Na L-ascorbyl-2-phosphate 0.05, indomethacin 0.001, glycerin 5.0, methylparaben 0.1, **citric acid** 0.1, Na citrate 0.05, EtOH 7.0, and H2O to 100 wt.%.
ST **skin** lightening **cosmetic** indomethacin **ascorbate**; antiinflammatory **cosmetic** indomethacin **ascorbate**
IT Inflammation inhibitors
(inflammation-inhibiting **skin**-lightening **cosmetics** contg. indomethacin and **ascorbic acids**)
IT **Cosmetics**
(**skin**-lightening, inflammation-inhibiting **skin** -lightening **cosmetics** contg. indomethacin and **ascorbic acids**)
IT 53-86-1, Indomethacin 109620-90-8
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory **skin**-lightening **cosmetics** contg. indomethacin and **ascorbate**)
IT 25395-66-8, L-Ascorbyl stearate 28474-90-0, L-Ascorbyl dipalmitate 68536-31-2 84309-23-9
RL: BAC (Biological activity or effector, except adverse); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inflammation-inhibiting **skin**-lightening **cosmetics** contg. indomethacin and **ascorbic acids**)

L229 ANSWER 67 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:503131 HCAPLUS
DN 122:248033

TI **Cosmetic, skin**-renewal stimulating composition with long-term irritation control
IN Herstein, Morris
PA USA
SO PCT Int. Appl., 51 pp. .
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-00
ICS A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9503028	A1	19950202	WO 1994-US8388	19940725	<--
	W: CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 716589	A1	19960619	EP 1994-924009	19940725	<--
	R: DE, FR, GB, IT					
	US 5616332	A	19970401	US 1995-410387	19950327	<--
PRAI	US 1993-97380	19930723	<--			
	WO 1994-US8388	19940725	<--			

AB A **cosmetic skin**-renewal stimulating compn. suitable for daily use and providing anti-aging benefits with control of delayed irritation is disclosed. The invention adds small quantities of a naturally occurring small-mol., biol. active, aliph. aminodiol lipid, e.g. sphingosine, to **cosmetics** incorporating a **skin**-renewal stimulating acid, e.g. lactic, hydroxybenzoic or retinoic acid, to provide control of deferred hyperproliferative allergenicity induced by the **skin**-renewal stimulating acid. A **skin**-renewal stimulating toner contained **lactic acid** 1.00, EtOH 50.00, benzyl alc. 0.10, sphingosine 0.05, PP5-5-ceteth 20 1.00, PPG-3-myristyl ether 0.50, and water 47.35%.
ST **cosmetic skin** renewal lipid carboxylic acid; antiaging **cosmetic lactic acid** shingosine
IT **Carboxylic acids, biological studies**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alpha-**hydroxy**; **skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT Inflammation inhibitors
(**skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT Phytosphingosines
Sphingosines
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT Pharmaceutical natural products
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(aloe, **skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT **Cosmetics**
(antiaging, **skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT **Cosmetics**
(**creams**, **skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT Sphingosines
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(dihydro, **skin**-renewal stimulating **cosmetics** with long-term irritation control)
IT **Cosmetics**

(**lotions**, **skin**-renewal stimulating **cosmetics** with long-term irritation control)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo, **skin**-renewal stimulating **cosmetics** with long-term irritation control)

IT **Cosmetics**
(toners, **skin**-renewal stimulating **cosmetics** with long-term irritation control)

IT Hair preparations
(tonics, **skin**-renewal stimulating **cosmetics** with long-term irritation control)

IT **50-21-5**, **Lactic acid**, biological studies
50-81-7, **Ascorbic acid**, biological studies
59-02-9 **76-93-7**, biological studies **77-92-9**, **Citric acid**, biological studies **79-14-1**, **Glycolic acid**, biological studies **80-69-3**, **Tartronic acid 87-69-4**, **Tartaric acid**, biological studies 90-64-2, Mandelic acid 97-59-6, Allantoin 123-99-9, Azelaic acid, biological studies **127-17-3**, **Pyruvic acid**, biological studies 128-37-0, Bht, biological studies 302-79-4, Retinoic acid 473-81-4, Glyceric acid 500-38-9, Nordihydroguaiaretic acid **526-95-4**, **Gluconic acid 565-70-8**, 2-Hydroxybutyric acid **617-35-6**, **Ethyl pyruvate** 1406-18-4, Vitamin e **6915-15-7**, **Malic acid** 7235-40-7, .beta.-Carotene 9054-89-1, Superoxide dismutase 25013-16-5, Butylated hydroxyanisole 29656-58-4, Hydroxybenzoic acid
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**skin**-renewal stimulating **cosmetics** with long-term irritation control)

L229 ANSWER 68 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1995:452310 HCAPLUS
DN 122:222867
TI Antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, pruritic psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**
IN Staeb, Franz; Sauermann, Gerhard; Keyhani, Reza
PA Beiersdorf A.-G., Germany
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K007-44
ICS A61K007-48; A61K007-08
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4328871	A1	19950302	DE 1993-4328871	19930827 <--
	WO 9505852	A1	19950302	WO 1994-EP2831	19940826 <--
	W: CN, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 721347	A1	19960717	EP 1994-925480	19940826 <--
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 09501925	T2	19970225	JP 1994-507355	19940826 <--
PRAI	DE 1993-4328871	19930827 <--			
	WO 1994-EP2831	19940826 <--			

AB Antioxidants and agents which maintain **skin** metab. at a normal level and/or regulate the endogenous enzymic antioxidant system are useful for prophylaxis and treatment of the title **skin** conditions. Pharmaceuticals and topical prepns. contg. combinations of these agents are provided. Thus, a combination of active agents contained carnosine

3.0, histidine 0.8, urocanic acid 1.0, .beta.-carotene 0.5, palmitoylcystine 0.2, Mg ascorbyl palmitate 2.0, vitamin E acetate 3.5, oleylglutathione 0.2, glucosylcystamine 0.04, oleic acid 0.3, heptadecenoic acid 0.02, butylated hydroxyanisole 0.5, FADH2 0.02, glucose 6-phosphate 0.06, NADPH 0.05, and ubiquinol 0.5 wt. parts. A **lotion** contained this combination 25.00, Cremophor A25 1.000, Cremophor A6 1.000, glycerin mono/distearate 2.000, cetyl alc. 1.000, iso-Pr myristate 1.450, glycerin 1.000, PVP 0.500, and water to 100.000 wt.%.

ST **skin** disease antioxidant metab regulator

IT **Acne**
Antioxidants
Dermatitis
Pruritus
Psoriasis
Skin, disease
(antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **Skin, disease**
(aging, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT Enzymes
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidant, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **Dermatitis**
Eczema
(atopic, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT Animal metabolism
(energy, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **Skin, disease**
(ichthyosis, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **Dermatitis**
(neuro-, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **Skin, disease**
(photodermatosis, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT Ubiquinones
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reduced, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **Dermatitis**
(**seborrheic**, antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

IT **50-81-7**, **Vitamin C**, biological studies
50-99-7, D-Glucose, biological studies 50-99-7D, D-Glucose, cystamine derivs. 51-85-4D, Cystamine, glucose derivs. **52-90-4**, L-**Cysteine**, biological studies 53-57-6, NADPH 56-40-6, Glycine, biological studies 56-73-5, Glucose 6-phosphate 58-85-5, D-Biotin

58-95-7, Vitamin E acetate 59-30-3, Folic acid, biological studies 60-18-4, L-Tyrosine, biological studies 69-93-2, Uric acid, biological studies **70-18-8, Glutathione**, biological studies 71-00-1, L-Histidine, biological studies **77-92-9**, biological studies 79-81-2, Vitamin A palmitate 83-86-3, Phytic acid 104-98-3, Urocanic acid 112-80-1, Oleic acid, biological studies 137-66-6 150-38-9, Trisodium EDTA 153-18-4 305-84-0, Carnosine 1406-18-4, Vitamin E 1910-41-4, FADH2 2629-59-6, S-Ethylcysteine 3211-76-5, Selenomethionine 3458-28-4, Mannose 5853-00-9, D-Carnosine **6915-15-7** 7235-40-7, .beta.-Carotene 7699-35-6, cis-Urocanic acid 10139-18-1, Glucose 1,6-diphosphate 17627-10-0 25013-16-5, Butylated hydroxyanisole 25779-79-7, N-Acetylcystine 26265-99-6, Heptadecenoic acid 28542-76-9, N-Acetylglutathione 57828-26-9, Lipoic acid 67603-49-0 67603-51-4 69522-24-3, Arlacel 481 108333-82-0 145586-82-9 161889-64-1 161889-65-2 161889-66-3 162015-51-2
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidants and metabolic regulators for treatment of atopic **dermatitis**, pruritis, psoriasis, photodermatosis, ichthyosis, and hyperreactive conditions of sensitive **skin**)

L229 ANSWER 69 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:517387 HCAPLUS
DN 121:117387
TI **skin** preparations containing collagen metabolism activators
IN Yoshida, Masaki; Inoe, Shintaro; Matsui, Tadashi
PA Kanebo Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICA C12N009-50
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06157232	A2	19940603	JP 1992-332519	19921117 <--
	JP 3117823	B2	20001218		

AB **Skin** prepns. contain ethanolamine derivs., Na sulfate, pentoxifylline, serine derivs. and/or **ascorbic acid** derivs. as collagenase prodn. and collagen metab. activators to prevent **skin** aging. A **lotion** contained collagen metab. activator 1.0, ethanol 10.0, **lactic acid** 0.3, Na citrate 0.1, glycerin 2.0 wt.%, preservatives, perfumes, surfactants, and balance water.
ST **skin cosmetic** collagen metab activator
IT Collagens, biological studies
RL: BIOL (Biological study)
(metab. activators, **skin cosmetics** contg., to prevent **skin** aging)
IT **Cosmetics**
(**skin**, collagen metab. activators in, to prevent **skin** aging)
IT **Cosmetics**
(**lotions**, collagen metab. activators in, to prevent **skin** aging)
IT **50-81-7D, Ascorbic acid**, derivs. 56-45-1D, Serine, derivs. 109-83-1, N-Methylethanolamine 141-43-5D, Ethanolamine, derivs. 6493-05-6, Pentoxifylline 7757-82-6, Sodium sulfate, biological studies **56939-67-4, Ascorbic acid** sulfate 125913-31-7, **Ascorbic acid** phosphate
RL: BIOL (Biological study)
(as collagen metab. activator, **skin cosmetics** contg., to prevent **skin** aging)

IT 9001-12-1P, Collagenase
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, promotion of, ethanolamine derivs. and other substances for)

L229 ANSWER 70 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:517382 HCAPLUS
DN 121:117382
TI **Skin**-lightening **cosmetics** containing .gamma.-amino-. **beta.-hydroxybutyric acid**, diisopropylamine dichloroacetate, and L-**ascorbic acid** derivatives
IN Hasunuma, Kyotaro; Hirata, Minoru
PA Kanebo Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K031-19; A61K031-195; A61K031-375
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06100429	A2	19940412	JP 1992-278023	19920921 <--

AB **Cosmetics** contain .gamma.-amino-.**beta.**-**hydroxybutyric acid** (I) and/or its salts, diisopropylamine dichloroacetate (II), and L-**ascorbic acid** derivs. I 0.5, II 0.5, L-**ascorbic acid** phosphate ester Mg salt (III) 0.5, olive oil 15.0, iso-Pr myristate 5.0, polyoxyethylene nonyl Ph ether 0.5, glycerin 5.0, methylparaben 0.1, EtOH 7.0 wt.%, and H2O balance were mixed to give a 2-layer **lotion**. The **lotion** was used by volunteers to show higher horny layer turnover rate and **skin**-lightening effect than a control **lotion** contg. no III.
ST GABOB DADA **ascorbic acid cosmetic**; aminohydroxybutyric acid **skin** lightening **cosmetic**; isopropylamine chloroacetate **skin** lightening **cosmetic**; **skin** lightening butyric acid aminohydroxy; hydroxybutyric acid amine **skin** lightening
IT **Cosmetics**
(**skin**-lightening, aminohydroxybutyric acid and diisopropylamine dichloroacetate and **ascorbic acid** derivs. for, evaluation in humans of)
IT 352-21-6, .gamma.-Amino-.**beta.-hydroxybutyric acid** 660-27-5, Diisopropylamine dichloroacetate 108910-78-7 128808-22-0
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. diisopropylamine dichloroacetate and **ascorbic acid** deriv. and, evaluation in humans of)

L229 ANSWER 71 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:517366 HCAPLUS
DN 121:117366
TI Synergistic combinations for **cosmetic** and/or **dermatological** care of the **skin** and nails
IN Staeb, Franz; Schreiner, Volker; Sauermann, Gerhard; Schoenrock, Uwe
PA Beiersdorf A.-G., Germany
SO Ger. Offen., 21 pp.
CODEN: GWXXBX
DT Patent
LA German
IC ICM A61K007-48
ICS A61K031-415; A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4242876	A1	19940623	DE 1992-4242876	19921218 <--
	DE 4242876	C2	19971127		
	WO 9414412	A1	19940707	WO 1993-DE1166	19931207 <--
	W: CZ, FI, HU, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 674505	A1	19951004	EP 1994-900762	19931207 <--
	EP 674505	B1	19980805		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 08504774	T2	19960521	JP 1993-514667	19931207 <--
	AT 169211	E	19980815	AT 1994-900762	19931207 <--
	ES 2121178	T3	19981116	ES 1994-900762	19931207 <--
	US 5710177	A	19980120	US 1995-448620	19950811 <--
PRAI	DE 1992-4242876	19921218 <--			
	WO 1993-DE1166	19931207 <--			

OS MARPAT 121:117366

AB The title combinations, contg. biotin or a biotin ester, **citric acid**, and optionally .gtoreq.1 antioxidant, prevent dryness or aging of the **skin** and promote the synthesis of cutaneous lipids. Thus, a mixt. of Arlatone 985 4.00, Brij 78 2.00, Miglyol 812 5.00, and paraffin oil 5.00 was **emulsified** with a mixt. of propylene glycol 5.00, **citric acid** 0.50, and aq. preservative at 75.degree., cooled to 35.degree., and stirred with D-biotin 0.05 and perfume to provide 100.00 parts body **lotion**.

ST biotin citrate antioxidant **cosmetic; skin** dryness aging biotin citrate antioxidant

IT **Cosmetics**
(antioxidant and biotin (ester) and **citric acid** in, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

IT Antioxidants
Flavonoids
Tocopherols
Ubiquinones
RL: BIOL (Biological study)
(**cosmetics** contg. biotin (ester) and **citric acid** and, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

IT Bile
(ext., **cosmetics** contg. biotin (ester) and **citric acid** and, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

IT Lipids, biological studies
RL: FORM (Formation, nonpreparative)
(formation of, by **skin**, antioxidant-biotin (ester)-**citric acid** combination promotion of)

IT **Skin, disease**
(aging, treatment of, with antioxidant-biotin (ester)-**citric acid** combination)

IT **Skin, disease**
(dry, treatment of, with antioxidant-biotin (ester)-**citric acid** combination)

IT Tocopherols
RL: BIOL (Biological study)
(esters, **cosmetics** contg. biotin (ester) and **citric acid** and, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

IT Flavonoids
RL: BIOL (Biological study)
(oxo, **cosmetics** contg. biotin (ester) and **citric acid** and, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

IT **77-92-9, Citric acid**, biological studies
RL: BIOL (Biological study)
(**cosmetics** contg. antioxidant and biotin (ester) and, for

skin aging and dryness prevention and promotion of **skin** lipid formation)

IT 58-85-5, Biotin 58-85-5D, Biotin, esters
RL: BIOL (Biological study)
(**cosmetics** contg. antioxidant and **citric acid** and, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

IT **50-81-7, Ascorbic acid**, biological studies **50-81-7D, Ascorbic acid**, derivs. **52-90-4, Cysteine**, biological studies **52-90-4D, Cysteine**, derivs. **56-89-3, Cystine**, biological studies 58-95-7, Tocopheryl acetate 59-30-3, Folic acid, biological studies 60-18-4, Tyrosine, biological studies **70-18-8, Glutathione**, biological studies **70-18-8D, Glutathione**, esters 71-00-1, Histidine, biological studies 83-86-3, Phytic acid 128-37-0, BHT, biological studies 305-84-0, Carnosine 502-65-8, Lycopene 616-91-1, N-Acetylcysteine 1200-22-2, .alpha.-Lipoic acid 1314-13-2, Zinc oxide, biological studies 3465-72-3, trans-Urocanic acid 7235-40-7, .beta.-Carotene 7440-66-6D, Zinc, salts 7699-35-6, cis-Urocanic acid
RL: BIOL (Biological study)
(**cosmetics** contg. biotin (ester) and **citric acid** and, for **skin** aging and dryness prevention and promotion of **skin** lipid formation)

L229 ANSWER 72 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:491334 HCAPLUS
DN 121:91334
TI Retinol-containing **cosmetic** composition
IN Harding, Clive Roderick; Lee, Caroline Marian; Scott, Ian Richard
PA Unilever PLC, UK; Unilever N. V.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9409756	A1	19940511	WO 1993-EP3064	19931102 <--
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9454201	A1	19940524	AU 1994-54201	19931102 <--
	AU 680844	B2	19970814		
	ZA 9308173	A	19950502	ZA 1993-8173	19931102 <--
	EP 666735	A1	19950816	EP 1993-924575	19931102 <--
	EP 666735	B1	19981007		
	R: CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 08502742	T2	19960326	JP 1993-510720	19931102 <--
	ES 2123670	T3	19990116	ES 1993-924575	19931102 <--
	BR 9307375	A	19990831	BR 1993-7375	19931102 <--
PRAI	GB 1992-23235	19921105 <--			
	WO 1993-EP3064	19931102 <--			

AB A compn. for topical application to human **skin** in order to promote the repair of photo-damaged **skin** and/or to reduce or prevent the damaging effects of UV light on **skin** and/or to lighten the **skin** comprises retinol or its ester and a selected **skin** lightening agent. An anhyd. formulation contained retinol 0.2, cysteaminylphenol 1.0, isopropanol 10.0, volatile silicone 80.0, Et hexyl palmitate 8.7, and an antioxidant 0.1% by wt., resp.

ST retinol **cream lotion**

IT Placenta
Licorice
RL: BIOL (Biological study)
(exts., topical retinol compn. contg.)
IT Antioxidants
Beeswax
Emulsifying agents
Preservatives
Sunscreens
Surfactants
Amino acids, biological studies
Paraffin oils
Petrolatum
Siloxanes and Silicones, biological studies
RL: BIOL (Biological study)
(topical retinol compn. contg.)
IT **Alcohols, biological studies**
RL: BIOL (Biological study)
(**carboxy**, topical retinol compn. contg.)
IT Siloxanes and Silicones, biological studies
RL: BIOL (Biological study)
(cetyl Me, di-Me, topical retinol compn. contg.)
IT **Cosmetics**
(**creams**, retinol-contg., compns. of)
IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(**hydroxy**, topical retinol compn. contg.)
IT **Cosmetics**
(**lotions**, retinol-contg., compns. of)
IT **Cosmetics**
(**skin**-lightening, retinol-contg. compns. of)
IT 68-26-8, Retinol 79-81-2, Retinyl palmitate 127-47-9, Retinyl acetate 631-88-9, Retinyl oleate 631-89-0, Retinyl linoleate 1259-24-1, Retinyl laurate 7069-42-3, Retinyl propionate 32972-39-7, Retinol butyrate 79272-09-6, Retinol octanoate
RL: BIOL (Biological study)
(topical compns. of)
IT **50-21-5**, biological studies **50-81-7**, L-**Ascorbic acid**, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 59-67-6, Niacin, biological studies 60-81-1, Phloridzin 60-82-2, Phloretin 67-63-0, Isopropanol, biological studies 98-92-0, Niacinamide 107-88-0, 1,3-Butanediol 110-27-0, Isopropyl myristate 123-31-9, 1,4-Benzenediol, biological studies 147-85-3, L-Proline, biological studies 150-76-5, Hydroquinone monomethyl ether 497-76-7, Arbutin 501-30-4, Kojic acid 617-73-2, 2-Hydroxyoctanoic acid 5466-77-3, Parsol MCX 7647-14-5, Sodium chloride, biological studies 9005-00-9, Polyoxyethylene(2) stearyl ether 9007-48-1, Polyglyceryl-3 oleate 13463-67-7, Titanium dioxide, biological studies 34316-64-8, Hexyl laurate 36653-82-4, 1-Hexadecanol 91281-34-4, 4-S-Cysteaminylphenol 145686-34-6, Cetyl dimethicone copolyol
RL: BIOL (Biological study)
(topical retinol compn. contg.)

L229 ANSWER 73 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:442442 HCAPLUS
DN 121:42442
TI **Skin**-lightening **cosmetics** containing L-**ascorbic acids** and tea leaf extracts
IN Shinho, Tsuneo; Minematsu, Yoshihiro; Shibue, Juko; Suzuki, Juji; Masuda, Mitsuharu; Kimura, Mitsutoshi; Imokawa, Genji
PA Kao Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48

ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06072849	A2	19940315	JP 1992-294506	19921102 <--
PRAI JP 1992-183970	19920710 <--			

AB The **cosmetics** contain L-**ascorbic acid** (I) and/or water-sol. derivs. of I, tea leaf exts., and optional kudzu root exts. Glycerin monostearate 5.0, polyethylene glycol monostearate 2.0, squalane 8.0, glycerin trioctanoate 8.0, stearyl alc. 5.5, dimethylpolysiloxane 0.2, propylene glycol 5.0, disodium edetate 0.1, L-**ascorbic acid phosphate** Mg **3**.0, tea leaf ext. **3**.0, **citric acid**/Na citrate 1.0 wt.%, antiseptic, perfume, and H2O balance were mixed. to give a **cream**, which showed fine **skin**-lightening effect on UV-induced pigmentation.
ST **skin** lightening **cosmetic ascorbate** tea ext; kudzu ext **skin** lightening **cosmetic**
IT Tea (Camellia sinensis)
(leaf exts., **skin**-lightening **cosmetics** contg. **ascorbic acids** and)
IT Kudzu
(root exts., **skin**-lightening **cosmetics** contg. **ascorbic acids** and tea leaf ext. and)
IT **Cosmetics**
(**skin**-lightening, **ascorbic acids** and tea leaf exts. and optional kudzu root exts. for)
IT **50-81-7**, L-**Ascorbic acid**, biological studies
7317-67-1, L-**Ascorbic acid** sodium salt
108910-78-7, L-**Ascorbic acid** phosphate magnesium salt
128808-22-0, L-**Ascorbic acid** sulfate sodium salt
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. tea leaf exts. and)

L229 ANSWER 74 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:307117 HCAPLUS
DN 120:307117
TI **Skin**-lightening **cosmetics** containing **ascorbic acid** derivatives and clove extract
IN Shinho, Tsuneo; Kimura, Mitsutoshi; Masuda, Mitsuharu; Suzuki, Juji; Minematsu, Yoshihiro
PA Kao Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 06024955	A2	19940201	JP 1992-183971	19920710 <--

AB **Cosmetics** contain .gtoreq.1 compd. selected from L-**ascorbic acid** and its water-sol. derivs. and clove ext. Glycerin monostearate 5.0, polyethylene glycol monostearate 2.0, squalane 8.0, glycerin trioctanoate 8.0, stearyl alc. 5.5, dimethylpolysiloxane 0.2, propylene glycol 5.0, di-Na edetate 0.1, L-**ascorbic acid phosphate** Ma salt **3**.0, clove ext. **3**.0, **citric acid** 1.0, antiseptic, perfume, and H2O to 100 wt.% were mixed to give a **skin**-lightening **cream**.
ST **skin** lightening **cosmetic ascorbic acid**; clove ext **skin** lightening **cosmetic**

IT Clove
(ext., **skin**-lightening **cosmetics** contg. **ascorbic acid** or water-sol. derivs. and)
IT **Cosmetics**
(**skin**-lightening, **ascorbic acid** or water-sol. derivs. and clove ext. for)
IT **50-81-7**, L-**Ascorbic acid**, biological studies
134-03-2, L-**Ascorbic acid** sodium salt
108910-78-7, L-**Ascorbic acid** phosphate magnesium salt
128808-22-0, L-**Ascorbic acid** sulfate sodium salt
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. clove ext. and)

L229 ANSWER 75 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:307105 HCAPLUS
DN 120:307105
TI **Skin**-conditioning composition containing salicylic acid and carboxylic acids
IN Smith, Walter P.
PA USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-74
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9406440	A1	19940331	WO 1993-US8583	19930913	<--
	W: AU, CA, JP, NO, RU					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	EP 660720	A1	19950705	EP 1993-922177	19930913	<--
	R: AT, BE, CH, DE, ES, FR, GB, IE, IT, LI, NL, PT, SE					
	JP 08501553	T2	19960220	JP 1993-508208	19930913	<--
	RU 2113216	C1	19980620	RU 1995-122759	19930913	<--
	AU 697389	B2	19981001	AU 1993-51272	19930913	<--
PRAI	US 1992-944503	19920914	<--			
	WO 1993-US8583	19930913	<--			

AB A **skin**-conditioning compn. is disclosed which can be applied to topically to improve **skin** cell renewal rates with low irritation levels and comprises salicylic acid and a hydrophobic .alpha.-hydroxy aliph. acid formulated into an acidic **cosmetic** compn., optionally with an anti-irritant or antioxidant additive. For example, a **cream** contg. salicylic acid 1, **lactic acid** 2, antioxidant (1% catalase soln. and 2% superoxide dismutase soln.) 5, and other ingredients to 100% was formulated.
ST **skin** conditioning salicylate lactate antioxidant
IT Antioxidants
Inflammation inhibitors
(**skin**-conditioning compns. contg. salicylate and lactate and)
IT **Alcohols, biological studies**
RL: BIOL (Biological study)
(**carboxy**, C3-10, **skin**-conditioning compns. contg. salicylate and)
IT **Cosmetics**
(conditioners, salicylic acid and .alpha.-**hydroxy carboxylic acids** in)
IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(**hydroxy**, C3-10, **skin**-conditioning compns. contg. salicylate and)
IT Hair preparations
(tonics, salicylic acid and .alpha.-**hydroxy carboxylic acids** in)
IT 38304-91-5, Minoxidil

RL: BIOL (Biological study)
(hair prepns. contg. salicylate and lactate and)
IT **50-21-5, Lactic acid**, biological studies
69-72-7, Salicylic acid, biological studies
RL: BIOL (Biological study)
(**skin**-conditioning compns. contg.)
IT 498-36-2, 2-Hydroxy isohexanoic acid **565-70-8**, 2-Hydroxybutanoic acid **594-61-6**, 2-Hydroxy isobutyric acid 617-31-2, 2-Hydroxy pentanoic acid 4026-18-0, 2-Hydroxy isovaleric acid 6064-63-7, 2-Hydroxy hexanoic acid
RL: BIOL (Biological study)
(**skin**-conditioning compns. contg. salicylate and)
IT **50-81-7, Vitamin c**, biological studies
58-08-2, Caffeine, biological studies 128-37-0, Butylated hydroxytoluene, biological studies 496-65-1, Pantetheine 500-38-9 1406-18-4, Vitamin e 7235-40-7, .beta.-Carotene 9054-89-1, Superoxide dismutase 25013-16-5, Butylated hydroxyanisole
RL: BIOL (Biological study)
(**skin**-conditioning compns. contg. salicylate and lactate and)

L229 ANSWER 76 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:226555 HCAPLUS
DN 120:226555
TI Stable **cosmetics** containing **ascorbic acid** phosphate magnesium salt and carboxyl group-containing compounds
IN Yamada, Yasuhiro; Yoshioka, Akiko
PA Noevir Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05339123	A2	19931221	JP 1991-143764	19910520 <--
JP 3095455	B2	20001003		

AB **Cosmetics** contain **ascorbic acid** phosphate Mg salt (I) and C2-6 org. acids having carboxyl group(s) and OH group(s), and/or salts of the org. acids or water-sol. polymers contg. carboxyl group(s). A **skin**-lightening **lotion** contg. I 2.0, Na gluconate 1.0, glycerin 5.0, polyoxyethylene hydrogenated castor oil 0.2, methylparaben 0.1, perfume 0.2, and H2O 91.5 wt.% was kept at 50.degree. to show no pptn. even 90 days later.
ST **skin** lightening **ascorbate** phosphate magnesium; carboxylate **ascorbate** phosphate **skin** lightening; water sol polymer **ascorbate cosmetic**
IT **Alcohols, biological studies**
RL: BIOL (Biological study)
(**carboxy, skin**-lightening **cosmetics** contg. **ascorbic acid** phosphate magnesium salt and, stable)
IT Polymers, biological studies
RL: BIOL (Biological study)
(carboxy-contg., water-sol., **skin**-lightening **cosmetics** contg. **ascorbic acid** phosphate magnesium salt and, stable)
IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(**hydroxy, skin**-lightening **cosmetics** contg. **ascorbic acid** phosphate magnesium salt and, stable)
IT **Cosmetics**
(**skin**-lightening, contg. **ascorbic acid**

phosphate magnesium salt and carboxy-contg. compds.)
IT 527-07-1, Sodium gluconate 9004-32-4, Carboxymethyl cellulose sodium salt
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. **ascorbic acid** phosphate magnesium salt and, stable)
IT 108910-78-7, **Ascorbic acid** phosphate magnesium salt
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. carboxy-contg. compds. and, stable)

L229 ANSWER 77 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1994:200189 HCAPLUS
DN 120:200189
TI Singlet oxygen-scavenging compositions as inhibitors for peroxidation in the **skin** conditioning
IN Kono, Yoshuki; Sakamoto, Okihiko; Umeya, Junichiro
PA **Shiseido** Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-48
ICS A61K007-00; A61K007-40
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05320036	A2	19931203	JP 1992-150011	19920519 <--

AB The title compns. contain singlet O scavengers and optional chain-breaking antioxidants. The compns. prevent formation of peroxides derived from sebum. A **lotion** contg. .beta.-carotene 0.01, BHT 0.01, **citric acid** 0.01, Na citrate 0.1, EtOH 7.0, polyoxyethylene oleyl ether 0.5 wt.%, and H2O balance was applied to the forehead of 5 healthy men and after 5 min the applied area were exposed to sunlight. Peroxides formed from 1 mol squalene in the sebum of forehead was 1.0 .times. 10-3 mol, vs. 4.7 .times. 10-3 mol for SOD.
ST singlet oxygen scavenger **cosmetic**; chain breaking antioxidant **cosmetic**
IT Antioxidants
(chain-breaking, singlet oxygen-scavenging compns. contg. singlet oxygen scavengers and, as peroxidn. inhibitors for **skin**)
IT **Skin, metabolism**
(lipid peroxidn. by, singlet oxygen-scavenging compns. as inhibitors for)
IT Peroxidation
(of lipids, in **skin**, singlet oxygen-scavenging compns. as inhibitors for)
IT Reactive oxygen species
RL: BIOL (Biological study)
(scavenging compns. contg. singlet oxygen scavengers and chain-breaking antioxidants for, as peroxidn. inhibitors fir **skin**)
IT Flavonoids
Tannins
RL: BIOL (Biological study)
(singlet oxygen-scavenging compns. contg. singlet oxygen scavengers and, as peroxidn. inhibitors for **skin**)
IT Carotenes and Carotenoids, biological studies
RL: BIOL (Biological study)
(singlet oxygen-scavenging compns. contg., as peroxidn. inhibitors for **cosmetics**)
IT **Cosmetics**
(**skin** peroxidn-inhibiting, singlet oxygen-scavenging compns. for)
IT Lipids, compounds
RL: FORM (Formation, nonpreparative)

(peroxides, formation of, in **skin**, singlet oxygen-scavenging compns. as inhibitors for)

IT 149-91-7D, Gallic acid, esters 25013-16-5, BHA **50-81-7**, **Ascorbic acid**, uses 128-37-0, BHT, uses
RL: BIOL (Biological study)
(singlet oxygen-scavenging compns. contg. singlet oxygen scavengers and, as peroxidn. inhibitors for **skin**)

IT 144-68-3, Zeaxanthin 148-03-8, .beta.-Tocopherol 465-42-9, Capsanthin 472-70-8, Cryptoxanthin 472-93-5, .gamma.-Carotene 502-65-8, Lycopene 534-22-5, 2-Methylfuran 625-86-5, 2,5-Dimethylfuran 955-83-9, 2,5-Diphenylfuran 5471-63-6, 1,3-Diphenylisobenzofuran 7235-40-7, .beta.-Carotene 7616-22-0, .gamma.-Tocopherol 10191-41-0, dl-.alpha.-Tocopherol 22777-03-3, 1,4-Diazacyclooctane 27876-94-4, Crocetin 29065-03-0, Isozeaxanthin 56-41-7, L-Alanine, uses 59-02-9, .alpha.-Tocopherol **63-68-3**, L-**Methionine**, uses 71-00-1, Histidine, uses 73-22-3, L-Tryptophan, uses 116-30-3, Rhodoxanthin 119-13-1, .delta.-Tocopherol 127-40-2, Lutein
RL: BIOL (Biological study)
(singlet oxygen-scavenging compns. contg., as peroxidn. inhibitors for **skin**)

IT 432-70-2, .alpha.-Carotene
RL: BIOL (Biological study)
(singlet oxygen-scavenging compns. contg., as peroxidn. inhibitors for **skin** conditioning)

IT 7782-44-7, Oxygen, uses
RL: USES (Uses)
(singlet, scavenging compns. for, as peroxidn. inhibitors for **skin**)

L229 ANSWER 78 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1993:45468 HCAPLUS
DN 118:45468
TI **Skin**-lightening **cosmetics** containing proteoglycans and **ascorbates**
IN Matsumoto, Yasunori; Kitahara, Michio; Nakada, Satoru
PA Nonogawa Shoji Y. K., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04210614	A2	19920731	JP 1990-410390	19901213 <--
JP 2998846	B2	20000117		

AB Storage-stable **skin**-lightening **cosmetics** comprise proteoglycan ext. solns. and **ascorbic acid** salts with **phosphate**. The proteoglycan ext. may be obtained from animal connective tissues (no hard data). Thus, a **lotion** contained EtOH 8.0, polyoxyethylene hydrogenated castor oil 0.4, glycerin 5.0, 1, **3**-butylene glycol **3**.0, proteoglycan exts. 10.0, L-**ascorbic acid** phosphoric acid Mg salt **3**.0, **citric acid** 0.5, Na citrate 1.0, perfumes q.s., and water to 100.0%. The **lotion** was tested in vitro for its melanin formation inhibiting activities.

ST **skin** lightening proteoglycan **ascorbate**

IT Proteoglycans, biological studies
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. **ascorbate** and)

IT **Cosmetics**
(**skin**-lightening, proteoglycans and **ascorbates** in)

IT 108910-78-7 128808-25-3
RL: BIOL (Biological study)

(**skin**-lightening **cosmetics** contg. proteoglycans and)

L229 ANSWER 79 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:639500 HCAPLUS
DN 117:239500
TI Topical **skin cream** composition
IN Jaffery, Manzoor H.
PA Perfective Cosmetics, Inc., USA
SO U.S., 4 pp. Cont. of U.S. Ser. No. 418,325, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-48
NCL 514847000
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5153230	A	19921006	US 1991-649148	19910201 <--
PRAI US 1989-418325	19891006 <--			

AB The title compn. contg. **glycolic acid** (I) and vitamin A (II) or E (III) is used for the control of **skin** aging. A **cream** contained I 2.1, II palmitate 1.00, III acetate 0.5, cetyl ester wax 8.4, stearyl alc. 10.0, cetyl alc. 4.0, glycerin 10.00, Me paraben 0.2, propylparaben 0.02, Quaternium-15 0.1, Na lauryl sulfate 2.5, and water to 100%.
ST **cream skin** aging **glycolic acid**
IT Carboxylic acids, biological studies
RL: BIOL (Biological study)
(**cream** contg., for treatment of **skin** aging)
IT **Skin, disease**
(aging, treatment of, with topical **cream** contg. carboxylic acids and vitamins)
IT **Cosmetics**
(antiaging, carboxylic acids and vitamins in)
IT 58-95-7, Vitamin e acetate 79-81-2, Vitamin a palmitate
RL: BIOL (Biological study)
(**cream** contg. carboxylic acid and, for treatment of **skin** aging)
IT **50-81-7, Ascorbic acid**, biological studies
56-84-8, L-Aspartic acid, biological studies **79-14-1, Glycolic acid**, biological studies **87-69-4, Tartaric acid**, biological studies 110-17-8, Fumaric acid, biological studies **526-95-4, Gluconic acid**
RL: BIOL (Biological study)
(**cream** contg., for treatment of **skin** aging)

L229 ANSWER 80 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:578120 HCAPLUS
DN 117:178120
TI **Skin** preparations containing polyphenols and sucrose fatty acid esters
IN Ota, Masakatsu; Kondo, Mitsuo
PA Kanebo, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K009-08; A61K031-19; A61K031-70; A61K047-26
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	JP 04117314	A2	19920417	JP 1990-237911	19900906 <--

AB **Skin** prepns. (**cosmetic creams**, shaving prepns., pharmaceutical topical prepns., etc.) contain polyphenols having .gtoreq.3 phenolic OH and sucrose fatty acid esters. The prepns. show good **skin** conditioning and astringent properties and the polyphenols do not ppt. during preservation. EtOH 10.0, **tannin** (extd. from fruit of Diospyros kaki) 0.5, **citric acid** 0.05, Na citrate 0.05, di-Na edetate 0.1, sucrose monolaurate 0.3, perfume 0.05, and H2O 88.95 wt.% were mixed to give a pptn.-free **cosmetic** soln.

ST **skin** prepn polyphenol sucrose ester

IT Shampoos
(polyphenols as astringents and sucrose fatty acid esters as surfactants in)

IT **Astringents**
(polyphenols in)

IT **Tannins**
RL: PREP (Preparation)
(**skin** prepns. contg. sucrose fatty acid esters and, as astringents)

IT Surfactants
(sucrose fatty acid esters, for **skin** prepns. contg. astringent polyphenols)

IT Shaving preparations
(aftershaves, polyphenols as astringents and sucrose fatty acid esters as surfactants in)

IT Fatty acids, esters
RL: PREP (Preparation)
(esters, with sucrose, **skin** prepns. contg. astringent polyphenols and, as surfactants)

IT Phenols, biological studies
RL: PREP (Preparation)
(polyhydric, **skin** prepns. contg. sucrose fatty acid esters and, as astringents)

IT Pharmaceutical dosage forms
(topical, polyphenols as astringents and sucrose fatty acid esters as surfactants in)

IT 25339-99-5, Sucrose monolaurate 25496-92-8, Sucrose monooleate 26446-38-8 37266-93-6, Ryoto Sugar Ester L-1695 82591-69-3, Sucrose dierucate
RL: BIOL (Biological study)
(**skin** prepns. contg. astringent polyphenols and, as surfactant)

L229 ANSWER 81 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:537427 HCAPLUS
DN 117:137427
TI Methods and compositions for amelioration of **skin** wrinkles
IN Majewski, Wojciech
PA Narhex Ltd., Hong Kong
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48
ICS A61K037-12
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9207587	A1	19920514	WO 1991-AU492	19911025 <--

W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN,

GR, IT, LU, ML, MR, NL, SE, SN, TD, TG

	AU 9188574	A1	19920526	AU 1991-88574	19911025 <--
	AU 653368	B2	19940929		
	GB 2264058	A1	19930818	GB 1993-8478	19930423 <--
	GB 2264058	B2	19940810		
PRAI	AU 1990-3009	19901025 <--			
	WO 1991-AU492	19911025 <--			

AB Elastin (I), at least some of which has a mol. wt. <10,000, is used topically or by s.c. injection for the amelioration of **skin** wrinkles. It may be used with an agent for reducing corneocyte cohesion of the lower levels of the hyperkeratotic stratum of the **skin**, e.g .alpha.-hydroxy acids. A **cream** contained bovine I (prepn. given) 2, nonionic surfactants 9, oils 23, thickeners 0.5, glycols 8, parabens 0.4, sunscreen 3, and water 100%. The effect of **cream** on male and female **skin** wrinkle amelioration was studied.

ST **skin** wrinkle elastin **cream**; hydroxy acid elastin **skin** wrinkle

IT **Sunscreens**
(antiwrinkle compn. contg. elastin and)

IT Elastins
RL: BIOL (Biological study)
(wrinkle-preventing compn. contg.)

IT **Alcohols, biological studies**
RL: BIOL (Biological study)
(**carboxy**, antiwrinkle compn. contg. elastin and)

IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(**hydroxy**, antiwrinkle compn. contg. elastin and)

IT Pharmaceutical dosage forms
(injections, s.c., elastin in, for **skin** wrinkle prevention)

IT Pharmaceutical dosage forms
(topical, elastin in, for **skin** wrinkle prevention)

IT **Cosmetics**
(wrinkle-preventing, elastin in)

IT **50-21-5**, **Lactic acid**, biological studies **50-81-7**, L-**Ascorbic acid**, biological studies **77-92-9**, biological studies **79-14-1**, **Glycolic acid**, biological studies **87-69-4**, biological studies 89-65-6 **90-80-2** **526-95-4**, D-**Gluconic acid** 526-99-8, Mucic acid **594-61-6**, Acetonic acid 2306-22-1, **Citramalic acid** 6556-12-3, Glucuronic acid **6915-15-7** 35054-79-6, Hydroxybutyric acid 50853-48-0, Hydroxyvaleric acid 143454-48-2
RL: BIOL (Biological study)
(antiwrinkle compn. contg. elastin and)

L229 ANSWER 82 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:180947 HCAPLUS
DN 116:180947
TI **Skin**-lightening **emulsions** containing kojic acids and N-acylmetyltaurines as **emulsifiers**
IN Sonozu, Hiroko
PA Kobayashi Kose Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04009310	A2	19920114	JP 1990-111546	19900426 <--
	JP 2949442	B2	19990913		

OS MARPAT 116:180947
AB **Skin**-lightening **emulsions** (pH 3.0-5.5) contain kojic

acid and/or its derivs. and N-(long-chain acyl)methyltaurine salts. N-Stearoylmethyltaurine Na salt 0.5, glycerin 10.0, glycerin monostearate 2.0, cetanol 5.0, liq. paraffin 5.0, macadamian nut oil 5.0, 1,3-butylene glycol 10.0, kojic acid 1.0, antiseptic agent 0.1, **lactic acid**, Na lactate, and H2O to 100% were mixed to give a **cream**, which was stable at 40.degree. for .gtoreq.6 mo.

ST kojic acid **taurine emulsifier cosmetic**; **skin** lightening kojic acid stearoylmethyltaurine

IT **Emulsifying** agents
(N-acylmethyltaurines, for kojic acid-contg. **cosmetics**)

IT **Cosmetics**
(**skin**-lightening, **emulsions**, contg. kojic acids and N-acylmethyltaurines, stability in relation to)

IT 149-39-3 18469-44-8
RL: BIOL (Biological study)
(**skin**-lightening **emulsions** contg. kojic acid and, stable)

IT 501-30-4, Kojic acid
RL: BIOL (Biological study)
(**skin**-lightening **emulsions** contg. N-acylmethyltaurines and, stable)

L229 ANSWER 83 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:180940 HCAPLUS
DN 116:180940
TI Stable **cosmetic lotions** containing **ascorbic acid** 2-phosphate sodium salt and polyalcohols
IN Matsura, Ichiro; Kizaki, Yoshiho
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 16
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 03275610	A2	19911206	JP 1990-73629	19900323 <--
JP 2954640	B2	19990927		

AB **Cosmetic lotions** (neutral or weakly acidic) contain 0.05-**3**.0 wt.% L-**ascorbic acid** 2-**phosphate** Na salt and 1-20 wt.% polyalcs. The **cosmetics** are stable and show **skin**-lightening and **moisturizing** effects. Pseudomonas azotocolligans was stirred with L-**ascorbic acid**, K4P2O7, Nissan Nymeen S-215, xylene, and an acetate buffer at 40.degree. and pH .apprx.4.0 for 36 h to manuf. L-**ascorbic acid** 2-**phosphate** (I), which was refluxed with aq. NaOH and EtOH to give 71% I Na salt. **Lactic acid** 0.05, Na lactate 0.45, L-serine 0.**3**, methylparaben 0.1, propylene glycol 8.5, I Na salt 83.87, polyoxyethylene glyceryl pyroglutamate isostearate diester 0.5, perfumes 0.03, and modified EtOH 8.0 wt.% were mixed to give a **cosmetic lotion** (pH 5).

ST **lotion skin** lightening polyalc **ascorbate**; **ascorbate** phosphate polyalc **skin** lightening

IT Alcohols, biological studies
RL: BIOL (Biological study)
(polyhydric, **skin**-lightening **cosmetic lotions** contg. **ascorbic acid** phosphate sodium salt and, stable)

IT **Cosmetics**
(**skin**-lightening, contg. **ascorbic acid** phosphate sodium salt and polyalcs., stable)

IT **23313-12-4P**, L-**Ascorbic acid** 2-phosphate
RL: IMF (Industrial manufacture); PREP (Preparation)

(manuf. and salt formation of, with sodium hydroxide for **skin** lightening **cosmetics**)

IT 109620-90-8P, L-**Ascorbic acid** 2-phosphate sodium salt
RL: PREP (Preparation)
(prepn. of, **skin**-lightening **cosmetic lotions** contg. polyalcs. and, stable)

IT 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 107-88-0, 1,3-Butylene glycol
RL: BIOL (Biological study)
(**skin**-lightening **cosmetic lotions** contg. **ascorbic acid phosphate** sodium salt and, stable)

L229 ANSWER 84 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:158610 HCAPLUS
DN 116:158610
TI **Skin**-lightening **cosmetics** containing Ganoderma lucidum extract and vitamins
IN Naeshiro, Hidekazu; Hashimoto, Akira; Ando, Hideya
PA Sunstar, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-42
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04009325	A2	19920114	JP 1990-112311	19900427 <--

AB The title **cosmetics** contain G. lucidum culture and/or its ext., and **ascorbic acid**, retinol, pyridoxine, **pantothenic acid**, tocopherol, and derivs. thereof as active ingredients. The **cosmetics** eliminate, attenuate, or prevent UV radiation-induced **skin** darkening or pigmentation with no irritation to the **skin**. A compn. contg. a G. lucidum EtOH ext. 0.5, I 0.5, EtOH 75, polyoxyethylene(40 mol) hydrogenated castor oil 2.0 wt.%, and H2O balance was applied to UV irradn.-induced pigmented **skin** of the guinea pig for 4 wk to show significant decrease of the pigmentation as compared with the control compn. contg. no I. A **cosmetic lotion** contg. G. lucidum EtOH ext. 0.5, I phosphate Mg salt 0.5, glycerin 6.0, EtOH 8.0, polyoxyethylene hydrogenated castor oil 0.8, p-HOC6H4CO2Me 0.05, **citric acid** 0.05, Na citrate 0.07, perfume 0.1 wt.%, and H2O balance was prepd.

ST Ganoderma ext **skin** lightening **cosmetic**; vitamin Gonoderma ext **cosmetic**

IT Ganoderma lucidum
(culture or ext. of, **skin**-lightening **cosmetics** contg. vitamins and)

IT Tocopherols
Vitamins
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. Ganoderma lucidum culture or ext. and)

IT **Cosmetics**
(**skin**-lightening, Ganodermalucidum culture or ext. and vitamins for)

IT **50-81-7**, **Ascorbic acid**, biological studies **50-81-7D**, **Ascorbic acid**, derivs. 65-23-6, Pyridoxine 65-23-6D, Pyridoxine, derivs. 68-26-8, Retinol 68-26-8D, Retinol, derivs. **79-83-4**, **Pantothenic acid** **79-83-4D**, **Pantothenic acid**, derivs. 1406-70-8, Tocopherol acetate 108910-78-7
RL: BIOL (Biological study)

(**skin**-lightening **cosmetics** contg. Ganoderma lucidum culture or ext. and)

L229 ANSWER 85 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:27850 HCAPLUS
DN 116:27850
TI Stable **skin**-lightening **cosmetics** containing L-**ascorbic acid** derivatives and water-soluble acidic substances
IN Matsui, Tadashi; Yamada, Toshimi; Shinomiya, Tatsuro
PA Kanebo, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03153609	A2	19910701	JP 1989-293694	19891111 <--

OS MARPAT 116:27850
GI



I

AB The title **cosmetics** contain L-**ascorbic acid** derivs. I (R = C1-22 alkyl or alkenyl), H2O-sol. acidic substances (salts), and H2O and have pH 3.0-6.0. 3-O-Ethyl-L-**ascorbic acid** 2.0, stearic acid 10.0, cetyl alc. 4.0, liq. paraffin 15.0, glycerin monostearate 2.0, propylene glycol 10.0, glycerin 4.0, methylparaben 0.1, KOH 0.5, **citric acid** 0.4, and H2O 52.0 wt.% were **emulsified** at 80.degree. and cooled to give a **cosmetic cream** (pH 5.0). The **cream** showed 74% inhibitory activity against tyrosinase and was stable at 45.degree. for 3 mo. The **cream** was applied to human **skin** to show good **skin**-lightening effect.
ST **ascorbate** stabilizer acid **skin** lightening
IT **Cosmetics**
(**skin**-lightening, **ascorbates** and water-sol. acid (salts) in)
IT 86404-04-8, 3-O-Ethyl-L-**ascorbic acid** 86404-06-0, 3-O-Isopropyl-L-**ascorbic acid** 106413-53-0
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg.)
IT 56-86-0, L-Glutamic acid, biological studies 68-04-2, Sodium citrate **77-92-9**, **Citric acid**, biological studies 7558-79-4, Disodium hydrogen phosphate 7664-38-2, Phosphoric acid, biological studies 7778-77-0, Potassium dihydrogen phosphate
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg. **ascorbates** and, stable)

L229 ANSWER 86 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1992:11030 HCAPLUS

DN 116:11030
TI **Skin** care composition containing retinoids and antioxidants
IN Clum, Charles E.; Wang, Jonas C. T.
PA Johnson and Johnson Consumer Products, Inc., USA
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K007-48
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 440398	A1	19910807	EP 1991-300627	19910128 <--
	EP 440398	B1	19931229		
	R: DE, ES, FR, GB, IT				
	AU 9169972	A1	19910801	AU 1991-69972	19910124 <--
	AU 639063	B2	19930715		
	JP 04210902	A2	19920803	JP 1991-22677	19910124 <--
	JP 3014780	B2	20000228		
	CA 2035086	AA	19910730	CA 1991-2035086	19910128 <--
	ZA 9100621	A	19921028	ZA 1991-621	19910128 <--
	ES 2048557	T3	19940316	ES 1991-300627	19910128 <--
	BR 9100360	A	19911022	BR 1991-360	19910129 <--
	US 5559149	A	19960924	US 1993-153543	19931116 <--
	US 5583136	A	19961210	US 1995-374011	19950118 <--
	US 5652263	A	19970729	US 1996-674474	19960702 <--

PRAI	US 1990-471760	19900129	<--
	US 1991-719264	19910627	<--
	US 1992-926606	19920806	<--
	US 1993-153543	19931116	<--
	US 1994-184736	19940121	<--

AB A **skin** care compn. contains a water-in-oil **emulsion** base comprising an antioxidant system, a chelating agent and .gtoreq.1 retinoid. A water-in-oil **cream** contained mineral oil 25.000, hydroxyoctacosanyl hydroxystearate (Elfacos C26) 6.000, sorbitol soln. 5.000, methoxy PEG-22/dodecyl glycol copolymer (Elfacos E200) 5.000, PEG-45/dodecyl glycol copolymer (Elfacos ST9) 3.000 stearoxytrimethylsilane 1.000, dimethicone 1.000, retinol 0.165, methylparaben 0.300, fragrance 0.25, propylparaben 0.2000, Quaternium 15 0.100, Na2EDTA 0.100 **ascorbic acid** 0.100, butylated hydroxytoluene 0.050, 50% aq. NaOH q.s. to pH 4.7, and water to 100.000%.

ST **skin cream** retinoid chelator antioxidant; EDTA retinol BHT **skin cream**

IT Retinoids
RL: BIOL (Biological study)
(**skin creams** contg. chelating agents and antioxidants and)

IT Antioxidants
(**skin creams** contg. chelating agents and retinoids and)

IT Chelating agents
(**skin creams** contg. retinoids and antioxidants and)

IT **Cosmetics**
(**creams**, retinoids and antioxidants and chelating agents in)

IT Pharmaceutical dosage forms
(**ointments**, **creams**, retinoids and antioxidants and chelating agents in)

IT 68-26-8, Retinol 79-81-2, Retinyl palmitate 116-31-4, Retinal 127-47-9, Retinyl acetate 302-79-4, all-trans-Retinoic acid 4759-48-2
RL: BIOL (Biological study)
(**skin creams** contg. chelating agents and antioxidants and)

IT **50-81-7, Ascorbic acid**, biological studies
52-89-1, **Cysteine** hydrochloride 59-02-9, .alpha.-Tocopherol

62-56-6, Thiourea, biological studies 68-11-1, Thioglycolic acid, biological studies 89-65-6, Isoascorbic acid 90-30-2 96-27-5, Thioglycerol 121-79-9, Propyl gallate 123-31-9, Hydroquinone, biological studies 128-37-0, BHT, biological studies 137-66-6, Ascorbyl palmitate 149-44-0, Sodium formaldehyde sulfoxylate 280-57-9, 1,4-Diazabicyclo[2.2.2]octane 500-38-9 7631-90-5, Sodium bisulfite 7681-57-4, Sodium metabisulfite 7757-83-7, Sodium sulfite 17040-04-9 25013-16-5, Butylated hydroxyanisole 43137-63-9, Thiosorbitol
RL: BIOL (Biological study)
(**skin creams** contg. chelating agents and retinoids and)

IT 60-00-4, EDTA, biological studies **77-92-9**, biological studies **87-69-4**, **Tartaric acid**, biological studies 139-33-3, Disodium EDTA 150-25-4, Dihydroxyethyl glycine
RL: BIOL (Biological study)
(**skin creams** contg. retinoids and antioxidants and)

L229 ANSWER 87 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:589747 HCAPLUS
DN 115:189747
TI Pharmaceutical and **cosmetic** composition containing .alpha.-hydroxy acids, .alpha.-keto-acids, and amphoteric agents
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K007-48
ICS A61K031-19
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): **62**

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 413528	A1	19910220	EP 1990-308828	19900810	<--
	EP 413528	B1	19951115			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
	US 5091171	A	19920225	US 1989-393749	19890815	<--
	US 5091171	B2	19970715			
	CA 2019273	AA	19910215	CA 1990-2019273	19900619	<--
	AU 9059139	A1	19910221	AU 1990-59139	19900718	<--
	AU 660917	B2	19950713			
	EP 671162	A2	19950913	EP 1995-105358	19900810	<--
	EP 671162	A3	19951227			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
	AT 130187	E	19951215	AT 1990-308828	19900810	<--
	ES 2081936	T3	19960316	ES 1990-308828	19900810	<--
	JP 3016588	B2	20000306	JP 1991-505539	19910121	<--
	US 5385938	A	19950131	US 1992-925877	19920807	<--
	US 5385938	B1	19920807			
	US 5091171	B1	19950926	US 1992-90002911	19921217	<--
	US 5702688	A	19971230	US 1993-135841	19931007	<--
	US 5637615	A	19970610	US 1995-467153	19950606	<--
	US 5643961	A	19970701	US 1995-466737	19950606	<--
	US 5643962	A	19970701	US 1995-466740	19950606	<--
	US 5643952	A	19970701	US 1995-466770	19950606	<--
	US 5643953	A	19970701	US 1995-467156	19950606	<--
	US 5643963	A	19970701	US 1995-471523	19950606	<--
	US 5648395	A	19970715	US 1995-466739	19950606	<--
	US 5648391	A	19970715	US 1995-469812	19950606	<--
	US 5648388	A	19970715	US 1995-471511	19950606	<--
	US 5650436	A	19970722	US 1995-467134	19950606	<--
	US 5650437	A	19970722	US 1995-470060	19950606	<--
	US 5650440	A	19970722	US 1995-471513	19950606	<--
	US 5652267	A	19970729	US 1995-469814	19950606	<--

US 5654340	A	19970805	US 1995-467989	19950606	<--
US 5656665	A	19970812	US 1995-466771	19950606	<--
US 5656666	A	19970812	US 1995-470829	19950606	<--
US 5670542	A	19970923	US 1995-465700	19950606	<--
US 5670543	A	19970923	US 1995-471521	19950606	<--
US 5674899	A	19971007	US 1995-465704	19950606	<--
US 5674903	A	19971007	US 1995-468079	19950606	<--
US 5677339	A	19971014	US 1995-466820	19950606	<--
US 5677340	A	19971014	US 1995-468077	19950606	<--
US 5716992	A	19980210	US 1995-469811	19950606	<--
US 5827882	A	19981027	US 1995-465695	19950606	<--
US 5654336	A	19970805	US 1995-483328	19950607	<--
US 5681853	A	19971028	US 1995-472317	19950607	<--
US 5684044	A	19971104	US 1995-472315	19950607	<--
US 5690967	A	19971125	US 1995-472310	19950607	<--
AU 9533110	A1	19960215	AU 1995-33110	19951006	<--
AU 701962	B2	19990211			
US 6060512	A	20000509	US 1998-185608	19981104	<--
US 6051609	A	20000418	US 1998-222997	19981230	
US 6191167	B1	20010220	US 1999-255702	19990223	

PRAI	US 1989-393749	19890815	<--
	US 1986-945680	19861223	<--
	US 1990-469738	19900119	<--
	US 1990-467958	19900122	<--
	EP 1990-308828	19900810	<--
	WO 1991-US412	19910121	<--
	US 1992-840149	19920224	<--
	US 1993-135841	19931007	<--
	US 1997-926030	19970909	
	US 1997-998864	19971229	
	US 1997-998871	19971229	
	US 1998-185608	19981104	

OS MARPAT 115:189747

AB A pharmaceutical or **cosmetic** topical compn. comprises an amphoteric or pseudoamphoteric agent and an .alpha.-hydroxy acid, an .alpha.-keto acid or a related compd. for the treatment of **skin** disorders. A compn. for dandruff or dry **skin** contained **glycolic acid** 7.6, L-arginine 8.7g, water 60, propylene glycol 20, and EtOH up to 100 mL. The pH of the compn. was 3.0.

ST topical **cosmetic** amphoteric hydroxyacid ketoacid; polymer amphoteric pharmaceutical **skin**

IT Imidazolium compounds
RL: BIOL (Biological study)
(cocoamphoglycine, **cosmetics** and pharmaceuticals contg., for **skin** disorder treatment)

IT Amphoteric substances
(**cosmetic** and pharmaceutical compn. contg. .alpha.-hydroxy acids and .alpha.-ketoacids and)

IT Phosphatidylethanolamines
Phosphatidylserines
Protamines
Quaternary ammonium compounds, biological studies
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-keto acid and .alpha.-hydroxy acid and)

IT Amino acids, biological studies
Oxides, biological studies
Proteins, biological studies
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and .alpha.-hydroxy acids and)

IT Antihistaminics
Bronchodilators
Hormones
Retinoids
RL: BIOL (Biological study)

(**cosmetic** compn. contg. .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids and)

IT Histones
Sphingomyelins
RL: BIOL (Biological study)
(**cosmetics** and pharmaceuticals contg., for **skin** disorder treatment)

IT Lecithins
RL: BIOL (Biological study)
(derivs., **cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and .alpha.-hydroxy acids and)

IT Cardiovascular agents
(topical, **cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids and)

IT **Skin, disease or disorder**
(treatment of, with pharmaceutical compn. contg. .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids)

IT **Athlete's foot**
Dandruff
Dermatitis
Eczema
(treatment of, with topical pharmaceutical compn. contg. .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids)

IT **Alcohols, biological studies**
RL: BIOL (Biological study)
(**carboxy, cosmetic** and pharmaceutical compns. contg. keto acids and amphoteric agents and)

IT Hair preparations
(conditioners, .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids in)

IT Peptides, biological studies
RL: BIOL (Biological study)
(di-, **cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and .alpha.-hydroxy acids and)

IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(**hydroxy, cosmetic** and pharmaceutical compns. contg. keto acids and amphoteric agents and)

IT **Skin, disease or disorder**
(keratinization, treatment of, with pharmaceutical compn. contg. keto acids and amphoteric agents and hydroxy acids)

IT Pharmaceutical dosage forms
(**ointments, creams**, alpha-ketoacids and amphoteric agents and .alpha.-hydroxy acids in)

IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(oxo, alpha-, **cosmetic** and pharmaceutical compn. contg. .alpha.-**hydroxy** acids and amphoteric agents and)

IT **Cosmetics**
(**skin**-lightening, alpha-ketoacids and amphoteric agents and .alpha.-hydroxy acids in)

IT **Sunburn and Suntan**
(**sunscreens, cosmetic** compn. contg. .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids and)

IT 50-03-3, Hydrocortisone 21-acetate 50-23-7, Hydrocortisone 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 58-95-7, Vitamin E acetate 59-46-1, Procaine 60-54-8, Tetracycline 60-87-7, Promethazine 68-88-2, Hydroxyzine 76-25-5, Triamcinolone acetonide 79-81-2, Vitamin A palmitate 94-36-0, Benzoyl peroxide, biological studies 96-88-8, Mepivacaine 103-16-2, Monobenzone 114-07-8, Erythromycin 123-31-9, Hydroquinone, biological studies 126-07-8, Griseofulvin 137-58-6, Lidocaine 140-65-8, Pramoxine 302-79-4, Retinoic acid 356-12-7 483-63-6, Crotamiton 525-66-6, Propranolol 2013-58-3, Meclocycline 4759-48-2 5593-20-4, Betamethasone dipropionate 10118-90-8, Minocycline 13609-67-1, Hydrocortisone 17-butyrate 15687-27-1, Ibuprofen 16110-51-3, Cromolyn 18323-44-9,

Clindamycin 18559-94-9, Albuterol 22204-53-1 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25122-46-7, Clobetasol propionate 57524-89-7, Hydrocortisone 17-=valerate 65277-42-1, Ketoconazole
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. amphoteric agent and .alpha.-keto acids and .alpha.-hydroxy acids and)

IT 55-10-7 **76-93-7**, **Benzilic acid**, biological studies **77-92-9**, **Citric acid**, biological studies **80-69-3**, **Tartronic acid** **87-69-4**, biological studies 87-73-0, Saccharic acid 90-64-2, Mandelic acid **90-80-2**, **Gluconolactone** **156-05-8** 306-23-0 389-36-6 473-81-4, Glyceric acid 488-30-2, D-Arabinonic acid 492-86-4 **515-30-0**, **Atrolactic acid** **526-95-4**, **Gluconic acid** 526-99-8, Mucic acid **599-04-2**, Pantoyllactone 617-31-2, 2-Hydroxypentanoic acid 617-73-2, 2-Hydroxyoctanoic acid 629-22-1, 2-Hydroxyoctadecanoic acid 636-69-1, 2-Hydroxyheptanoic acid 642-99-9, D-Mannonic acid 764-67-0, 2-Hydroxyhexadecanoic acid 775-01-9 1198-84-1 2507-55-3, 2-Hydroxytetradecanoic acid **2782-07-2** 2984-55-6, 2-Hydroxydodecanoic acid 3063-04-5, Glucoheptonolactone 3327-64-8, Gulonolactone 3695-24-7 3909-12-4, Threonic acid 3956-93-2, Idonic acid **5336-08-3** 5393-81-7, 2-Hydroxydecanoic acid 6064-63-7, 2-Hydroxyhexanoic acid 6803-09-4 **6915-15-7**, **Malic acid** 13382-27-9, **Galactonic acid** 13752-84-6, Erythronic acid 15896-36-3, 2-Hydroxynonanoic acid 16742-48-6, 2-Hydroxyeicosanoic acid **17812-24-7**, **Ribonic acid** 17828-56-7, Xylonic acid 19790-86-4, 2-Hydroxyundecanoic acid 20246-52-0, Talonic acid 20246-53-1, Gulonic acid 23351-51-1, Glucoheptonic acid 24871-35-0, Altronic acid 26301-79-1 28223-40-7, Lyxonic acid 28223-42-9, Allonic acid 28700-18-7, Galacturonolactone 32449-92-6, Glucuronolactone 136599-01-4 136656-29-6
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. amphoteric agents and .alpha.-ketoyacids and)

IT 52-52-8, Cycloleucine 2783-17-7, 1,12-Diaminododecane
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-hydroxy acids and)

IT **50-81-7**, L-**Ascorbic acid**, biological studies **127-17-3**, **Pyruvic acid**, biological studies **156-06-9**, **Phenylpyruvic acid** 298-12-4, Glyoxylic acid **320-77-4**, **Isocitric acid** 328-51-8, 2-Ketooctanoic acid **529-64-6**, **Tropic acid** 544-57-0, Cerebronic acid 600-18-0, 2-Ketobutanoic acid **600-22-6**, **Methyl pyruvate** **617-35-6**, **Ethyl pyruvate** 666-99-9, Agaricic acid **1112-33-0**, **Pantoic acid** **1603-79-8**, **Ethyl benzoylformate** 1713-85-5, 3-Chlorolactic acid 1821-02-9, 2-Ketopentanoic acid 2306-22-1, **Citramalic acid** 2492-75-3, 2-Ketohexanoic acid 6362-58-9 6613-41-8, Ethyl phenylpyruvate 7007-81-0, Trethocanic acid 13088-48-7, 2-Ketopheptanoic acid **15206-55-0**, **Methyl benzoylformate** 18299-27-9, Aleuritic acid **36413-60-2**, **Quinic acid** 41172-04-7, Methyl 2-ketooctanoate 73572-07-3, 2-Hydroxynervonic acid 80490-57-9, 2-Ketododecanoic acid
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-hydroxy acids and amphoteric agents and)

IT **50-21-5**, 2-Hydroxypropanoic acid, biological studies 51-35-4, 4-Hydroxyproline 51-48-9, Thyroxine, biological studies **52-90-4**, **Cysteine**, biological studies 56-12-2, 4-Aminobutanoic acid, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-84-8, L-Aspartic acid, biological studies 56-85-9, Glutamine, biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies **56-89-3**, **Cystine**, biological studies 57-00-1, Creatine 58-82-2,

Bradykinin 60-18-4, Tyrosine, biological studies 60-27-5 61-90-5, Leucine, biological studies 62-57-7, 2-Amino-2-methylpropanoic acid **63-68-3**, **Methionine**, biological studies 63-91-2, L-Phenylalanine, biological studies 69-91-0 **70-18-8**, **Glutathione**, biological studies 70-26-8, Ornithine 70-47-3, Asparagine, biological studies 70-78-0 71-00-1, Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, Threonine, biological studies 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 74-79-3, Arginine, biological studies 80-60-4 93-82-3 **107-35-7**, **Taurine** 107-43-7, Betaine 107-95-9, .beta.-Alanine 144-90-1 147-85-3, Proline, biological studies 156-86-5, Homoarginine 300-39-0 305-62-4 305-84-0, Carnosine 372-75-8 454-41-1, **Methionine** sulfoxide 462-10-2, Homocystine 495-27-2, Ophthalmic acid 496-93-5 515-94-6, 2,3-Diaminopropanoic acid 535-75-1, Pipecolic acid 543-38-4, Canavanine 556-50-3, Glycylglycine **565-70-8**, 2-Hydroxybutanoic acid 583-93-7, 2,6-Diaminopimelic acid 584-85-0, Anserine **594-61-6** 672-15-1, Homoserine 1078-17-7, 3-Phenylserine 1190-94-9, 5-Hydroxylysine 1314-13-2, Zinc oxide, biological studies 1344-28-1, Aluminum oxide, biological studies 1616-99-5 2260-12-0 2381-08-0, Cysteinesulfinic acid 2481-03-0 2524-31-4 2746-33-0, Ophidine 3005-85-4 3081-61-6, Theanine 3398-40-1 3650-73-5, Homocarnosine 4299-56-3, .beta.-Lysine **6027-13-0**, **Homocysteine** 7314-32-1, **Methionine** sulfone 7446-68-6 9007-92-5, Glucagon, biological studies 14916-76-8 16305-88-7, Norophthalmic acid 20182-63-2, Stearamidopropyl dimethylamine 22467-93-2, .beta.-Alanyllysine 67298-08-2D, N-cocoyl 90485-65-7 100869-33-8 136532-13-3D, N-cocoyl derivs.
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-keto acid and .alpha.-hydroxy acid and)

IT 95-96-5, Lactide 467-32-3, Benzilide 502-97-6, Glycolide 617-57-2, Lactyl lactate 6713-72-0 23243-68-7, Triglycolic acid 26009-03-0, Polyglycolic acid 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Polylactic acid 26124-68-5, Polyglycolic acid 30450-85-2 38436-21-4 64033-40-5 78024-33-6 102526-99-8 105653-00-7 133217-23-9 136532-14-4 136532-15-5 136532-16-6 136532-17-7 136532-18-8
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and amphoteric agents and)

IT 56-40-6, Glycine, biological studies
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and .alpha.-hydroxy acids and)

IT 28299-33-4D, Imidazoline, derivs.
RL: BIOL (Biological study)
(**cosmetic** and pharmaceutical compn. contg. .alpha.-ketoacids and .alpha.-hydroxyacids and)

IT 51-21-8, 5-Fluorouracil
RL: BIOL (Biological study)
(pharmaceutical compn. contg. .alpha.-ketoacids and amphoteric agents and .alpha.-hydroxy acids and)

L229 ANSWER 88 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1991:214180 HCAPLUS
DN 114:214180
TI Compositions and processes for improving the **cosmetic** appearance, growth or healing characteristics of tissue
IN Nechay, Bohdan R.
PA University of Texas System, USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-48

ICS A61K033-24; A61K031-28
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9012563	A1	19901101	WO 1990-US2175	19900420 <--
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	AU 9054484	A1	19901116	AU 1990-54484	19900420 <--
PRAI	US 1989-342993	19890424 <--			
	WO 1990-US2175	19900420 <--			

AB A **cosmetic** contains V compds. for alleviating **skin** wrinkles and for **skin** conditioning. The amt. of V present in a **cosmetic** is about 4.5 .times. 10-8 M as measured by vanadate ion. The V-contg. compds. are NaVO3, Na3VO4, Na4V2O7, KVO3, NH4VO3, Ca3(VO4)2, Fe(VO3)3, etc. A **cosmetic lotion** was prepd. that consisted of NaVO3 (2.55 ng V/mL) in 95% glycerol and 5% water.
ST **skin cosmetic** vanadium compd
IT **Cosmetics**
(**skin** conditioning, vanadium-contg. compds. for)
IT Mushroom
Tunicata
(vanadium compd. from, for **cosmetic skin** conditioners)
IT Flavanols
RL: BIOL (Biological study)
(vanadium complexes, **cosmetic skin** conditioners contg.)
IT Fatty acids, compounds
Glycols, compounds
Nucleic acids
Phospholipids, compounds
Prostaglandins
Retinoids
RL: BIOL (Biological study)
(complexes, with vanadium, **cosmetic skin** conditioners contg.)
IT Amino acids, compounds
RL: BIOL (Biological study)
(vanadium complexes, **skin** conditioners contg.)
IT **50-81-7D**, L-**Ascorbic acid**, vanadium complex
68-26-8D, Retinol, vanadium complex **70-18-8D**, **Glutathione**, vanadium complex **77-92-9D**, vanadium complex
116-31-4D, Retinal, vanadium complex 1314-62-1, Vanadium pentoxide, biological studies 7440-62-2D, Vanadium, compds. 7632-51-1, Vanadium tetrachloride 7718-98-1, Vanadium trichloride 7727-18-6, Vanadium oxytrichloride 7803-55-6, Ammonium metavanadate 10049-12-4, Vanadium trifluoride 10049-16-8, Vanadium tetrafluoride 10213-09-9, Vanadium oxydichloride 11117-79-6 12036-21-4, Vanadium dioxide 12379-22-5, Vanadate (V3O93-) 13470-26-3, Vanadium tribromide 13517-26-5, Sodium pyrovanadate 13520-87-1 13520-88-2 13520-89-3 13520-90-6, Vanadium oxytribromide 13550-42-0, Calcium orthovanadate 13568-68-8
13595-30-7, Vanadium tetrabromide 13718-26-8, Sodium metavanadate
13721-39-6, Sodium orthovanadate 13769-43-2, Potassium metavanadate
13814-83-0 14293-78-8, Potassium orthovanadate 14638-93-8
15469-60-0, Zinc orthovanadate 15513-94-7, Vanadium triiodide
16229-43-9, Vanadyl sulfate 17497-76-6 23344-62-9 37368-10-8, Aluminum vanadium oxide 63643-82-3, Vanadate (V2(OH)O63-) 65842-03-7, Iron vanadium oxide (FeV3O9)
RL: BIOL (Biological study)
(**cosmetic skin** conditioners contg.)

L229 ANSWER 89 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:637566 HCAPLUS

DN 113:237566
TI **Cosmetic** and hair composition comprising emollient oil and **emulsifiers**
IN Pereira, Mavis Claire
PA Unilever PLC, UK; Unilever N. V.
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K007-06
ICS A61K007-08
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 358528	A2	19900314	EP 1989-309146	19890908 <--
EP 358528	A3	19910403		
EP 358528	B1	19940615		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
US 4981845	A	19910101	US 1989-399643	19890825 <--
CA 1332568	A1	19941018	CA 1989-610359	19890905 <--
JP 02121906	A2	19900509	JP 1989-232689	19890907 <--
JP 06084291	B4	19941026		
AU 8941206	A1	19900315	AU 1989-41206	19890908 <--
AU 622478	B2	19920409		
ZA 8906885	A	19910529	ZA 1989-6885	19890908 <--
ES 2056220	T3	19941001	ES 1989-309146	19890908 <--
PRAI GB 1988-21129	19880909 <--			

AB A **cosmetic** or hair **emulsion** comprises a **skin**-benefiting agent 0.01-20, ethoxylated 21-stearyl alc. (I) **emulsifier** 0.1-20, and emollient oil 0.5-70% by wt. The **skin**-benefiting agent is an amino acid, a sunscreen, retinoic acid, **ascorbic acid**, tocopherol, etc. The emollient is lanolin, cetyl alc., dimethylpolysiloxanes, etc. The **emulsion** also comprises a delivery enhancer, i.e. butane-1,3-diol, glycerol, propane-1,4-diol, and di-Bu sebacate. An oil-in-water **skin lotion** comprised tocopherol 0.2, **ascorbic acid** 0.3, I 0.8, avocado oil 0.5, arnica oil 0.5, isopropyl myristate 2.0, cetyl palmitate 2.0, wax 2.0, fatty alc. 1.2, silicone oil 6.0, xanthan gum 0.5, butane-1,3-diol 7.5, whitener 0.2, preservative 0.36, perfume 0.1, and water to 100%.

ST **skin** emollient oil **emulsifier**; hair **emulsion** ethoxylated steryl alc
IT Ozocerite
Amino acids, biological studies
Lanolin
RL: BIOL (Biological study)
(**cosmetic** and hair **emulsion** contg.)
IT **Cosmetics**
Hair preparations
(emollient oil and nutrients in)
IT Oils, glyceridic
RL: BIOL (Biological study)
(arnica seed, **cosmetic** and hair **emulsion** contg.)
IT Oils, glyceridic
RL: BIOL (Biological study)
(avocado, **cosmetic** and hair **emulsion** contg.)
IT Siloxanes and Silicones, biological studies
RL: BIOL (Biological study)
(di-Me, **cosmetic** and hair **emulsion** contg.)
IT Oils, glyceridic
RL: BIOL (Biological study)
(evening primrose, **cosmetic** and hair **emulsion** contg.)
IT Polyethers, biological studies
RL: BIOL (Biological study)

(perfluoro, **cosmetic** and hair **emulsion** contg.)
IT Fluoropolymers
RL: BIOL (Biological study)
(polyether-, **cosmetic** and hair **emulsion** contg.)
IT **Sunburn and Suntan**
(**sunscreens, cosmetic** and hair **emulsion** contg.)
IT Oils, glyceridic
RL: BIOL (Biological study)
(wheat germ, **cosmetic** and hair **emulsion** contg.)
IT 50-03-3, Hydrocortisone acetate **50-21-5**, biological studies **50-81-7, Ascorbic acid**, biological studies 51-35-4, Hydroxyproline **52-90-4**, L-**Cysteine**, biological studies 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 56-45-1, L-Serine, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 56-84-8, L-Aspartic acid , biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies **56-89-3, Cystine** , biological studies 57-55-6, 1,2-Propanediol, uses and miscellaneous 60-18-4, Tyrosine, biological studies 61-90-5, L-Leucine, biological studies **63-68-3, Methionine**, biological studies 63-91-2, L-Phenylalanine, biological studies 71-00-1, L-Histidine, biological studies 72-18-4, Valine, biological studies 72-19-5, L-Threonine, biological studies 73-22-3, L-Tryptophan, biological studies 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine, biological studies 79-81-2, Retinyl palmitate 98-79-3 98-79-3D, salts 104-28-9, 2-Ethoxyethyl p-methoxycinnamate 107-88-0, 1,3-Butanediol 109-43-3, Dibutyl sebacate 110-27-0, Isopropyl myristate 112-92-5, 1-Octadecanol 118-56-9, Homomenthyl salicylate 118-60-5, 2-Ethylhexyl salicylate 131-56-6, 2,4-Dihydroxybenzophenone 131-57-7 136-44-7 137-66-6, Ascorbyl palmitate 147-85-3, Proline, biological studies 150-13-0 302-79-4, Retinoic acid 538-23-8, Caprylic acid triglyceride 540-10-3 617-73-2, 2-Hydroxyoctanoic acid 621-71-6, Capric acid triglyceride 1406-70-8, Tocopherol acetate 5466-77-3, Ethylhexyl p-methoxycinnamate 6064-63-7, 2-Hydroxyhexanoic acid 9004-61-9, Hyaluronic acid 9004-61-9D, Hyaluronic acid, salts 9004-94-8 9004-99-3 27503-81-7 30687-20-8 36653-82-4, 1-Hexadecanol 38102-62-4 58882-17-0 63250-25-9 112725-59-4, Butylmethoxydibenzoylmethane
RL: BIOL (Biological study)
(**cosmetic** and hair **emulsion** contg.)

L229 ANSWER 90 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:429129 HCAPLUS
DN 113:29129
TI **Skin**-lightening **cosmetics** containing kojic acid and stabilizers
IN Nagashima, Tetsuya; Nakajima, Kazuo; Suzuki, Yachio; Nomoto, Kaoru
PA Kawaken Fine Chemicals Co., Ltd., Japan; Sansei Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02028105	A2	19900130	JP 1988-159600	19880627 <--
	JP 2751965	B2	19980518		

PRAI JP 1988-107959 19880430 <--
AB Stable **cosmetics** contain (1) kojic acid, (2) .gtoreq.1 compds. chosen from org. monocarboxylic acids, neutral amino acids, basic amino acids, and their salts, and (3) .gtoreq.1 compds. chosen from org. dicarboxylic acids, org. tetracarboxylic acids, polycarboxylic acids, acidic amino acids, and their salts. Cold **cream** was prepd. from

liq. paraffin 38.0, solid paraffin 12.0, beeswax 12.0, poly(oxyethylene) cetyl ether 2.5, poly(oxyethylene) oleyl ether 4.1, poly(oxyethylene) sorbitan laurate 0.8, Bu p-hydroxybenzoate 0.2, nicotinic acid 0.3, .gamma.-linolenic acid 0.2, vitamin A acid 0.2, kojic acid 1.0, and H2O to 100 wt.%.

ST kojic acid **cosmetic** stability carboxylate; amino acid kojic **cosmetic** stability

IT Amino acids, biological studies
Carboxylic acids, biological studies
RL: BIOL (Biological study)
(stable **cosmetics** contg. kojic acid and)

IT **Cosmetics**
(**skin**-lightening, kojic acid and stabilizers in)

IT 501-30-4, Kojic acid
RL: BIOL (Biological study)
(**skin**-lightening **cosmetics** contg., stabilizers for)

IT **50-21-5**, **Lactic acid**, biological studies
51-35-4, L-Hydroxyproline 56-40-6, Glycine, biological studies 56-45-1, L-Serine, biological studies 56-84-8, L-Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies **59-51-8**, DL-**Methionine** 59-67-6, Nicotinic acid, biological studies 60-32-2, .epsilon.-Aminocaproic acid 61-90-5, L-Leucine, biological studies 64-02-8, Tetrasodium ethylenediaminetetraacetate 72-17-3 72-19-5, L-Threonine, biological studies 74-79-3, L-Arginine, biological studies **77-92-9**, **Citric acid**, biological studies **87-69-4**, **Tartaric acid**, biological studies 139-33-3, Disodium ethylenediaminetetraacetate 142-47-2, Monosodium L-glutamate 147-85-3, L-Proline, biological studies 302-79-4, Vitamin A acid 471-53-4, Glycyrrhetic acid 506-26-3, .gamma.-Linolenic acid 532-32-1, Sodium benzoate 868-18-8 3792-50-5, Monosodium L-aspartate **6915-15-7**, **Malic acid** 7239-50-1 9004-61-9, Hyaluronic acid 9005-38-3, Sodium alginate 9007-28-7, Chondroitin sulfuric acid 10098-89-2, L-Lysine hydrochloride 16690-92-9, Disodium L-glutamate 32221-81-1, Monosodium DL-glutamate 54571-67-4, PCA Soda 55901-20-7
RL: BIOL (Biological study)
(stable **cosmetics** contg. kojic acid and)

L229 ANSWER 91 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:411957 HCAPLUS
DN 113:11957
TI Multi-purpose body powder composition containing talc
IN Harvey, Norman A.
PA USA
SO U.S., 5 pp. Cont.-in-part of U.S. Ser. No. 837,650, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-035
NCL 424069000
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4913896	A	19900403	US 1988-158917	19880222 <--
PRAI US 1985-696260	19850130 <--			
US 1986-837650	19860305 <--			

AB A talc-based body powder with a unique compn. of desirabl characteristics including **moisture** absorbency, anti-ammonia, antibacterial, and antifungal effects, making it specially useful for infant **skin** care purposes, is presented. Thus, a powder compn. comprises talc 78, corn starch 14, Ca undecylenate 7, and **citric acid** 1%.

ST talc body powder formulation

IT Perfumes and Essences
Kaolin, biological studies

Olive oil
RL: BIOL (Biological study)
(body powder compn. contg. talc and)
IT **Cosmetics**
(baby powders, talc-based, formulation and properties of)
IT **Cosmetics**
(powders, talc-based, formulation and properties of)
IT **50-81-7, Ascorbic acid,** biological studies
77-92-9, Citric acid, biological studies
1314-13-2, Zinc oxide, biological studies 1322-14-1, Calcium undecylenate 4485-12-5, Lithium stearate 9005-25-8, Starch, biological studies 41423-37-4
RL: BIOL (Biological study)
(body powder compn. contg. talc and)
IT 14807-96-6, Talcum, biological studies
RL: BIOL (Biological study)
(body powder compn. contg., formulation and properties of)
IT 7664-41-7, Ammonia, biological studies
RL: RCT (Reactant)
(talc-based powder neutralization of)

L229 ANSWER 92 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:240298 HCAPLUS
DN 112:240298
TI Enhancing the esthetic aspect of the **skin** with vitamin-containing **cosmetics** and oral preparations
IN Griat, Jacqueline; Soudant, Etienne; Zabotto, Arlette; Fanchon, Chantal; Pradier, Francois
PA Oreal S. A., Fr.
SO Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K007-48
ICS A61K031-68; A61K031-07
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 330583	A2	19890830	EP 1989-400531	19890224	<--
	EP 330583	A3	19910313			
	EP 330583	B1	19930818			
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE					
	JP 01268617	A2	19891026	JP 1989-45032	19890223	<--
	AU 8930756	A1	19890831	AU 1989-30756	19890224	<--
	AU 612004	B2	19910627			
	EP 530862	A2	19930310	EP 1992-119446	19890224	<--
	EP 530862	A3	19931110			
	EP 530862	B1	19960410			
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE					
	AT 93135	E	19930915	AT 1989-400531	19890224	<--
	AT 136455	E	19960415	AT 1992-119446	19890224	<--
	ES 2086617	T3	19960701	ES 1992-119446	19890224	<--
PRAI	LU 1988-87145	19880226	<--			
	EP 1989-400531	19890224	<--			

AB The esthetic appearance of the **skin** is improved by combined daily topical and oral administration of vitamins. A topical **cream** comprised vitamin E 1.5, vitamin A 0.3, vitamin B2 0.003, vitamin B5 1, vitamin H 0.02, vitamin F 2, folic acid 0.008, Mg lanolate 7, lanolin alc. 3, iso-Pr myristate 8, sunflower oil 30, vaseline 10, Me p-hydroxybenzoate 0.2, Pr p-hydroxybenzoate 0.1, and water to 100%. An oral capsule comprised peanut oil 103, hydrogenated soybean oil 15, carthamus oil 85, .beta.-carotene (20%) 3.45, vitamin E 7.5, vitamin B2 0.78, vitamin B2 0.863, vitamin B5 5, vitamin H 0.15, **vitamin C** 25, and yeast 70 mg.
ST vitamin **skin cosmetic** oral capsule

IT Vitamins
RL: BIOL (Biological study)
(**cosmetic** prepns. and oral formulations contg., for improvement of **skin** conditions)
IT **Cosmetics**
(vitamins in, for improvement of **skin** conditions)
IT Fatty acids, biological studies
RL: BIOL (Biological study)
(essential, **cosmetic** prepns. and oral formulations contg., for improvement of **skin** conditions)
IT **50-81-7, Vitamin C**, biological studies
58-85-5, Vitamin H 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies **79-83-4**, Vitamin B5 83-88-5, Vitamin B2, biological studies 1406-16-2, Vitamin D 1406-18-4, Vitamin E 7235-40-7, .beta.-Carotene 8059-24-3, Vitamin B6
RL: BIOL (Biological study)
(**cosmetic** prepns. and oral formulations contg., for improvement of **skin** conditions)

L229 ANSWER 93 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:145353 HCAPLUS
DN 112:145353
TI **Cosmetics** containing water-soluble **ascorbates** and gluconates
IN Imamura, Akihiro; Kamegawa, Hiroko; Mizutani, Cheko; Sato, Midori; Motonaga, Chiho
PA Kobayashi Kose Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01213212	A2	19890828	JP 1988-39081	19880222 <--

AB **Cosmetics** contain water-sol. **ascorbic acid** derivs. and **gluconic acid** and/or its salts. The **ascorbic acids** are stabilized by **gluconic acids** even when mixed with polyalcs. or EtOH. A **cosmetic lotion** was prepd. from EtOH 15.0, poly(oxyethylene)(50) hydrogenated castor oil 0.5, dl-.alpha.-tocopherol acetate 0.1, fragrance 0.1, Me p-hydroxybenzoate 0.1, witch hazel ext. 1.0, L-**ascorbic acid** sulfate ester 3.0, Na gluconate 0.5, and H2O to 100%.
ST **ascorbate** gluconate **skin lotion**
IT **Cosmetics**
(contg. **ascorbates** and gluconates)
IT **526-95-4, Gluconic acid** 527-07-1, Sodium gluconate
RL: BIOL (Biological study)
(**cosmetics** contg. **ascorbate** and)
IT **56939-67-4** 108910-78-7 125913-31-7
RL: BIOL (Biological study)
(**cosmetics** contg. gluconate and)

L229 ANSWER 94 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:25387 HCAPLUS
DN 112:25387
TI **Cosmetics** with **skin**-lightening properties containing kojic acid derivatives and melanin synthesis-inhibiting compounds
IN Oyama, Yasuaki
PA Sansei Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent

LA English
IC ICM A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 308919	A1	19890329	EP 1988-115543	19880922	<--
	R: FR, GB, IT					
	JP 01083011	A2	19890328	JP 1987-241966	19870925	<--
	JP 2565513	B2	19961218			
	AU 8821520	A1	19890406	AU 1988-21520	19880825	<--
	AU 614299	B2	19910829			
	DE 3832219	A1	19890413	DE 1988-3832219	19880922	<--
	US 4990330	A	19910205	US 1988-248693	19880923	<--
PRAI	JP 1987-241966	19870925	<--			

OS MARPAT 112:25387
GI



I

AB **Cosmetics** for topical use which have melanin synthesis-inhibiting activity comprise kojic acid or its esters (I; R1, R2 = C1-20-acyl, or one of R1, R2 = H and the other is C3-20-acyl) and .gtoreq.1 compds. selected from azelaic acid, tropolone, lipoic acid, sorbic acid, glucosamine, glucosamine derivs., tunicamycin, deoxynorjirimicyn, **glutathione**, **cysteine**, hydroquinone, derivs. of hydroquinone, dehydroacetic acid, chelidonic acid, and lipoamide. An **ointment** contained polyoxyethylene (60) monostearate 1.00, polyoxyethylene (60) sorbitol tetraoleate 1.50, glycerol monostearate 1.50, bees wax 2.00, paraffin 2.00, stearic acid 3.00, behenyl alc. 3.00, shea butter 12.00, liq. paraffin 5.00, natural vitamin E 0.04, Me polysiloxane 0.01, kojic acid monobenzoate 3.00, antiseptics, fragrance, 1,3-butylene glycol 5.00, **citric acid**, 0.30, Na dl-lauroyl-l-glutamate 0.50, lipoic acid 2.00, and H2O to 100%. The **cosmetics** have **skin**-whitening and antisuntan properties. Kojic acid and its esters are tyrosinase inhibitors and the combination with the other particular compds. mentioned here is synergistic.

ST **skin** lightener kojic acid lipoic

IT Melanins
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(biosynthesis of, inhibition of, synergistic kojic acid-contg. mixts. for)

IT **Cosmetics**
(**skin**-lightening, contg. kojic acid mixts. with melanin synthesis inhibitors)

IT 19130-96-2D, mixts. with kojic acid derivs. 26880-92-2D, mixts. with melanin synthesis-inhibiting compds. 79725-98-7D, Kojic acid dipalmitate, mixts. with melanin synthesis-inhibiting compds. 79725-99-8D, Kojic acid dibutyrate, mixts. with melanin synthesis-inhibiting compds. 79726-00-4D, Kojic acid dioleate, mixts. with melanin synthesis-inhibiting compds. 79726-01-5D, mixts. with melanin synthesis-inhibiting compds. 95566-77-1D, mixts. with melanin synthesis-inhibiting compds. 122753-71-3, Hydroquinone-kojic acid mixt. 122881-08-7, Kojic acid monobenzoate-lipoic acid mixt. 122881-09-8, Kojic acid monopalmitate-tunicamycin mixt. 122906-93-8, Azelaic acid-kojic acid mixt. 122906-94-9, Tropolone-kojic acid mixt.

122906-95-0, Lipoic acid-kojic acid mixt. 122906-96-1, Sorbic acid-kojic acid mixt. 122906-97-2 122906-98-3 122906-99-4, Tunicamycin-kojic acid mixt. 122907-00-0, **Glutathione**-kojic acid mixt. 122907-01-1 122907-02-2, Arbutin-kojic acid mixt. 122907-03-3, Dehydroacetic acid-kojic acid mixt. 122907-04-4 122922-99-0 122999-11-5, Lipoamide-kojic acid mixt.
RL: BIOL (Biological study)
(**skin cosmetics** contg.)

L229 ANSWER 95 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1990:11795 HCAPLUS
DN 112:11795
TI **Skin**-whitening **cosmetics** containing kojic acid-**vitamin C** mixtures
IN Hatae, Shinkichi
PA Sansei Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM A61K007-42
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 308918	A1	19890329	EP 1988-115542	19880922 <--
	R: FR, GB, IT				
	JP 01083010	A2	19890328	JP 1987-241965	19870925 <--
	AU 8821523	A1	19890406	AU 1988-21523	19880825 <--
	AU 606200	B2	19910131		
	DE 3832218	A1	19890413	DE 1988-3832218	19880922 <--
	US 4919921	A	19900424	US 1988-248684	19880923 <--
PRAI	JP 1987-241965	19870925 <--			

OS MARPAT 112:11795
GI



I

AB A **skin cosmetic** which has melanin synthesis-inhibiting properties contains kojic acid or its deriv. I (R1, R2 = C3-20-acyl, or one of R1, R2 = H and the other is C3-20-acyl) and **vitamin C** or a **vitamin C** deriv. Kojic acid esters are selected from the monobutyrate, monocaproate, monopalmitate, monostearate, monocinnamate, monobenzoate, dibutyrate, dipalmitate, distearate, and dioleate. **Vitamin C** derivs. are selected from the alkyl ester, sulfate, phosphate, and their metal salts. A **cosmetic lotion** contained polyoxyethylene (60) hydrogenated castor oil 1.00, EtOH 15.00, **citric acid** 0.10, Na citrate 0.30, 1,3-butylene glycol 4.00, kojic acid 1.00, Na L-ascorbyl 2-phosphate 2.00, antiseptic q.s., fragrance q.s., and H2O to 100% by wt. The **skin**-whitening effect of I and **vitamin C** is synergistic. Esterification of kojic acid improves stability against pH and sunlight while maintaining a **skin**-whitening effect similar to that of kojic acid.
ST **skin** whitener kojic acid **vitamin C**
IT Melanins
RL: FORM (Formation, nonpreparative)
(formation of, inhibition of, **skin**-whitening

cosmetics contg. kojic acid-**vitamin C** mixts. for)

IT **Cosmetics**
(**skin**-lightening, contg. kojic acid-**vitamin C** mixts.)

IT **50-81-7D**, L-**Ascorbic acid**, esters, mixts. with kojic acid derivs. **23313-12-4D**, salts, mixts. with kojic acid derivs. **56939-67-4D**, salts, mixts. with kojic acid derivs.
79725-98-7D, mixts. with **vitamin C** derivs.
79725-99-8D, mixts. with **vitamin C** derivs.
79726-00-4D, mixts. with **vitamin C** derivs.
79726-01-5D, mixts. with **vitamin C** derivs.
123377-43-5D, mixts. with **vitamin C** derivs.
123377-44-6D, mixts. with **vitamin C** derivs.
123377-45-7D, mixts. with **vitamin C** derivs.
123495-66-9D, mixts. with **vitamin C** derivs.
123999-45-1 123999-46-2 123999-47-3 124011-37-6 124011-39-8
124011-40-1D, mixts. with **vitamin C** derivs.
124011-41-2D, mixts. with **vitamin C** derivs.
124029-86-3
RL: BIOL (Biological study)
(**skin**-whitening **cosmetics** contg.)

L229 ANSWER 96 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:601374 HCAPLUS
DN 111:201374
TI Sunscreens containing porphyrins as UV-absorbers and chelating agents
IN Kumagai, Myako
PA Lion Corp., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C09K003-00
ICS A61K007-00; A61K007-06; A61K007-075; A61K007-08; A61K007-11; A61K007-42; A61K007-50; C08K005-34
CC 62-1 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01135887	A2	19890529	JP 1987-293183	19871120 <--

OS MARPAT 111:201374
AB UV-absorbing compns. contain porphyrins and chelating agents. The compns. effectively absorb UV-A, have good storage stability, and are safe and useful as sunscreens. A sunscreen **cream** comprised stearic acid 10.0, cetyl alc. 1.0, glycerin monomyristate 5.0, iso-Pr myristate 7.0, oleyl alc. 4.0, Et 2-ethylhexyl-p-methoxycinnamate 3.0, Na Fe chlorphyllin 2.0, diethanolamine cetyl phosphate 3.0, propylene glycol 6.0, di-Na edetate 0.2, perfume 0.2, an antiseptic agent 0.2, and H2O to 100% by wt.
ST sunscreen porphyrin chelating agent **cosmetic**; UV absorber porphyrin sunscreen **cosmetic**
IT Bacteriochlorophyllins
Chlorophyllins
Chlorophylls, biological studies
Hemocyanins
Hemoglobins
Myoglobins
Porphyrins
RL: BIOL (Biological study)
(sunscreen **cosmetics** contg. chelating agent and, stable)
IT Chelating agents
(sunscreen **cosmetics** contg. porphyrins and, stable)
IT Porphyrins
RL: BIOL (Biological study)
(complexes, sunscreen **cosmetics** contg. chelating agent and, stable)

IT Chlorophylls, compounds
RL: BIOL (Biological study)
(complexes, with metals, sunscreen **cosmetics** contg. chelating agent and, stable)
IT Chlorophyllins
RL: BIOL (Biological study)
(iron complexes, sodium salts, sunscreen **cosmetics** contg. chelating agent and, stable)
IT Chlorophyllins
RL: BIOL (Biological study)
(metal complexes, sunscreen **cosmetics** contg. chelating agent and, stable)
IT Polyphosphoric acids
RL: BIOL (Biological study)
(sodium salts, sunscreen **cosmetics** contg. porphyrins and, stable)
IT Hair preparations
Sunburn and Suntan
(**sunscreens**, contg. porphyrins and chelating agents)
IT 68-19-9, Vitamin B12 448-65-7, Deuteroporphyrin 493-90-3, Mesoporphyrin 553-12-8, Protoporphyrin 7439-88-5D, Iridium, complexes with chlorophylls and chlorophyllins 7439-89-6D, Iron, complexes with chlorophylls and chlorophyllins 7439-96-5D, Manganese, complexes with chlorophylls and chlorophyllins 7439-97-6D, Mercury, complexes with chlorophylls and chlorophyllins 7439-98-7D, Molybdenum, complexes with chlorophylls and chlorophyllins 7440-02-0D, Nickel, complexes with chlorophylls and chlorophyllins 7440-03-1D, Niobium, complexes with chlorophylls and chlorophyllins 7440-04-2D, Osmium, complexes with chlorophylls and chlorophyllins 7440-05-3D, Palladium, complexes with chlorophylls and chlorophyllins 7440-06-4D, Platinum, complexes with chlorophylls and chlorophyllins 7440-15-5D, Rhenium, complexes with chlorophylls and chlorophyllins 7440-16-6D, Rhodium, complexes with chlorophylls and chlorophyllins 7440-18-8D, Ruthenium, complexes with chlorophylls and chlorophyllins 7440-20-2D, Scandium, complexes with chlorophylls and chlorophyllins 7440-22-4D, Silver, complexes with chlorophylls and chlorophyllins 7440-25-7D, Tantalum, complexes with chlorophylls and chlorophyllins 7440-26-8D, Technetium, complexes with chlorophylls and chlorophyllins 7440-32-6D, Titanium, complexes with chlorophylls and chlorophyllins 7440-33-7D, Tungsten, complexes with chlorophylls and chlorophyllins 7440-43-9D, Cadmium, complexes with chlorophylls and chlorophyllins 7440-47-3D, Chromium, complexes with chlorophylls and chlorophyllins 7440-48-4D, Cobalt, complexes with chlorophylls and chlorophyllins 7440-50-8D, Copper, complexes with chlorophylls and chlorophyllins 7440-57-5D, Gold, complexes with chlorophylls and chlorophyllins 7440-58-6D, Hafnium, complexes with chlorophylls and chlorophyllins 7440-65-5D, Yttrium, complexes with chlorophylls and chlorophyllins 7440-67-7D, Zirconium, complexes with chlorophylls and chlorophyllins 14459-29-1, Hematoporphyrin 26316-36-9, Uroporphyrin 26608-34-4, Etioporphyrin 27121-71-7, Coproporphyrin
RL: BIOL (Biological study)
(sunscreen **cosmetics** contg. chelating agent and, stable)
IT **50-81-7, Ascorbic acid**, biological studies
52-90-4, Cysteine, biological studies 56-45-1, Serine, biological studies 56-87-1, Lysine, biological studies 60-00-4, EDTA (chelating agent), biological studies 68-04-2, Sodium citrate 74-79-3, Arginine, biological studies **77-92-9, Citric acid**, biological studies 110-15-6, Succinic acid, biological studies 139-33-3, Disodium edetate 150-38-9, Trisodium edetate **526-95-4, Gluconic acid** 50813-16-6, Sodium metaphosphate
RL: BIOL (Biological study)
(sunscreen **cosmetics** contg. porphyrins and, stable)

L229 ANSWER 97 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:520635 HCAPLUS

DN 111:120635
TI Antioxidant **skin cosmetics** containing ascorbyl esters and thiols and complexing agents
IN Nguyen, Quang Lan; Griat, Jacqueline; Millecamps, Francois
PA Oreal S. A., Fr.
SO Fr. Demande, 16 pp.
CODEN: FRXXBL
DT Patent
LA French
IC ICM C07D307-32
ICS A61K007-40; A23L003-34
ICA A23D003-04; A23D005-04
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	FR 2610626	A1	19880812	FR 1987-1539	19870209	<--
	FR 2610626	B1	19890519			
	EP 280606	A1	19880831	EP 1988-400283	19880208	<--
	EP 280606	B1	19920415			
	R: BE, CH, DE, FR, GB, IT, LI, NL					
	JP 63225689	A2	19880920	JP 1988-25874	19880208	<--
	US 5023235	A	19910611	US 1988-153450	19880208	<--
PRAI	FR 1987-1539	19870209	<--			

AB **Cosmetics** contain an antioxidant compn. based on .gtoreq.1 stabilized **ascorbate** esters, .gtoreq.1 complexing agents, and .gtoreq.1 thiols. The **cosmetics** protect the lipids in the **skin** from oxidn. Suitable complexing agents are EDTA, penta-Na diethylenetriaminepentaacetate, hexadecylamine salicylate, **citric acid**, **tartaric acid**, Na tartrate, phytic acid, dibenzyldithiocarbamate, or their mixts. Suitable thiols are N-acetylcysteine, **glutathione**, or their mixts. A preferred antioxidant system contains tocopherols or caffeic acid 2.5-20, **ascorbate** ester 20-70, complexing agent 20, and thiol 30% by wt. The degree of degrdn. of ascorbyl palmitate (I) after storage for 40 days in form of a mixt. contg. I 0.05, N-acetylcysteine 0.01, and EDTA 0.01% by wt. was 30%, whereas I had completely decompd. in a mixt. contg. I and EDTA or I and N-acetylcysteine. A mixt. contg. I 0.20, hexadecylamine salicylate 0.20, N-acetylcysteine 0.10, and tocopherols 0.20% by wt. stabilized vitamin F against oxidn. for 114 min, whereas oxidn. was induced within 15 min in the absence of stabilizers or in the presence of 0.20% by wt. hexadecylamine salicylate alone and 0.1% by wt. N-acetylcysteine alone, and within 60 min in the presence of tocopherols as stabilizers. An antioxidant system contained I 76, **citric acid** 16, and N-acetylcysteine 8% by wt. A **skin cream** in the form of a water-in-oil **emulsion** contained Mg lanolate 14.4, lanolin alc. 3.6, tournesol oil 40.0, iso-Pr myristate 8.0, ozokerite 4.0, vitamin F 2.0, **ascorbic acid** 0.5, soy lecithin 5, tocopherols 0.25, I 1.0, **glutathione** 0.1, N-acetylcysteine 0.05, **citric acid** 0.05, EDTA 0.15, perfume 0.8, methylparaben 0.3, and H2O to 100% by wt.

ST **ascorbate** thiol complexant **cosmetic** antioxidant; lipid **skin** antioxidant **cosmetic**

IT **Cosmetics**
(antioxidant, contg. **ascorbic acid** esters and complexing agents and thiols)

IT Thiols, biological studies
RL: BIOL (Biological study)
(**cosmetic** antioxidant compns. contg. **ascorbic acid** esters and complexing agents and)

IT Chelating agents
(**cosmetic** antioxidant compns. contg. **ascorbic acid** esters and thiols and)

IT Antioxidants
(for **cosmetics**, ascorbyl esters and thiols and complexing agent compns. as)

IT **Skin, metabolism**
(lipid oxidn. by, inhibition of, antioxidant compns. contg. **ascorbate** esters and complexing agents and thiols for)
IT Lipids, biological studies
RL: RCT (Reactant)
(oxidn. of, in **skin**, prevention of, **cosmetic** contg. ascorbyl esters and complexing agents and thiols for)
IT **70-18-8, Glutathione**, biological studies 616-91-1, N-Acetylcysteine
RL: BIOL (Biological study)
(**cosmetic** antioxidant compns. contg. **ascorbic acid** esters and complexing agents and)
IT 50-70-4, Sorbitol, biological studies 60-00-4, EDTA, biological studies **77-92-9, Citric acid**, biological studies 83-86-3, Phytic acid **87-69-4, Tartaric acid**, biological studies 99-22-9 140-01-2, Pentasodium diethylenetriamine pentaacetate 14475-11-7, Sodium tartrate 122608-76-8
RL: BIOL (Biological study)
(**cosmetic** antioxidant compns. contg. **ascorbic acid** esters and thiols and)
IT 137-66-6, Ascorbyl palmitate 25395-66-8, Ascorbyl stearate 27707-41-1, Ascorbyl laurate
RL: BIOL (Biological study)
(**cosmetic** antioxidant compns. contg. chelating agents and thiols and)

L229 ANSWER 98 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:502551 HCAPLUS
DN 111:102551
TI Astringent **cosmetics** containing plant extracts and amino acids
IN Mizuno, Yuko; Ito, Kenzo
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01047708	A2	19890222	JP 1987-204920	19870818 <--

AB **Cosmetics** contain Nuphar japonicum rhizome ext. and vitamin B6-HCl, L-**ascorbic acid** (I), its derivs., asparagine, glutamine, Iris florentina rhizome ext., ginseng ext., and/or Lamium album ext. The **cosmetics** show improved astringent effect at pH 5.0-6.5 and are stable to heat and long-term storage. An astringent **lotion** contained water 81.82, dipropylene glycol 2.0, **citric acid** 0.03, Na citrate 0.05, N. japonicum rhizome ext. 0.3, I 0.05, denatured 95% EtOH 15.0, methylparaben 0.1, P.O.E.(15) oleyl ether 0.5, perfume 0.1, UV absorbers 0.03 wt.%, and colorant q.s.
ST **lotion** Nuphar ext **ascorbate cosmetic**
IT Lamium album
Nuphar japonicum
(ext. of, astringent **cosmetics** contg.)
IT **Astringents**
(plant exts and amino acids in)
IT Iris germanica florentina
(rhizome of, ext. of, astringent **cosmetics** contg.)
IT Ginseng
(P. pseudoginseng, ext. of, astringent **cosmetics** contg.)
IT **50-81-7, L-Ascorbic acid**, biological studies 56-85-9, Glutamine, biological studies 70-47-3, Asparagine, biological studies 12001-77-3, Vitamin B6 hydrochloride
RL: BIOL (Biological study)
(astringent **cosmetics** contg.)

L229 ANSWER 99 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:121118 HCAPLUS
DN 110:121118
TI Perfumed composition with a deodorizing or antiperspirant activity
IN Holzner, Guenter
PA Firmenich S. A., Switz.
SO Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DT Patent
LA French
IC ICM A61K007-38
CC 62-5 (Essential Oils and **Cosmetics**)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 279328	A2	19880824	EP 1988-101861	19880209 <--
	EP 279328	A3	19890104		
	EP 279328	B1	19920603		
	R: DE, ES, FR, GB, IT				
	CH 675966	A	19901130	CH 1987-647	19870220 <--
	ES 2033948	T3	19930401	ES 1988-101861	19880209 <--
	ZA 8801101	A	19881026	ZA 1988-1101	19880217 <--
	US 4803195	A	19890207	US 1988-157422	19880217 <--
	AU 8811967	A1	19880825	AU 1988-11967	19880219 <--
	AU 609356	B2	19910426		
	BR 8800690	A	19881004	BR 1988-690	19880219 <--
	JP 64000012	A2	19890105	JP 1988-35432	19880219 <--
	JP 2574365	B2	19970122		
	CA 1299108	A1	19920421	CA 1988-559292	19880219 <--
PRAI	CH 1987-647		19870220 <--		

AB The title compn. comprises an antiperspirant, such as an Al compd. and a fragrance. The fragrance is an aq. **emulsion**, or is microencapsulated, and comprises a film-forming support [poly(vinyl acetate), poly(vinyl alc.), dextrin, starch, pectin, gum, cellulose derivs., etc] and an **emulsifier**, such as mono- or diglycerides, fatty acid sorbitol or sugar esters, their alkoxylated derivs., etc. The compn. releases the fragrance upon contact with **moisture**, such as sweat, and is spontaneously reincapsulated upon drying in situ, such as on the **skin**. The compn. may be formulated as sticks, roll-ons, smooth-ons, aerosols, or powders. A soln. of 8.9 g Glucidex 21 (maltodextrin), 1.0 g Nadex 722 (maltodextrin), and 0.1 g Na alginate in 658 g H2O was treated with 20 g Locron L (50% Al hydroxychloride soln.), and, at 70.degree., with 4 g Emulgrade 1000 NI (self-**emulsifying** nonionic wax) and, at, 40.degree., with a perfume, to give an antiperspirant, which was shaped in the form of a roll-on.

ST antiperspirant perfume microencapsulated **emulsified**
IT Gums and Mucilages
(film-forming agent, for perfumes in antiperspirants)
IT Lipopolysaccharides
RL: BIOL (Biological study)
(film-forming agents, for perfumes in antiperspirants)
IT **Emulsifying** agents
(for perfumes, for antiperspirants)
IT Antiperspirants
(microencapsulated- or **emulsified** perfumes-contg.)
IT Glycerides, biological studies
RL: BIOL (Biological study)
(di-, **emulsifiers**, for perfumes in antiperspirants)
IT Carbohydrates and Sugars, esters
RL: BIOL (Biological study)
(esters, with fatty acids, **emulsifiers**, for perfumes in antiperspirants)
IT Fatty acids, esters
RL: BIOL (Biological study)
(esters, with polyhydric alcs., **emulsifiers**, for perfumes in

antiperspirants)
IT Castor oil
RL: BIOL (Biological study)
(hydrogenated, ethoxylated, **emulsifier**, for perfumes in antiperspirants)
IT Glycerides, biological studies
RL: BIOL (Biological study)
(mono-, **emulsifiers**, for perfumes in antiperspirants)
IT 97-59-6D, aluminum hydroxychloride complexes 1327-41-9, Aluminum hydroxychloride 1327-41-9D, allantoin complexes 117848-21-2, Rezal 36P
RL: BIOL (Biological study)
(antiperspirant contg. perfume and)
IT 3380-34-5, Irgasan DP 300 9005-64-5, Tween 20 55070-07-0, Lamacit 877 65862-82-0, Triton CG 110 84750-06-1, Arlacel 165 117849-34-0, Emulgade 1000NI
RL: BIOL (Biological study)
(**emulsifier**, for perfumes in antiperspirants)
IT **50-21-5D, Lactic acid**, esters **50-81-7D, Ascorbic acid**, esters **77-92-9D, Citric acid**, esters **87-69-4D, Tartaric acid**, esters
RL: BIOL (Biological study)
(**emulsifiers**, for perfumes in antiperspirants)
IT 9000-69-5, Pectin 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinylacetate 9004-32-4, Carboxymethylcellulose 9004-54-0, Dextran, biological studies 9004-62-0, Hydroxyethylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-38-3 9050-36-6, Maltodextrin 11138-66-2, Xanthan gum
RL: BIOL (Biological study)
(film-forming agent, for perfumes in antiperspirants)
IT 50-70-4D, Sorbitol, esters
RL: BIOL (Biological study)
(with fatty acids, as **emulsifiers**, for perfumes in antiperspirants)

L229 ANSWER 100 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1989:121107 HCAPLUS
DN 110:121107
TI Anti-inflammatory **cosmetics** containing S-lactoylglutathiones
IN Kimura, Hikari; Murata, Kosaku; Kuryama, Kinya; Konishi, Hiroaki
PA Nonogawa Shoji Y. K., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63267711	A2	19881104	JP 1987-101094	19870423 <--
JP 07098729	B4	19951025		

AB Anti-inflammatory **cosmetics** contain S-lactoylglutathione (I) and/or its salts. In rat paw edema test, I at 200 mg/kg i. p. inhibited .apprx.55% carrageenan-induced swelling 4 h after. A **skin** prepn. was prepd. from I 0.1, glycerin 4.0, 1,3-butylene glycol 3.0, EtOH 7.0, poly(oxyethylene) lauryl ether 0.5, Me p-hydroxybenzoate 0.1, **citric acid** 0.01, Na citrate 0.1, flavor 0.05, Japan Green 3 0.00001, and H2O to 100% by wt. The prepn. showed much better **moisturizing**, smoothing, and shining effects on the **skin**, than a control not contg. I.
ST antiinflammatory lactoylglutathione **cosmetic**; **glutathione** lactoyl antiinflammatory **cosmetic**
IT **Cosmetics**
Hair preparations

(anti-inflammatory S-lactoylglutathione in)
IT Inflammation inhibitors
(S-lactoylglutathione, **cosmetics** contg.)
IT 25138-66-3, S-Lactoylglutathione 119587-40-5, S-Lactoylglutathione sodium salt 119587-41-6, S-Lactoylglutathione calcium salt
RL: BIOL (Biological study)
(anti-inflammatory **cosmetics** contg.)

L229 ANSWER 101 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1987:143812 HCAPLUS
DN 106:143812
TI **Skin cosmetics** containing amino acids, vitamins, and sugars
IN Matsumoto, Katsuo; Matsugami, Michio; Obara, Yasuhiro
PA Pola Chemical Industries, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K031-70
ICI A61K031-70, A61K031-195, A61K045-06
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61289016	A2	19861219	JP 1985-131537	19850617 <--

AB A **skin cosmetic** contains (1) .gtoreq.3 compds. selected from the group comprising essential amino acids, glutamine, or their salts, (2) .gtoreq.2 vitamins including the vitamin B group, and (3) glucose or its analogs. The **cosmetic** stimulates **skin** metab., conditions the tissue, and prevents wrinkles. Thus, a **cosmetic** emollient **cream** was prepd. by combining cetanol 2, whale wax 5, squalane 7, olive oil 24, stearic acid 7, sorbitan monostearate 4, polyoxyethylene sobitan monostearate 4, propylene glycol 3.5, ethylparaben 0.1, H2O 42.8, and a cell-stimulating compn. 0.2 part. The cell-stimulating compn. consisted of isoleucine 100, tryptophan 50, threonine 100, valine 100, phenylalanine 50, **methionine** 50, lysine 150, leucine 100, glutamine 600, isoinositol 7, vitamin B6 4, **pantothenic acid** 4, nicotinamide 4, glucose 1000, and succinic acid 1 part by wt.
ST amino acid sugar vitamin **cosmetic**
IT **Cosmetics**
(contg. amino acids and sugars and vitamins)
IT Carbohydrates and Sugars, biological studies
RL: BIOL (Biological study)
(**skin cosmetics** contg. amino acids and vitamins and)
IT Vitamins
RL: BIOL (Biological study)
(**skin cosmetics** contg. sugars and vitamins and)
IT Amino acids, biological studies
RL: BIOL (Biological study)
(**skin cosmetics** contg. vitamins and sugars and)
IT 110-15-6, Succinic acid, biological studies
RL: BIOL (Biological study)
(**skin cosmetics** contg.)
IT 87-89-8, Isoinositol
RL: BIOL (Biological study)
(**skin cosmetics** contg. amino acids and)
IT **79-83-4, Pantothenic acid** 83-88-5, Riboflavin, biological studies 98-92-0, Nicotinamide 137-08-6, Calcium pantothenate 8059-24-3, Vitamin B6
RL: BIOL (Biological study)
(**skin cosmetics** contg. amino acids and sugars and)
IT 50-99-7, D-Glucose, biological studies

RL: BIOL (Biological study)
(**skin cosmetics** contg. amino acids and vitamins and)

IT 56-45-1, L-Serine, biological studies 56-85-9, L-Glutamine, biological studies 56-87-1, L-Lysine, biological studies 61-90-5, L-Leucine, biological studies **63-68-3**, L-**Methionine**, biological studies 63-91-2, L-Phenylalanine, biological studies 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 73-22-3, L-Tryptophan, biological studies
RL: BIOL (Biological study)
(**skin cosmetics** contg. vitamins and sugars and)

L229 ANSWER 102 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1987:55649 HCAPLUS
DN 106:55649
TI Topical formulations containing 4-(1,1-dimethylethyl)-4'-methoxydibenzoylmethanol and organic carboxylates
IN Takada, Sadashige
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-42
ICS A61K007-00
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61215318	A2	19860925	JP 1985-56491	19850320 <--
JP 06004529	B4	19940119		

AB Topical formulations contain the title compd. (I) and org. acids or their salts as stabilizers. They are esp. useful as sunscreens. Thus, a **cream** was prepd. consisting of stearic acid 10.0, stearyl alc. 4.0, Bu stearate 8.0, monoglyceryl stearate 2.0, I 2.0, a perfume 0.4, propylene glycol 10.0, glycerin 4.0, maltitol 1.0, KOH 0.4, Na lactate 0.05, a perfume q.s., and H2O to 100% by wt.
ST benzoylmethane deriv carboxylate **cosmetic**; sunscreen dibenzoylmethane carboxylate
IT **Cosmetics**
(foundations, contg. tert-butylmethoxydibenzoylmethane and carboxylic acids)
IT Carboxylic acids, compounds
RL: BIOL (Biological study)
(salts, **cosmetics** contg. tert-butylmethoxydibenzoylmethane and)
IT **Sunburn and Suntan**
(**sunscreens**, contg. tert-butylmethoxydibenzoylmethane and carboxylic acids)
IT 70356-09-1
RL: BIOL (Biological study)
(**cosmetics** contg. carboxylates and)
IT **50-81-7**, **Ascorbic acid**, biological studies 72-17-3, Sodium lactate **77-92-9**, **Citric acid**, biological studies 994-36-5, Sodium citrate
RL: BIOL (Biological study)
(**cosmetics** contg. tert-butylmethoxydibenzoylmethane and)

L229 ANSWER 103 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1987:55630 HCAPLUS
DN 106:55630
TI **Cosmetics** containing gourd juice, **ascorbic acid**, and its esters
IN Kurakake, Junko; Ito, Kenzo
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICA C12N009-99
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 11
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61194008	A2	19860828	JP 1985-35595	19850225 <--
JP 01018044	B4	19890403		

AB A **skin**-lightening **cosmetic** contains gourd juice and .gtoreq.1 compd. selected from the group consisting of L-**ascorbic acid** or its esters. Thus, a formulation consists of L-**ascorbic acid** 0.2, gourd juice 0.1, glycerin 2.0, propylene glycol 1.0, **citric acid** 0.2, 95% EtOH 10.0, a perfume q.s., polyoxyethylene lauryl ether 0.5, and H2O to 100% by wt.
ST gourd juice **ascorbate cosmetic**
IT Cucurbitaceae
(juice, **cosmetic lotion** contg. **ascorbate** and)
IT **Cosmetics**
(**skin**-lightening, contg. **ascorbic acid** deriv. and gourd juice)
IT **50-81-7**, L-**Ascorbic acid**, biological studies
1330-84-3, L-**Ascorbic acid** monopalmitate 65907-80-4
92353-27-0, L-**Ascorbic acid** dioleate 100441-38-1
RL: BIOL (Biological study)
(**cosmetic lotion** contg. gourd juice and, for **skin** lightening)

L229 ANSWER 104 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1987:38244 HCAPLUS
DN 106:38244
TI **Cosmetics** containing **ascorbic acid** and hydroquinone **glycosides**
IN Fujinuma, Yoshimori; Toyoda, Hidekazu; Tamaoki, Shiyuya
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K031-70
ICA A61K047-00
ICI A61K031-70, A61K031-375
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61207316	A2	19860913	JP 1985-49663	19850313 <--
JP 05033683	B4	19930520		

AB A topical **cosmetic** contains ROC6H4OH-4 (R = sugar residue) in addn. to L-**ascorbic acid** or its deriv. The **cosmetic** is a stable **skin**-whitening prepn. Thus, 95% EtOH 10 and polyoxyethylene lauryl ether 0.5 g and perfume q.s. were mixed, and to this mixt. was added glycerin 2, propylene glycol 1, **citric acid** 0.2, L-**ascorbic acid** 0.1, and hydroquinone .beta.-D-**glucoside** 0.1 g to give a **lotion**.
ST hydroquinone **glucoside ascorbate skin** whitening **cosmetic**
IT **Glycosides**
RL: BIOL (Biological study)
(hydroxyphenyl, **cosmetic lotions** contg.

ascorbic acid and)
IT **Cosmetics**
(**skin**-lightening, contg. **ascorbic acid** and hydroquinone **glucoside**)
IT 497-76-7
RL: BIOL (Biological study)
(**cosmetic lotion** contg. **ascorbic acid** and)
IT **50-81-7**, biological studies
RL: BIOL (Biological study)
(**cosmetic lotion** contg. hydroquinone glucoside and)
IT 123-31-9D, **glycosides**
RL: BIOL (Biological study)
(**cosmetic lotions** contg. **ascorbic acid** and)

L229 ANSWER 105 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1986:74811 HCAPLUS
DN 104:74811
TI **Cosmetics** containing L-**ascorbic acid** and mucopolysaccharides
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-06
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60116618	A2	19850624	JP 1983-226448	19831130 <--

GI



I

AB **Cosmetics** for **skin** care consist of mucopolysaccharides and L-**ascorbic acid** (I) [**50-81-7**] or its esters. Thus, a **lotion** was prepd. contg. glycerol 3.0, propylene glycol 4.0, EtOH 8.0, polyoxyethylene oleyl ether 0.5, chondroitin 6-sulfate [25322-46-7] 0.001, I monopalmitate [1330-84-3] 0.001, I monooleate [28518-50-5] 0.05, methylparaben 0.1, **citric acid** 0.001, Na citrate 0.1, perfumes 0.05, and ion-exchanged H2O 84.197%.
ST **ascorbate** mucopolysaccharide **cosmetic**; chondroitin sulfate **ascorbate cosmetic**
IT **Cosmetics**
(**ascorbate** and mucopolysaccharides for)
IT Mucopolysaccharides, biological studies
RL: BIOL (Biological study)
(**cosmetics** contg. **ascorbate** and)
IT 24967-93-9 25322-46-7 34410-22-5 99549-29-8
RL: BIOL (Biological study)
(**cosmetics** contg. **ascorbate** and)
IT **50-81-7**, biological studies 1330-84-3 **27556-18-9** 28474-90-0 28518-50-5
RL: BIOL (Biological study)

(**cosmetics** contg. mucopolysaccharides and)

L229 ANSWER 106 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1985:509772 HCAPLUS
DN 103:109772
TI **Cosmetics** containing **ascorbates** and brown sugar pigments
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICS A61K007-42
ICA C12N009-99
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60078912	A2	19850504	JP 1983-187277	19831006 <--
JP 04056003	B4	19920907		

AB **Skin**-whitening **cosmetics** contain 1 or more compd(s). selected from L-**ascorbic acid** [**50-81-7**] and its esters in addn. to brown sugar pigments. Thus, a **skin lotion** consists of L-**ascorbic acid** 0.2, a sugar dye 0.001, glycerin 2, propylene glycol, **citric acid** 0.2, 95% EtOH 10, small amts. of perfume, polyoxyethylene lauryl ether 0.5, and H2O to 100% by wt.
ST **skin** whitening **cosmetic**; **ascorbate** **skin** whitening **cosmetic**; sugar **skin** whitening **cosmetic**; pigment **skin** whitening **cosmetic**
IT Carbohydrates and Sugars, biological studies
RL: BIOL (Biological study)
(brown pigments, **skin**-whitening **cosmetics** contg. **ascorbates** and)
IT **Cosmetics**
(**skin**-lightening, **ascorbate** and brown sugar pigments for)
IT **50-81-7**, biological studies 25395-66-8 **27556-18-9** 28474-90-0 65907-80-4 92353-27-0
RL: BIOL (Biological study)
(**skin**-whitening **cosmetics** contg. brown sugar pigment and)

L229 ANSWER 107 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1985:492650 HCAPLUS
DN 103:92650
TI **Cosmetics** containing organ extracts and vitamins
PA **Shiseido** Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM A61K007-00
ICA C12N009-99
CC 62-4 (Essential Oils and **Cosmetics**)
Section cross-reference(s): 18
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 60064908	A2	19850413	JP 1983-173397	19830920 <--

AB **Cosmetics** for whitening of the **skin** contain aq. exts. from the liver and spleen and 1 compd. selected from **vitamin C** [**50-81-7**], vitamin B6 [8059-24-3], **pantothenic acid** [**79-83-4**], or their salts. Thus, a **lotion** consists of **vitamin C** 0.025,

an aq. ext. of bovine spleen 0.025, and H2O to 100% by wt. The **lotion** inhibited the formation of melanin in the **skin**.
ST organ ext vitamin **cosmetic**
IT Vitamins
RL: BIOL (Biological study)
(**cosmetics** contg. organ ext. and, for inhibition of melanin formation in **skin**)
IT Liver extracts
(**cosmetics** contg. vitamins and)
IT Spleen
(exts., **cosmetics** contg. vitamins and)
IT Melanins
RL: FORM (Formation, nonpreparative)
(formation of, in **skin**, organ exts. and vitamins for inhibition of)
IT **Skin**
(melanin inhibition in, by vitamin and organ exts.)
IT **Cosmetics**
(**skin**-lightening, organ exts. and vitamins for)
IT **50-81-7**, biological studies **79-83-4** 137-08-6
8059-24-3 65907-80-4
RL: BIOL (Biological study)
(**cosmetics** contg. organ ext. and, for inhibition of melanin formation in **skin**)

L229 ANSWER 108 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1985:190821 HCAPLUS
DN 102:190821
TI The stabilities of **cosmetics**, fats and oils against oxidation
AU Kanbe, Naoyuki; Imai, Hiroaki; Hiramatsu, Isao
CS Res. Dev. Lab., POLA Corp., Yokohama, 221, Japan
SO J. SCCJ (**1984**), 18(2), 112-20
CODEN: JOSCDQ
DT Journal
LA Japanese
CC 62-4 (Essential Oils and **Cosmetics**)
AB **Cosmetics** (**creams**) and **cosmetic** materials (fats, oils) were exposed to artificial light to det. their stability to oxidn. Peroxide values (POV; mequiv/kg) were used as parameters for the evaluation. **Cosmetics** were quite stable when they were not exposed to artificial light. Following exposure to artificial light, POV of samples increased, presumably due to an oxidn. of unsatd. oils. Oils and fats showed an increase in their **skin** irritation potential, when measured POV was >100 mequiv/kg. d-.delta.-Tocopherol [59-02-9] (antioxidant) and oxybenzone [131-57-7] (UV absorber) in **creams** showed a synergistic effect against photo-irradn.
ST fat **cosmetic** stability oxidn; oxidn oil fat **cosmetic** stability
IT Beeswax
Carnauba wax
Candelilla wax
Castor oil
Fats, biological studies
Lanolin
Oils
Olive oil
Paraffin oils
Safflower oil
RL: BIOL (Biological study)
(**cosmetic** contg., stability of, to oxidn.)
IT Amino acids, biological studies
Carboxylic acids, biological studies
RL: BIOL (Biological study)
(**cosmetics** photooxidn. stabilization by oxybenzone and tocopherol in relation to)
IT Oxidation, photochemical

(**cosmetics** stability to, antioxidants and UV absorbers in relation to)
IT **Cosmetics**
(stability of, to oxidn., antioxidants and UV absorbers in relation to)
IT 104-98-3 131-57-7 832-01-9 21245-02-3 27538-35-8
RL: BIOL (Biological study)
(UV absorbent, for **cosmetics**, photoirradn. in relation to)
IT 59-02-9 119-13-1 128-37-0, biological studies
RL: BIOL (Biological study)
(antioxidant, for **cosmetics**, photoirradn. in relation to)
IT 110-27-0 111-02-4 112-80-1, biological studies 604-35-3 1338-43-8
7360-38-5 9004-96-0 22801-45-2 26266-58-0 26658-19-5 27640-89-7
RL: BIOL (Biological study)
(**cosmetic** contg., stability of, to oxidn.)
IT **50-81-7**, biological studies **63-68-3**, biological studies
72-19-5, biological studies **77-92-9**, biological studies
83-86-3 97-53-0 110-16-7, biological studies 139-33-3 154-23-4
7664-38-2, biological studies 7757-83-7
RL: BIOL (Biological study)
(**cosmetics** photooxidn. stabilization by oxybenzone and tocopherol in relation to)

L229 ANSWER 109 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1981:162762 HCAPLUS
DN 94:162762
TI Additives enhancing topical corticosteroid action
IN Van Scott, Eugene J.; Yu, Ruey J.
PA USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC A01N045-00; A61K031-56
NCL 424240000
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4246261	A	19810120	US 1979-65332	19790809 <--

AB The therapeutic efficacy of corticosteroids in topical treatment of psoriasis, eczema, seborrheic **dermatitis**, and other inflammatory **skin** conditions can be greatly enhanced by adding various hydroxy acids in small amts. The addn. of 0.2% **atrolactic acid** [**515-30-0**], **gluconolactone** [**90-80-2**] or mandelic acid [90-64-2], to a **cream** contg. 0.2% hydrocortisone 21-acetate [50-03-3] enhanced remission of lesions in the psoriatic patients tested. A combination of hydrocortisone [50-23-7] with mandelic acid or **Et pyruvate** [**617-35-6**] was most effective in eradicating the lesions of psoriasis completely.
ST corticosteroid **skin** hydroxy acid; psoriasis corticosteroid hydroxy acid; eczema corticosteroid hydroxy acid; seborrhea corticosteroid hydroxy acid
IT **Eczema**
Psoriasis
Seborrhea
Skin, disease or disorder
(corticosteroid topical compns. contg. hydroxy acids for treatment of)
IT Corticosteroids, biological studies
RL: BIOL (Biological study)
(topical compns. contg., hydroxy acids enhancement of effects of)
IT **Carboxylic acids, biological studies**
RL: BIOL (Biological study)
(**hydroxy**, topical corticosteroid compns. contg., for enhanced effects)
IT **50-21-5**, biological studies 76-30-2 **77-92-9**,
biological studies **79-14-1**, biological studies **87-69-4**

, biological studies 87-73-0 90-64-2 **90-80-2** 110-16-7,
biological studies **127-17-3**, biological studies 141-05-9
142-45-0 **156-05-8 156-06-9 300-85-6**
389-36-6 473-81-4 488-31-3 498-36-2 **515-30-0** 526-84-1
526-95-4 526-99-8 **565-70-8 594-61-6**
599-04-2 600-22-6 611-73-4 617-35-6
624-48-6 685-73-4 762-21-0 762-42-5 923-11-5 1001-13-4
1112-33-0 1113-60-6 1198-69-2 **1603-79-8** 2381-08-0
2782-07-2 3913-50-6 4026-18-0 6556-12-3 **6915-15-7**
13100-82-8 13382-27-9 **15206-55-0** 23351-51-1
32449-92-6 77228-68-3 77340-56-8
RL: BIOL (Biological study)
(corticosteroid topical compns. contg., for enhanced activity)
IT 50-03-3 50-23-7 76-25-5 13609-67-1 57524-89-7
RL: BIOL (Biological study)
(topical compns. contg., hydroxy acids enhancement of effect of)

L229 ANSWER 110 OF 110 HCAPLUS COPYRIGHT 2001 ACS
AN 1975:89985 HCAPLUS
DN 82:89985
TI Ascorbic and urocanic acids for **cosmetics**
IN Hasunuma, Kyotaro
PA Kanebo, Ltd., Japan
SO Japan. Kokai, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
NCL 31B0
CC 62-4 (Essential Oils and **Cosmetics**)
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 49086554	A2	19740819	JP 1973-437	19721225 <--
JP 55043443	B4	19801106		

AB **Ascorbic acid** [**50-81-7**] and its esters are whitening agents for the **skin** and their activities are enhanced in the presence of urocanic acid [104-98-3]and its esters. Thus, a **lotion** was prepd. by dissolving a mixt. of glycerin 2, propylene glycol 1, **citric acid** 0.2, **ascorbic acid** 1, urocanic acid 0.5 g, and H2O 85.3 g in 95% EtOH (10 g). The **lotion** has an excellent whitening effect when applied to the **skin** once a day for 3 months.
ST **cosmetic lotion ascorbate** urocanate; **skin lotion ascorbate** urocanate
IT **Lotions**
Ointments
(ascorbic and urocanic acids in)
IT **Skin**
(lightening compns. for, **ascorbic acid**-urocanic acids in)
IT **Cosmetics**
(**skin**-lightening, **ascorbate** and urocanate in)
IT 25395-66-8
RL: BIOL (Biological study)
(**skin cosmetics** contg. urocanate and)
IT 104-98-3
RL: BIOL (Biological study)
(**skin lotion** contg. **ascorbate** and)
IT **50-81-7**, biological studies
RL: BIOL (Biological study)
(**skin lotions** contg. urocanate and)

=> d his l229-

(FILE 'HCAPLUS' ENTERED AT 15:59:05 ON 13 MAR 2001)
L229 110 S L223,L228

FILE 'HCAPLUS' ENTERED AT 16:31:05 ON 13 MAR 2001
SEL HIT RN L229

FILE 'REGISTRY' ENTERED AT 16:33:20 ON 13 MAR 2001
L230 51 S E1-E54

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:33:39 ON 13 MAR 2001

STRUCTURE FILE UPDATES: 12 MAR 2001 HIGHEST RN 326849-80-3
DICTIONARY FILE UPDATES: 12 MAR 2001 HIGHEST RN 326849-80-3

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> d ide can tot

L230 ANSWER 1 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **146684-33-5** REGISTRY
CN L-Ascorbic acid, O-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]-, bis(dihydrogen phosphate), dipotassium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H58 O13 P2 . 2 K
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

CM 1

CRN 10191-41-0
CMF C29 H50 O2



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:185278

REFERENCE 2: 118:154156

L230 ANSWER 2 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **146614-91-7** REGISTRY
CN L-Ascorbic acid, O-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]-, bis(dihydrogen phosphate) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H58 O13 P2
CI IDS
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

CM 1

CRN 10191-41-0
CMF C29 H50 O2



CM 2

CRN 7664-38-2
CMF H3 O4 P



CM 3

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 129:113305

REFERENCE 2: 118:154156

L230 ANSWER 3 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **56939-67-4** REGISTRY
CN L-Ascorbic acid, sulfate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ascorbic acid sulfate
FS STEREOSEARCH
DR 33981-97-4
MF C6 H8 O6 . x H2 O4 S
LC STN Files: AGRICOLA, BIOSIS, CA, CAPLUS, EMBASE, NAPRALERT, TOXLIT, USPATFULL

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



22 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:286242

REFERENCE 2: 132:185262

REFERENCE 3: 131:276783

REFERENCE 4: 131:35670

REFERENCE 5: 130:200936

REFERENCE 6: 126:1109

REFERENCE 7: 125:123289

REFERENCE 8: 123:17504

REFERENCE 9: 123:17500

REFERENCE 10: 121:117387

L230 ANSWER 4 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **37627-95-5** REGISTRY
CN L-Ascorbic acid, 2-(hydrogen sulfate) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ascorbic acid 2-sulfate
CN L-Ascorbic acid 2-sulfate
FS STEREOSEARCH
MF C6 H8 O9 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, TOXLINE, TOXLIT, USPATFULL, VETU
(*File contains numerically searchable property data)

Absolute stereochemistry.



176 REFERENCES IN FILE CA (1967 TO DATE)
176 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:21285

REFERENCE 2: 132:218268

REFERENCE 3: 132:83408

REFERENCE 4: 132:63541

REFERENCE 5: 131:314101

REFERENCE 6: 131:283573

REFERENCE 7: 131:223518

REFERENCE 8: 131:204411

REFERENCE 9: 131:106620

REFERENCE 10: 130:335337

L230 ANSWER 5 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **36413-60-2** REGISTRY
CN Cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-,
(1.alpha.,3R,4.alpha.,5R)-rel- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-,
(1.alpha.,3.alpha.,4.alpha.,5.beta.)-
OTHER NAMES:
CN Quinic acid
FS STEREOSEARCH
DR 1010-25-9
MF C7 H12 O6
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMINFORMRX, CHEMLIST,
CIN, DDFU, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, MEDLINE,
PROMT, SPECINFO, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.



436 REFERENCES IN FILE CA (1967 TO DATE)
16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
436 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:146580

REFERENCE 2: 133:190134

REFERENCE 3: 133:168183

REFERENCE 4: 133:163196

REFERENCE 5: 133:94512

REFERENCE 6: 133:79034

REFERENCE 7: 133:34492

REFERENCE 8: 133:3826

REFERENCE 9: 132:261672

REFERENCE 10: 132:236188

L230 ANSWER 6 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **27556-18-9** REGISTRY
CN L-Ascorbic acid, mono(dihydrogen phosphate) (8CI, 9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C6 H9 O9 P
CI IDS
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

CM 1

CRN 7664-38-2
CMF H3 O4 P



CM 2

CRN 50-81-7
CMF C6 H8 O6

Absolute stereochemistry.



14 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
14 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:21285

REFERENCE 2: 132:26654

REFERENCE 3: 131:204411

REFERENCE 4: 124:269986

REFERENCE 5: 123:349917

REFERENCE 6: 123:296267

REFERENCE 7: 118:169521

REFERENCE 8: 118:146241

REFERENCE 9: 109:236756

REFERENCE 10: 104:74811

L230 ANSWER 7 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **23313-12-4** REGISTRY
CN L-Ascorbic acid, 2-(dihydrogen phosphate) (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Ascorbic acid 2-phosphate
CN L-Ascorbic acid 2-phosphate
CN L-Ascorbic acid 2-phosphate (ester)
CN L-Ascorbyl-2-phosphate
FS STEREOSEARCH
DR 172173-78-3, 81877-56-7
MF C6 H9 O9 P
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, PROMT, TOXLINE, TOXLIT, USPATFULL, VETU
(*File contains numerically searchable property data)

Absolute stereochemistry.



211 REFERENCES IN FILE CA (1967 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
211 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:29559

REFERENCE 2: 134:21285

REFERENCE 3: 134:4358

REFERENCE 4: 133:361254

REFERENCE 5: 133:332793

REFERENCE 6: 133:295828

REFERENCE 7: 133:251316

REFERENCE 8: 133:238118

REFERENCE 9: 133:187700

REFERENCE 10: 133:146767

L230 ANSWER 8 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **17812-24-7** REGISTRY
CN Ribonic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C5 H10 O6
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, GMELIN*, IFICDB, IFIPAT, IFIUDB, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Relative stereochemistry.



56 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
56 REFERENCES IN FILE CAPLUS (1967 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:79034

REFERENCE 2: 133:19495

REFERENCE 3: 131:285686

REFERENCE 4: 130:286821

REFERENCE 5: 130:271870

REFERENCE 6: 130:110466

REFERENCE 7: 130:17102

REFERENCE 8: 130:7288

REFERENCE 9: 129:335760

REFERENCE 10: 128:208784

L230 ANSWER 9 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **15206-55-0** REGISTRY
CN Benzeneacetic acid, .alpha.-oxo-, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glyoxylic acid, phenyl-, methyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN .alpha.-Oxobenzeneacetic acid methyl ester
CN Methyl .alpha.-oxobenzeneacetate
CN Methyl benzoylformate
CN Methyl oxophenylacetate
CN Methyl phenylglyoxylate
CN Methyl phenyloxoacetate
CN Phenylglyoxylic acid methyl ester
CN Vicure 55
FS 3D CONCORD
DR 71833-42-6
MF C9 H8 O3
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, PROMT, SPECINFO, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



637 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
638 REFERENCES IN FILE CAPLUS (1967 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:162878

REFERENCE 2: 134:133222

REFERENCE 3: 134:131065

REFERENCE 4: 134:86314

REFERENCE 5: 134:71352

REFERENCE 6: 134:18563

REFERENCE 7: 134:14582

REFERENCE 8: 133:334159

REFERENCE 9: 133:309559

REFERENCE 10: 133:267220

L230 ANSWER 10 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **13100-82-8** REGISTRY
CN Alanine, 3-sulfo- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Amino-3-sulfopropionic acid
CN 3-Sulfoalanine
CN Cysteate
CN Cysteic acid
CN DL-Cysteic acid
FS 3D CONCORD
DR 3024-83-7
MF C3 H7 N O5 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, CHEMINFORMRX, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, PIRA, PROMT, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)



299 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
299 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:29671

REFERENCE 2: 133:253803

REFERENCE 3: 133:160972

REFERENCE 4: 133:39530

REFERENCE 5: 132:342522

REFERENCE 6: 132:223782

REFERENCE 7: 131:292477

REFERENCE 8: 131:225710

REFERENCE 9: 131:127041

REFERENCE 10: 129:42269

L230 ANSWER 11 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **7317-67-1** REGISTRY
CN L-Ascorbic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C6 H8 O6 . x Na
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
CRN (50-81-7)

Absolute stereochemistry.



● x Na

49 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
49 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:204913

REFERENCE 2: 133:121343

REFERENCE 3: 133:104190

REFERENCE 4: 133:34424

REFERENCE 5: 131:324230

REFERENCE 6: 131:189477

REFERENCE 7: 131:103298

REFERENCE 8: 130:45209

REFERENCE 9: 128:320929

REFERENCE 10: 128:217843

L230 ANSWER 12 OF 51 REGISTRY COPYRIGHT 2001 ACS

RN **6915-15-7** REGISTRY
CN Butanedioic acid, hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Malic acid (8CI)
OTHER NAMES:
CN (.+-.)-Malic acid
CN .alpha.-Hydroxysuccinic acid
CN 2-Hydroxybutanedioic acid
CN 2-Hydroxyethane-1,2-dicarboxylic acid
CN 2-Hydroxysuccinic acid
CN Deoxytetraric acid
CN DL-Malic acid
CN dl-Malic acid
CN FDA 2018
CN Hydroxybutanedioic acid
CN Hydroxysuccinic acid
CN Musashi-no-Ringosan
CN Pomalus Acid
CN R,S(.+-.)-Malic acid
FS 3D CONCORD
DR 617-48-1, 41308-42-3
MF C4 H6 O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



12357 REFERENCES IN FILE CA (1967 TO DATE)
577 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12369 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:172474

REFERENCE 2: 134:170774

REFERENCE 3: 134:168357

REFERENCE 4: 134:167213

REFERENCE 5: 134:166924

REFERENCE 6: 134:164874

REFERENCE 7: 134:163898

REFERENCE 8: 134:162241

REFERENCE 9: 134:162210

REFERENCE 10: 134:162185

L230 ANSWER 13 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **6027-13-0** REGISTRY

CN L-Homocysteine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butyric acid, 2-amino-4-mercapto-, L- (8CI)
OTHER NAMES:
CN (S)-2-Amino-4-mercaptobutanoic acid
CN (S)-Homocysteine
CN 2-Amino-4-mercapto-L-butyric acid
CN 2-Amino-4-mercaptobutyric acid
CN Butanoic acid, 2-amino-4-mercapto-, (S)-
CN Homocysteine
FS STEREOSEARCH
DR 454-28-4, 1867-00-1
MF C4 H9 N O2 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PROMT, RTECS*, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



2186 REFERENCES IN FILE CA (1967 TO DATE)
58 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2192 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:162315

REFERENCE 2: 134:161237

REFERENCE 3: 134:161202

REFERENCE 4: 134:161154

REFERENCE 5: 134:160889

REFERENCE 6: 134:160888

REFERENCE 7: 134:160887

REFERENCE 8: 134:160886

REFERENCE 9: 134:160885

REFERENCE 10: 134:160884

L230 ANSWER 14 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **5336-08-3** REGISTRY
CN D-Ribonic acid, .gamma.-lactone (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ribonic acid, .gamma.-lactone, D- (8CI)
OTHER NAMES:
CN (+)-Ribonolactone
CN D-(+)-Ribonic acid .gamma.-lactone
CN D-(+)-Ribonic acid lactone
CN D-(+)-Ribonolactone
CN D-Ribono-.gamma.-lactone

CN D-Ribono-1,4-lactone
CN D-Ribonolactone
CN D-Ribopentono-1,4-lactone
CN Ribonic acid 1,4-lactone
FS STEREOSEARCH
MF C5 H8 O5
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, IFICDB, IFIPAT, IFIUDB, IPA, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



241 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
241 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:158980

REFERENCE 2: 133:321814

REFERENCE 3: 133:267064

REFERENCE 4: 133:252639

REFERENCE 5: 133:238213

REFERENCE 6: 133:4863

REFERENCE 7: 132:15480

REFERENCE 8: 131:257829

REFERENCE 9: 131:32097

REFERENCE 10: 130:237779

L230 ANSWER 15 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **3374-22-9** REGISTRY
CN Cysteine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cysteine, DL- (8CI)
CN DL-Cysteine
OTHER NAMES:
CN (.+-.)-Cysteine
FS 3D CONCORD
MF C3 H7 N O2 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DIOGENES, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT,

USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



303 REFERENCES IN FILE CA (1967 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
303 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:107439

REFERENCE 2: 134:82890

REFERENCE 3: 134:65629

REFERENCE 4: 134:42441

REFERENCE 5: 134:30379

REFERENCE 6: 133:322122

REFERENCE 7: 133:286465

REFERENCE 8: 133:252691

REFERENCE 9: 133:159968

REFERENCE 10: 133:159498

L230 ANSWER 16 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **2937-54-4** REGISTRY
CN Ethanesulfonothioic acid, 2-amino- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Taurine, thio- (6CI, 7CI, 8CI)
OTHER NAMES:
CN Thiotaurine
FS 3D CONCORD
MF C2 H7 N O2 S2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CHEMLIST, EMBASE, MEDLINE, PROMT, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



36 REFERENCES IN FILE CA (1967 TO DATE)
36 REFERENCES IN FILE CAPLUS (1967 TO DATE)
28 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:9169

REFERENCE 2: 133:147655

REFERENCE 3: 131:303228

REFERENCE 4: 131:174831

REFERENCE 5: 131:75747

REFERENCE 6: 131:63244

REFERENCE 7: 130:100335

REFERENCE 8: 129:280778

REFERENCE 9: 127:319283

REFERENCE 10: 127:278351

L230 ANSWER 17 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **2782-07-2** REGISTRY
CN D-Galactonic acid, .gamma.-lactone (6CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Galactonic acid, .gamma.-lactone, D- (8CI)
OTHER NAMES:
CN .gamma.-D-Galactonolactone
CN 1,4-D-Galactonolactone
CN D-Galactonic acid 1,4-lactone
CN D-Galactono-.gamma.-lactone
CN D-Galactono-1,4-lactone
FS STEREOSEARCH
MF C6 H10 O6
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, GMELIN*, HODOC*, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



159 REFERENCES IN FILE CA (1967 TO DATE)
159 REFERENCES IN FILE CAPLUS (1967 TO DATE)
15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:101084

REFERENCE 2: 134:14663

REFERENCE 3: 133:327696

REFERENCE 4: 133:278963

REFERENCE 5: 133:79034

REFERENCE 6: 132:127462

REFERENCE 7: 132:122915

REFERENCE 8: 132:32500

REFERENCE 9: 132:10777

REFERENCE 10: 131:88113

L230 ANSWER 18 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **1603-79-8** REGISTRY
CN Benzeneacetic acid, .alpha.-oxo-, ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glyoxylic acid, phenyl-, ethyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN .alpha.-Oxobenzeneacetic acid ethyl ester
CN Ethyl .alpha.-oxobenzeneacetate
CN Ethyl 2-oxo-2-phenylacetate
CN Ethyl benzoylformate
CN Ethyl oxophenylacetate
CN Ethyl phenylglyoxylate
CN Phenylglyoxylic acid ethyl ester
FS 3D CONCORD
MF C10 H10 O3
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



408 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
410 REFERENCES IN FILE CAPLUS (1967 TO DATE)
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:115820

REFERENCE 2: 134:55567

REFERENCE 3: 134:17292

REFERENCE 4: 134:14582

REFERENCE 5: 133:334159

REFERENCE 6: 133:309559

REFERENCE 7: 133:286182

REFERENCE 8: 133:281528

REFERENCE 9: 133:266975

REFERENCE 10: 133:222168

L230 ANSWER 19 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **1112-33-0** REGISTRY
CN Butanoic acid, 2,4-dihydroxy-3,3-dimethyl-, (2R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Butanoic acid, 2,4-dihydroxy-3,3-dimethyl-, (R)-
CN Butyric acid, 2,4-dihydroxy-3,3-dimethyl-, D- (8CI)
OTHER NAMES:
CN (-)-Pantoic acid
CN D-Pantoic acid
CN Pantoic acid
FS STEREOSEARCH
MF C6 H12 O4
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB, IPA, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



61 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
61 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 133:79034

REFERENCE 2: 133:29683

REFERENCE 3: 133:29682

REFERENCE 4: 133:29681

REFERENCE 5: 131:296904

REFERENCE 6: 130:7288

REFERENCE 7: 129:335760

REFERENCE 8: 129:286610

REFERENCE 9: 129:199789

REFERENCE 10: 127:149069

L230 ANSWER 20 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **828-01-3** REGISTRY
CN Benzenepropanoic acid, .alpha.-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenepropanoic acid, .alpha.-hydroxy-, (.+-.)-
CN Lactic acid, 3-phenyl-, DL- (8CI)
OTHER NAMES:
CN (.+-.)-.beta.-Phenyllactic acid
CN (.+-.)-3-Phenyllactic acid
CN (RS)-3-Phenyllactic acid
CN .alpha.-Hydroxy-.beta.-phenylpropionic acid
CN .alpha.-Hydroxybenzenepropanoic acid
CN .beta.-Phenyllactic acid
CN 2-Hydroxy-3-phenylpropanoic acid
CN 2-Hydroxy-3-phenylpropionic acid
CN 3-Phenyl-2-hydroxypropanoic acid
CN 3-Phenyllactic acid
CN Ba 2653

CN DL-.beta.-Phenyllactic acid
CN DL-2-Hydroxy-3-phenylpropionic acid
CN DL-3-Phenyllactic acid
FS 3D CONCORD
DR **156-05-8**
MF C9 H10 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, NIOSHTIC, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



171 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
172 REFERENCES IN FILE CAPLUS (1967 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:105605

REFERENCE 2: 134:83506

REFERENCE 3: 134:71355

REFERENCE 4: 134:14878

REFERENCE 5: 134:3531

REFERENCE 6: 133:368884

REFERENCE 7: 133:368869

REFERENCE 8: 133:362538

REFERENCE 9: 133:319358

REFERENCE 10: 133:318954

L230 ANSWER 21 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **617-35-6** REGISTRY
CN Propanoic acid, 2-oxo-, ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyruvic acid, ethyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN Ethyl 2-oxopropanoate
CN Ethyl 2-oxopropionate
CN Ethyl methylglyoxylate
CN Ethyl pyruvate
FS 3D CONCORD
MF C5 H8 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



1073 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1074 REFERENCES IN FILE CAPLUS (1967 TO DATE)
44 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:147579

REFERENCE 2: 134:147218

REFERENCE 3: 134:131628

REFERENCE 4: 134:115672

REFERENCE 5: 134:115053

REFERENCE 6: 134:100876

REFERENCE 7: 134:85875

REFERENCE 8: 134:85874

REFERENCE 9: 134:71549

REFERENCE 10: 134:56556

L230 ANSWER 22 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **611-73-4** REGISTRY
CN Benzeneacetic acid, .alpha.-oxo- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glyoxylic acid, phenyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN .alpha.-Ketophenylacetic acid
CN .alpha.-Oxobenzeneacetic acid
CN 2-Oxo-2-phenylacetic acid
CN Benzoylformic acid
CN Formic acid, benzoyl-
CN Oxophenylacetic acid
CN Phenylgloxylic acid
CN Phenylglyoxylic acid
CN Phenyloxoacetic acid
FS 3D CONCORD
MF C8 H6 O3
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NIOSHTIC, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



861 REFERENCES IN FILE CA (1967 TO DATE)

19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
861 REFERENCES IN FILE CAPLUS (1967 TO DATE)
41 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:115987

REFERENCE 2: 134:100757

REFERENCE 3: 134:86193

REFERENCE 4: 134:71141

REFERENCE 5: 134:68211

REFERENCE 6: 134:67972

REFERENCE 7: 134:26269

REFERENCE 8: 134:26241

REFERENCE 9: 134:14608

REFERENCE 10: 134:14582

L230 ANSWER 23 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **600-22-6** REGISTRY
CN Propanoic acid, 2-oxo-, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyruvic acid, methyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN Methyl 2-oxopropanoate
CN Methyl 2-oxopropionate
CN Methyl acetoformate
CN Methyl pyruvate
CN Methylglyoxylic acid methyl ester
FS 3D CONCORD
MF C4 H6 O3
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



683 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
684 REFERENCES IN FILE CAPLUS (1967 TO DATE)
17 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:162878

REFERENCE 2: 134:131065

REFERENCE 3: 134:115820

REFERENCE 4: 134:115520

REFERENCE 5: 134:102880

REFERENCE 6: 134:100486

REFERENCE 7: 134:41847

REFERENCE 8: 134:15602

REFERENCE 9: 134:14582

REFERENCE 10: 133:362791

L230 ANSWER 24 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **600-15-7** REGISTRY
CN Butanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butanoic acid, 2-hydroxy-, (.+-.)-
CN Butyric acid, 2-hydroxy-, DL- (8CI)
OTHER NAMES:
CN (.+-.)-.alpha.-Hydroxybutyric acid
CN (.+-.)-2-Hydroxy-n-butyric acid
CN (.+-.)-2-Hydroxybutanoic acid
CN (.+-.)-2-Hydroxybutyric acid
CN (RS)-2-Hydroxybutyric acid
CN .alpha.-Hydroxy-n-butyric acid
CN .alpha.-Hydroxybutanoic acid
CN .alpha.-Hydroxybutyric acid
CN 2-Hydroxybutanoic acid
CN 2-Hydroxybutyric acid
CN DL-.alpha.-Hydroxybutyric acid
CN DL-2-Hydroxybutanoic acid
CN DL-2-Hydroxybutyric acid
FS 3D CONCORD
DR **565-70-8**
MF C4 H8 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, PROMT, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



202 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
202 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:153108

REFERENCE 2: 134:151952

REFERENCE 3: 134:120597

REFERENCE 4: 134:109910

REFERENCE 5: 134:50669

REFERENCE 6: 134:48595

REFERENCE 7: 134:30192

REFERENCE 8: 134:14878

REFERENCE 9: 134:1422

REFERENCE 10: 133:368869

L230 ANSWER 25 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **599-04-2** REGISTRY
CN 2(3H)-Furanone, dihydro-3-hydroxy-4,4-dimethyl-, (3R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2(3H)-Furanone, dihydro-3-hydroxy-4,4-dimethyl-, (R)-
CN 2(3H)-Furanone, dihydro-3-hydroxy-4,4-dimethyl-, D-(-)- (8CI)
OTHER NAMES:
CN (-)-(R)-Pantolactone
CN (-)-2-Hydroxy-3,3-dimethyl-.gamma.-butyrolactone
CN (-)-D-Pantolactone
CN (-)-Pantolactone
CN (-)-Pantoyl lactone
CN (R)-(-)-Pantolactone
CN (R)-.alpha.-Hydroxy-.beta.,.beta.-dimethyl-.gamma.-butyrolactone
CN (R)-Pantolactone
CN D-(-)-.alpha.-Hydroxy-.beta.,.beta.-dimethyl-.gamma.-butyrolactone
CN D-(-)-Pantolactone
CN D-(-)-Pantoyl lactone
CN D-Pantolactone
CN D-Pantoyl lactone
CN Pantolactone
CN Pantothenic lactone
CN Pantoyl lactone
FS STEREOSEARCH
DR 631-68-5, 16562-48-4
MF C6 H10 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, NAPRALERT, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



571 REFERENCES IN FILE CA (1967 TO DATE)
572 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:172482

REFERENCE 2: 134:163221

REFERENCE 3: 134:131628

REFERENCE 4: 134:115866

REFERENCE 5: 134:99899

REFERENCE 6: 134:86402

REFERENCE 7: 134:71387

REFERENCE 8: 134:42022

REFERENCE 9: 134:38916

REFERENCE 10: 133:309795

L230 ANSWER 26 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **594-61-6** REGISTRY
CN Propanoic acid, 2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Lactic acid, 2-methyl- (8CI)
OTHER NAMES:
CN .alpha.-HIB
CN .alpha.-Hydroxy-.alpha.-methylpropanoic acid
CN .alpha.-Hydroxyisobutanoic acid
CN .alpha.-Hydroxyisobutyric acid
CN 2-Hydroxy-2-methylpropanoic acid
CN 2-Hydroxy-2-methylpropionic acid
CN 2-Hydroxyisobutyric acid
CN 2-Methyllactic acid
CN Acetonic acid
CN Hydroxydimethylacetic acid
FS 3D CONCORD
DR 27909-95-1
MF C4 H8 O3
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, CSNB, DETHERM*, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, NIOSHTIC, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



689 REFERENCES IN FILE CA (1967 TO DATE)
47 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
689 REFERENCES IN FILE CAPLUS (1967 TO DATE)
25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:167213

REFERENCE 2: 134:164229

REFERENCE 3: 134:116239

REFERENCE 4: 134:80351

REFERENCE 5: 134:65535

REFERENCE 6: 134:50669

REFERENCE 7: 134:48366

REFERENCE 8: 134:41908

REFERENCE 9: 134:33402

REFERENCE 10: 133:367150

L230 ANSWER 27 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **552-63-6** REGISTRY
CN Benzeneacetic acid, .alpha.-(hydroxymethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, .alpha.-(hydroxymethyl)-, (.+-.)-
CN Tropic acid, (.+-.)- (8CI)
OTHER NAMES:
CN (.+-.)-2-Phenyl-3-hydroxypropionic acid
CN (.+-.)-3-Hydroxy-2-phenylpropionic acid
CN (.+-.)-Tropic acid
CN .alpha.-(Hydroxymethyl)benzeneacetic acid
CN 2-Phenyl-3-hydroxypropionic acid
CN 2-Phenylhydracrylic acid
CN 3-Hydroxy-2-phenylpropionic acid
CN dl-Tropic acid
CN DL-Tropic acid
CN Tropic acid
FS 3D CONCORD
DR **529-64-6, 28845-94-5**
MF C9 H10 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



107 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
107 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:166271

REFERENCE 2: 134:48595

REFERENCE 3: 134:46895

REFERENCE 4: 134:14878

REFERENCE 5: 133:368878

REFERENCE 6: 133:368869

REFERENCE 7: 133:335449

REFERENCE 8: 133:193275

REFERENCE 9: 133:79034

REFERENCE 10: 133:48996

L230 ANSWER 28 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **526-95-4** REGISTRY
CN D-Gluconic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gluconic acid, D- (8CI)
OTHER NAMES:
CN Gluconic acid
AR 133-42-6
FS STEREOSEARCH
MF C6 H12 O7
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



3677 REFERENCES IN FILE CA (1967 TO DATE)
506 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3686 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:170720

REFERENCE 2: 134:168318

REFERENCE 3: 134:162240

REFERENCE 4: 134:161955

REFERENCE 5: 134:159263

REFERENCE 6: 134:152283

REFERENCE 7: 134:149359

REFERENCE 8: 134:149358

REFERENCE 9: 134:149357

REFERENCE 10: 134:149224

L230 ANSWER 29 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **515-30-0** REGISTRY
CN Benzeneacetic acid, .alpha.-hydroxy-.alpha.-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Atrolactic acid (6CI)
CN Mandelic acid, .alpha.-methyl- (7CI, 8CI)
OTHER NAMES:
CN (.+-.)-.alpha.-Hydroxy-.alpha.-methylbenzeneacetic acid
CN (.+-.)-2-Hydroxy-2-phenylpropionic acid

CN (.+-.)-2-Phenyllactic acid
CN (.+-.)-Atrolactic acid
CN (RS)-2-Phenyllactic acid
CN .alpha.-Hydroxy-.alpha.-phenylpropionic acid
CN .alpha.-Hydroxy-2-phenylpropionic acid
CN .alpha.-Methylmandelic acid
CN .alpha.-Phenyllactic acid
CN 2-Hydroxy-2-phenylpropanoic acid
CN 2-Hydroxy-2-phenylpropionic acid
CN 2-Phenyl-2-hydroxypropionic acid
CN 2-Phenyllactic acid
CN Atrolactinic acid
CN DL-.alpha.-Methylmandelic acid
CN DL-.alpha.-Phenyllactic acid
CN DL-2-Phenyllactic acid
CN DL-Atrolactic acid
CN dl-Atrolactic acid
FS 3D CONCORD
DR 4607-38-9
MF C9 H10 O3
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, NIOSHTIC, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



162 REFERENCES IN FILE CA (1967 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
162 REFERENCES IN FILE CAPLUS (1967 TO DATE)
33 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:86150

REFERENCE 2: 133:114787

REFERENCE 3: 133:79034

REFERENCE 4: 133:48996

REFERENCE 5: 132:342518

REFERENCE 6: 132:293432

REFERENCE 7: 132:236712

REFERENCE 8: 132:222045

REFERENCE 9: 132:78218

REFERENCE 10: 131:317117

L230 ANSWER 30 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **320-77-4** REGISTRY
CN Pentaric acid, 3-carboxy-2,3-dideoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:

CN Isocitric acid (8CI)
OTHER NAMES:
CN 1-Hydroxy-1,2,3-propanetricarboxylic acid
FS 3D CONCORD
DR 25406-69-3, 20591-42-8, 21788-50-1, 29274-10-0
MF C6 H8 O7
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, NIOSHTIC, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



1191 REFERENCES IN FILE CA (1967 TO DATE)
28 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1192 REFERENCES IN FILE CAPLUS (1967 TO DATE)
43 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:159260

REFERENCE 2: 134:130481

REFERENCE 3: 134:128604

REFERENCE 4: 134:55586

REFERENCE 5: 134:41740

REFERENCE 6: 134:41684

REFERENCE 7: 134:33042

REFERENCE 8: 134:15293

REFERENCE 9: 134:14878

REFERENCE 10: 133:355254

L230 ANSWER 31 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **300-85-6** REGISTRY
CN Butanoic acid, 3-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butyric acid, 3-hydroxy- (8CI)
OTHER NAMES:
CN (.+-.)-.beta.-Hydroxybutyric acid
CN (.+-.)-3-Hydroxy-n-butyric acid
CN (.+-.)-3-Hydroxybutanoic acid
CN (.+-.)-3-Hydroxybutyric acid
CN .beta.-Hydroxy-n-butyric acid
CN .beta.-Hydroxybutanoic acid
CN .beta.-Hydroxybutyric acid
CN 3-Hydroxybutanoic acid
CN 3-Hydroxybutyric acid
CN DL-.beta.-Hydroxybutyric acid
CN DL-3-Hydroxybutyric acid
FS 3D CONCORD
DR 625-71-8
MF C4 H8 O3

CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PROMT, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



3563 REFERENCES IN FILE CA (1967 TO DATE)
71 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3570 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:162326

REFERENCE 2: 134:162001

REFERENCE 3: 134:153108

REFERENCE 4: 134:151952

REFERENCE 5: 134:146847

REFERENCE 6: 134:146830

REFERENCE 7: 134:146799

REFERENCE 8: 134:145845

REFERENCE 9: 134:130856

REFERENCE 10: 134:130803

L230 ANSWER 32 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **300-84-5** REGISTRY
CN Ethanesulfinic acid, 2-amino- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Aminoethylsulfinic acid
CN Cystaminesulfinic acid
CN Hypotaurine
FS 3D CONCORD
MF C2 H7 N O2 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMCATS, CSCHEM, DDFU, DRUGU, EMBASE, MEDLINE, PROMT, TOXLINE, TOXLIT, USPATFULL, VETU
(*File contains numerically searchable property data)



366 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

366 REFERENCES IN FILE CAPLUS (1967 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:128770

REFERENCE 2: 134:120573

REFERENCE 3: 134:110319

REFERENCE 4: 133:205916

REFERENCE 5: 133:147655

REFERENCE 6: 133:99554

REFERENCE 7: 133:99497

REFERENCE 8: 133:14825

REFERENCE 9: 133:13612

REFERENCE 10: 132:266827

L230 ANSWER 33 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **156-06-9** REGISTRY
CN Benzenepropanoic acid, .alpha.-oxo- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyruvic acid, phenyl- (8CI)
OTHER NAMES:
CN .beta.-Phenylpyruvic acid
CN 2-Oxo-3-phenylpropanoic acid
CN 2-Oxo-3-phenylpropionic acid
CN 3-Phenyl-2-oxopropanoic acid
CN 3-Phenylpyruvic acid
CN Phenylpyroracemic acid
CN Phenylpyruvic acid
FS 3D CONCORD
MF C9 H8 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, PROMT, SPECINFO, TOXLINE, TOXLIT, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



986 REFERENCES IN FILE CA (1967 TO DATE)
12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
986 REFERENCES IN FILE CAPLUS (1967 TO DATE)
45 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:130401

REFERENCE 2: 134:100864

REFERENCE 3: 134:85808

REFERENCE 4: 134:82670

REFERENCE 5: 134:28493

REFERENCE 6: 134:14878

REFERENCE 7: 134:14608

REFERENCE 8: 134:3531

REFERENCE 9: 133:362970

REFERENCE 10: 133:334341

L230 ANSWER 34 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **134-03-2** REGISTRY
CN L-Ascorbic acid, monosodium salt (8CI, 9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ascorbic acid, sodium deriv. (6CI, 7CI)
OTHER NAMES:
CN 3-Oxo-L-gulofuranolactone sodium
CN Ascorbic acid sodium salt
CN Ascorbicin
CN Ascorbin
CN ASK-P 10KR
CN Cebitate
CN Cenolate
CN CK 40
CN CK 40 (ascorbate)
CN HBL 508
CN Iskia-C
CN L-Ascorbic acid sodium salt
CN Monosodium ascorbate
CN Natrascorb
CN Natri-C
CN Sodascorbate
CN Sodium ascorbate
CN Sodium L-ascorbate
CN Vitamin C sodium
FS STEREOSEARCH
DR 129940-98-3, 156683-68-0
MF C6 H8 O6 . Na
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (50-81-7)

Absolute stereochemistry.



● Na

1555 REFERENCES IN FILE CA (1967 TO DATE)
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1557 REFERENCES IN FILE CAPLUS (1967 TO DATE)
17 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:168074

REFERENCE 2: 134:152647

REFERENCE 3: 134:146648

REFERENCE 4: 134:130672

REFERENCE 5: 134:120629

REFERENCE 6: 134:120628

REFERENCE 7: 134:105856

REFERENCE 8: 134:85316

REFERENCE 9: 134:70681

REFERENCE 10: 134:65894

L230 ANSWER 35 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **127-17-3** REGISTRY
CN Propanoic acid, 2-oxo- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Pyruvic acid (8CI)
OTHER NAMES:
CN .alpha.-Ketopropionic acid
CN 2-Oxopropanoic acid
CN 2-Oxopropionic acid
CN Acetylformic acid
CN BTS
CN Pyroracemic acid
FS 3D CONCORD
DR 1892-67-7
MF C3 H4 O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



15342 REFERENCES IN FILE CA (1967 TO DATE)
218 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
15353 REFERENCES IN FILE CAPLUS (1967 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:167773

REFERENCE 2: 134:167213

REFERENCE 3: 134:162903

REFERENCE 4: 134:161959

REFERENCE 5: 134:160489

REFERENCE 6: 134:160108

REFERENCE 7: 134:159371

REFERENCE 8: 134:159365

REFERENCE 9: 134:159275

REFERENCE 10: 134:157563

L230 ANSWER 36 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **107-35-7** REGISTRY
CN Ethanesulfonic acid, 2-amino- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Taurine (8CI)
OTHER NAMES:
CN .beta.-Aminoethylsulfonic acid
CN 1-Aminoethane-2-sulfonic acid
CN 2-Aminoethanesulfonic acid
CN 2-Aminoethylsulfonic acid
CN 2-Sulfoethylamine
CN O-Due
CN Taufon
CN Taukard
CN Tauphon
FS 3D CONCORD
DR 91105-79-2
MF C2 H7 N O3 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



9060 REFERENCES IN FILE CA (1967 TO DATE)

482 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9064 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:168357

REFERENCE 2: 134:168350

REFERENCE 3: 134:159640

REFERENCE 4: 134:158628

REFERENCE 5: 134:157311

REFERENCE 6: 134:146766

REFERENCE 7: 134:146665

REFERENCE 8: 134:146575

REFERENCE 9: 134:145810

REFERENCE 10: 134:145772

L230 ANSWER 37 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **90-80-2** REGISTRY
CN D-Gluconic acid, .delta.-lactone (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Gluconic acid lactone (6CI)
CN Gluconic acid, .delta.-lactone, D- (8CI)
CN Gluconic acid, lactone, D- (7CI)
OTHER NAMES:
CN .delta.-Gluconolactone
CN 1,5-Gluconolactone
CN D-(+)-Gluconic acid .delta.-lactone
CN D-Gluconic acid 1,5-lactone
CN D-Gluconic acid lactone
CN D-Glucono-.delta.-lactone
CN D-Glucono-1,5-lactone
FS STEREOSEARCH
DR 1335-57-5, 71033-49-3, 4253-68-3, 302547-96-2
MF C6 H10 O6
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



1425 REFERENCES IN FILE CA (1967 TO DATE)
41 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1427 REFERENCES IN FILE CAPLUS (1967 TO DATE)
55 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:168258

REFERENCE 2: 134:161955

REFERENCE 3: 134:146786

REFERENCE 4: 134:127968

REFERENCE 5: 134:116233

REFERENCE 6: 134:115081

REFERENCE 7: 134:71998

REFERENCE 8: 134:70685

REFERENCE 9: 134:57141

REFERENCE 10: 134:56901

L230 ANSWER 38 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **87-69-4** REGISTRY
CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Butanedioic acid, 2,3-dihydroxy- [R-(R*,R*)]-
CN Tartaric acid, L-(+)- (8CI)
OTHER NAMES:
CN (+)-(R,R)-Tartaric acid
CN (+)-L-Tartaric acid
CN (+)-Tartaric acid
CN (2R,3R)-(+)-Tartaric acid
CN (2R,3R)-Tartaric acid
CN (R,R)-(+)-Tartaric acid
CN (R,R)-Tartaric acid
CN 1,2-Dihydroxyethane-1,2-dicarboxylic acid
CN 2,3-Dihydroxybutanedioic acid
CN 2R,3R-Tartaric acid
CN d-.alpha.,.beta.-Dihydroxysuccinic acid
CN d-Tartaric acid
CN Dextrotartaric acid
CN L-(+)-Tartaric acid
CN L-Tartaric acid
CN Natural tartaric acid
CN Tartaric acid
CN Threaric acid
AR 526-83-0
FS STEREOSEARCH
DR 8014-54-8, 8059-77-6, 1336-18-1
MF C4 H6 O6
CI COM
LC STN Files: AGRICOLA, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



11520 REFERENCES IN FILE CA (1967 TO DATE)
1175 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11528 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:172325

REFERENCE 2: 134:172298

REFERENCE 3: 134:170774

REFERENCE 4: 134:168881

REFERENCE 5: 134:168857

REFERENCE 6: 134:168423

REFERENCE 7: 134:168357

REFERENCE 8: 134:168318

REFERENCE 9: 134:167619

REFERENCE 10: 134:167136

L230 ANSWER 39 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **80-69-3** REGISTRY
CN Propanedioic acid, hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Tartronic acid (6CI, 8CI)
OTHER NAMES:
CN .alpha.-Hydroxymalonic acid
CN Hydroxymalonic acid
CN Hydroxypropanedioic acid
FS 3D CONCORD
MF C3 H4 O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



386 REFERENCES IN FILE CA (1967 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
388 REFERENCES IN FILE CAPLUS (1967 TO DATE)
36 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:131949

REFERENCE 2: 134:105605

REFERENCE 3: 134:102908

REFERENCE 4: 134:50669

REFERENCE 5: 134:5102

REFERENCE 6: 134:4607

REFERENCE 7: 133:337265

REFERENCE 8: 133:318526

REFERENCE 9: 133:198651

REFERENCE 10: 133:182711

L230 ANSWER 40 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **79-83-4** REGISTRY
CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-
CN Pantothenic acid, D- (8CI)
OTHER NAMES:
CN (+)-Pantothenic acid
CN (D)-(+)-Pantothenic acid
CN Chick antidermatitis factor
CN D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine
CN D-Pantothenic acid
CN Pantothenic acid
CN Vitamin B3
CN Vitamin B5
FS STEREOSEARCH
DR 3563-85-7
MF C9 H17 N O5
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



2207 REFERENCES IN FILE CA (1967 TO DATE)
88 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2208 REFERENCES IN FILE CAPLUS (1967 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:168321

REFERENCE 2: 134:168074

REFERENCE 3: 134:152647

REFERENCE 4: 134:141603

REFERENCE 5: 134:136767

REFERENCE 6: 134:136704

REFERENCE 7: 134:128353

REFERENCE 8: 134:125903

REFERENCE 9: 134:99997

REFERENCE 10: 134:83111

L230 ANSWER 41 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **79-33-4** REGISTRY
CN Propanoic acid, 2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Lactic acid, L- (8CI)
CN Propanoic acid, 2-hydroxy-, (S)-
OTHER NAMES:
CN (+)-Lactic acid
CN (S)-(+)-Lactic acid
CN (S)-2-Hydroxypropanoic acid
CN (S)-2-Hydroxypropionic acid
CN (S)-Lactic acid
CN d-Lactic acid
CN Espiritin
CN L-(+)-.alpha.-Hydroxypropionic acid
CN L-(+)-Lactic acid
CN L-Lactic acid
CN Paralactic acid
CN PH 90
CN PURAC
CN Sarcolactic acid
CN Tisulac
FS STEREOSEARCH
DR 1715-99-7
MF C3 H6 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, RTECS*, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



2353 REFERENCES IN FILE CA (1967 TO DATE)
58 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2359 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:162302

REFERENCE 2: 134:157281

REFERENCE 3: 134:147850

REFERENCE 4: 134:146722

REFERENCE 5: 134:146715

REFERENCE 6: 134:146573

REFERENCE 7: 134:146483

REFERENCE 8: 134:145008

REFERENCE 9: 134:130392

REFERENCE 10: 134:130342

L230 ANSWER 42 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **79-14-1** REGISTRY
CN Acetic acid, hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycolic acid (7CI, 8CI)
OTHER NAMES:
CN .alpha.-Hydroxyacetic acid
CN 2-Hydroxyacetic acid
CN Glycocide
CN GlyPure
CN Hydroxyacetic acid
CN Hydroxyethanoic acid
FS 3D CONCORD
DR 259744-22-4
MF C2 H4 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, ULIDAT, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



5670 REFERENCES IN FILE CA (1967 TO DATE)
546 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5677 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 134:170774

REFERENCE 2: 134:168321

REFERENCE 3: 134:168315

REFERENCE 4: 134:167213

REFERENCE 5: 134:166271

REFERENCE 6: 134:162160

REFERENCE 7: 134:159275

REFERENCE 8: 134:155241

REFERENCE 9: 134:152392

REFERENCE 10: 134:149358

L230 ANSWER 43 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **77-92-9** REGISTRY
CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Citric acid (8CI)
OTHER NAMES:
CN 2-Hydroxy-1,2,3-propanetricarboxylic acid
CN 3-Carboxy-3-hydroxypentane-1,5-dioic acid
CN Aciletten
CN Chemfill
CN Citretten
CN Citro
CN F 0001 (polycarboxylic acid)
CN Hydrocerol A
FS 3D CONCORD
DR 12262-73-6, 43136-35-2, 245654-34-6
MF C6 H8 O7
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSDIRECTORY, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



33796 REFERENCES IN FILE CA (1967 TO DATE)
2199 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33838 REFERENCES IN FILE CAPLUS (1967 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:172474

REFERENCE 2: 134:172081

REFERENCE 3: 134:170774

REFERENCE 4: 134:168857

REFERENCE 5: 134:168402

REFERENCE 6: 134:168359

REFERENCE 7: 134:168357

REFERENCE 8: 134:168353

REFERENCE 9: 134:168314

REFERENCE 10: 134:168116

L230 ANSWER 44 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **76-93-7** REGISTRY
CN Benzeneacetic acid, .alpha.-hydroxy-.alpha.-phenyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzilic acid (7CI, 8CI)
OTHER NAMES:
CN .alpha.,.alpha.-Diphenyl-.alpha.-hydroxyacetic acid
CN .alpha.,.alpha.-Diphenylglycolic acid
CN .alpha.-Hydroxy-.alpha.-phenylbenzeneacetic acid
CN .alpha.-Hydroxy-2,2-diphenylacetic acid
CN .alpha.-Hydroxydiphenylacetic acid
CN 2,2-Diphenyl-2-hydroxyacetic acid
CN 2-Hydroxy-2,2-diphenylacetic acid
CN Diphenylglycolic acid
CN Diphenylhydroxyacetic acid
CN Hydroxydiphenylacetic acid
FS 3D CONCORD
MF C14 H12 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



557 REFERENCES IN FILE CA (1967 TO DATE)
42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
558 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:166271

REFERENCE 2: 134:123557

REFERENCE 3: 134:123539

REFERENCE 4: 134:115500

REFERENCE 5: 134:105605

REFERENCE 6: 134:100932

REFERENCE 7: 134:85822

REFERENCE 8: 134:11437

REFERENCE 9: 133:339981

REFERENCE 10: 133:339965

L230 ANSWER 45 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **70-18-8** REGISTRY
CN Glycine, L-.gamma.-glutamyl-L-cysteinyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glutathione (8CI)
CN Glycine, N-(N-L-.gamma.-glutamyl-L-cysteinyl)-
OTHER NAMES:
CN .gamma.-Glutamylcysteinylglycine
CN .gamma.-L-Glutamyl-L-cysteinylglycine
CN Agifutol S
CN Copren
CN Deltathione
CN Glutathion
CN Glutathione (GSH)
CN Glutathione-SH
CN Glutide
CN Glutinal
CN GSH
CN Isethion
CN L-Glutathione
CN Neuthion
CN Reduced glutathione
CN Tathion
CN Tathione
CN Triptide
FS STEREOSEARCH
MF C10 H17 N3 O6 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, ULIDAT, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



25388 REFERENCES IN FILE CA (1967 TO DATE)
1200 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
25438 REFERENCES IN FILE CAPLUS (1967 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:172290

REFERENCE 2: 134:168749

REFERENCE 3: 134:168631

REFERENCE 4: 134:162280

REFERENCE 5: 134:161219

REFERENCE 6: 134:161147

REFERENCE 7: 134:161100

REFERENCE 8: 134:160604

REFERENCE 9: 134:160497

REFERENCE 10: 134:159673

L230 ANSWER 46 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **63-68-3** REGISTRY
CN L-Methionine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methionine, L- (8CI)
OTHER NAMES:
CN (S)-2-Amino-4-(methylthio)butanoic acid
CN .alpha.-Amino-.gamma.-methylmercaptobutyric acid
CN .gamma.-Methylthio-.alpha.-aminobutyric acid
CN 134: PN: WO0055199 SEQID: 94 claimed sequence
CN 2-Amino-4-(methylthio)butyric acid
CN 54: PN: WO9957282 SEQID: 46 claimed sequence
CN Butanoic acid, 2-amino-4-(methylthio)-, (S)-
CN Cymethion
CN h-Met-oh
CN L-(-)-Methionine
CN L-.alpha.-Amino-.gamma.-methylthiobutyric acid
CN L-Homocysteine, S-methyl-
CN l-Methionine
CN Methionine
CN S-Methionine
CN Toxin WAR (Bacillus thuringiensis strain PS205C)
FS STEREOSEARCH
DR 7005-18-7, 24425-78-3
MF C5 H11 N O2 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



24318 REFERENCES IN FILE CA (1967 TO DATE)
621 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
24342 REFERENCES IN FILE CAPLUS (1967 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:172499

REFERENCE 2: 134:172476

REFERENCE 3: 134:170720

REFERENCE 4: 134:168866

REFERENCE 5: 134:165268

REFERENCE 6: 134:163295

REFERENCE 7: 134:162315

REFERENCE 8: 134:162312

REFERENCE 9: 134:162233

REFERENCE 10: 134:162061

L230 ANSWER 47 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **59-51-8** REGISTRY
CN Methionine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN DL-Methionine
CN Methionine, DL- (8CI)
OTHER NAMES:
CN (.+-.)-Methionine
CN .alpha.-Amino-.gamma.-methylmercaptobutyric acid
CN Acimetion
CN Banthionine
CN Cynaron
CN DL-2-Amino-4-(methylthio)butyric acid
CN Dyprin
CN Lactet
CN Lobamine
CN Meonine
CN Methilanin
CN Metione
CN Neston
CN Racemethionine
FS 3D CONCORD
MF C5 H11 N O2 S
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, DIOGENES, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXLINE, TOXLIT, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



2543 REFERENCES IN FILE CA (1967 TO DATE)
59 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2543 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:146857

REFERENCE 2: 134:139155

REFERENCE 3: 134:127206

REFERENCE 4: 134:121440

REFERENCE 5: 134:115189

REFERENCE 6: 134:113130

REFERENCE 7: 134:71243

REFERENCE 8: 134:65629

REFERENCE 9: 134:55978

REFERENCE 10: 134:50794

L230 ANSWER 48 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **56-89-3** REGISTRY
CN L-Cystine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cystine, L- (8CI)
OTHER NAMES:
CN (-)-Cystine
CN .beta.,.beta.'-Diamino-.beta.,.beta.'-dicarboxydiethyl disulfide
CN .beta.,.beta.'-Dithiodialanine
CN 3,3'-Dithiobis(2-aminopropanoic acid)
CN Bis(.beta.-amino-.beta.-carboxyethyl) disulfide
CN Cystine
CN Cystine acid
CN Dicysteine
CN L-(-)-Cystine
CN L-Alanine, 3,3'-dithiobis-
CN L-Cysteine disulfide
CN L-Cystin
CN l-Cystine
CN Oxidized L-cysteine
CN Propanoic acid, 3,3'-dithiobis[2-amino-, [R-(R*,R*)]-
CN [R-(R*,R*)]-3,3'-Dithiobis[2-aminopropanoic acid]
AR 24645-67-8
FS STEREOSEARCH
DR 24645-67-8
MF C6 H12 N2 O4 S2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



7496 REFERENCES IN FILE CA (1967 TO DATE)
199 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7501 REFERENCES IN FILE CAPLUS (1967 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:170720

REFERENCE 2: 134:160604

REFERENCE 3: 134:147052

REFERENCE 4: 134:146777

REFERENCE 5: 134:146683

REFERENCE 6: 134:145810

REFERENCE 7: 134:144735

REFERENCE 8: 134:144559

REFERENCE 9: 134:142179

REFERENCE 10: 134:141135

L230 ANSWER 49 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **52-90-4** REGISTRY
CN L-Cysteine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cysteine, L- (8CI)
OTHER NAMES:
CN (R)-2-Amino-3-mercaptopropanoic acid
CN (R)-Cysteine
CN .beta.-Mercaptoalanine
CN 19: PN: US6087398 PAGE: 14 claimed sequence
CN 2-Amino-3-mercaptopropionic acid
CN Cystein
CN Cysteine
CN Half-cystine
CN L-(+)-Cysteine
CN L-Alanine, 3-mercapto-
CN L-Cys
CN NSC 8746
CN Propanoic acid, 2-amino-3-mercapto-, (R)-
CN Thioserine
FS STEREOSEARCH
DR 4371-52-2
MF C3 H7 N O2 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, ULIDAT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



24398 REFERENCES IN FILE CA (1967 TO DATE)
1198 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
24432 REFERENCES IN FILE CAPLUS (1967 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:172476

REFERENCE 2: 134:172290

REFERENCE 3: 134:170720

REFERENCE 4: 134:168244

REFERENCE 5: 134:162061

REFERENCE 6: 134:162054

REFERENCE 7: 134:161908

REFERENCE 8: 134:160620

REFERENCE 9: 134:160614

REFERENCE 10: 134:160604

L230 ANSWER 50 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **50-81-7** REGISTRY
CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Ascorbic acid
CN 3-keto-L-Gulofuranolactone
CN 3-Oxo-L-gulofuranolactone
CN Adenex
CN Allercorb
CN Antiscorbic vitamin
CN Antiscorbutic vitamin
CN Ascoltin
CN Ascorbajen
CN Ascorbic acid
CN Ascorbutina
CN Ascorin
CN Ascorteal
CN Ascorvit
CN C-Quin
CN C-Vimin
CN Cantan
CN Cantaxin
CN Catavin C
CN Ce-Mi-Lin
CN Ce-Vi-Sol
CN Cebicure
CN Cebion
CN Cebione
CN Cecon
CN Cegiolan
CN Ceglion
CN Celaskon
CN Celin
CN Cemagyl
CN Cenetone
CN Cereon
CN Cergona
CN Cescorbat
CN Cetamid
CN Cetemican

CN Cevalin
CN Cevatine
CN Cevex
CN Cevimin
CN Cevital
CN Cevitamic acid
CN Cevitamin
CN Cevitan
CN Cevitex
CN Chewcee
CN Ciamin
CN Cipca
CN Citrovit
CN Colascor
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
DR 56533-05-2, 57304-74-2, 57606-40-3, 56172-55-5, 129940-97-2, 14536-17-5, 50976-75-5, 154170-90-8, 89924-69-6, 30208-61-8, 259133-78-3
MF C6 H8 O6
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSDIRECTORY, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PHAR, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



41312 REFERENCES IN FILE CA (1967 TO DATE)
1018 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
41363 REFERENCES IN FILE CAPLUS (1967 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:170720

REFERENCE 2: 134:168378

REFERENCE 3: 134:168357

REFERENCE 4: 134:168352

REFERENCE 5: 134:168329

REFERENCE 6: 134:168321

REFERENCE 7: 134:168110

REFERENCE 8: 134:168079

REFERENCE 9: 134:168078

REFERENCE 10: 134:168074

L230 ANSWER 51 OF 51 REGISTRY COPYRIGHT 2001 ACS
RN **50-21-5** REGISTRY
CN Propanoic acid, 2-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Lactic acid (7CI, 8CI)
OTHER NAMES:
CN (.+-.)-Lactic acid
CN .alpha.-Hydroxypropanoic acid
CN .alpha.-Hydroxypropionic acid
CN 2-Hydroxypropanoic acid
CN 2-Hydroxypropionic acid
CN Biolac
CN Chem-Cast
CN DL-Lactic acid
CN dl-Lactic acid
CN Milk acid
CN Tonsillosan
FS 3D CONCORD
DR 152-36-3, 598-82-3
MF C3 H6 O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIOGENES, DIPPR*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



33241 REFERENCES IN FILE CA (1967 TO DATE)
1123 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33278 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 134:168428

REFERENCE 2: 134:168353

REFERENCE 3: 134:168179

REFERENCE 4: 134:168063

REFERENCE 5: 134:167814

REFERENCE 6: 134:167532

REFERENCE 7: 134:167213

REFERENCE 8: 134:167142

REFERENCE 9: 134:166271

REFERENCE 10: 134:164872